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Abstract 
Introduction: 
Despite substantial improvements in treatment, adherence to guideline 
indicated treatment for acute myocardial infarction (AMI) patients remains 
sub-optimal. Therefore, the purpose of this research project was to investigate 
the quality of care and associated outcomes of patients hospitalised with AMI 
using electronic health record data.  
Methods: 
This thesis was based on prospective cohort data from the nationwide 
population-based clinical registry: Myocardial Ischaemia National Audit 
Project (MINAP) (2003-13). MINAP records all AMI admissions from 247 
hospitals in England and Wales. The research conducted in this thesis 
consisted of four research strands all in the framework of assessing quality of 
care and outcomes for AMI patients which included: 1) determining the excess 
mortality associated with sub-optimal management of AMI (restricted to Non-
ST-elevation myocardial infarction phenotype (NSTEMI)), 2) assessing 
variation in receipt of NSTEMI care, 3)  investigating the association of 
temporal changes in clinical factors and therapeutic strategies with 
improvements in survival following ST-elevation myocardial infarction 
(STEMI) and 4) determining the efficacy of β blockers in treating AMI patients 
without heart failure or left ventricular systolic dysfunction (LVSD).   
Results: 
The majority (86.9% (n=337,881)) of the NSTEMI patients evaluated did not 
receive one or more guideline-indicated care interventions for which they were 
eligible and the identified sub-optimal care was found to be associated with 
32,765 potentially avoidable deaths (95% CI 30,531 to 33,509). Most of the 
excess variation (99.6%) in receipt of care was due to between hospital 
differences (median 64.7%, IQR 57.4% to 70.0%; between hospital variance: 
1.92, 95% CI 1.51 to 2.44; ICC 0.996, 0.976 to 0.999). For the STEMI 
phenotype the temporal improvements in six months and one year survival 
that have been noted between 2004 and 2013 were associated  with the 
introduction of reperfusion (PPCI) and temporal improvements in P2Y12 
 - viii -  
inhibitors prescription at hospital discharge. No significant differences in 
average time to death were found if all the AMI patients without heart failure 
or LVSD in the population had received β blockers compared with if no 
patients had received β blockers.      
Conclusion: 
The thesis provides evidence of important care deficits in an otherwise 
modern and efficient national health care system. The deficits in receipt care 
identified were found to be associated with avoidable deaths and most of the 
variation in receipt of care was explained by hospital differences in provision 
of care. The thesis also provides evidence that the introduction of PPCI and 
increased prescription of P2Y12 inhibitors at discharge was associated with 
improved survival improvements that have been noted for STEMI patients 
admitted between 2004 and 2013. However, among survivors of 
hospitalisation with AMI without heart failure or LVSD as recorded in hospital, 
the use of β blockers was not associated with a lower risk of death at up to 
one year. Only through higher resolution investigations using whole 
healthcare system clinical registries can modifiable deficits of care be 
identified and, therefore, addressed. 
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Chapter 1  
 
1.1 Introduction 
In Europe cardiovascular disease (CVD) is the leading cause of mortality, 
causing approximately 4.1 million (46%) deaths annually, with 20% (1.8 
million) of these deaths being attributed to coronary heart disease (CHD)(1).  
Of the 4.1 million deaths, 1.4 million have been reported to be pre-mature 
deaths (deaths before the age of 75 years)(2). Globally, the Global Burden 
of Disease (GBD) report has reported that CVD has caused approximately 
17.3 million deaths(2).  
The purpose of this research project was to explore the association 
between quality of care and outcomes for AMI, the most common 
manifestation of CHD. The research investigated both sub-types of AMI, 
ST-elevation Myocardial Infarction (STEMI) and Non-ST-elevation 
Myocardial Infarction (NSTEMI), and for each subtype selected a particular 
theme based on literature reviews which assessed the knowledge gaps. 
The thesis will be in the area of cardiovascular epidemiology. Advanced 
statistical techniques such as latent class analysis, multilevel accelerated 
failure time models, multilevel Poisson regression, survival-time inverse-
probability weighting, flexible parametric survival modelling, instrumental 
variable analysis, and mediation analysis were explored. 
 
1.2 Thesis outline  
A detailed description of the background of AMI is provided within this 
chapter. The description includes information on the definition of AMI, 
burden, care pathway and available data sources for validation of mortality, 
morbidity and treatment of AMI patients. This will be followed by Chapter 2, 
which explored the available literature on adherence to guideline-indicated 
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care for AMI patients and associated outcomes. The review aimed to 
explore AMI adherence to guideline-indicated care interventions 
prevalence, identify key components in determinants of poor adherence as 
well as investigate outcomes associated with non-adherence to guideline-
indicated care for AMI patients. This knowledge base was then used to build 
the rationale for this current research and develop the research questions 
used to achieve the research aim.   
 
Chapter 3 gives a detailed description of the study design, data source, and 
statistical methods that were used throughout the thesis. The main results 
of the research are presented in four chapters focusing on: quantifying the 
excess mortality associated with sub-optimal care of NSTEMI patients and 
determining the predictors of sub-optimal care (chapter 4), assessing 
geographic variation in receipt of care for NSTEMI patients (chapter 5), 
investigating the association of clinical factors and therapeutic strategies 
with improvements in survival following STEMI (chapter 6), and estimating 
the efficacy of β-blockers in treating AMI patients without heart failure or  left 
ventricular systolic dysfunction (LVSD) (chapter 7). Each result chapter 
included: interpretation of the descriptive, analytical and sensitivity analysis 
results, as well as a summary and conclusion of the main findings. 
 
Chapter 8 provides a detailed and critical discussion of the thesis, 
highlighting the main contributions of this work in the context of previous 
research and policy as well as a discussion of the strengths and limitations, 
and recommendations for future work. 
 
1.3 Background of acute myocardial infarction  
Acute coronary syndromes (ACS) consist of three main conditions which 
include STEMI, NSTEMI and unstable angina (UA)(3). These conditions 
result from reduced or terminated blood flow to the heart due to blockage of 
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the arteries that supply the heart muscle with blood (oxygen), which in turn 
causes myocardial cell death(4, 5). Blockage is mainly caused by 
atherosclerosis with thrombus(4, 5). STEMI is characterised by complete 
total blockage of the coronary artery, NSTEMI by partial blockage of the 
coronary artery and UA by restricted blood supply to the heart but with no 
permanent damage to the heart(6). Of the three ACS types UA is 
considered the least serious, with STEMI being considered the most 
serious(6). However, if NSTEMI is left untreated it can cause severe heart 
damage and even progress to being a STEMI(6). The leading symptom that 
starts the diagnostic and therapeutic cascade in ACS patients is chest 
pain(4). Severity of damage as a result of the ACS depends on size and 
location of infarction. The extent of infarction being determined by the level 
of blockage of arteries, severity and duration of ischaemia with no residual 
flow(7). The work of this research will focus on the two phenotypes 
considered most serious of the three ACS conditions, which are STEMI and 
NSTEMI, and collectively known as AMI. 
 
1.3.1 Universal definition of myocardial infarction  
The most recent (2015/2016) universal definition of AMI defines the 
condition as the rise or fall of cardiac biomarkers (high-sensitivity cardiac 
troponin) together with either presenting features; 1) symptoms of 
ischaemia, 2) new or presumed new significant ST-T wave changes or left 
bundle branch block on 12-lead ECG, 3) development of pathological Q 
wave on ECG, 4) imaging evidence of new or presumed new loss of viable 
myocardium or regional wall motion abnormality and 5) intracoronary 
thrombus detected on angiography or autopsy(4). The definition was further 
stratified to five sub-categories, that is type 1: spontaneous AMI (usually 
related to coronary artery blockage and ceased or decreased blood flow), 
type 2: an AMI secondary to an ischaemic imbalance, type 3: AMI resulting 
in death, type 4: AMI related to stent thrombosis and type 5: AMI related to 
coronary artery bypass grafting (CABG)(5). For this thesis, the research 
work was based on AMI of type 1 (spontaneous myocardial infarction) as 
the data source used (Myocardial Ischaemia National Audit Project 
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(MINAP)) records only information on AMI type 1(8), thus assessments of 
quality of care and outcomes could only be possible for this type.  
 
1.4 Epidemiology of acute myocardial infarction  
Acute myocardial infarction is a major cause of death and disability world-
wide(5), with  ischaemic heart disease being named as one of the top 10 
causes of death, accounting for 15 million deaths in 2015 combined with 
stroke(9).  The World Health Organisation (WHO) fact sheet has reported 
that these diseases have continued to be the principal cause of death 
globally for the last 15 years(9).  In Europe it has been approximated that 
every sixth man and every seventh woman will die from myocardial 
infarction(4). 
 
In the United Kingdom (UK) CVD has been related to more than 1.6 million 
NHS hospital episodes in 2012/13, accounting for 10% of all inpatient 
episodes among men and 6.2% among women(10, 11). Of the 10% male 
inpatient episodes 3.5% were attributed to coronary heart disease (CHD) 
and of the 6.2% female inpatient episodes, 1.5% were attributed to CHD 
(10, 11), with the most common manifestation of CHD being an AMI. 
Specifically, focusing on AMI, approximately 200,000 hospital visits 
annually have been attributed to AMI(12). Also 26% of all deaths in the UK 
have been attributed to CVD, i.e. approximately 160,000 deaths annually 
(435 per day and approximately one death every three minutes)(12). 
Annually, approximately 42,000 premature deaths have been reported in 
the UK(12).  
 
The 2012 British Heart Foundation (BHF) coronary heart disease 
compendium of health statistics reported that although there have been 
decreased incidence rates of AMI in England, some regional differences 
were still evident with the highest incidences noted in the North and lowest 
in the South. It is estimated that there are around 50,000 heart attacks in 
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men, 32,000 heart attacks in women in England, and 8,000 heart attacks in 
men, 5,000 heart attacks in women in Scotland(13). Assuming that the rates 
of heart attacks in England were comparable to Wales and Northern Ireland, 
the compendium of health statistics reported that annually the UK would 
have approximately have 103,000 heart attacks cases(13). The most recent 
MINAP audit report (2015/2016) reported over 85,123 AMI cases in 
England, Wales and Isle of Man(8). Of these reported AMI cases, 39% 
(33,797) were diagnosed as STEMI and 60.3% (51,326) were diagnosed 
as NSTEMI(8). For England alone, 67% of the patients who suffered a heart 
attack were male and the majority of the STEMI patients (71%) were male. 
The females tended to be older than males for both AMI phenotypes(8). 
However, for both sexes the median age was greater for those who had 
suffered an NSTEMI compared to the STEMI, with most of the NSTEMIs 
being aged 70 years old or older(8). The associated production losses due 
to mortality and morbidity as a result of CHD amount to over £3 billion for 
the UK(14). Across Europe CHD accounts for 20% (1.8 million) of all deaths 
annually(1). Associated productivity losses, direct health care costs and 
informal care, due to mortality and morbidity, cost the European Union 
economy approximately €60 billion a year(15). 
 
In 2014 the National Institute for Health and Care Excellence (NICE) 
estimated the population prevalence in the UK of STEMI patients to range 
between 750-1250 per million people and due to NSTEMI’s difficult 
diagnosis thus harder to estimate, the annual incidence of hospitalisation is 
3 per 1000 people (16). The incidence of AMI in the UK has been 
approximated to be around 200-220 per 100,000 men and 80-90 per 
100,000 women, corresponding to an annual rate of 124,000 cases(17). 
The incidence data are usually derived from annual records of inpatient 
episodes from NHS hospitals (18). However using hospital records as a 
source of incidence data can result to overestimation of the number of new 
cases if an individual has multiple hospital episodes, the true number of new 
cases maybe overestimated. Also the incidence data can be 
underestimated in situations where a patient suffers a condition and does 
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not attend hospital. Usually this is quite common for conditions with high 
mortality rates, for example if a patient dies after a heart attack before 
reaching hospital their episode may not be recorded in the hospital records. 
Collecting accurate incidence rate data can prove difficult because unlike 
death, the presence and onset of disease is not absolute for example 
accurate case ascertainment for NSTEMI phenotype of AMI can be 
challenging due to the heterogeneous nature of symptoms which makes it 
harder to diagnose. As such availability of sources of robust incidence rates 
data for AMI in the UK are limited(18).   
 
1.5 The management of acute myocardial infarction  
The care pathway for AMI patients is characterised by five stages namely;  
 Pre-hospital care (characterised by performance of an 
electrocardiogram (ECG) and receipt of aspirin before hospital 
admission, usually done by the attending paramedic or ambulance 
staff) 
 Early hospital care (characterised by recording of an ECG and 
receipt of cardio-protective drugs) 
 In hospital care (characterised by receipt of an invasive strategy 
angioplasty/ thrombolysis) 
 Hospital discharge care (characterised by prescription of cardio-
protective drugs and education on smoking cessation and dietary 
advice)  
 Post hospital discharge care (characterised by comprehensive 
cardiac rehabilitation and long term drug therapy) 
The five stages are preceded by a patient seeking medical help after 
suffering AMI symptoms which comprise of pain, pressure or discomfort in 
the chest, shortness of breath, sweating or feeling sick to the stomach and 
pain in the neck, jaw or shoulders(19).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
The care pathways for the two phenotypes of AMI are quite different, with 
the major difference being that STEMI patients care encompasses prompt 
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diagnosis and timely treatment (through Primary Percutaneous Coronary 
Intervention (PPCI) or thrombolysis) to revive the obstructed coronary artery 
(20) whilst for NSTEMI patients performance of an angiogram and coronary 
intervention within 2-4 days is essential depending on the risk profile of the 
NSTEMI patient(21). 
The European Society of Cardiology (ESC) and American College of 
Cardiology/American Heart Association (ACC/AHA) have published 
consensus guidelines to define the ACS care pathway and promote the use 
of the evidence-based therapies(4, 20-24). 
The main categories of diagnosis and treatment of AMI are described briefly 
in §1.5.1 and §1.5.2 below, respectively. 
 
1.5.1 Acute myocardial infarction: Diagnostics  
The guidelines recommend that an ECG be taken within 10 minutes of the 
patient’s arrival in the emergency room or at first contact with the 
emergency medical services, as the first line diagnostic tool in the 
assessment of the patient(4, 22). STEMI diagnosis is characterised by 
persistent ST elevation with suggestive signs and symptoms(4). For 
NSTEMIs the ECG maybe normal, however some characteristic 
abnormalities maybe observed for some of the patients that is ST 
depression, transient ST elevation and T-wave changes(4). 
1.5.1.1 Biomarkers 
Due to the fact that for NSTEMI patients a normal ECG maybe observed, 
diagnosis should be complemented by measurement of a biomarker of 
cardiomyocyte injury. Preferably cardiac troponins as they are more 
sensitive and specific than creatinine kinase, its isoenzyme CK-MB and 
myoglobin(4). An elevation of cardiac troponin above the 99th percentile of 
healthy individuals indicates AMI(4).  
 
 
 
 - 8 -  
1.5.2 Acute myocardial infarction: Treatment   
1.5.2.1 Pharmacological treatment of ischaemia 
The goal of pharmacological anti-ischaemic therapy is to change how the 
heart or blood circulation works i.e. to decrease myocardial oxygen demand 
or to increase myocardial oxygen supply(4, 25). Details on the main 
categories of pharmacological drugs used to treat AMI and how they work 
are given below.    
1.5.2.1.1 Antiplatelet therapy  
Antiplatelet therapy is the cornerstone in the management of AMI patients. 
The three types of drugs that constitute antiplatelet therapy for AMI patients 
include; acetylsalicylic acid (aspirin), P2Y12 receptor inhibitors and GP 
IIb/IIIa antagonists(4, 22). These cardio-protective drugs work by preventing 
blood clotting, which is achieved by inhibiting platelets from sticking 
together to form a thrombus (clot)(19, 25). This reduces the risk of re-
infarction(26). 
1.5.2.1.2 Anticoagulants 
Anticoagulants are used in the treatment of AMI to prevent harmful blood 
clots from forming(4, 14, 22). They work by inhibiting thrombin generation 
and are more effective if used in conjunction with platelet inhibitors 
(antiplatelet therapy)(4, 25). Examples include enoxaparin, fondaparinux, 
warfarin and unfractionated heparin. Use of this pharmacotherapy does 
come with a side effect of increased risk of bleeding(25). 
1.5.2.1.3 Angiotensin-converting enzyme (ACE) inhibitors  
Angiotensin-converting enzyme (ACE) inhibitors are used to regulate high 
blood pressure in the management of AMI(25). They work by making the 
blood vessels relax and widen by preventing the body from making the 
hormone that makes the blood vessels tighten, angiotensin II(19, 25). The 
lowering of the blood pressure ensures that the heart does not have to work 
so hard to pump blood through the vessels thus making the heart more 
efficient(19). Examples of ACE inhibitors include Ramipril and 
perindopril(25).  
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1.5.2.1.4 Angiotensin-II antagonists / Angiotensin receptor blockers 
(ARBs) 
Angiotensin receptor blockers (ARBs) are also used for regulating high 
blood pressure like ACE inhibitors but less likely to cause some side effects 
that can be experienced when taking ACE inhibitors(19). Examples of ARBs 
include losartan and candesartan(25). They are usually given to patients 
who cannot take ACE inhibitors.  
1.5.2.1.5 β blockers  
Beta blockers act by slowing the heart rate and lowering the blood 
pressure(4, 22, 25). This is achieved by supressing the hormone 
adrenaline(19). When adrenaline is stopped the heart slows down, making 
blood flow through the vessels slow thus the pressure inside the vessels 
drops and the heart works less(19, 25). β blockers use reduces the risk of 
re-infarction(25).  
1.5.2.1.6 Statins   
Statins are lipid lowering drugs that lower blood low density lipoprotein 
(LDL) cholesterol (bad type of cholesterol)(19, 25). They act in several 
ways, that is: some change the way the liver processes cholesterol and fat, 
others affect the way the body digests nutrients whilst others prevent 
cholesterol from flowing though the blood vessels(19). The most commonly 
prescribed lipid lowering drug in the UK are Statins and they work by 
reducing the amount of cholesterol produced by the liver(25).  
1.5.2.2 Invasive strategy  
In order to restore or improve blood flow to the heart, coronary angioplasty 
is implemented(4, 22). Coronary angioplasty is sometimes called 
Percutaneous Coronary Intervention (PCI), Percutaneous Transluminal 
Coronary Angioplasty (PTCA), balloon angioplasty or coronary stent 
implantation(27). If the coronary angioplasty is done as an emergency 
treatment, it is called Primary Percutaneous Coronary Intervention (PPCI). 
Coronary angioplasty involves the insertion of a deflated balloon by aid of a 
catheter through the groin or wrist of the AMI patient to look for thickening 
and hardening of the coronary artery. To aid visibility by X-ray, a dye is 
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injected into the catheter. After identification of the affected area the balloon 
is then lined up next to the plaque and then inflated resulting in flattening of 
the plaque within the walls of the artery. This will reopen the artery and 
blood flow will be restored. To keep the artery re-opened a stent (short tube 
of stainless steel mesh) can be inserted, usually same time as the balloon. 
Different types of stents can be used, with the main type being the drug-
eluting stents and bare-metal stents. If the narrowed region of the vessel is 
not responsive to this approach then bypass surgery is implemented, that 
is CABG. CABG surgery  involves bypassing the narrowings in the coronary 
arteries(27).  
 
 As described in §1.5 for STEMI patients’ prompt diagnosis and timely 
treatment is required thus they receive PPCI (performed within 12 hours 
from symptom onset)(22). However if this is not possible immediate 
fibrinolysis or thrombolysis should be performed. Both procedures involve 
the enzymatic dissolution of blood clots.   
1.5.2.3 Invasive vs. conservative strategy for NSTEMI 
NSTEMI patients can be treated by two approaches that is the invasive care 
(plus cardio-protective drugs) approach or the conservative strategy(4). The 
conservative strategy patients are initially treated with the drugs only and 
only those that persist with ischemic symptoms or ongoing artery narrowing 
(noted via stress testing or imaging) undergo coronary angiography and 
revascularisation(4). NSTEMI patients in whom invasive care is withheld as 
indicated by the guidelines include the very elderly/frail patients, patients 
with comorbidities such as dementia, severe chronic renal insufficiency or 
cancer and those at high risk of bleeding complications(4). 
 
1.5.3 Risk assessment   
Accurate risk assessment is essential in the treatment of AMI patients; 
especially for NSTEMI patients where after diagnosis further treatment is 
based on responsiveness to anti-anginal treatment and risk of mortality(4). 
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The Global Registry of Acute Coronary Events (GRACE) risk score is the 
most commonly used risk score as it is derived from an international registry 
(approximately 100,000 patients in 30 countries) of “real world” patients and 
is applicable to all types of ACS types predicting short and long-term 
mortality(28). Timely risk stratification is vital as the benefits of aggressive 
treatment are mainly observed in those at higher risk of adverse clinical 
events(21, 29, 30). Use of the risk score allows for easier identification of 
the high risk patients by clinicians at time of presentation(28).  The GRACE 
risk score prediction model includes eight predictors namely: age, heart 
rate, systolic blood pressure, renal function, congestive heart failure, ST-
segment deviation, cardiac arrest and elevated biomarkers(28). The risk 
score is recommended for use by both the ESC and National Institute for 
Health and Clinical Excellence (NICE)(4, 16). However, NICE utilises a 
modified version of the GRACE risk score in which the model uses 
“prescription of a loop diuretic during admission” as a surrogate for Killip 
class and creatinine concentration re-coded as a categorical variable. This 
version of the score was termed adjusted mini-GRACE risk score(31).  
 
1.5.4 Cardiac rehabilitation  
Following an AMI, hospital stay is usually a few days and the patient can 
usually go back to normal daily life within a few weeks. However to prevent 
hospital readmissions the patients are enrolled into cardiac rehabilitation as 
indicated by the guidelines(4, 22). Cardiac rehabilitation is characterised by 
detailed and evidence-based plan of care that promotes medication 
adherence, timely follow-up with the healthcare team, appropriate dietary 
and physical activities. Patients are also educated on the importance of 
stopping smoking as well as avoiding second-hand smoke. 
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1.6 Data sources for validation of mortality, morbidity and 
treatment of AMI 
There are several data sources that provide information on mortality, 
morbidity and treatment of AMI namely: Office for National Statistics (ONS) 
(mainly mortality data), Clinical Practice Research Datalink (CPRD), 
Hospital Episode Statistics (HES), British Cardiovascular Intervention 
Society (BCIS), ResearchOne database, and Myocardial Ischaemia 
National Audit Project (MINAP) (Table 1.1). The use of these data sources 
for research is governed by several factors which include: 
representativeness, relevance, quality and accessibility of the data.
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Table 1.1 Characteristics of the data sources commonly used in the evaluation of mortality, morbidity and treatment of AMI.  
Data source 
Characteristic MINAP  CPRD*  ONS 
(mortality 
statistics) 
ResearchOne HES BCIS  
Type of data source  Nationwide register 
for acute coronary 
syndrome    
Primary healthcare 
database  
National 
death 
data  
Pseudo-anonymous 
clinical research 
database  
National hospital 
episodes 
database  
Nationwide registry of all 
percutaneous coronary 
intervention (PCI) 
procedures. 
Who is included Patients admitted 
with ACS in 247 
NHS hospitals   
Patients registered with 
participating GP practices 
in the UK 
All deaths Patient data from 
primary and secondary 
healthcare providers 
which include: 
 General 
practice 
 Child health 
 Community 
care 
 Palliative 
hospital  
 Out of Hours  
 Urgent care 
 Accident & 
Emergency 
 Acute hospital 
 Social services  
Hospitalisation 
data of all 
admitted patients 
in NHS trusts. 
All patients admitted to 
all hospitals performing 
PCI in the UK. 
Year start of data 
collection  
2000 1987 2001 2013 1989 1994 
Area covered  England and 
Wales  
England, Wales, Northern 
Ireland and Scotland  
England 
and 
Wales  
England  England UK 
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Data source 
Characteristic MINAP  CPRD*  ONS 
(mortality 
statistics) 
ResearchOne HES BCIS  
Data description    Patient 
demographics 
 Admission 
method  
 Clinical 
features and 
investigations  
 Medical history  
 Drug treatment 
in-hospital and 
at discharge 
 Clinical 
complications  
 Interventional 
treatments  
Collected across 
130 fields.   
 Patient 
demographics 
 Prescriptions 
details   
 Preventive care 
provided 
 Specialist referrals  
 Immunisations 
 Behavioural 
factors  
 Tests  
  lifestyle factors 
 Clinical events 
(symptoms, 
diagnoses) 
Date and 
cause of 
death. 
 Diagnostic 
codes  
 Procedure 
codes  
 Pathology test 
data 
 Prescribing 
data  
 Deprivation 
indices  
 Care pathways  
All admissions, 
outpatient 
appointments, 
patient reported 
outcome 
measures, adult 
critical care, A&E 
attendances and 
mortality data. 
 Patient 
demographics 
 Indications for 
PCI 
 Procedural 
details  
 Outcomes 
Collected across 113 
fields. 
Representativeness 
of the data 
MINAP records 
most of the STEMI 
cases, however 
fewer NSTEMI 
cases in England 
and Wales.  
Approximately 6.9% of the 
UK population. 
All death 
records 
for 
England 
and 
Wales  
A representative 
sample of the English 
population (~26 million 
patients) 
Representative of 
all the 
hospitalised 
population as it 
covers all NHS 
trusts in England, 
including acute 
hospitals, primary 
care trusts and 
mental health 
trusts.  
All hospitals performing 
PCI in the UK. (>97% of 
PCI cases are included 
in the audit). 
*Clinical Practice Research Datalink (CPRD)(32) has taken on the original work of GPRD since 2012. 
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1.6.1 CPRD 
1.6.1.1 Overview  
The CPRD is a primary care database that was set up from the General 
Practice Research Database (GPRD) in 2012, with GPRD having been 
started in 1987(32). Data from this database is collected (on-going) from 
674 practices in the UK (approximately 11.3 million coverage), to date with 
4.4 million of the recorded patients being considered as active(32). Patient 
information collected includes: demographics, symptoms, tests, diagnoses, 
therapies, health-related behaviours and referrals to secondary care(32). 
Data is collected in participating GP practices during normal clinical care 
and the data is then transferred to the CPRD servers monthly(32).     
1.6.1.2 Strengths  
Key strengths of CPRD data include: 
 Breadth of coverage, i.e. CPRD database is one of the few large 
databases that collect data including morbidity and life-style data 
with linkage to secondary care and mortality data.   
 Size, i.e. to date CPRD database has information on approximately 
11 million patients, with 4.4 million of them being active (alive, 
currently registered). 
 Long term follow-up, i.e. the median follow-up time for the active 
patients is 9.4 years (interquartile range (IQR) 3.4-13.9) and for the 
overall patient population in CPRD (including the inactive ones) is 
5.1 years (IQR 1.8-11.1years). 
 Representativeness, i.e. the patients recorded in CPRD were found 
to be representative of the UK population in terms of age and sex 
when compared to the UK census carried out in 2011. 
 Data quality, i.e. the Quality and Outcomes Framework (33) 
launched in 2004 has prompted an improvement in recording of data 
in the English general practice and also CPRD data is maintained by 
high standard validation checks supported by independent 
studies(34).       
1.6.1.3 Weaknesses  
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As with other sources of data arising from electronic health records (EHRs), 
the major weakness that CPRD database has is missing data and dealing 
with the missing data for researchers can prove challenging as missing data 
patterns are complex(32). The missing data include, data from over the 
counter prescriptions and morbidities in which the patient does not require 
GP consultation. Another weakness of the CPRD data is misclassification, 
i.e. the absence of a read code for disease is interpreted as an absence of 
the disease(34). This usually arises as a result of either patients failing to 
present to the GP with the disease or variation between GPs in coding 
diagnoses of the diseases(34).   
 
1.6.2 BCIS  
1.6.2.1 Overview  
The British Cardiovascular Intervention Society (BCIS) registry  is a 
nationwide registry for all PCI procedures performed in the UK(35). The 
registry was initiated when the BCIS was started in 1988(35). The main 
aims of society included creating an all-encompassing and accurate registry 
of all PCI procedures done in the UK, in order to allow for audit by assessing 
quality of care and driving improvements, and also to provide data for 
research(35, 36).  Data collection at time of commencement was for 
descriptive survey purposes which developed over time with the aid of the 
electronic methods for data collection developed by the Central Cardiac 
Audit Database (CCAD) group(35). Full UK-wide involvement was reached 
in 2005(35). In March 2010 it was reported that BCIS-CCAD database had 
approximately 460,000 patient records, with an estimated annual addition 
of 80,000 new patient records(35).  
Patient information is collected across 113 fields in the BCIS registry and it 
includes information on: patient demographic features and identification 
information, indication for PCI, details of the PCI operators, technical 
aspects of the PCI procedure and adverse outcomes/complications(35). 
Data entry is done by healthcare professionals and data entry clerks(35). 
The data is uploaded into local software systems (e.g. the Lotus Notes 
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software and Microsoft Access database), encrypted and transferred to 
CCAD data servers(35). Mortality data is added through linkage with ONS 
by the Medical Research Information System (MRIS) using the patients’ 
unique NHS numbers(35).   
1.6.2.2 Strengths  
Key strengths of BCIS data include: 
 Size and population coverage, i.e. BCIS database contains all PCI 
procedures performed UK-wide and in March 2014 it was reported 
to have approximately 747,000 patients recorded.  
 Data quality, i.e. in the course of uploading the data to central servers 
internal checks for consistency and range checks are done to ensure 
the data is of high quality. Log files of serious errors are kept to allow 
for cleaning and correction, and re-uploading.   
 Depth of detail of the data    
1.6.2.3 Weaknesses  
Major weaknesses when using BCIS data include: 
 Outcome data, i.e. death data acquired through linkage to ONS data 
is all-cause death and not cause specific.  
 There are no independent data validation checks for BCIS data. 
  Missingness in some data fields. 
 
1.6.3 ResearchOne 
1.6.3.1 Overview  
ResearchOne is a comprehensive pseudo-anonymised clinical research 
database which was launched in February 2013(37, 38). ResearchOne is 
potentially one of the largest databases in the world (containing 
approximately 28 million records held on the TPP SystmOne clinical 
system), with the data recorded in it being from various settings in England 
i.e. from both primary and secondary care providers (General Practice, 
Child Health, Community, Palliative Hospital, Out of Hours, A&E and 
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Community Hospital)(38). Approximately, 5 million health records (non-
identifiable) were approved and became available for researchers in 2013. 
Over 400 organisations are active members contributing towards data for 
ResearchOne and data is collected from them weekly. The data collected 
includes diagnostic codes, procedure codes, pathology test data, 
prescribing data, deprivation indices and care pathways. ResearchOne was 
created with the aim to establish a clinical database that enables high 
quality research that will result to improvement in patient care and health 
services(38). Projects currently supported by ResearchOne carrying out 
this type of research include Medical Research, Health Services Research 
and eHealth Research.  
1.6.3.2 Strengths  
 ResearchOne offers the opportunity to utilise integrated electronic 
health records that allow investigation of health care through a whole 
systems approach i.e. allows for longitudinal assessments.   
 Representativeness, i.e. the sample of patients recorded in 
ResearchOne was derived from a representative sample of the 
English population (extracted from over 26 million patients 
(approximately 300 million years of patients records) hosted in 
SystmOne from 4500 organisations that include 2100 general 
practices, 170 community services and 80 palliative care 
organisations).  
 Large sample sizes, i.e. five million health records were made 
available for researchers in 2013. 
 Depth of detail of the data, i.e. ResearchOne has consolidated data 
from various sources that are involved in patients care.  
 Data linkage is possible with ResearchOne data i.e. ResearchOne 
has national ethical and governance approval to request linkage.  
 Was created with the aim to improve patient healthcare. 
 Timely data i.e. ResearchOne is updated weekly. 
 
1.6.3.3 Weaknesses  
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 Accessibility of integrated EHRs is still quite difficult thus infrequent 
use of such data sources.  
 ResearchOne requires consent from contributing organisations 
(based on the “provider opt-in” model). Patients also have the 
opportunity to opt out from providing non-identifiable data through 
the “patient opt-out” mechanism. This may compromise 
ResearchOne data representativeness due to data exclusion of the 
non-consenting organisations or patients from ResearchOne 
database.    
 
1.6.4 MINAP  
1.6.4.1 Overview  
MINAP is a nationwide registry of ACS patients admitted to one of the 247 
National Health Service (NHS) hospitals in England and Wales(39). MINAP 
was started in 2000 and is now mandated by the Department of Health(39). 
The registry was started for auditing purposes for hospital performances 
against the National Service Framework for Coronary Heart Disease. Data 
are collected prospectively at each hospital and transferred online to a 
central database electronically encrypted(39). The CCAD(40) manages and 
stores the data for up-to-date analysis and dissemination.  
The ACS patients’ information recorded in MINAP is collected across 130 
fields, with the information including the method and timing of admission, 
patient demographics, patient medical history, inpatient investigations, 
results and treatment, hospital outcome, and (if applicable) date of death 
from linkage to the ONS(8, 39). Every two years the registry is revised 
taking into account developments that would have occurred in ACS 
management as well requirements of the users of the dataset(39). This 
process includes adding new options to the registry and archiving old fields 
that would have become redundant. MINAP’s major application, is being an 
auditing tool for assessing ACS management in participating hospitals and 
benchmarking against guidelines(39).   
1.6.4.2 Strengths  
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Key strengths of MINAP data include: 
 Size and population coverage, i.e. data is collected from every acute 
hospital in England and Wales (247 hospitals) and participating 
hospitals are required to enter all patients with suspected MI(8). 
Annually, approximately 90,000 records are uploaded and to date 
the registry contains over 1.25 million records, potentially making it 
the largest database of its kind in the world(8).  
 Representativeness, i.e. data in MINAP is collected from 247 acute 
hospitals in England and Wales. 
 Definition of AMI phenotype, i.e. compared with other data sources, 
MINAP is the only database that distinguishes between STEMI and 
NSTEMI.  
 Data quality, i.e. MINAP data application has error-checking routines 
as well yearly data validation exercises. Guidance is given to staff 
entering via a dedicated telephone help desk. 
 Completeness, i.e. in 20 key fields completeness is closely 
monitored and is above 99%, these fields include hospital mortality, 
hospital discharge diagnosis, NHS number and secondary 
prevention prescription at hospital discharge. An assessment carried 
out in 2008 showed that in the other fields completeness was over 
80%.  
 Depth of detail of the data, i.e. data is collected across 130 fields in 
MINAP. Data on method and timing of admission, patient 
demographics, patient medical history, inpatient investigations, 
results and treatments, hospital outcome and date of death through 
linkage to ONS.      
1.6.4.3 Weaknesses  
Major weaknesses when using MINAP data include: 
 Case ascertainment, i.e. MINAP reports great majority of patients 
having STEMI, however there is under-reporting of NSTEMI patients 
in MINAP. This is mainly due to the difficulty in diagnosing NSTEMI, 
heterogeneous pathways of care for NSTEMI as well the fact that 
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some NSTEMI patients are not always admitted to cardiology wards. 
The 2012 MINAP report, reported that HES data captured 
approximately 105,000 MI hospital admissions annually with MINAP 
reporting 30,000 STEMIs admissions vs. only 50,000 NSTEMIs 
admissions annually. However the actual expected appropriate 
number of NSTEMI admissions annually is around 80,000.  
 Missingness in some data fields, i.e. although completeness of key 
20 fields which collect data on discharge diagnosis, NHS number, 
hospital mortality and secondary prevention medication on discharge 
has been reported to be > 95%, missingness in the other data fields 
has been reported to range between 31-80%(39) 
 Outcome data, i.e. death data acquired through linkage to ONS data 
is all-cause death and not cause specific.  
 
1.6.5 HES 
1.6.5.1 Overview  
Hospital Episodes Statistics (HES) is a data warehouse established in 1987 
and  it comprises of six datasets namely; inpatient, outpatient, accidents 
and emergencies (A&E), patient reported outcome measures (PROMs), 
adult critical care, and mortality data(41). The inpatient dataset contains all 
admissions to NHS hospitals in England from 1989 onwards (approximately 
over 16 million episodes annually). The  outpatient dataset contains 
information on all outpatient of hospital appointments of the patients from 
2003 onwards (approximately 60 million new records annually), and the 
A&E dataset contains diagnosis, investigations and treatment codes for all 
A&E visits from 2007 onwards (approximately 12 million records 
annually)(41). The mortality dataset was created by linkage to ONS 
mortality data. The PROMs dataset contains information reporting 
outcomes and  quality of care from the patients’ perspective for four 
procedures, namely: hip replacement, knee replacement, varicose vein, 
and groin hernia surgery from 2009 onwards(41). The critical care dataset 
contains all records for adult patients’ critical care hospital stays(41). Private 
patients treated in NHS hospitals are also included in HES.  
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Patient information recorded in HES include: demographics (age group, 
gender and ethnicity), diagnoses and operations, administrative information 
(time waited, dates and methods of admission and discharge) and 
geographical information (where patients are treated and where they 
live)(41). HES data was developed for several functions which include: 
 studying the epidemiology of hospitalised disease  
 monitoring trends and patterns in NHS hospital activity  
 assessing effectiveness of delivery of care in hospitals 
 revealing health trends over time 
 determining fair access to health care  
 Hospital payments  
 developing, monitoring and evaluating government policy(41). 
HES data was derived from the regular exchanges of information between 
providers and commissioners of healthcare for NHS patients in 
England(41). Providers submit the data to the Secondary Uses Service 
(SUS), which makes it available to commissioners as well as being copied 
to a database(41). Data extraction for HES  is done monthly at pre-arranged 
dates from the SUS data warehouse(41). Providers are allowed to update 
their monthly submissions in a process called an annual refresh(41). 
 
Three set of codes are used when collecting HES data (World Health 
Organisation International Classification of Diseases Tenth Revision (ICD-
10), Office of Population, Census and Surveys Classification of 
Interventions and Procedures fourth revision (OPCS-4), and A&E Clinical 
Codes)(41). The ICD-10 codes are used for collecting data for hospital 
admission treatment (inpatient data), OPCS-4 codes for data collection for 
procedures and interventions performed and the A&E clinical codes for data 
collection for diagnoses, investigations and procedures during A&E 
attendance.   
 
Data is recorded in HES as finished consultant episodes (FCE), i.e. “time a 
patient spends under the care of each consultant”. A patient can have one 
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or more FCEs per hospital admission if the patient is treated by more than 
one consultant. In the case that a patient has several FECs, they can be 
grouped together to form spells, i.e. total number of FCEs per single hospital 
admission for a patient(41).    
1.6.5.2 Strengths  
Key strengths of HES data include: 
 Size and population coverage, i.e. annually, HES data processes 
over 125 million admitted patient, outpatient and A&E records 
(unselected sample of hospital episodes). 
 Representativeness, i.e. data in HES is collected from all NHS trusts 
in England, including acute hospitals, primary care trusts and mental 
health trusts. 
 Data quality, i.e. HES data extraction involves thorough procedures 
and checks. Upon receipt of the data, the data quality team cleans 
and validates the data in four stages; 1) provider code mapping 
(which involves ensuring that the hospital codes are correct and 
usable), 2) duplicate removal, 3) data cleaning (involves removal of 
errors in the dataset for example extra characters in the codes) and 
derivations (involves cleaning common and obvious data quality 
errors as well as deriving additional data items to populate the HES 
dataset(41). 
 Longitudinal linkage, i.e. HES can be linked to other datasets using 
the HESID and the long period of data collection of approximately 19 
years allows for long-term follow-up.  
 Use of International Classification of Disease (ICD-10) coding of the 
data allows for international comparisons since ICD-10 coding is 
used across UK, Europe, Canada, Australia and New Zealand. 
1.6.5.3 Weaknesses  
 The major challenge when using HES data is that the data are mainly 
collected for purposes of administering the health service and not 
specifically for research purposes as such there maybe limitations to 
the usefulness of this data for research purposes(42). 
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 Inaccurate diagnostic coding practices as coding may vary between 
hospitals(42).    
 As with other sources of data arising from EHRs, HES data has 
missing data and incomplete records(42).  
 Data on drugs prescribed through hospital pharmacies to in-patients 
is not available in HES.  
 
1.6.6 ONS 
1.6.6.1 Overview  
In the UK the ONS is the source of mortality statistics as well as the 
database for mortality data and main diseases or injuries causing death. 
The ONS was created in April 1996 from the merger of the “Central 
Statistics Office” (CSO) and the “Office of Population Census and Surveys” 
(OPCS)(43). The ONS provides a wide range of statistical information which 
includes national accounts, measures of inflation, business statistics, labour 
market indicators, vital statistics on births, marriages and deaths, and 
population estimates and projections(43). However for the purpose of this 
thesis work, the description of ONS will be restricted to the mortality data 
information. The Births and Deaths Act 1836 made it a legal requirement 
for all deaths to be registered from July 1837(44). The mortality statistics 
are derived from information when deaths are certified and registered(45). 
The medical practitioner using the Medical Certificate of Cause of Death 
certifies most deaths. An informant, usually   a relative of the deceased then 
takes the certificate to the registrar. Most of  deaths are registered this way, 
with a quarter of the deaths being certified by the coroner(45).  The death 
registration is recorded on an online system (Registration Online (RON)) by 
the registrars. The death data are coded using the ICD-10 coding system 
(since January 2001 in England and Wales), which allows for international 
comparisons(46). The underlying cause of death recording is governed by 
the recommendation of the World Health Organisation, i.e. defined as; 
 the disease or injury that initiated the train of events directly leading 
to death 
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 the circumstances of the accident or violence that produced the fatal 
injury(45). 
To ensure that the data are usable for analysis, the data pass through a 
series of automated validation processes which highlight any 
inconsistencies(45). The validation checks include; identification of missing 
data entries, checking for duplicates, misplaced records, checks on 
registrars who have not sent over their data by the recommended time and 
for paper records checking for completeness and correct death date vs. 
registration date ranges(45). The ONS has developed guidelines for 
measuring statistical quality which are based on five European Statistical 
System Quality Dimensions to aid quality output from ONS data(45). 
1.6.6.2 Strengths      
 Representativeness, i.e. the Births and Deaths Registration Act of 
1836 made it compulsory  for all deaths to be registered from July 
1837.  
 ONS data not only records date and place of death, but also cause 
of death. Thich enables a better understanding of specific diseases 
in the death process.    
  Use of International Classification of Disease (ICD-10) coding of the 
data allows for greater consistency and easier comparison.  
1.6.6.3 Weaknesses  
 Mortality data made available in registries  like MINAP is all-cause 
mortality  data. 
 A small proportion of deaths are labelled ‘uncertified’ and these 
include deaths for which the doctor who completed the medical 
certificate would have not fulfilled all the legal requirements for 
completing the medical certificate.  
 Recording of multiple causes of death can result to biased 
recording of underlying cause of death, i.e. some conditions are 
always selected as the underlying cause of death whenever they 
appear on the medical certificate for example major cancers and 
acute cardiovascular events (myocardial infraction and stroke). 
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Chapter 2 : Literature Review 
Quality of care and outcomes of AMI patients 
2.1 Introduction  
The ESC and ACC/AHA have published consensus guidelines to define 
ACS care and promote the use of the evidence-based therapies as defined 
earlier in Chapter one(4, 20-24). Despite the evidence of efficacy of the 
guideline indicated care interventions, sub-optimal adherence still remains 
a major public health concern(47-49). In this chapter, I provide a systematic 
literature review of the existing evidence on the prevalence of adherence to 
guideline indicated care for AMI patients, predictors of poor adherence and 
associated outcomes. 
 
Chapter 2 is structured such that the first section comprises of the search 
strategy implemented (§2.1.1), followed by the results of the search 
conducted §2.1.2. A detailed discussion on the existing evidence (§2.1.3) 
follows the results section, followed by a critical appraisal of literature (§2.2), 
summary of the gaps in knowledge and the PhD aim (§2.3). The chapter is 
concluded by highlighting the study objectives (§2.3.1). 
 
2.1.1 Methods  
The literature review was undertaken on three databases: Medline (1946-
2016), Embase + Embase classic (1946-2016) and Google scholar (2005-
2016). The literature search was based on the research question “What is 
the available evidence regarding combined use (optimal medical therapy) 
of guideline recommended care for AMI patients and associated 
outcomes?” The question was broken down using the PICO (Population – 
AMI, Intervention – guideline indicated care, Comparison (not used as there 
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was no comparator) and Outcomes - mortality) (50) approach to literature 
reviews. The search was conducted using keywords and medical 
subheadings of the three categories derived from PubMed given in Table 
2.1. 
Table 2.1 List of the literature review key words using the PIO strategy. 
Patient  Intervention  Outcome  
Acute coronary syndrome* Optimal medical therapy Mortality 
ACS Optimal medical treatment Survival 
Acute myocardial 
infarction 
Combined therapy Death 
AMI Combined medical therapy Dead 
Myocardial infarction Guideline recommended 
care 
Premature mortality 
MI Evidence based care Premature death 
Heart attack* Process measure* Outcome* 
Infarct, Myocardial Performance measure*  
Myocardial Infarcts Guideline indicated care*  
 Early intervention  
 Evidence-based practice  
 Policy compliance  
 Compliance, policy  
 Protocol compliance  
 Compliance  
 Adherence  
 Health care quality  
 Quality of healthcare  
Abbreviations: AMI; acute myocardial infarction, ACS; acute coronary syndrome. 
 
2.1.2 Results  
Initially, 105 citations were obtained from Medline, 183 from Embase + 
Embase classic and 35 from Google scholar. From these three databases 
a total of 273 articles were obtained. 127 articles were excluded after 
screening for duplication using Endnote, giving a total of 146 non-duplicate 
papers. Considering the title and abstract 70 articles were excluded from 
the 146 to give a total of 76 articles. An eligibility criteria which comprised 
as listed below was set up to further screen the articles:  
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 Include adult studies only (aged >18 years) 
 Include English language and human studies only 
 Include studies that assess adherence to guideline indicated care 
interventions  
 Exclude studies investigating single-drug effects for the 
management of AMI 
 Exclude articles that are not full text for example published 
conference abstracts 
 Exclude all case studies.  
Thirty articles were excluded as they were focusing on efficacy of individual 
care interventions and did not assess adherence to optimal/combined 
guideline indicated care. After full text review of 46 papers, 17 papers were 
excluded to give a resultant 29 articles for literature reviewing. The details 
of the papers filtering are shown in Figure 2.1. Table 2.2-Table 2.5 provide 
the details of the key papers that were considered relevant for this present 
research study. 
 
 
 
 
 
 
 - 29 -  
 
 
Figure 2.1. Flowchart for literature search and filtering.
 - 30 -  
 
 
2.1.3 Summary of findings from literature  
2.1.3.1 Prevalence of adherence to guideline indicated care for AMI  
Of the 29 studies retrieved from the literature search, 11 quantified the 
prevalence of receipt of Optimal Medical Therapy (OMT) (receipt of all 
guideline indicated care interventions the patients’ were eligible for). 
Receipt of OMT in the studies was low (median 46.2%, IQR 29.1-49.4%) 
(Table 2.2), with OMT being defined as receipt of all the five main 
pharmacotherapy drugs (ACEi/ARBs, β-blockers, statins, aspirin and P2Y12 
inhibitors,  unless contraindicated at hospital discharge)(51-61). Only one 
study defined OMT including reperfusion as well(59). Assessing long term 
(one year) adherence of the cardio-protective drugs after hospital 
discharge, OMT adherence rates were noted to be as low as 18.2%, with 
non-adherence to aspirin, β-blockers, ACEi/ARBs or statins individually 
being shown to be approximated 50%(60). Comparing 6 months follow-up 
with 12 months follow up, Bi et al.(54) found that OMT declined from 48% 
to 41%, with marked reductions for clopidogrel (25%) and combination of 
antiplatelets (21%)(54). Despite poor receipt of OMT individual prescription 
of the cardio-protective medication was very high, with one study reporting 
84% of the eligible patients receiving statins, 89% aspirin, 70% P2Y12 
inhibitors, 90% β-blockers and 81% ACEi / ARBs at hospital discharge and 
other studies showed similar findings(51, 59, 62).
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Table 2.2 Literature reviews on studies assessing prevalence of adherence to guideline indicated care for AMI patients.   
Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis  Key findings 
Bramlage 
et al (2010) 
Germany Nationwide 
registry 
(February 
2003 and 
October 
2004). 
Patients with 
AMI (STEMI or 
NSTEMI) 
admitted to 79 
hospitals with a 
cardiology unit 
or internal 
medicine 
department. 
SAMI 
(N=5353) 
Pharmacotherapy 
use at hospital 
discharge 
(Optimal medical 
therapy (OMT): 
aspirin, 
ACEi/ARB, β-
blockers, statin 
and clopidogrel, 
unless 
contraindicated) 
Medication 
adherence.   
Data summarised as 
frequencies and 
percentages. 
At hospital discharge 89% of the 
patients received aspirin, 90% β-
blockers, 84% statins, 81% ACEi 
/ ARB, 70% clopidogrel and 
46.2% OMT. 
 
Rasmussen 
et al (2007) 
Canada Population-
based, 
observational, 
longitudinal 
study (April 1, 
1999 and May 
1, 2003). 
Elderly (aged 66 
years or older) 
AMI survivors 
(surviving at 
least 1 year 3 
months after 
hospitalization) 
recorded in the 
Ontario 
Myocardial 
Infraction 
Database 
(N=31,455) 
Pharmacotherapy 
medication use 
following hospital 
discharge after 
AMI (β-blockers, 
statin and calcium 
channel blockers). 
Medication 
adherence.   
Data summarised as 
frequencies and 
percentages, and 
means and standard 
deviations (SD). 
Mean 1-year adherence rates, as 
determined 
by the PDC, were 87.5% (SD, 
20.5%) for statins, 83.9 (SD, 
24%) for 
β-blockers, and 78.9 (SD, 28.8%) 
for 
calcium channel blockers.  
 
Within the entire median 2.4 
years follow-up time 13.2% 
(Statins), 19.6% (β-blockers) and 
33.5% (calcium channel blockers) 
of patients permanently 
discontinued treatment. 
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis  Key findings 
Chew et al 
(2009) 
Australia Nationwide 
registry 
(November 
2005 and May 
2006). 
Large-scale 
randomised 
clinical trials 
or meta-
analyses. 
AMI (STEMI or 
NSTEMI) 
admissions from 
39 hospitals 
across Australia 
recorded in 
ACACIA. 
(N=1,630) 
Pharmacotherapy 
use at discharge 
(aspirin, statin, 
clopidogrel, 
ACEi/ARBs and 
β-blockers). 
Timely 
management for 
STEMI (timely 
reperfusion and 
early invasive 
management with 
concomitant 
glycoprotein 
IIb/IIIa inhibition). 
 
Timely 
management for 
NSTEMI (timely 
use of invasive 
management and 
glycoprotein 
IIb/IIIa inhibition). 
Medication 
adherence 
and 
revasculari
sation.    
Data summarised as 
frequencies and 
percentages. 
26% of the patients received less 
than four guideline-indicated 
chronic pharmacotherapies. 
13.5% of the STEMI patients 
received optimal care. 
12.4% of the NSTEMI patients 
received optimal care. 
4% of the entire population 
received optimal care 
(discharged on four or five drugs) 
and maintained late adherence. 
 
Bauer et al 
(2010) 
Germany Multicentre, 
prospective, 
observational 
study. (June  
2000 and 
November  
2002) 
Hospital 
survivors of AMI 
(STEMI or 
NSTEMI) from 
155 hospitals 
enrolled in the 
ACOS registry.  
(N=11,823) 
Five discharge 
medication drugs: 
acetyl salicylic 
acid, clopidogrel, 
β-blockers, ACEi/ 
sartan and statin. 
Dichotomised 
receipt of care 
Medication 
adherence.   
Data summarised as 
frequencies and 
percentages. 
 
29.1 % (3,439) eligible patients 
received < four drugs. 
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis  Key findings 
composite score 
i.e. patients 
receiving < 4 
drugs (group 1) or 
receiving 4-5 
drugs (group 2). 
Bi et al 
(2009) 
China Multi-centre 
prospective 
study. 
(September  
2004 and May 
2006) 
Patients 
diagnosed with 
suspected AMI 
or UA admitted 
to 51 hospitals 
participating in 
CPACS. 
(N=2,973 ; 
n=345  NSTEMI, 
n=1,251 UAP 
and n=1,305 
STEMI) 
Four drug 
combination 
therapy: 
antiplatelet, β-
blockers, ACEi/ 
ARB and statin. 
Medication 
adherence   
Data summarised as 
frequencies and 
percentages. 
 
Almost half (48%) of the eligible 
patients received the 4-drug 
combination therapy at 
discharge, with the proportion 
decreasing to 44% at 6 months 
and to 41% at 1-year follow-up. 
Individual prescription of the 
cardio-protective drugs at 
discharge was high (> 90% for 
aspirin, 70% for β-blockers and 
ACEi, and 80% for statin) with the 
exception of clopidogrel (44.6%). 
Decreasing at 6 months follow-up 
((88% for aspirin, 72% for β-
blockers, 60% ACEi, 35% for 
clopidogrel and 66% for statin) 
with a further reduction at 1 year 
follow-up (87% for aspirin, 70% 
for β-blockers, 61% ACEi, 19% 
for clopidogrel and 59% for 
statin).  
Yan et al 
(2007) 
Canada Prospective, 
multicentre, 
observational 
study 
51 hospitals 
participating in 
Canadian ACS 
registry I 
Pharmacotherapy 
 (antiplatelet/ 
anticoagulant, β-
blockers, ACEi 
Medication 
adherence. 
Temporal 
changes in 
Data summarised as 
frequencies and 
percentages. 
Overall, 35.6% (2,091) received 
optimal care at discharge. 
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis  Key findings 
(September 
1999-June 
2001 and 
October 2002-
December 
2003). 
(N=5,312; 
n=4,627 ACS) 
36 hospitals 
participating in 
Canadian ACS 
registry II 
(N=2,359; 
n=1,956 ACS) 
and lipid 
modifying 
therapies) 
 
medical 
manageme
nt. 
 
Differences in 
continuous and 
categorical data 
were compared 
using the Mann-
Whitney U test and 
χ2 test (or χ2 for 
trend, where 
appropriate) 
Comparing the receipt of care  
between ACS I vs ACS II an 
increase was noted (optimal care 
28.9% and 51.8%, antiplatelet/ 
anticoagulant 94.1% vs 94.3%, β-
blockers 76.9% vs 85.3%, ACEi 
56.4% vs 67.0% and lipid 
modifying therapies 55.4% vs 
83.5%, respectively; p-value 
<0.001)  
 
The rates of optimal care were 
similar at discharge and at 1 year 
(P = 0.46), however use of 
antiplatelet/anticoagulant (P = 
.002), β-blocker (P < 0.001), and 
ACE inhibitor (P = 0.01) therapies 
declined, whereas the use of lipid 
modifying agents increased (P < 
0.001). 
Tuppin et al 
(2009) 
France Analysis from 
a large 
administrative 
database. 
(January –
June 2006) 
All 
hospitalizations 
from January to 
June 2006 with 
a diagnosis-
related group of 
MI  were 
selected from 
the PMSI health 
insurance 
Cardio-protective 
medication 
(antiplatelet 
drugs, ACEi\ 
ARBs, statins and 
β-blockers). 
 
Post 
hospital 
discharge 
adherence 
to 
combined 
medication 
6 months 
after 
hospital 
admission. 
Data summarised as 
frequencies and 
percentages. 
 
After hospitalisation 82% of the 
patients were reimbursed for β-
blockers, 92% for antiplatelets, 
85% for statins, 80% for 
ACEi/ARBs, 80% clopidogrel, 
84% aspirin, 72% both (aspirin 
and clopidogrel) and 62% for all 
four classes of drugs. 
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis  Key findings 
scheme 
(N=11,671) 
Amar et al 
(2008) 
France Nationwide 
cross-
sectional 
PREVENIR-4 
study (2006) 
 
Patients 
recruited by 621 
cardiologists in 
all French 
regions 
(N=1700) 
Combination 
therapy consisting 
of β-blockers, an 
antiplatelet, 
statins and ACEi 
(BASI) 
Long term 
adherence 
persistence 
of BASI in 
‘real world’ 
patients   
Data summarised as 
frequencies and 
percentages.  
Individual drug prescription at 
discharge had an intermediate to 
high variation that 82.4% of the 
patients were prescribed β-
blockers, 98.9% antiplatelets, 
89.2% statins and 58% ACEi. 
Persistence to adherence to the 
drugs was greater than 86% 
during follow-up to consultation 
time (14±4 months).   
 
Combination medical therapy 
was initiated in 46.2% of the 
patients, of whom 80.2% were 
persistent to adherence during 
follow-up to consultation time. 
Dachin et 
al (2005) 
France Nationwide 
French 
registry 
(November 1-
November 30 
2000) 
Forty-three 
university 
hospitals, 229 
public hospitals 
and 97 private 
clinics. 
USIC 2000 
study. 
(N=2,119 AMI) 
OMT 
(combination of 
antiplatelets 
agents, β-
blockers and 
statins (triple 
therapy)). 
Medication 
adherence 
Data summarised as 
frequencies and 
percentages. 
 
Of the 2,119 patients discharged 
alive, 52% (1,095) were 
prescribed a combination of 
antiplatelet agents, β-blockers, 
and statins (triple therapy) 
 
Longeneck
er et al 
(2013) 
6 middle 
eastern 
countries
: Bahrain 
Prospective 
cohort study 
(January-June 
2007) 
72 hospitals, 
Gulf GRACE 
(N=5,813 AMI) 
Performance 
measure: 
Adherence 
to 
performanc
Data summarised as 
frequencies and 
percentages. 
 
Optimal care was provided to 
40.4% of the patients. 
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis  Key findings 
Kuwait 
Qatar 
Oman 
United 
Arab 
Emirates 
and 
Yemen 
aspirin and β-
blockers within 24 
h on admission 
 aspirin, β-
blockers and 
ACEi\ ARB and 
lipid lowering 
therapy on 
discharge 
Indicated 
reperfusion 
therapy 
Measurement of 
LDL cholesterol 
levels during 
hospitalisation. 
OMT derived as a 
composite score 
e measures 
for AMI. 
 
Adherence was above 90% for 
aspirin, reperfusion, and lipid-
lowering therapies; between 60% 
and 82% for β-blockers, ACEi, 
statins, time-to-balloon within 90 
minutes and LDL-cholesterol 
measurement and 33% for time-
to-needle 30 minutes. 
 
Hamood et 
al (2015) 
Israel Patient based 
retrospective 
cohort study 
(January 
2005-
December 
2010) 
 
Members of the 
Leumit Health 
Services  
(N=4,655, AMI) 
Pharmacological 
treatment: aspirin, 
β-blockers, ACEi\ 
ARBs, statins and 
combined 
therapy. 
Outpatient 
adherence 
to 
evidence-
based 
cardio-
protective 
medication
s were 
measured 
using the 
PDC metric 
and defined 
Data summarised as 
frequencies and 
percentages. 
 
Non-adherence to the cardio-
protective drugs individually 
approximated 50%, with 
combined use approximating to 
18.2%. Adherence to at least one 
cardio-protective drug was 
78.8%. 
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis  Key findings 
as 
proportion 
of days 
covered 
≥80% 
Simms et al 
(2015) 
England 
and 
Wales 
Prospective 
cohort data 
from the 
nationwide 
population-
based 
registry; 
MINAP 
(January 
2003-
December 
2010 
247 hospitals in 
England and 
Wales 
(N=112,286, 
STEMI) 
Nine guideline-
recommended 
care opportunities 
along the pathway 
of STEMI care: 
the recording of a 
pre-hospital ECG; 
use of acute 
aspirin; timely 
coronary 
reperfusion (PPCI 
within 120 
minutes or 
thrombolysis 
within 60 minutes 
of the call for 
help); the 
individual 
prescriptions of 
aspirin, 
thienopyridine 
inhibitor, β-
blocker, 
angiotensin 
converting 
enzyme inhibitor 
Medication 
adherence 
Data summarised as 
frequencies and 
percentages. 
Fixed-effects 
univariable logistic 
regression models. 
 
Of patients eligible for all nine 
components, 50.6% missed ≥1 
opportunity. 
Pre-hospital ECG and timely 
reperfusion were most frequently 
missed, predicting further missed 
care at discharge (pre-hospital 
ECG incident rate ratio [95% CI]: 
1.64 [1.58–1.70]; timely 
reperfusion 9.94 [9.51–10.40]).  
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis  Key findings 
(ACEi) or 
angiotensin 
receptor blocker 
(ARB), HMG CoA 
reductase 
enzyme inhibitor 
(statin); and 
enrolment into a 
cardiac 
rehabilitation 
programme at the 
time of discharge 
from hospital. 
Timoteo et 
al (2008) 
Portugal Retrospective 
study 
(2002 and  
2005) 
368 patients 
admitted in 2002 
and 420 patients 
admitted in 2005 
for ACS (with 
and without ST-
segment 
elevation). 
Pharmacological 
treatment: aspirin, 
statins, β-
blockers, ACEi, 
clopidogrel and 
glycoprotein IIb\ 
IIIa antagonists. 
Reperfusion 
strategy:  PCI. 
Temporal 
improveme
nts in 
medication 
adherence.  
Data summarised as 
frequencies and 
percentages. 
 
Treatment with clopidogrel (6% 
vs 87%), β-blockers (54% vs 
79%), ACEi (72% vs 84%) and 
statins (78% vs 91%) increased 
(P<0.001). 
There was slight decrease in the 
use of aspirin (98% vs 95%, 
P=0.039). 
The use of PCI increased (53% 
vs 67%, P<0.001). 
Mehta et al 
(2006) 
United 
States 
CRUSADE 
(January 
2002-
September 
2004) 
434 US 
hospitals 
participating in 
CRUSADE 
(N=113,595, 
NSTE-ACS) 
Acute measures: 
aspirin, heparin, 
β-blocker, 
glycoprotein IIb\ 
IIIa antagonists. 
Discharge 
measures: 
aspirin, 
Temporal 
changes in 
adherence 
to guideline 
indicated 
treatments. 
 
 
Data summarised as 
frequencies and 
percentages. 
 
Comparing the first quarter to the 
last quarter of the study time : 
In the acute phase use of 
antiplatelet agents, β-blockers 
and heparin increased by 5%, 
12% and 6%, respectively. At 
discharge, antiplatelet agents, β-
blockers, clopidogrel, lipid-
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis  Key findings 
clopidogrel, β-
blocker, ACEi, 
lipid lowering 
agent, smoking 
cessation 
counselling, 
dietary 
modification 
counselling and 
cardiac 
rehabilitation 
referral. 
lowering agents and ACEi use 
increased by 3%, 8%, 21%, 11% 
and 5%, respectively.   
 
An increase in dietary and 
lifestyle modification was also 
noted with an absolute increase 
varying from 17-28%. 
Revascularization increased by 
8%. 
 
Adherence improved over the 
study period (72% to 81%), 
however many patients failed to 
receive 100% indicated 
treatments (OMT increased from 
30 to 48%). 
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis  Key findings 
Mehta et al 
(2015) 
United 
States 
CRUSADE 
(January 
2002-
September 
2004) 
283 US 
hospitals 
participating in 
CRUSADE 
(N=39,291, 
NSTE-ACS) 
ACC/AHA 2002 
Class I guideline 
recommended 
therapies which 
included: aspirin 
and/or 
clopidogrel, 
glycoprotein 
IIb/IIIa inhibitor, 
any heparin 
(unfractionated or 
low molecular 
heparin), and β-
blockers.  
 
 
Medication 
adherence 
Data summarised as 
frequencies and 
percentages. 
 
Overall composite median 
adherence rate to the ACC/AHA 
guidelines recommended 
therapies was 85% (IQR 82-88%) 
and the median hospital safe 
drug-dosing rate was 53% (45-
60%). 
 
There was a low but statistically 
significant correlation between 
composite guideline medications 
use and the dosing 
appropriateness (r=0.16, 
p=0.008). 
 
The mostly missed care 
interventions included aspirin,  β-
blockers, glycoprotein IIbIIIa 
inhibitors  within 24 hours of 
admission and ACEi/ARBs, 
clopidogrel and statins at 
discharge.    
 
Abbreviations: OMT; optimal medical therapy, ACEi; angiotensin-converting enzyme inhibitors, ARB; angiotensin-receptor blocker, AMI; acute myocardial infarction, ACACIA; Acute Coronary Syndromes Prospective Audit, 
GWTG-CAD; Get with the Guidelines- Coronary Artery Disease, ACOS; Acute Coronary Syndromes Registry, PCI; percutaneous coronary artery intervention, PPCI; primary PCI, CABG; coronary artery bypass graft, CPACS; 
Clinical Pathways for Acute Coronary Syndromes in China, GRACE; Global Registry of Acute Coronary Events, BMIR; Berlin Myocardial Infarction Registry, RCTs; Randomised controlled trials, EUROASPIRE; European Action 
on Secondary and Primary Prevention by Intervention to Reduce Events, CVD; Cardiovascular disease,  TASPIC-CRO; Treatment and secondary prevention of ischemic coronary events in Croatia, CHD; Coronary heart disease, 
PTCA; percutaneous transluminal coronary angioplasty, PCI; percutaneous coronary intervention, CABG; coronary artery bypass graft, PMSI; programme de médicalisation des sytèmes d’information, ENACT; European Network 
for Acute Coronary Treatment, ACS; acute coronary syndromes, Gulf GRACE; Gulf Registry of Acute Coronary Events, CRUSADE; Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With 
Early Implementation of the ACC/AHA Guidelines, RBC; red blood cell, MI; myocardial infarction, OASIS; Organisation to Assess Strategies for Ischaemic Syndromes, AUBMC; American University of Beirut Medical Centre, 
PDC; proportion of days covered, LHS; Leumit Health Services, BASI; β-blockers, Antiplatelet, statins and ACEi . 
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2.1.3.2 Regional variation in adherence to guideline indicated care   
The results of the studies in literature that have assessed between country 
geographic variation in receipt of AMI care are summarised in Table 2.3. In 
Europe the ESC carried out three surveys termed: European Action on 
Secondary and Primary Prevention by Intervention to Reduce Events 
(EUROASPIRE) surveys for assessing lifestyle, risk factors, and use of 
cardio-protective medications in coronary patients(63). The first 
EUROASPIRE survey was carried out from 1995-96 in 9 European 
countries, second from 1999-00 in 15 countries and the third from 2006-07 
in 22 European countries including eight from EUROASPIRE I and II. A 
comparison between the three EUROASPIRE surveys found that the 
incorporation of cardiovascular disease prevention into daily practice was 
inadequate and there were large between country variation in use of cardio-
protective drug treatments across Europe with a continuing gap between 
the standards set in cardiovascular disease prevention guidelines and 
clinical practice(63). Results from the surveys gave an insight on the 
geographic variation in guideline adherence over time.  
 
The main objective of the third survey (EUROASPIRE III) was to investigate 
whether the Joint European Guidelines on Coronary Vascular Disease 
(CVD) prevention were being followed in patients with CHD and if the 
practice of preventive cardiology in patients with established coronary 
disease had improved by comparison with those centres that had 
participated in EUROASPIRE I and II(48). Underuse of the evidence-based 
treatments recommended by the Joint European Societies’ guidelines for 
CVD prevention (aspirin or other platelet modifying drugs unless 
contraindicated, β-blockers in those after AMI, ACEi/ARBs in those with 
impaired left ventricular function, lipid lowering drugs (statins) in all patients 
and anticoagulants in those at risk of systematic embolization) were noted 
in the survey. β-blockers use ranged from 60% (in Cyprus and Spain) to 
90% (in The Czech Republic and Finland), ACEi/ARBs use from 50% (in 
Belgium and Spain) to 80% (in France, Hungary, Poland and Slovenia), lipid 
lowering medication use ranged from 42% (in Lithuania) to 90% (in Cyprus, 
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Finland, Greece, Ireland, The Netherlands and Slovenia). Less than half of 
the eligible coronary patients were advised to participate in cardiac 
rehabilitation programmes and three quarters of the advised patients 
actually attended the sessions(48). 
 
Longenecker et al(59). assessed regional adherence to guideline indicated 
care for ACS patients from six Middle Eastern Gulf countries (Bahrain, 
Kuwait, Qatar, Oman, United Arab Emirates and Yemen) and found that full 
adherence to all indicated treatment only occurred in 40.4% of the 
patients(59). A comparison study of the patients with ACS in the Arab 
Middle East with a multinational and predominantly western population 
found that patients from the Arab Middle East were unlikely to receive 
guideline indicated treatment compared with the ACS patients from the 
westernised population for example; ACEi/ARBs receipt 69% vs. 75%, β-
blockers 65% vs. 87%, Clopidegrol 54% vs. 73%, Calcium channel blockers 
9% vs. 19%, GP IIb/IIa 11% vs. 23% and low molecular weight heparin 47% 
vs. 61%.(64) However, although receipt of aspirin, nitrates and statins was 
high in both populations the Arab Middle East had higher proportions (98% 
vs. 94%, 82% vs. 72% and 91% vs. 81%, respectively)(64). Studies that 
have been conducted to compare the developed countries with developing 
countries have found marked underutilisation of all pharmacotherapy drugs 
in the developing countries(64, 65). Largely most of the inter regional 
differences have been attributed to differences in health care models and 
rapidity in adopting evidence-based medicine guidelines with Europe and 
the United States having been reported to adopt more aggressively than 
the rest of the world(64, 66). 
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Table 2.3 Literature reviews on studies assessing geographic variation in adherence to AMI guideline indicated care..  
Author 
(Year) 
Country Design 
(Interval 
data 
collected) 
Setting (N) Treatment Outcomes Statistical 
analysis 
Key findings 
Maier et 
al 
(2008) 
Germany Multi-centre 
observational 
study 
(1999 and  
2004) 
22 hospitals in 
Berlin 
participating in 
BMIR 
(N=6,080 ; 
n=1,766  
NSTEMI and 
n=4,314  
STEMI) 
Concomitant therapy with 
aspirin, β-blockers, statins, 
ACEi, GP IIb/IIIa and acute 
percutaneous coronary 
intervention. 
Medication 
adherence. 
Data 
summarised as 
frequencies and 
percentages. 
 
An increase in the use of acute 
PCI was noted for both AMI 
phenotypes (NSTEMI; 15.3% to 
62.3% and for STEMI from 
24.7% to 71.8%). 
 
Prescription of cardio-protective 
drugs also increased for the 
phenotypes of AMI across the 
considered time period 1999 to 
2004 (NSTEMI :aspirin from 
89.7% to 97.0%, , β-blockers 
from 68.1 to 90.8, statins from 
32.8% to 71.4%, ACEi from 
49.5 to 69.2 and GP IIb/IIIa 
from 12.3 to 43.7, STEMI: 
aspirin from 91.8 to 98.0 , β-
blockers from 68.5 to 89.5, 
statins from 30.5 to 72.9, ACEi 
from 45.8 to 71.6 and GP 
IIb/IIIa from 16.1 to 53.3) 
 
Decrease in hospital mortality 
was more pronounced for 
NSTEMI (13.5% vs. 4.6%, 
p<0.001; OR 0.18, 95 CI 0.08-
0.41) than with STEMI patients 
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Author 
(Year) 
Country Design 
(Interval 
data 
collected) 
Setting (N) Treatment Outcomes Statistical 
analysis 
Key findings 
(13.0% vs. 9.4%, p= 0.005; OR 
0.41, 95%CI 0.25-0.71). 
Kotseva 
et al 
(2009) 
22 
European 
countries: 
The 
Czech 
Republic 
Finland 
France 
Germany 
Hungary 
Italy 
The 
Netherlan
ds 
Slovenia 
Spain 
Belgium 
Greece 
Ireland 
Poland 
UK 
Bulgaria  
Croatia 
Cyprus 
Latvia 
Lithuania 
Romania 
EUROASPIR
E III survey 
2006-2007 
76 centres 
from selected 
geographical 
areas in 22 
countries in 
Europe. 
(N=13,935 
CHD reviewed 
and 8,966 
patients 
interviewed) 
Reported lifestyle and other 
risk factor management in 
relation to smoking, diet 
(including weight reduction), 
exercise, blood pressure, 
lipids and glucose. 
Cardio-protective medication 
(antiplatelets, β-blockers, 
ACEi/ARBs, calcium channel 
blockers and statins). 
Level of education, school 
attendance and employment 
status. 
Between 
country 
variation in 
patients’ 
lifestyle, 
risk factor 
prevalence
s and use 
of cardio-
protective 
medication 
for a 6 
month 
follow-up 
time. 
Descriptive 
statistics were 
used to estimate 
the prevalence 
of risk factors 
and medication 
by survey, 
country and 
diagnostic 
category.  
The use of cardio-protective 
medication was: antiplatelets 
91%, β-blockers 80%, 
ACEi/ARBs 71%, calcium 
channel blockers 25% and 
statins 78%. 
 
There was considerable 
variation between European 
countries in patients’ lifestyle, 
risk factor prevalences and use 
of cardio-protective medication. 
There is still considerable 
potential throughout Europe to 
raise standards of preventive 
care in order to reduce the risk 
of recurrent disease and deaths 
in patients with CHD. 
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Author 
(Year) 
Country Design 
(Interval 
data 
collected) 
Setting (N) Treatment Outcomes Statistical 
analysis 
Key findings 
Russian 
Federatio
n 
and 
Turkey 
 
Reiner 
et al 
(2006) 
Croatia Five surveys 
(1 June 
1998-31 
March 2003) 
TASPIC-CRO 
study. 
Seven 
university 
hospitals, 25 
general 
hospitals and 
three 
rehabilitation 
hospitals in 28 
Croatian cities 
covering the 
geographical 
area of the 
whole of 
Croatia. 
(N=15,520 
CHD) 
Cardio-protective medication 
(aspirin, ACEi, diuretics, 
calcium antagonists, statin 
and β-blockers). 
 
Within 
country 
variation in 
patients’ 
risk factor 
prevalence
s, use of 
cardio-
protective 
medication. 
Descriptive 
statistics were 
used to estimate 
the prevalence 
of risk factors 
and medication 
Across the five surveys 
prevalence of receipt of the 
care interventions was as 
follows: At admission; aspirin 
46%, 52%, 50%, 47%, and 
overall 49%, respectively, ACEi 
30%, 37%, 39%, 35%, 
respectively and overall 36%, 
calcium antagonists 18%, 21%, 
18%, 18%, respectively and 
overall 19%, β-blockers 25%, 
32%, 32%, 29%, respectively 
and overall 30%, diuretics 22%, 
23%, 20%, 20%, respectively 
and overall 21%, statins 15%, 
23%, 26%, 28%, respectively 
and overall 23%. 
At discharge; aspirin 81%, 
85%, 83%, 84%, and overall 
83%, respectively, ACEi 51%, 
53%, 55%, 52%, respectively 
and overall 53%, calcium 
antagonists 18%, 18%, 16%, 
19%, respectively and overall 
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Author 
(Year) 
Country Design 
(Interval 
data 
collected) 
Setting (N) Treatment Outcomes Statistical 
analysis 
Key findings 
18%, β-blockers 41%, 57%, 
60%, 49%, respectively and 
overall 53%, diuretics 35%, 
30%, 31%, 30%, respectively 
and overall 31%, statins 42%, 
55%, 57%, 71%, respectively 
and overall 57%. 
 
High use of statins, β-blockers 
and ACEi, however most 
coronary heart disease patients 
are still not achieving the 
recommended goals. 
 
The survey showed high 
prevalence of modifiable risk 
factors in Croatian patients with 
CHD with more men being 
smokers and having low HDL 
cholesterol, but more women 
having elevated total and LDL 
cholesterol, hypertension and 
diabetes. 
Fox et al 
(2000) 
17 
European 
countries 
Survey  
(April-June 
1999) 
1638 patients 
in community 
hospitals, 
1095 in 
university/teac
hing hospitals 
and 343 in 
Pharmacological treatment, 
reperfusion therapy, 
angiography and 
percutaneous coronary 
intervention. 
Between 
country 
variation in 
care of 
ACS 
patients. 
Descriptive 
statistics were 
used to estimate 
the prevalence 
of risk factors 
and medication 
Most of the participants 
received aspirin (90%), nitrates 
(80%) and heparin (90%) and 
there was little variation 
between countries. However, 
there were large inter-country 
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Author 
(Year) 
Country Design 
(Interval 
data 
collected) 
Setting (N) Treatment Outcomes Statistical 
analysis 
Key findings 
university-
affiliated 
hospitals 
ENACT study. 
(N=3,092, 
n=1,431 
UA/NSTEMI, 
n=1,205 MI 
and n=445 
with suspected 
ACS) 
differences in use cardio-
protective medications. 
 
There were wide variations in 
use of care interventions 
namely; thrombolysis (26-72%), 
primary PCI (<1-19%), 
angiography (6-79%), calcium 
antagonists (3-21%), β-
blockers (54-84%), LMW 
heparin (11-64%) and 
glycoprotein IIb/IIIa inhibitors 
(2-34%). 
 
Primary PCI was mostly carried 
out in university teaching (11%) 
and university-affiliated (17%) 
hospitals than in community 
hospitals (4%). 
Awad et 
al 
(2011) 
Internatio
nal 
comparis
on: 6 
Arab 
Middle 
Eastern 
countries 
(Kuwait, 
Oman, 
United 
Non-
randomised, 
prospective, 
multinational, 
multicentre 
study 
(1999-2007) 
vs 
Prospective 
cohort study 
GRACE, 
(n=4,445 ACS) 
vs Gulf 
GRACE, 
(n=6,706 ACS) 
(N=11,151). 
Pharmacological treatment: 
aspirin, nitrates, statins, β-
blockers, ACEi\ ARB, 
calcium channel blockers, 
clopidogrel, glycoprotein IIb\ 
IIIa antagonists, and 
intravenous heparin. 
Reperfusion strategy: 
thrombolysis or PCI. 
Adherence 
to 
guideline-
indicated 
care. 
 
Data 
summarised as 
frequencies and 
percentages. 
 
Patients in Gulf RACE had 
higher odds of receiving aspirin 
(98% vs 93%), nitrates (74% vs 
71%), statins (92% vs 85%) 
and a lower likelihood of 
receiving ACEi/ARBs (78% vs 
69%), β-blockers (87% vs 
67%), and clopidogrel (82% vs 
60%) at discharge during their 
index hospitalization compared 
with patients in GRACE. 
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Author 
(Year) 
Country Design 
(Interval 
data 
collected) 
Setting (N) Treatment Outcomes Statistical 
analysis 
Key findings 
Arab 
Emirates, 
Yemen, 
Qatar, 
and 
Bahrain) 
vs 14 
countries 
in North 
and South 
America, 
Europe, 
Australia, 
and New 
Zealand. 
(January-
June 2007) 
 
Cardiac catheterization was 
performed nearly 4 times as 
frequently in GRACE compared 
to Gulf RACE in patients with 
STEMI (81.1% vs 18.0%) and 
those with NSTE-ACS (59.4% 
vs 13.1%). 
In-hospital case–fatality rates 
were not significantly different 
between patients in Gulf RACE 
and those in GRACE. 
Patients in Gulf RACE were at 
significantly greater risk for 
developing heart failure (HR 
2.23, 95% CI 1.91-2.56), 
cardiogenic shock (1.39, 1.06-
1.83), and stroke (2.45, 1.25-
4.82) and at lower risk for 
developing major bleeding 
(0.37, 0.25-0.54) during their 
index hospitalization. 
 
Of the two reperfusion 
strategies, thrombolysis was 
the strategy of choice for 
STEMI patients enrolled in Gulf 
RACE and PPCI for STEMI 
patients enrolled in GRACE. 
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Author 
(Year) 
Country Design 
(Interval 
data 
collected) 
Setting (N) Treatment Outcomes Statistical 
analysis 
Key findings 
Fox et al 
(2002) 
Argentina, 
Australia, 
Austria, 
Belgium, 
Brazil, 
Canada, 
France, 
Germany, 
Italy, New 
Zealand, 
Poland, 
Spain, 
United 
Kingdom 
and  
United 
States 
Non-
randomised, 
prospective, 
multinational, 
multicentre 
study 
(April 1999-
31 December 
2000) 
95 hospitals in 
GRACE were 
organized into 
18 population-
based clusters 
in 14 
countries. 
(N=11,543, 
n=4,999 UA, 
n=4,100 MI, 
n=957 
suspected MI, 
n=745 chest 
pain, n=381 
other cardiac, 
n=125 non-
cardiac) 
Use of pharmacological and 
interventional therapies 
during hospitalization, 
discharge and at 6 months 
follow-up. 
 
Use of 
pharmacolo
gical and 
intervention
al therapies 
during 
hospitalizati
on and 
discharge 
by hospital 
type. 
Use of 
pharmacolo
gical and 
intervention
al therapies 
during 
hospitalizati
on and 
discharge 
by 
geographic 
region. 
 
Chi-square test 
was used for 
categorical 
variables and t-
test for 
continuous 
variables. 
The use of aspirin was similar 
across all hospital types and 
geographical regions (<91%). 
 
The use of PCI, glycoprotein 
IIb/IIIa inhibitors and calcium 
channel blockers was 
statistically higher (P<0.01) in 
teaching hospitals and 
hospitals with on-site 
catheterization facilities.  
 
The use of LMW heparin was 
statistically lower (P<0.0001) in 
teaching hospitals and those 
with a catheterization 
laboratory. 
 
The use of statins and β-
blockers was lower (P<0.0001) 
in teaching hospitals and 
hospitals with on-site 
catheterization facilities. 
 
ACEi use was consistent 
between teaching and non-
teaching hospitals but however 
use was higher (P<0.0001) in 
hospitals without on-site 
catheterization facilities. 
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Author 
(Year) 
Country Design 
(Interval 
data 
collected) 
Setting (N) Treatment Outcomes Statistical 
analysis 
Key findings 
 
The use of antiplatelet agents 
and anticoagulants was lower 
in non-teaching hospitals 
(P<0.0001) but was similar in 
hospitals with and without a 
catheterization laboratory. 
 
The use of percutaneous 
coronary intervention and 
glycoprotein IIb/IIIa inhibitors 
was considerably higher in the 
United States compared with 
other regions. 
The 
ACCES
S 
investig
ators 
(2011) 
Africa, 
Latin 
America 
and 
Middle 
Eastern 
countries 
Prospective 
observational
, 
multinational 
registry. 
(January 
2007-
January 
2008). 
134 sites in 19 
countries in 
North Africa, 
South Africa, 
Latin America 
and the Middle 
East. 
(N=11,731 
ACS, n=4,936 
Latin America, 
n=4,493 
Middle East, 
n=1,687 North 
Africa, n=615 
South Africa) 
All admission and discharge 
cardio-protective medication. 
Interventions and procedures 
(CABG, PCI and coronary 
angiography) 
Adherence 
to 
guideline-
indicated 
care. 
 
Data 
summarised as 
frequencies and 
percentages. 
 
In-hospital the use of cardio-
protective drugs was high 
(aspirin 93%, statins or other 
lipid-lowering drugs 94%, 
thienopyridines 81%, and β-
blockers 78%). 
 
Prescription of cardio-protective 
drugs at discharge was high 
(aspirin 90%, statins 89%, β-
blockers 76%, thienopyridines 
76% and dual antiplatelet 
therapy 89% (of patients who 
had PCI with a stent)). 
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Author 
(Year) 
Country Design 
(Interval 
data 
collected) 
Setting (N) Treatment Outcomes Statistical 
analysis 
Key findings 
Fifty eight percent of the 
patients had an angiogram with 
38% having PCI performed.  
 All-cause death at 12 months 
was 7.3% and was higher in 
patients with STEMI versus 
non–ST elevation–ACS. 
Clinical factors associated with 
higher risk of death at 12 
months included cardiac arrest, 
antithrombin treatment, 
cardiogenic shock, and age 
>70 years. 
 
Mandelz
weig et 
al 
(2006) 
32 
European 
countries 
and the 
Mediterra
nean 
basin 
Prospective 
survey 
(March 2004 
– October 
2004) 
190 medical 
centres in 32 
countries. 
EHS–ACS-I vs 
EHS–ACS-II 
(N=6,385 
ACS) 
Pharmacological treatment: 
aspirin, statins, β-blockers, 
ACEi\ ARBs, thienopyridines, 
and glycoprotein IIb\ IIIa 
antagonists. 
In-hospital use of invasive 
and non-invasive diagnostic 
and therapeutic techniques. 
Adherence 
to 
guidelines. 
Data 
summarised as 
frequencies and 
percentages. 
 
 
Proportion of patients with an 
initial diagnosis of ACS with 
ST-elevation rose from 42% 
(EHS-ACS-I) to 47% (EHS-
ACS-II). 
Proportion of patients with an 
initial diagnosis of ACS with no 
ST-elevation fell from 51% 
(EHS-ACS-I)  to 48% (EHS-
ACS-II) 
In EHS-ACS-II, more patients 
were hospitalized in coronary 
care units (70 vs. 62.4%), 
whereas fewer were treated in 
cardiology wards (19.1 vs. 
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Author 
(Year) 
Country Design 
(Interval 
data 
collected) 
Setting (N) Treatment Outcomes Statistical 
analysis 
Key findings 
22%), and in internal medicine 
wards (7 vs 13.85%). 
Coronary angiography, 
percutaneous coronary 
interventions (PCIs), and 
intracoronary stents were used 
more frequently in ACS-II than 
in ACS-I (STEMI: 56.3% VS 
70.2%, NSTEMI: 52.0% VS 
62.9%; STEMI: 40.4% VS 
57.8%, NSTEMI: 25.4% VS 
37.1%, respectively). 
A greater proportion of patients 
received evidence-based 
medications during their 
hospitalization and at discharge 
in ACS-II compared with ACS-I, 
particularly in the use of 
thienopyridnes. 
 
Kotseva 
et al 
(2009) 
Czech 
Republic, 
Finland, 
France, 
Germany, 
Hungary, 
Italy, the 
Netherlan
ds, and 
Slovenia 
EUROASPIR
E I (1995-
96), 
II (1999-00), 
and III (2006-
07) surveys 
3,180 patients 
interviewed in 
the first 
survey, 2,975 
in the second 
and 2,392 in 
the third (AMI 
and ischaemia 
patients). 
Cardio-protective drug 
treatments. 
Adherence 
to 
guidelines. 
Data 
summarised as 
frequencies and 
percentages. 
 
The use of cardio-protective 
drug treatments, apart from 
anticoagulants and calcium-
channel blockers, increased 
between the first and the third 
survey, with large variations 
between countries and 
diagnostic categories. 
 
 - 53 -  
 
Author 
(Year) 
Country Design 
(Interval 
data 
collected) 
Setting (N) Treatment Outcomes Statistical 
analysis 
Key findings 
More men smoked than women 
in all three surveys. 
Mean bodyweight was higher in 
EUROASPIRE III compared to 
II and I (84.7 kg (SD 15.1), 82.0 
kg (SD 14.5) and 79.8 kg 
(13.4), respectively. 
 
Frequencies of overweight and 
obese patients was also higher 
in the third survey (5.1% 95% 
CI 1.1-9.1%, p=0.02). 
Yusuf et 
al 
(1998) 
Australia, 
Brazil, 
Canada, 
USA, 
Hungary 
and 
Poland 
Registry-
based study; 
OASIS 
(1995-96) 
 
95 hospitals in 
six countries. 
(N=7,987, 
unstable 
angina or 
suspected 
myocardial 
infarction 
without ST-
segment 
elevation). 
Use of invasive cardiac 
catheterisation and 
revascularisation procedures. 
Between 
country 
variation in 
use of 
invasive 
cardiac 
catheterisat
ion and 
revasculari
sation 
procedures. 
 
Data 
summarised as 
frequencies and 
percentages. 
Natural 
randomisation 
by rates of 
catheterisation 
by country.  
Rates of angiography during 
the first 7 days showed wide 
variations between countries 
(highest in Brazil and USA 
(60%; 95% CI 58-63%, 58%; 
55-61%, respectively) and 
lowest in Poland and Hungary 
(2%; 1-3%, 15%; 13-17%, 
respectively)). 
After 7 days the rates of 
angiography and 
revascularization showed less 
variation, however at 6 months 
the rates showed pronounced 
variation with a two-fold higher 
rate in Brazil and the USA. 
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Author 
(Year) 
Country Design 
(Interval 
data 
collected) 
Setting (N) Treatment Outcomes Statistical 
analysis 
Key findings 
Patients mostly admitted to 
hospitals with catheterisation 
facilities were low risk patients.  
Karrown
i et al 
(2010) 
USA 
Europe 
Australia 
Canada 
New 
Zealand 
Argentina 
Brazil 
and 
Lebanon 
Non-
randomised, 
prospective, 
multinational, 
multicentre 
study vs 
Prospective 
cohort study 
ACS patients 
admitted at 
AUBMC 
(N=1,025) vs 
ACS  patients 
admissions 
recorded in 
GRACE 
(N=60,000) 
Pharmacological treatment: 
aspirin, clopidogrel, β-
blocker, ACEi/ ARBs, statins 
and glycoprotein IIb\ IIIa 
antagonists. 
Interventions and procedures 
(CABG, PCI, reperfusion and 
coronary angiography) 
Use of 
cardio-
protective 
drug 
treatments. 
Use of 
invasive 
cardiac 
catheterisat
ion and 
revasculari
sation 
procedures. 
Data 
summarised as 
frequencies and 
percentages. 
Chi-square test 
was used for 
categorical 
variables. 
The rate of coronary 
angiography was slightly higher 
in patients admitted in AUBMC 
compared with GRACE (74% 
vs. 69%). 
PCI was more commonly 
performed in GRACE (45% vs. 
32%, P<0.05) while bypass 
surgery was more commonly 
performed in patients admitted 
in AUBMC (16% vs. 4%, 
P<0.01). 
Overall revascularization rate 
was similar between the two 
studies (48% vs. 49%). 
Reperfusion rate for STEMI 
was higher in GRACE (71% vs. 
61%, P<0.05). 
Utilization rate of the other 
medications including aspirin 
(96% vs 84%), clopidogrel 
(75% vs 57%), β-blockers (91% 
vs 49%), ACE inhibitors/ARB 
(79% vs 44%), GP IIb/IIIa 
inhibitors (27% vs 13%), and 
statins (84% vs 60%) were 
consistently higher in GRACE, 
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Author 
(Year) 
Country Design 
(Interval 
data 
collected) 
Setting (N) Treatment Outcomes Statistical 
analysis 
Key findings 
this was associated with lower 
in-hospital mortality in GRACE 
(3.1% vs 3.9%, P<0.05) 
Fox et al 
(2003) 
Argentina, 
Australia, 
Austria, 
Belgium, 
Brazil, 
Canada, 
France, 
Germany, 
Italy, New 
Zealand, 
Poland, 
Spain, 
United 
Kingdom 
and  
United 
States 
Non-
randomised, 
prospective, 
multinational, 
multicentre 
study 
(July 1999- 
December 
2001). 
94 hospitals 
located in 14 
countries 
participating in 
GRACE 
(N=12,666, 
ACS; n=6,041, 
NSTEMI; 
n=6,625, 
STEMI). 
Pharmacological treatment: 
aspirin, statins, β-blockers, 
ACEi\ ARBs, thienopyridines, 
and glycoprotein IIb\ IIIa 
antagonists. 
In-hospital use of invasive 
techniques. 
Uptake of 
evidence-
based 
guideline 
recommend
ations. 
Between 
country 
variation in 
uptake of 
evidence-
based 
guideline 
recommend
ations. 
 
Chi-square test 
for trend. 
(Sequential 6-
month intervals). 
Contrasting geographical 
variations were seen in the use 
of PCI in NSTEMI: 39.5% USA, 
34.6% Europe, 33.5% 
Argentina/ Brazil, 25.0% 
Australia/ New 
Zealand/Canada.  
Hospital and geographical 
factors had a marked influence 
on the uptake of evidence-
based therapies in ACS 
management. 
The presentation and 
publication of major 
international guidelines was not 
associated with a measurable 
change in the temporal pattern. 
Abbreviations: OMT; optimal medical therapy, ACEi; angiotensin-converting enzyme inhibitors, ARB; angiotensin-receptor blocker, AMI; acute myocardial infarction, ACACIA; Acute Coronary Syndromes Prospective Audit, 
GWTG-CAD; Get with the Guidelines- Coronary Artery Disease, ACOS; Acute Coronary Syndromes Registry, PCI; percutaneous coronary artery intervention, PPCI; primary PCI, CABG; coronary artery bypass graft, CPACS; 
Clinical Pathways for Acute Coronary Syndromes in China, GRACE; Global Registry of Acute Coronary Events, BMIR; Berlin Myocardial Infarction Registry, RCTs; Randomised controlled trials, EUROASPIRE; European Action 
on Secondary and Primary Prevention by Intervention to Reduce Events, CVD; Cardiovascular disease,  TASPIC-CRO; Treatment and secondary prevention of ischemic coronary events in Croatia, CHD; Coronary heart disease, 
PTCA; percutaneous transluminal coronary angioplasty, PCI; percutaneous coronary intervention, CABG; coronary artery bypass graft, PMSI; programme de médicalisation des sytèmes d’information, ENACT; European Network 
for Acute Coronary Treatment, ACS; acute coronary syndromes, Gulf GRACE; Gulf Registry of Acute Coronary Events, CRUSADE; Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With 
Early Implementation of the ACC/AHA Guidelines, RBC; red blood cell, MI; myocardial infarction, OASIS; Organisation to Assess Strategies for Ischaemic Syndromes, AUBMC; American University of Beirut Medical Centre, 
PDC; proportion of days covered, LHS; Leumit Health Services, BASI; β-blockers, Antiplatelet, statins and ACEi . 
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2.1.3.3 Predictors of poor adherence to guideline indicated care  
Despite the proven beneficial effects of receiving OMT as recommended by 
the guidelines, the literature review showed that prevalence of sub-optimal 
care was high(51-61). Potential predictors for this non-adherence to 
guideline indicated care were identified in the studies considered and 
explored below. The identified predictors included: patient age, 
comorbidities, adherence to other guideline indicated care interventions, 
availability of healthcare facilities, attending physician and AMI phenotype 
(Table 2.4). 
2.1.3.4 Age  
Advanced age is an established predictor of receipt of guideline indicated 
care. Several studies have investigated the association of age and medical 
therapy adherence using different cut offs to get the specific age range with 
a positive or negative impact on adherence(53, 55, 56, 67).  Age >70 years 
has been reported as a negative predictor of OMT, for example Bauer et 
al(53). found that advanced age >70 years was a negative predictor of 
prescription of statins (OR 1.7, 95% CI: 1.6–1.9) and was associated with 
high discontinuation rates of aspirin(53, 56, 68). The elderly usually do not 
receive treatment due to concerns over their vulnerability to comorbidities, 
adverse drug reactions and problems of consenting. Problems with 
consenting noted for the elderly patients have been attributed to the high 
prevalence of psychiatric illnesses and comorbidities such as Parkinson’s 
disease, Alzheimer’s disease or dementia in this sub-group of AMI 
patients(56, 57, 67). 
2.1.3.5  Comorbidities   
Poor adherence to guideline indicated care was found to be most prevalent 
in comorbid patients(54, 59). Comorbidities such as prior heart failure, renal 
dysfunction, chronic obstructive pulmonary disease (COPD), peripheral 
artery disease, dyslipidemia and hypertension were identified as negative 
independent predictors of OMT in the literature review(53, 55). In one study  
high discontinuation rates for aspirin were found to be high in those with 
heart failure(68). However, after adjusted analysis using multivariable 
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regression  analysis, high rates of use of aspirin were found to be highly 
associated with care by a cardiologist, β-blockers  use with hypertension 
and AMI phenotype (with STEMIs being more likely to receive β-blockers), 
ACEi use with prior heart failure, and statin under use with 
hypertension(68). A study carried out by Bauer et al(53). found that with 
increasing median number of risk factors the number of secondary 
prevention drugs prescribed at discharge incrementally decreased. These 
findings have been attributed to treating physician prescribing preferences 
and  education, that is physicians are more likely to offer care interventions 
to patients at low risk of adverse events “treatment-risk paradox”, (69). For 
example COPD (OR 4.1, 95% CI: 3.5–4.8) and peripheral arterial disease 
(OR 1.7, 95% CI: 1.4–2.1) were negative predictors for prescription of β 
blockers at hospital discharge (53), this was likely due to the fact that 
historically β blockers were thought to be contraindicated in patients with 
these conditions(9). Education and awareness of treating physicians with 
the current recommendation of the guidelines will help eradicate grey areas 
when treating AMI patients. Also renal insufficiency was found to be a strong 
negative predictor of ACEi/ARBs (OR 2.8, 95% CI: 2.2–3.5), a finding which 
has been attributed to physicians not prescribing the treatment to patients 
with pre-existing renal impairment in fear of worsening the condition(53). 
However, no contraindication has been noted in the guidelines for this sub-
group of patients(70).      
2.1.3.6 AMI phenotype  
Although different diagnoses, guideline recommendations for the care 
management of the two phenotypes of AMI (STEMI and NSTEMI) are 
relatively similar(71). However several studies have reported that patients 
presenting with STEMI were more likely to be given more aggressive 
medical treatment(53, 55, 71). The National Cardiovascular Data Registry 
report also showed that NSTEMI patients showed lower adherence for 
statin, ACEi and β-blockers on admission and hospital discharge compared 
with STEMI patients(72). The low adherence rates to guideline 
recommended care for the NSTEMI patients  have been attributed to “acute 
referral bias”, whereby emergency medical service systems have been 
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reported to refer STEMI patients to larger tertiary or teaching hospitals with 
cardiac-catheterisation facilities and staff(71). These hospitals have been 
noted to have higher adherence rates compared with smaller non-tertiary 
or academic hospitals(71). Also the NSTEMI patients have been noted to 
be a very heterogeneous group of patients, which makes them difficult to 
treat. The negative predictors of receipt of care have been noted to be highly 
prevalent among the NSTEMI, i.e. they are usually older and more 
comorbid(53, 71).  
2.1.3.7 Healthcare facilities / attending physician 
An association has been reported between healthcare service utilisation 
and adherence to evidence-based treatment(60, 73). With AMI patients 
admitted to tertiary or teaching hospitals been noted to have high receipt of 
guideline indicated care interventions at hospital discharge and those 
treated in hospitals with cardiac-catheterisation facilities being more likely 
to be referred for angiography or other invasive procedures(73-75). Care by 
cardiologists has been reported in the past literature as vital for receipt of 
guideline-indicated care(56, 68).  
2.1.3.8 Adherence to other guideline-indicated care interventions   
Patients who received reperfusion were reported to have high receipt rates 
of the secondary prevention drugs at hospital discharge compared with 
patients who were treated with fibrinolysis or those who received no 
treatment at all(53). Not receiving timely PPCI was a negative predictor of 
being prescribed clopidogrel (Odds ratio (OR) 10.4, 95% CI: 9.4–11.6), ASA 
(OR 2.6, 95% CI: 2.2–3.1), ACEi/ARBs (OR 1.5, 95% CI: 1.3–1.6)  and 
statins (OR 2.1, 95% CI: 1.9–2.4) (53). Also concomitant treatments have 
been reported to have a negative impact on receiving care interventions for 
example chronic oral anticoagulation medications have been found to be a 
negative predictor of prescription of aspirin (OR 19.6, 95% CI: 15.9–24.0) 
and clopidogrel (OR 1.5, 95% CI: 1.3–1.6)(53).  
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2.1.3.9 Other factors  
Other factors that were identified in the literature review to influence 
adherence to guideline-indicated care interventions include treatment side 
effects, patient refusal and physician education. For example side effects 
such as muscle pain and liver damage were reported to potentially 
contribute to underutilisation of statins(53). Incidences of hospital bleeding 
complications have also been found to be negative predictors of 
prescription of aspirin (OR 3.0, 95% CI: 2.2–4.2)(53). 
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Table 2.4 Literature reviews on studies assessing predictors of adherence to guideline indicated care for AMI patients. 
Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis 
and potential 
predictors 
investigated 
Key findings 
Rasmussen 
et al (2007) 
Canada Population-
based, 
observational, 
longitudinal 
study (April 1, 
1999 and May 
1, 2003). 
Elderly (aged 66 
years or older) 
AMI survivors 
(surviving at 
least 1 year 3 
months after 
hospitalization) 
recorded in the 
Ontario 
Myocardial 
Infraction 
Database 
(N=31,455) 
Pharmacotherapy 
medication use 
following hospital 
discharge after 
AMI (β-blockers, 
statin and calcium 
channel blockers). 
Predictors 
of receipt of 
guideline-
indicated 
care. 
Multivariable logistic 
regression models. 
 
Age, sex, 
socioeconomic status, 
year of admission, 
speciality of attending 
physician, comorbidity at 
index AMI, inter-current 
hospitalisations and use 
of respective drug within 
six months prior to 
admission, concomitant 
use of ACEi, statins, β-
blockers and calcium 
channel antagonists.   
Increasing age, psychiatric 
illnesses and increasing 
number of admissions within 
the year following AMI were 
independent determinants of 
poorer adherence. 
Bauer et al 
(2010) 
Germany Multicentre, 
prospective, 
observational 
study. (June  
2000 and 
November  
2002) 
Hospital 
survivors of AMI 
(STEMI or 
NSTEMI) from 
155 hospitals 
enrolled in the 
ACOS registry.  
(N=11,823) 
Five discharge 
medication drugs: 
acetyl salicylic 
acid, clopidogrel, 
β-blockers, ACEi/ 
sartan and statin. 
Dichotomised 
receipt of care 
composite score 
i.e. patients 
receiving < 4 
Predictors 
of receipt of 
guideline-
indicated 
care. 
Multiple logistic 
regression models. 
Age >70, sex, prior MI, 
prior stroke, diabetes 
mellitus, peripheral 
artery disease, smoking, 
hypercholesterolemia, 
hypertension, chronic 
obstructive lung 
disease, renal 
insufficiency, 
Patients in group one  were 
more likely to be older 
(median age 71.1 IQR 61.8-
79.0), more co-morbid (prior 
MI 24% vs 17.7%; P-
value<0.0001, prior stroke 8.6 
vs 5.7; P-value<0.0001, 
peripheral artery disease 10.2 
vs 6.2; P-value<0.0001, 
chronic obstructive lung 
disease 11.8 vs 5.0; P-
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis 
and potential 
predictors 
investigated 
Key findings 
drugs (group 1) or 
receiving 4-5 
malignancy, atrial 
fibrillation, left bundle 
branch block, reduced 
left ventricular function, 
acute NSTEMI and 
percutaneous coronary 
intervention within 48 
hours.   
value<0.0001, chronic 
obstructive lung disease 11.8 
vs 5.0; P-value<0.0001, 
diabetes mellitus 31.3 vs 
26.1; P-value<0.0001, renal 
insufficiency 5.3 vs 2.1; P-
value<0.0001, cardiogenic 
shock 7.1 vs 3.5; P-
value<0.0001, atrial fibrillation 
12.9 vs 4.6; P-value<0.0001, 
ejection fraction ≤ 40% 28.0 
vs 19.1; P-value<0.0001 ), 
more likely to be NSTEMIs 
(58.6 vs 47.7; P-
value<0.0001) and less often 
received reperfusion therapy 
(68.9 vs 32.7; P-
value<0.0001). 
 
Patients in group two were 
hypertensive (65.1 vs 61.3; P-
value<0.001), smokers (35.1 
vs 24.4; P-value<0.0001) and 
had hypercholesterolemia 
(70.0 vs 52.1; P-
value<0.0001). 
 
Patients with STEMI (4.1) 
were discharged with more 
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis 
and potential 
predictors 
investigated 
Key findings 
drugs than those with 
NSTEMI (3.8, P < 0.0001). 
 
Comorbidities and no 
interventional treatment were 
strong negative predictors for 
guideline-adherent discharge 
medication.  
Bi et al 
(2009) 
China Multi-centre 
prospective 
study. 
(September  
2004 and May 
2006) 
Patients 
diagnosed with 
suspected AMI 
or UA admitted 
to 51 hospitals 
participating in 
CPACS. 
(N=2,973 ; 
n=345  NSTEMI, 
n=1,251 UAP 
and n=1,305 
STEMI) 
4 drug 
combination 
therapy: 
antiplatelet, β-
blockers, ACEi/ 
ARB and statin. 
Reasons 
for non-
adherence 
at 6 and 12 
months 
follow-up. 
Logistic regression 
Age ≥65, education level 
(completion high 
school), manual labour, 
high income (≥12,000), 
medical insurance, 
interaction between 
medical insurance and 
high income, interaction 
between high school 
and manual labour, 
whether the patient had 
invasive therapy, 
whether the patient had 
MI, diabetes, 
hypertension, and 
dyslipidemia, and 
smoking status.   
4 drug combination 
prescription was low for high 
risk patients (GRACE score 
200-300) at discharge (35%). 
 
Medical insurance, 
dyslipidemia, hypertension, 
and administration of invasive 
therapy (PCI / CABG) were 
important in determining use 
of treatment at discharge and 
during follow-up. 
 
Reasons for non-adherence 
for antiplatelet therapy or β-
blockers was mainly patient 
refusal and for ACEi or stains 
were adverse effects and 
financial costs, respectively.   
Yan et al 
(2007) 
Canada Prospective, 
multicentre, 
observational 
51 hospitals 
participating in 
Canadian ACS 
Pharmacotherapy 
 (antiplatelet/ 
anticoagulant, β-
Predictors 
of receipt of 
guideline-
Hierarchical multivariate 
logistic regression.  
Advanced age, female sex, 
prior heart failure, renal 
dysfunction and coronary by-
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis 
and potential 
predictors 
investigated 
Key findings 
study 
(September 
1999-June 
2001 and 
October 2002-
December 
2003). 
registry I 
(N=5,312; 
n=4,627 ACS) 
36 hospitals 
participating in 
Canadian ACS 
registry II 
(N=2,359; 
n=1,956 ACS) 
blockers, ACEi 
and lipid 
modifying 
therapies) 
 
indicated 
care. 
Enrolment into ACS II 
registry, age > 65, sex, 
previous heart failure, 
dyslipidemia, previous 
PCI, previous CABG, 
ST-segment elevation, 
abnormal cardiac 
biomarker in hospital, 
serum creatinine >120 
µmol/L and CABG 
during index admission. 
pass surgery during surgery 
were negative independent 
predictors of optimal medical 
therapy. 
 
Tuppin et al 
(2009) 
France Analysis from 
a large 
administrative 
database. 
(January –
June 2006) 
All 
hospitalizations 
from January to 
June 2006 with 
a diagnosis-
related group of 
MI  were 
selected from 
the PMSI health 
insurance 
scheme 
(N=11,671) 
 
Cardio-protective 
medication 
(antiplatelet 
drugs, ACEi\ 
ARBs, statins and 
β-blockers). 
 
Predictors 
of receipt of 
guideline-
indicated 
care. 
Multivariable logistic 
regression analysis. 
Sex, age, full healthcare 
coverage for low 
earners, one or more 
outpatient cardiologist 
appointments, 
admission unit, hospital 
type, hospital volume, 
stent implantation, 
length of stay, 
comorbidities and 
concomitant medication.   
Age had a significant effect on 
use statins, ACEi/ARBs, β-
blockers, antiplatelet agents 
and combined therapy with 
low β-blockers use being 
observed in those aged ≤ 75 
years, low antiplatelet agents 
use in those aged ≤ 85 years 
and combined therapy being 
less frequently observed in 
those aged ≤ 75 years. 
 
High use rates of statins, 
ACEi/ARBs, β-blockers, 
antiplatelet agents and 
combined therapy were 
observed in patients admitted 
to university hospitals, those 
who had at least one visit to a 
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis 
and potential 
predictors 
investigated 
Key findings 
private cardiologist and those 
with a stent implantation.  
Comorbidities such as cancer, 
kidney failure, Parkinson’s 
disease and Alzheimer’s were 
found to have a negative 
impact on the use of the 
individual drugs as well 
combined use, however 
diabetes was associated with 
higher rates of use. 
Amar et al 
(2008) 
France Nationwide 
cross-
sectional 
PREVENIR-4 
study (2006) 
 
Patients 
recruited by 621 
cardiologists in 
all French 
regions 
(N=1700) 
Combination 
therapy consisting 
of β-blockers, an 
antiplatelet, 
statins and ACEi 
(BASI) 
Predictors 
of receipt of 
guideline-
indicated 
care 
Multivariate logistic 
regression model. 
History of atrial 
fibrillation, at least one 
severe non-
cardiovascular disease 
and significant coronary 
stenosis.  
Negative predictors of BASI 
included atrial fibrillation (OR 
2.98, 95%CI 1.65-5.41) and at 
least one severe non-
cardiovascular disease (OR 
1.72, 95%CI 1.09-2.73), i.e. 
depression, Alzheimer’s 
disease or dementia, severe 
renal failure, respiratory 
failure, cancer and cirrhosis. 
Longeneck
er et al 
(2013) 
6 middle 
eastern 
countries
: Bahrain 
Kuwait 
Qatar 
Oman 
Prospective 
cohort study 
(January-June 
2007) 
72 hospitals, 
Gulf GRACE 
(N=5,813 AMI) 
Performance 
measure: 
Aspirin and β-
blockers within 24 
h on admission 
Aspirin, β-
blockers and 
ACEi\ ARB and 
lipid lowering 
Predictors 
of 
adherence 
to 
performanc
e measures 
Multivariate logistic 
regression model.  
Age, sex, nationality, 
cardiovascular disease, 
hypertension, any 
diabetes, smoking, Killip 
class, and GRACE 
score. 
 
Patient characteristics that 
were significantly associated 
with high performance 
composite score (>85%) 
included Asian ethnicity 
compared to Gulf Arabs 
(adjusted OR, AOR=1.3; 
p=0.01) and history of 
hyperlipidemia (AOR=1.4; 
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis 
and potential 
predictors 
investigated 
Key findings 
United 
Arab 
Emirates 
and 
Yemen 
therapy on 
discharge 
Indicated 
reperfusion 
therapy 
Measurement of 
LDL cholesterol 
levels during 
hospitalisation. 
OMT derived as a 
composite score. 
 p=0.001). those associate 
with a low performance score 
included age>65 (AOR=0.8; 
p-trend =0.03), atypical chest 
pain versus typical chest pain 
(AOR=0.6; p=0.003), 
symptoms other than chest 
pain (AOR=0.5; pb0.0001) 
and high GRACE score 
(AOR=0.6; p<0.001). 
 
Hamood et 
al (2015) 
Israel Patient based 
retrospective 
cohort study 
(January 
2005-
December 
2010) 
 
Members of the 
Leumit Health 
Services  
(N=4,655, AMI) 
Pharmacological 
treatment: aspirin, 
β-blockers, ACEi\ 
ARBs, statins and 
combined 
therapy. 
Predictors 
of 
medication 
adherence. 
 
Multiple logistic 
regression models. 
Age, gender, ethnicity, 
district, comorbid 
conditions, 
revascularisation, prior 
use of drug, severity of 
disease, and health 
services utilisation.   
Factors significantly 
associated with reduced 
adherence were presence of 
comorbid conditions, 
particularly chronic ischemic 
heart disease (AOR 0.69; 
95% CI, 0.57–0.83) and 
readmissions (AOR, 0.65; 
95% CI, 0.55–0.78). 
Eagle et al 
(2004) 
14 
countries
: 
Argentin
a 
Australia 
Austria  
Belgium  
Brazil  
Canada 
Non-
randomised, 
prospective, 
multinational, 
multicentre 
study 
(April 1999 
and March 
2003) 
MI or UA 
patients 
admitted to 104 
tertiary and 
community 
hospitals 
participating in 
GRACE 
(N=21,408 ; 
n=4,137  
Pharmacotherapy 
(aspirin, β-
blockers, statins 
and ACEi) 
Medication 
adherence 
rates at 6 
months 
after 
hospital 
discharge 
Logistic regression 
models with a random 
effect included. 
Region of care (United 
States vs. other 
country), age, sex, prior 
medical diseases 
including heart failure, 
diabetes, renal 
insufficiency, 
Patients who discontinued 
aspirin were older (OR=0.65, 
95% CI: 0.53 to 0.80), more 
likely to have heart failure 
(OR=0.80, 95% CI: 0.65 to 
0.99) and more likely to be 
treated by non-cardiologists. 
Care by cardiologist was a 
positive predictor for 
adherence to aspirin 
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis 
and potential 
predictors 
investigated 
Key findings 
France  
Germany  
Italy 
New 
Zealand  
Poland  
Spain  
United 
Kingdom 
United 
States   
 
NSTEMI, 
n=5,031 UAP 
and n=4,662 
STEMI) 
hypertension, in-hospital 
development of 
pulmonary edema or 
shock, type of acute 
coronary syndrome 
(STEMI, NSTEMI, or 
unstable angina), type of 
caregiver (cardiologist 
vs. non-cardiologist), 
and type of hospital 
providing care (teaching 
vs. nonteaching). 
(OR=1.45, 95% CI: 1.19 to 
1.75). 
 
Higher rates of adherence to 
β-blockers were noted in 
patients treated in the United 
States, hypertensive 
(OR=1.33, 95% CI: 1.15 to 
1.54) and are STEMI 
(OR=1.33, 95% CI: 1.11 to 
1.61).   
 
Male sex (1.32, 1.09-1.61) 
and prior heart failure (1.67, 
1.23-2.22) were independent 
predictors of ACEi adherence. 
 
Hypertension was a negative 
predictor for statin therapy 
adherence (OR=0.85, 95% 
CI: 0.74 to 0.99). 
Soma et al 
(2012) 
USA National 
registry (May 
1,  2006 and 
March 21, 
2010) 
AMI (STEMI or 
NSTEMI) 
admissions from 
237 hospitals 
participating in 
the GWTG-CAD 
registry. 
(N=72,352 ; 
n=48,966 
Performance 
measures: 
Aspirin therapy 
before hospital 
admission or 
within 24 hours. 
Discharge 
medications 
(aspirin, β-
Predictors 
of 
adherence 
to guideline 
indicated 
medical 
therapy. 
Multivariable logistic 
regression. 
Generalized estimating 
equations. 
Age, sex, race (white 
versus non-white), 
medical history of 
chronic obstructive 
pulmonary disease or 
STEMI patients were more 
likely to be treated at larger 
hospitals (35.7% vs 28.45, P-
value<0.0001), more likely to 
be treated at academic 
medical centres (58.0 vs 54.4, 
P-value<0.0001) and mostly 
likely to smoke (41.2 vs 27.3, 
P-value<0.0001). 
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis 
and potential 
predictors 
investigated 
Key findings 
NSTEMI and 
n=23,386 
STEMI) 
blockers, 
ACEi/ARBs, lipid 
lowering therapy, 
smoking 
cessation 
counselling) 
Composite 
compliance with 
all performance 
measures 
β-blockers 
before hospital 
admission or 
within 24 hours. 
Discharge 
medications 
(ACEi/ARBs, 
clopidogrel, lipid 
lowering therapy) 
Rehabilitation, 
diabetes mellitus 
treatment, 
physical activity 
and weight 
 
 
 
 
 
 
asthma, diabetes 
mellitus (combined 
insulin dependent and 
noninsulin dependent), 
hyperlipidemia, 
hypertension, peripheral 
vascular disease, stroke 
or transient ischemic 
attack, heart failure, 
renal insufficiency, 
smoking, geographic 
region of the United 
States, teaching hospital 
and hospital size 
represented by number 
of beds  
 
The composite of compliance 
with all applicable 
performance measures was 
higher in STEMI patients 
(94.3% versus 91.1%; 
P<0.0001). 
 
After confounder adjustment, 
STEMI patients were more 
likely to receive: 
Aspirin within 24 hours 
98.5% vs 97.1% (AOR, 1.63; 
95%CI 1.32-2.02) 
Aspirin at discharge 98.5 vs 
97.3 (1.33; 1.19-1.49) 
β-blockers 98.2 vs 96.9 
(1.48; 1.35-1.63)  
β-blockers within 24hours 
93.9 vs 90.8 (1.57; 1.37-1.79) 
Lipid lowering medication 
96.8 vs 91.0 (1.85; 1.61-2.13) 
ACEi/ARBs at discharge 
85.3 vs 77.4 (1.62; 1.51-1.75) 
Clopidogrel at discharge 
85.6 vs 67.0 (2.42; 2.23-2.61) 
Lipid lowering drugs at 
discharge 94.8 vs 88.0 (1.71; 
1.56-1.86). 
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis 
and potential 
predictors 
investigated 
Key findings 
Mehta et al 
(2015) 
United 
States 
CRUSADE 
(January 
2002-
September 
2004) 
283 US 
hospitals 
participating in 
CRUSADE 
(N=39,291, 
NSTE-ACS) 
ACC/AHA 2002 
Class I guideline 
recommended 
therapies which 
included: aspirin 
and/or 
clopidogrel, 
glycoprotein 
IIb/IIIa inhibitor, 
any heparin 
(unfractionated or 
low molecular 
heparin), and β-
blockers.  
 
Composite use of 
ACC/AHA 
guideline-
indicated 
therapies 
(adherence) 
score.  
Predictors 
of 
adherence 
to guideline 
indicated 
medical 
therapy. 
Logistic generalized 
estimating equations 
method. 
 
Age, male sex, body 
mass index, white race, 
insurance status, 
hypertension, diabetes 
mellitus, current/recent 
smoking, previous 
myocardial infarction, 
renal insufficiency, 
positive cardiac 
markers, clinical signs of 
heart failure on 
presentation, presenting 
heart rate, and systolic 
blood pressure. Hospital 
characteristics in the 
model included total 
number of hospital beds, 
geographic region 
(West, Northeast, 
Midwest, or South), 
revascularization 
capabilities (no services, 
diagnostic 
catheterization only, 
percutaneous coronary 
intervention without on-
Patients who were treated in 
low composite adherence to 
guideline-based therapies and 
medication dosing safety 
profiles were older, female, 
have higher heart rate, have 
lower systolic blood pressure, 
have low creatinine clearance 
on admission and more likely 
to be comorbid (e.g. having 
diabetes mellitus or prior 
congestive heart failure). The 
hospitals were smaller, less 
likely to have 
revascularization capabilities 
and the patients less likely to 
be treated by a cardiologist.  
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis 
and potential 
predictors 
investigated 
Key findings 
site cardiac surgery, 
percutaneous coronary 
intervention with on-site 
cardiac surgery), and 
hospital affiliation 
(academic versus non-
academic) 
Abbreviations: OMT; optimal medical therapy, ACEi; angiotensin-converting enzyme inhibitors, ARB; angiotensin-receptor blocker, AMI; acute myocardial infarction, ACACIA; Acute Coronary Syndromes Prospective Audit, 
GWTG-CAD; Get with the Guidelines- Coronary Artery Disease, ACOS; Acute Coronary Syndromes Registry, PCI; percutaneous coronary artery intervention, PPCI; primary PCI, CABG; coronary artery bypass graft, CPACS; 
Clinical Pathways for Acute Coronary Syndromes in China, GRACE; Global Registry of Acute Coronary Events, BMIR; Berlin Myocardial Infarction Registry, RCTs; Randomised controlled trials, EUROASPIRE; European Action 
on Secondary and Primary Prevention by Intervention to Reduce Events, CVD; Cardiovascular disease,  TASPIC-CRO; Treatment and secondary prevention of ischemic coronary events in Croatia, CHD; Coronary heart disease, 
PTCA; percutaneous transluminal coronary angioplasty, PCI; percutaneous coronary intervention, CABG; coronary artery bypass graft, PMSI; programme de médicalisation des sytèmes d’information, ENACT; European Network 
for Acute Coronary Treatment, ACS; acute coronary syndromes, Gulf GRACE; Gulf Registry of Acute Coronary Events, CRUSADE; Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With 
Early Implementation of the ACC/AHA Guidelines, RBC; red blood cell, MI; myocardial infarction, OASIS; Organisation to Assess Strategies for Ischaemic Syndromes, AUBMC; American University of Beirut Medical Centre, 
PDC; proportion of days covered, LHS; Leumit Health Services, BASI; β-blockers, Antiplatelet, statins and ACEi . 
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2.1.3.10 Non-adherence and associated outcomes 
The results of the studies in literature that have assessed poor adherence 
to guideline indicated AMI care and associated outcomes are summarised 
in Table 2.5. Receiving OMT is essential for improved outcomes for AMI 
patients(51-53, 55, 58). Bramlage et al.(51) found that AMI patients who 
received OMT, 1-year mortality was reduced by 74% (adjusted odds ratio 
(OR), 0.26; 95% CI 0.18 to 0.38) compared with those not receiving OMT. 
The OMT risk reduction disappeared after withdrawal of β-blockers and or 
a combination of aspirin and clopidogrel(51). The risk reduction finding was 
consistent with findings by a study by Yan et al.(55) who reported a 46% 
reduction in 1-year mortality for optimally treated patients (adjusted OR 
0.54, 95% CI 0.36-0.81) compared with sub-optimally treated patients. 
Bauer et al (2010)(53) found that patients in group 1 (those who were 
prescribed <4 of the five main cardio-protective drugs) had an elevated risk 
for death at 1-year follow-up (OR 1.6, 95% CI: 1.4–1.9). 
 
A study by Chew et al.(52) assessing the AMI mortality benefits of OMT in 
terms of avoidable deaths found that across the AMI analytical cohort 4 
lives/10,000 (for STEMI 23 lives/10,000 and for NSTEMI 43 lives/10,000)  
could have been potentially saved if all the AMI patients received OMT. The 
study reported that for STEMI patients 213/10,000 non-fatal events could 
have been prevented if all the patients received OMT, likewise 55/10,000 
patients for NSTEMIs(52). Furthermore taking into account long term 
adherence, Chew et al.(52) found that a further 104 lives/10,000 and 191 
recurrent ischaemic events/10,000 could have been prevented if all patients 
received guideline-recommended treatments at hospital discharge and fully 
adhered to them long term. Lower incidence of non-fatal strokes have been 
noted when AMI patients received OMT(53).     
 
Although many of the studies have reported mortality benefits for AMI 
patients receiving OMT as stated above, Danchin et al.(58) found that in 
patients with an ejection fraction of ≤ 35% combined therapy had no survival 
 - 71 -  
 
benefit. Also Bi et al.(54) found that at 12 months follow-up 20 patients from 
the initial analytical cohort had been readmitted for AMI (reinfarction), of 
whom 80% had been adherent to the four drug combination therapy. 
However, Danchin et al.(58) found no survival benefits were observed after 
receipt of OMT for AMI patients with an ejection fraction ≤35%, only β 
blockers and ACEi use had a prognostic value.
 - 72 -  
 
Table 2.5 Literature reviews on studies assessing health outcomes associated with poor adherence to guideline indicated care for 
AMI patients. 
Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis 
and confounders 
adjusted for  
Key findings 
Bramlage 
et al (2010) 
Germany Nationwide 
registry 
(February 
2003 and 
October 
2004). 
Patients with 
AMI (STEMI or 
NSTEMI) 
admitted to 79 
hospitals with a 
cardiology unit 
or internal 
medicine 
department. 
SAMI 
(N=5353) 
Pharmacotherapy 
use at hospital 
discharge 
(Optimal medical 
therapy (OMT): 
aspirin, 
ACEi/ARB, β-
blockers, statin 
and clopidogrel, 
unless 
contraindicated) 
1-year 
mortality 
Logistic regression. 
Age, cardiac arrest on 
presentation, heart rate, 
systolic blood pressure, 
Killip class, ST-segment 
deviation, abnormal 
cardiac biomarker, 
serum creatinine, 
previous MI and heart 
failure, and in-hospital 
revascularisation.   
Total mortality was reduced 
by 74% in patients receiving 
OMT (adj OR 0.26; 95% CI 
0.18 to 0.38). 
 
Withdrawal of β-blockers (adj 
OR 0.63; 95% CI 0.34 to 
1.16) and/or a combination of 
aspirin/clopidogrel (adj OR 
0.59; 95% CI 0.20 to 1.17) 
abolished the risk reduction 
conferred by OMT. 
Rasmussen 
et al (2007) 
Canada Population-
based, 
observational, 
longitudinal 
study (April 1, 
1999 and May 
1, 2003). 
Elderly (aged 66 
years or older) 
AMI survivors 
(surviving at 
least 1 year 3 
months after 
hospitalization) 
recorded in the 
Ontario 
Myocardial 
Infraction 
Database 
Pharmacotherapy 
medication use 
following hospital 
discharge after 
AMI (β-blockers, 
statin and calcium 
channel blockers). 
Long term 
mortality 
(Maximum 
follow-up 
time: 6 
years 4 
months, 
median : 
2.4 years) 
Kaplan-Meier 
plots and the log-rank 
test. 
Cox proportional  
hazards models. 
 
Age, sex, 
socioeconomic status, 
year of admission, 
speciality of attending 
physician, severity of 
Mortality was not associated 
with adherence to calcium 
channel blockers. 
Risk of mortality was highest 
for low statin adherers 
(deaths in 261/1071 (24%) vs 
2310/14 345 (16%); adjusted 
hazard ratio, 1.25; 95% 
confidence interval, 1.09-1.42; 
P=.001 and intermediary for 
intermediate adherers (deaths 
in 472/2407 (20%); adj HR, 
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis 
and confounders 
adjusted for  
Key findings 
(N=31,455) illness, inter-current 
hospitalisations and use 
of respective drug within 
six months prior to 
admission, concomitant 
use of ACEi, statins, β-
blockers and calcium 
channel antagonists.   
1.12; 95% CI, 1.01-1.25; 
P=.03). 
A similar but less pronounced 
dose-response–type 
adherence-mortality 
association was observed for 
β-blockers. (low adherers, HR 
1.13, 95% CI: 1.03-1.25) 
 
Chew et al 
(2009) 
Australia Nationwide 
registry 
(November 
2005 and May 
2006). 
Large-scale 
randomised 
clinical trials 
or meta-
analyses. 
AMI (STEMI or 
NSTEMI) 
admissions from 
39 hospitals 
across Australia 
recorded in 
ACACIA. 
(N=1,630) 
Pharmacotherapy 
use at discharge 
(aspirin, statin, 
clopidogrel, 
ACEi/ARBs and 
β-blockers). 
Timely 
management for 
STEMI (timely 
reperfusion and 
early invasive 
management with 
concomitant 
glycoprotein 
IIb/IIIa inhibition). 
 
Timely 
management for 
MI or stroke 
by 30 days 
and 30 
days to 12 
months. 
Mant–Hicks cumulative 
relative-benefit 
approach for quality of 
care assessment. 
Analysis-of-extremes 
methodology. 
 
Optimal secondary treatment 
saved 23/10,000 (STEMI, 213 
non-fatal events/10,000) and 
43/10,000 (NSTEMI, 55 
recurrent events/10,000) lives 
by 30 days, 104/10,000 by 
12months (both phenotypes 
combined) and prevented 191 
recurrent ischaemic 
events/10,000. 
The novel treatment would 
save a further 4/10,000 lives 
by 12 months. 
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis 
and confounders 
adjusted for  
Key findings 
NSTEMI (timely 
use of invasive 
management and 
glycoprotein 
IIb/IIIa inhibition). 
Bauer et al 
(2010) 
Germany Multicentre, 
prospective, 
observational 
study. (June  
2000 and 
November  
2002) 
Hospital 
survivors of AMI 
(STEMI or 
NSTEMI) from 
155 hospitals 
enrolled in the 
ACOS registry.  
(N=11,823) 
Five discharge 
medication drugs: 
acetyl salicylic 
acid, clopidogrel, 
β-blockers, ACEi/ 
sartan and statin. 
Dichotomised 
receipt of care 
composite score 
i.e. patients 
receiving < 4 
drugs (group 1) or 
receiving 4-5 
1-year 
survival. 
Multiple logistic 
regression models. 
Age >70, sex, prior MI, 
prior stroke, diabetes 
mellitus, peripheral 
artery disease, smoking, 
hypercholesterolemia, 
hypertension, chronic 
obstructive lung 
disease, renal 
insufficiency, 
malignancy, atrial 
fibrillation, left bundle 
branch block, reduced 
left ventricular function, 
acute NSTEMI and 
percutaneous coronary 
intervention within 48 
hours.   
Sub-optimal treatment was 
associated with an increased 
risk of death at 1-year follow-
up (OR 1.6, 95% CI: 1.4–1.9). 
Bi et al 
(2009) 
China Multi-centre 
prospective 
study. 
Patients 
diagnosed with 
suspected AMI 
4 drug 
combination 
therapy: 
Non-fatal 
outcomes  
N/A At 12 months of follow-up, 
20 patients had been 
readmitted for MI or 
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis 
and confounders 
adjusted for  
Key findings 
(September  
2004 and May 
2006) 
or UA admitted 
to 51 hospitals 
participating in 
CPACS. 
(N=2,973 ; 
n=345  NSTEMI, 
n=1,251 UAP 
and n=1,305 
STEMI) 
antiplatelet, β-
blockers, ACEi/ 
ARB and statin. 
reinfarction, of whom most 
(80%) were adherent to 4-
drug combination 
therapy. 
 
Yan et al 
(2007) 
Canada Prospective, 
multicentre, 
observational 
study 
(September 
1999-June 
2001 and 
October 2002-
December 
2003). 
51 hospitals 
participating in 
Canadian ACS 
registry I 
(N=5,312; 
n=4,627 ACS) 
36 hospitals 
participating in 
Canadian ACS 
registry II 
(N=2,359; 
n=1,956 ACS) 
Pharmacotherapy 
 (antiplatelet/ 
anticoagulant, β-
blockers, ACEi 
and lipid 
modifying 
therapies) 
 
1-year 
mortality. 
 
Hierarchical multivariate 
logistic regression.  
Propensity score 
analysis. 
GRACE risk score 
variables (age, cardiac 
arrest on presentation, 
heart rate, systolic blood 
pressure, Killip class, 
ST-segment deviation, 
abnormal cardiac 
biomarker and serum 
creatinine) and in 
hospital 
revascularisation.    
Patients receiving optimal 
care had a significantly lower 
1-year mortality (adjusted OR 
0.54, 95% CI 0.36-0.81, 
p=0.003). 
 
Optimal care was a strong 
independent predictor of one 
year mortality.( adjOR 0.58, 
95%CI 0.37-0.91, p-
value=0.017; propensity 
adjusted OR 0.51, 95%CI 
0.31-0.84, p-value=0.008). 
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis 
and confounders 
adjusted for  
Key findings 
Dachin et 
al (2005) 
France Nationwide 
French 
registry 
(November 1-
November 30 
2000) 
Forty-three 
university 
hospitals, 229 
public hospitals 
and 97 private 
clinics. 
USIC 2000 
study. 
(N=2,119 AMI) 
OMT 
(combination of 
antiplatelets 
agents, β-
blockers and 
statins (triple 
therapy)). 
1-year 
survival 
Multivariate Cox 
regression analysis 
including a propensity 
score analysis for 
prescription of combined 
therapy. 
Age, sex, history of 
hypertension, diabetes 
mellitus, current 
smoking, history of 
myocardial infarction, 
history of congestive 
heart failure, history of 
peripheral arterial 
disease, history of 
stroke, history of chronic 
renal failure, anterior 
location of infarction, 
admission systolic blood 
pressure, admission 
heart rate, use and type 
of reperfusion therapy, 
LVEF, worst Killip class 
during hospital stay, 
development of atrial 
fibrillation, high-degree 
Compared with the 
prescription of any single 
class of secondary prevention 
medications, combination 
therapy offers additional 
protection in patients with AMI 
(HR 0.52, 95% CI 0.33-0.81). 
 
In patients with ejection 
fraction ≤35%, β-blockers and 
angiotensin-converting 
enzyme inhibitors were 
independent predictors of 
survival, and combination 
therapy had no additional 
prognostic value. 
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis 
and confounders 
adjusted for  
Key findings 
atrioventricular block, 
use of percutaneous 
coronary intervention 
during hospital stay, 
prescription of diuretics, 
digitalis, nitrates, triple 
combination therapy at 
discharge, and 
propensity score for the 
use of triple combination 
therapy. 
Longeneck
er et al 
(2013) 
6 middle 
eastern 
countries
: Bahrain 
Kuwait 
Qatar 
Oman 
United 
Arab 
Emirates 
and 
Yemen 
Prospective 
cohort study 
(January-June 
2007) 
72 hospitals, 
Gulf GRACE 
(N=5,813 AMI) 
Performance 
measure: 
Aspirin and β-
blockers within 24 
h on admission 
 Aspirin, β-
blockers and 
ACEi\ ARB and 
lipid lowering 
therapy on 
discharge 
Indicated 
reperfusion 
therapy 
Measurement of 
LDL cholesterol 
In-hospital 
mortality. 
 
Multivariate logistic 
regression. 
Age, sex, nationality, 
cardiovascular disease, 
hypertension, any 
diabetes, smoking, Killip 
class, and GRACE 
score. 
 
Low in-hospital mortality was 
associated with provision of 
reperfusion therapy (OR 0.54, 
p=0.047) and β-blockers 
within 24 hours (OR 0.33, 
P=0.005). 
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis 
and confounders 
adjusted for  
Key findings 
levels during 
hospitalisation. 
OMT derived as a 
composite score 
Hamood et 
al (2015) 
Israel Patient based 
retrospective 
cohort study 
(January 
2005-
December 
2010) 
 
Members of the 
Leumit Health 
Services  
(N=4,655, AMI) 
Pharmacological 
treatment: aspirin, 
β-blockers, ACEi\ 
ARBs, statins and 
combined 
therapy. 
All-cause 
mortality  
Multiple logistic 
regression models. 
Age, gender, ethnicity, 
district, comorbid 
conditions, 
revascularisation, prior 
use of drug, severity of 
disease, and health 
utilisation. 
Compared with patients 
adherent to all four drugs, the 
risk of mortality was 38% 
higher for patients non-
adherent to all medications 
(adj HR, 1.38; 95% CI, 1.06-
1.80; P=0.017).   
Simms et al 
(2015) 
England 
and 
Wales 
Prospective 
cohort data 
from the 
nationwide 
population-
based 
registry; 
MINAP 
(January 
2003-
December 
2010 
247 hospitals in 
England and 
Wales 
(N=112,286, 
STEMI) 
Nine guideline-
recommended 
care opportunities 
along the pathway 
of STEMI care: 
the recording of a 
pre-hospital ECG; 
use of acute 
aspirin; timely 
coronary 
reperfusion (PPCI 
within 120 
minutes or 
thrombolysis 
Risk-
adjusted 
30-day 
mortality 
1-year 
mortality 
Fixed-effects univariable 
logistic regression 
models. 
Kaplan–Meier curves. 
Multi-level fixed effects 
models. 
GRACE risk score 
variables, previous 
history of AMI, angina, 
diabetes mellitus, 
hypertension, peripheral 
Patients ineligible for care had 
higher RAMR than those 
eligible for care (30-days: 
1.7% vs. 1.1%; 1-year: 8.6% 
vs. 5.2%), whilst those with no 
missed care had lower 
mortality than patients with ≥4 
CMOC (30-days: 0.5% vs. 
5.4%, adjusted OR (aOR) per 
CMOC group 1.22, 95% CI: 
1.05–1.42; 1-year: 3.2% vs. 
22.8%, aOR 1.23, 1.13–1.34). 
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis 
and confounders 
adjusted for  
Key findings 
within 60 minutes 
of the call for 
help); the 
individual 
prescriptions of 
aspirin, 
thienopyridine 
inhibitor, β-
blocker, 
angiotensin 
converting 
enzyme inhibitor 
(ACEi) or 
angiotensin 
receptor blocker 
(ARB), HMG CoA 
reductase 
enzyme inhibitor 
(statin); and 
enrolment into a 
cardiac 
rehabilitation 
programme at the 
time of discharge 
from hospital. 
vascular disease, 
previous 
revascularisation, 
coronary angiography, 
stroke, chronic 
obstructive pulmonary 
disease, chronic renal 
failure and chronic heart 
failure. 
Timoteo et 
al (2008) 
Portugal Retrospective 
study 
(2002 and  
2005) 
368 patients 
admitted in 2002 
and 420 patients 
admitted in 2005 
for ACS (with 
Pharmacological 
treatment: aspirin, 
statins, β-
blockers, ACEi, 
clopidogrel and 
In-hospital 
mortality. 
30-day 
mortality. 
Data summarised as 
frequencies and 
percentages. 
There was no difference in in-
hospital mortality (8.2% vs 
6.4%) or 30-day mortality 
(9.0% vs 8.6%), but mortality 
was lower at one-year follow-
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis 
and confounders 
adjusted for  
Key findings 
and without ST-
segment 
elevation). 
glycoprotein IIb\ 
IIIa antagonists. 
Reperfusion 
strategy:  PCI. 
1-year 
mortality. 
Multivariable logistic 
regression.   
Age and sex. 
up (17.1% vs 11.7%, 
P=0.039). 
Statins and β-blockers were 
independent predictors of 
mortality during follow-up, 
with a protective effect. 
Yusuf et al 
(1998) 
Australia
, Brazil, 
Canada, 
USA, 
Hungary 
and 
Poland 
Registry-
based study; 
OASIS (1995-
96) 
 
95 hospitals in 
six countries. 
(N=7,987, 
unstable angina 
or suspected 
myocardial 
infarction 
without ST-
segment 
elevation). 
Use of invasive 
cardiac 
catheterisation 
and 
revascularisation 
procedures. 
Mortality, 
stroke, 
bleeding, 
refractory 
angina and  
readmissio
n for 
unstable 
angina.  
Multilevel logistic 
regression modelling.  
Natural randomisation 
by rates of 
catheterisation by 
country. 
Age, heart rate, systolic 
blood pressure, 
abnormal ECG, 
diabetes, and history of 
heart failure. 
No association was noted 
between rates of cardiac 
catheterisation and major 
cardiac outcomes (death, 
myocardial infarction and 
stroke) at 7 days. 
Rates of refractory angina at 
6 months were lower in the 
two countries with highest 
rates of catheterisation, 
however rates of stroke and 
major bleeding were higher in 
the two countries with highest 
rates of invasive strategies.  
Mehta et al 
(2015) 
United 
States 
CRUSADE 
(January 
2002-
September 
2004) 
283 US 
hospitals 
participating in 
CRUSADE 
(N=39,291, 
NSTE-ACS) 
ACC/AHA 2002 
Class I guideline 
recommended 
therapies which 
included: aspirin 
and/or 
clopidogrel, 
glycoprotein 
All cause 
in-hospital 
mortality 
and major 
bleeding. 
 
 
Logistic generalized 
estimating equations 
method.  
age, male sex, body 
mass index, white race, 
insurance status, 
hypertension, diabetes 
mellitus, current/recent 
For every 10% increase in 
composite adherence at a 
centre, the patients’ in-
hospital mortality fell by 20% 
(OR 0.80, 95% CI 0.67-0.94) 
and for every 10% increase in 
appropriate dosing (safety) at 
a centre, patients’ in-hospital 
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis 
and confounders 
adjusted for  
Key findings 
IIb/IIIa inhibitor, 
any heparin 
(unfractionated or 
low molecular 
heparin), and β-
blockers.  
 
Composite use of 
ACC/AHA 
guideline-
indicated 
therapies 
(adherence) 
score. 
smoking, previous 
myocardial infarction, 
renal insufficiency, 
positive cardiac 
markers, clinical signs of 
heart failure on 
presentation, presenting 
heart rate, and systolic 
blood pressure. Hospital 
characteristics in the 
model included total 
number of hospital beds, 
geographic region 
(West, Northeast, 
Midwest, or South), 
revascularization 
capabilities (no services, 
diagnostic 
catheterization only, 
percutaneous coronary 
intervention without on-
site cardiac surgery, 
percutaneous coronary 
intervention with on-site 
cardiac surgery), and 
hospital affiliation 
(academic versus non-
academic) 
mortality fell by 10% (OR 
0.90, 95% CI 0.83-0.98). 
Non-CABG in-hospital major 
bleeding was directly related 
to guideline-based 
adherence, with a 10% 
increase being associated 
with an increased risk of 
bleeding (OR 1.25, 95% CI 
1.08-1.44). Safety was 
inversely related to major 
bleeding (10% increment OR 
0.93, 95% CI 0.87-0.98).   
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Author 
(Year) 
Country Design 
(Interval data 
collected) 
Setting (N) Treatment Outcomes Statistical analysis 
and confounders 
adjusted for  
Key findings 
Wald et al 
(2003) 
 
N/A Systematic 
review 
(RCTs) 
Published meta-
analyses of 
randomised 
trials and cohort 
studies and a 
meta-analysis of 
15 trials of low 
dose (50-125 
mg/day) aspirin 
Formulation of 
statin, three blood 
pressure lowering 
drugs (thiazide, β-
blockers and 
ACEi), folic acid 
and aspirin. The 
formulation 
defined as the 
pollypill 
Proportiona
l reduction 
in 
ischaemic 
heart 
disease 
(IHD) 
events and 
strokes; life 
years 
gained; and 
prevalence 
of adverse 
effects 
N/A The polypill strategy was 
estimated to reduce 
ischaemic heart disease 
events by 88% (95% CI 84%-
91%) and stroke by 80% 
(71%-87%) 
The polypill strategy could 
largely prevent heart attacks 
and stroke if taken by 
everyone aged 55 and older, 
and everyone with existing 
cardiovascular disease. 
Abbreviations: OMT; optimal medical therapy, ACEi; angiotensin-converting enzyme inhibitors, ARB; angiotensin-receptor blocker, AMI; acute myocardial infarction, ACACIA; Acute Coronary Syndromes Prospective Audit, 
GWTG-CAD; Get with the Guidelines- Coronary Artery Disease, ACOS; Acute Coronary Syndromes Registry, PCI; percutaneous coronary artery intervention, PPCI; primary PCI, CABG; coronary artery bypass graft, CPACS; 
Clinical Pathways for Acute Coronary Syndromes in China, GRACE; Global Registry of Acute Coronary Events, BMIR; Berlin Myocardial Infarction Registry, RCTs; Randomised controlled trials, EUROASPIRE; European Action 
on Secondary and Primary Prevention by Intervention to Reduce Events, CVD; Cardiovascular disease,  TASPIC-CRO; Treatment and secondary prevention of ischemic coronary events in Croatia, CHD; Coronary heart disease, 
PTCA; percutaneous transluminal coronary angioplasty, PCI; percutaneous coronary intervention, CABG; coronary artery bypass graft, PMSI; programme de médicalisation des sytèmes d’information, ENACT; European Network 
for Acute Coronary Treatment, ACS; acute coronary syndromes, Gulf GRACE; Gulf Registry of Acute Coronary Events, CRUSADE; Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With 
Early Implementation of the ACC/AHA Guidelines, RBC; red blood cell, MI; myocardial infarction, OASIS; Organisation to Assess Strategies for Ischaemic Syndromes, AUBMC; American University of Beirut Medical Centre, 
PDC; proportion of days covered, LHS; Leumit Health Services, BASI; β-blockers, Antiplatelet, statins and ACEi . 
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2.2 Critical appraisal of literature   
Critical appraisal of the considered papers was conducted guided by the 
Critical Appraisal Skills Programme (CASP) checklist for cohort studies(76). 
The critical appraisal tool for cohort studies was used because the review 
papers were cohort studies. Of the 29 studies considered for the literature 
review, eleven studies assessed the impact of optimal medical therapy on 
survival of AMI patients(51-61). Assessment of these studies showed that 
although there have been major improvements in the care and outcomes of 
patients with AMI, which is mostly attributed to upstroke in the prescription 
of evidence-based pharmacological therapy, invasive strategies and 
cardiac rehabilitation, a large proportion of eligible patients (median 46.2%, 
IQR 29.1-49.4%), fail to receive appropriate care(51-56, 58-61). 
 
 Definition of optimal medical therapy (OMT) was mainly based on the “all 
or none approach”, which compares AMI patients who have received all the 
considered care interventions they were eligible for versus those who miss 
one or more, for most of the studies(51, 54-58). Chew et al.(52) defined 
receipt of optimal care as being discharged on four or five of the main 
cardio-protective drugs whilst Longenecker et al.(59) created a composite 
score of receipt of care by dividing the total number of care interventions 
received by the patients divided by the total number of care interventions 
they were eligible for amongst the considered care interventions for the 
study. The score was then dichotomised at >85%, using the median to 
guide the cut-off choice. Of the methods applied by the studies the “all or 
none approach has been considered the most robust way of assessing 
quality of care, with this method being considered as the gold standard 
when assessing optimal management of AMI patients. However, the “all or 
nothing” approach has been criticized on being too strict of a criteria to use 
when trying to capture ‘real world’ clinical practice. There is a gap in 
knowledge on the best way to assess quality of care for AMI patients 
capturing ‘real world’ clinical practice.  
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Randomised clinical trials (RCTs) have been conducted and have 
determined the efficacy of the care interventions indicated by the guidelines, 
that is antiplatelet agents, β-blockers, statins, ACEi/ARBs, revascularization 
and reperfusion procedures, and anticoagulants(4, 21-23). However, all the 
studies mainly focused on assessing combined use (OMT) focusing on 
certain care interventions on the AMI care management pathway i.e. the 
main five cardio-protective drugs (aspirin, β-blockers, statins, ACEi/ARBs 
and P2Y12 inhibitors). Only one study included (beyond the five cardio-
protective drugs) reperfusion in the definition of receipt of optimal care(59). 
A major benefit should be expected in receiving all the care interventions 
for which the patient is eligible i.e. coronary angioplasty, enrolment into 
cardiac rehabilitation as well as the cardio-protective drugs. Limiting the 
assessment of optimal medical therapy to select care interventions can 
potentially bias the survival benefits of OMT. Further research is thus 
required investigating the survival benefits offered by the combined use of 
all guideline-indicated care interventions for which the AMI patients are 
eligible, that is across the entire AMI care pathway.  
 
Most of the studies (n=21) considered in the literature review focusing on 
association of mortality or morbidity and quality of care for AMI were based 
on select cohorts (median sample size 6,080, IQR 3,180-11,671), which can 
compromise generalisability as well as statistical power of the studies. Data 
are lacking on evaluation of guideline adherence as well as associated 
outcomes for the larger populations of AMI patients mirroring “real-life 
practice”. In this “Big Data” era, increased availability of vast quantities of 
clinical and administrative data provides an opportunity to evaluate AMI 
adherence to guideline-indicated care and associated outcomes on a 
nationwide basis(77). These electronic health records also provide an 
important opportunity to continuously monitor clinical practice(77). 
 
Receipt of guideline-indicated care as mentioned earlier has been 
confirmed to improve survival for AMI patients in RCTs and similarly in this 
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literature review survival benefits have been reported in past studies for 
patients who receive OMT. However, most of the studies investigated in-
hospital, 30 day and one year survival(51-53, 55, 58, 59, 64, 78). Only one 
study by Rasmussen et al.(67) investigated the association of adherence to 
guideline-indicated care and survival post one year(67). It should be 
expected that optimal care offers survival benefits beyond one year, thus 
further research is needed to assess what impact OMT has on long term 
survival beyond 1 year and to quantify the burden (preventable harm) of not 
receiving optimal care. Excess mortality associated with non-adherence to 
guideline-indicated care for AMI patients should be evaluated. Although 
most of the studies found that combined use of AMI care 
interventions/optimal medical therapy  conferred survival benefits, Danchin 
et al.(58) found that for AMI patients with an ejection fraction ≤35% optimal 
medical therapy (defined as combined use of antiplatelet agents, β blockers 
and statins) had no survival benefits. However only β blockers and ACEi 
use had a prognostic value(58).  
 
Of the two phenotypes of AMI, NSTEMI patients care was reported in the 
literature review to be sub-optimal as they were less likely to receive 
guideline-indicated care interventions compared with their STEMI 
counterparts(53, 71, 79). A lot of extensive work focusing on STEMI quality 
of care only has been undertaken (61, 80, 81), yet the NSTEMI patients are 
possibly the most vulnerable of the AMI phenotypes as they are usually 
significantly older and more comorbid(71) and have poorer survival 
outcomes(53, 78). Extensive research of NSTEMI management is 
essential.  
 
2.2.1 Limitations of statistical methods used in previous 
research  
Logistic regression analysis was employed by most of the studies to assess 
impact of receipt sub-optimal care for AMI patients on mortality i.e. using a 
binary outcome (died: yes/no). With some of the studies implementing 
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multilevel logistic regression models to take into account the clustered 
nature of the data i.e. patients nested within hospitals, which is the correct 
strategy of modelling data as not taking into account data clustering can 
result in underestimation of standard errors hence biased estimates. 
However, implementing logistic regression for time to event data (in this 
instance time to death as they were assessing mortality) can bias the impact 
on mortality of any exposure(82). Analysing  time to event data using 
survival models takes into account not only the fact that the event occurred 
but also when the event occurred(83). Methods like logistic regression are 
not suited to take into account both the event and time aspects during 
modelling. Logistic regression analysis is not designed to handle censoring, 
which is a special type of missing data that occurs in time to event data 
analysis when participants do not suffer the event during the study time 
(follow-up time) or are lost to follow-up (due to change of address/migration 
or they withdraw from the study)(83). Survival models utilize the partial 
information on each subject with censored data to provide unbiased survival 
estimates. The studies found in the literature review should have 
implemented time to event methods such as survival models that cope with 
censored data. However, the logistic regression has been reported to 
suffice for time to event data were the condition is rare and the follow-up 
time short. So the studies that had really short follow-up time for example 
in-hospital mortality, the bias from using this approach could have been 
minimal(82). A few studies did use time to event models in their survival 
modelling; the methods undertaken include Kaplan Meier curves and the 
cox proportional hazards modelling. However, none of the studies gave 
details of checking if the proportional hazards assumption was assessed 
after fitting the cox model.  
 
The main challenge when using observational data is the bias inherent due 
to systematic differences between the observations. The literature review 
conducted mainly focused on observational studies, however only two 
studies used advanced causal inference techniques (i.e. propensity scoring 
and instrumental variable analysis) beyond simple confounder adjustment 
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using multivariable regression models (which is heavily flawed if confounder 
selection is not done correctly).  Yan et al.(55) in their study to evaluate 
optimal medical therapy at hospital discharge in patients with ACS used 
propensity scoring to even out systematic differences between cases and 
controls in their modelling. Yusuf et al.(73) in their study to investigate 
variations between countries in invasive cardiac procedures and outcomes 
in patients with unstable angina or MI without initial ST elevation used a 
natural randomisation approach modelling rates of catheterisation by 
country than the actual catheterisation treatment which is affected by 
selection bias. The rest of the studies did adjust for confounders, however 
no extra detail was given on what governed the choice made to adjust for 
the particular variables adjusted for as confounding variables. Usually 
clinical as well statistical input should be considered when deciding on the 
choice of confounders. Casual diagrams approaches such Directed Acyclic 
Graphs (DAGs)(84) can be used to aid applied researchers when choosing 
a minimal set of variables to adjust for as confounders in statistical 
modelling  when using observational data(84, 85). Adjusting for variables 
on the causal pathway for example mediators can further bias the estimates 
and this is known as the Simpson’s paradox in Epidemiological 
research(84). None of the studies considered in the literature review used 
DAGs to inform their confounder variable choices.  
             
2.3 Key Gaps in the Knowledge and PhD aim  
The literature review conducted in this study showed that the majority of 
previous studies focused on survival benefits  of receipt of optimal care of 
up to one year after AMI. There is a paucity of studies of survival benefits 
beyond one year. Furthermore the definitions of optimal care used by 
previous studies were limited in that they did not include all the care 
interventions for which the patients were eligible for on the AMI care 
pathway. Traditional statistical methods such as multivariable logistic 
regression used by some of the previous studies may produce biased 
results because they do not take into account the time to event aspect of 
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survival data. There is need for more research to assess survival benefits 
beyond one year of receipt of optimal care considering all the care 
interventions on the AMI care pathway beyond the five main 
pharmacotherapy drugs.  
 
However, extensive work needs to be focused on the more vulnerable of 
the two AMI phenotypes which is NSTEMI.  Advanced time to event 
statistical methods need to be applied when assessing the efficacy of 
optimal care. Also, appropriate techniques to minimise measured and 
unmeasured confounding inherent when using observational data need to 
be applied. The increased availability and accessibility to electronic health 
records data allow for higher resolution investigation of sequential care 
deficits significantly associated with premature cardiovascular death. 
Therefore, the aim of this PhD project was to investigate the quality of care 
and associated outcomes of patients hospitalised with AMI using electronic 
health records focusing mainly on NSTEMI patients. The utility of using  
robust statistical methods of adjusting for potential confounders was also 
explored. 
 
2.3.1 Research objectives  
1. Quantifying excess mortality (avoidable deaths) associated with sub-
optimal treatment of NSTEMI patients and determining predictors of 
sub-optimal treatment (results reported in Chapter 4). 
2. Assess geographic variation in receipt of care for NSTEMI patients 
and determine the factors that explain the variation (results reported 
in Chapter 5). 
3. Investigating the association of clinical factors and therapeutic 
strategies with improvements in survival following STEMI. (results 
reported in Chapter 6). 
4. Determining the efficacy of β-blockers during and after AMI in 
patients without heart failure or LVSD. (results reported in Chapter 
7).
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Chapter 3 : Materials and Methods 
3.1 Introduction  
This chapter gives an account of the methods used in the thesis. Firstly, an 
overview of the study population and design is given in §3.2. This is followed 
by a description of the data source (§3.3) that was used for the thesis as 
well as a detailed description of the corresponding ethical considerations 
(§3.3.1). The details of the guideline-indicated care pathway for NSTEMI 
patients as recommended by the ESC guidelines and ESC Expert 
Consensus Documents (published from 2002-2011) will then follow (§3.4), 
including a detailed description of how the NSTEMI care interventions were 
mapped to MINAP data fields (Table 3.1). Quality of care definition is given 
in §3.4.1. §3.5 focuses on statistical analyses methodology used throughout 
the thesis, this includes details of the descriptive data analyses, methods 
for handling missing data, and statistical modelling for each of the PhD 
objectives in turn as listed below; 
 Quantifying excess mortality (avoidable deaths) associated with 
sub-optimal implementation of care for NSTEMI patients and 
determining predictors of sub-optimal care (objective 1, results 
reported in Chapter 4). §3.6 
  Assess geographic variation in receipt of care for NSTEMI patients 
and determine the factors that explain the variation (objective 2, 
results reported in Chapter 5).§3.7  
 Investigating the association of clinical factors and therapeutic 
strategies with improvements in survival following STEMI. 
(objective 3, results reported in Chapter 6).§3.8  
 Determining the efficacy of β-blockers during and after AMI in 
patients without heart failure or LVSD. (objective 4, results 
reported in Chapter 7).§3.9  
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3.2 Study population and design  
The study aimed to provide a comprehensive investigation of quality of care 
and outcomes of patients hospitalised with AMI using electronic health 
records (EHRs), therefore a retrospective analysis of all patients recorded 
in MINAP was carried out. The study population consisted of all patients 
aged over 18 years recorded within MINAP between 1st January 2003 and 
30th June 2013 (787,202 AMI observations to date), who had been 
hospitalised with AMI. For patients with multiple admission of AMI recorded 
in MINAP, only the first record was used. Focusing on the first record of 
each patient was conducted so as to reduce potential bias from previous 
treatment in relation to subsequent admissions.  
3.3 Data sources  
Of the data sources discussed in Chapter 1, §1.6, MINAP was considered 
most appropriate to carry out the work for the thesis. MINAP was deemed 
appropriate as it is a comprehensive large national registry of ACS across 
one health system (the National Health Service (NHS) in England and 
Wales). MINAP strengths also lies in that it was specifically designed to 
assess quality of ACS care and its diagnostic records (highly likely to fulfil 
international diagnostic criteria) are not available in other data sources(86).  
 
3.3.1 Ethical approval and data security  
Ethical approval was not required for this study as the National Institute for 
Cardiovascular Outcomes Research (NICOR), where the MINAP database 
(Ref: NIGB: ECC 1-06 (d)/2011) was obtained has support under section 
251 of the NHS Act 2006 to use patient information for medical research 
without consent. The MINAP data obtained from NICOR was 
pseudonymised patient data, and according to the Health Research 
Association (HRA), secondary use of anonymised patient data for research 
purposes were not subject to further ethical approval. I also used the HRA 
decision tool to further confirm I did not need approval from the NHS 
 - 91 -  
 
Research Ethics Committee (REC) for my study. Approval was not needed 
by the NHS REC. (See Appendix A for HRA-decision tool output) 
The MINAP patient data used for this thesis were fully anonymised and 
stored on the University of Leeds N Drive, which has restricted access only 
to the authorised members within the Cardiovascular Epidemiology 
research group. Access to University of Leeds computing resources 
requires a credential check on log in, and compulsory data security training.  
 
3.4 Guideline indicated care interventions  
Treatment of AMI patients is defined by several national and international 
guidelines(4, 16, 22-24, 87). Cardiologists in the UK use guidelines from the 
NICE and from the ESC to guide clinical decision making(88). 
Recommendations from both guidelines are based on the same evidence 
base(88). For this thesis, the ESC international guidelines were used to 
assess adherence to guidelines during the management of NSTEMI 
patients because the ESC guidelines are updated more frequently/timely in 
response to temporal developments in management of AMI compared to 
NICE guidelines and ESC guidelines are more generalisable to an 
international audience as they are derived intended for implementation 
across 56 countries. The full NSTEMI care pathway as described within the 
ESC guidelines and ESC consensus documents (published from 2002-
2011) is summarised in Figure 3.1. (21, 89-92)   
 
The identified NSTEMI care interventions from the treatment pathway as 
recommended by the guidelines, were mapped to MINAP data fields in 
order to determine which care interventions could be reliably assessed, 
based on data availability and adequate data quality or recording, using 
MINAP (Table 3.1). Figure 3.1 also gives information on which interventions 
from the full care pathway were and were not used and Table 3.1 gives a 
detailed description of the reasons why the excluded care interventions 
were not considered for the analyses.   
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Figure 3.1 European Society of Cardiology guidelines for the management of NSTEMI, care interventions and corresponding MINAP 
data availability. 
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Table 3.1. Mapping of corresponding ESC guidelines for the management of NSTEMI to MINAP data fields. 
Care Pathway Components – Detail 
Care Pathway 
Components 
Eligibility Criteria Opportunity Received Include in OMT definition 
(Yes/No)  
12 lead ECG    
          Pre-Hospital All patients arriving via ambulance 
 
if admission method=1 (2.39)  
ecg_place (1.23) = 1 Yes 
          In-Hospital All patients not already received ECG pre-hospital 
 
if pre hospital ecg = no. 
(Ecg_app!=. or ecg_place!=.) 
and no pre-hospital ECG. 
Yes  
Aspirin    
         Pre-Hospital All patients arriving via ambulance and not already 
on aspirin or contraindicated 
 
if admission method=1 (2.39) AND where was 
aspirin given (2.04)!=1,4 or 8   
Where was aspirin given 
(2.04)=2 
Yes  
          
         In-Hospital 
 
All patients not already on aspirin or contraindicated 
 
if pre-hospital aspirin = no AND where was aspirin 
given (2.04)!=1,4 or 8  
 
Where was aspirin given 
(2.04)=3 
Yes 
          
      At Discharge 
 
All patients not already on aspirin or contraindicated 
 
if pre-hospital aspirin= no AND in-hospital aspirin=no 
AND where was aspirin given (2.04)!=1,4 or 8 AND 
discharged on aspirin (4.08)!=2,3,4 or 8. 
 
Discharged on aspirin (4.08)=1 
 
Yes 
P2Y12 inhibitor    
         In-Hospital All patients not contraindicated and without high risk 
of bleeding 
 
If thienopyridine (3.22)=1 No- not well recorded in 
MINAP. 
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Care Pathway Components – Detail 
Care Pathway 
Components 
Eligibility Criteria Opportunity Received Include in OMT definition 
(Yes/No)  
        At Discharge All patients not contraindicated and without high risk 
of bleeding 
 
If discharged on thienopyridine (4.27)!=2,3,4 or 8  
Or if discharged on ticagrelor!=2,3,4,8  
 
If discharged on 
thienopyridine=1 or if 
discharged on ticagrelor=1 
Yes 
Glycoprotein (GP) 
IIb/IIIa 
 
High risk patients already treated with aspirin and 
P2Y12 inhibitor and low risk of bleeding. 
 
If aspirin=yes at any time point (including taken at 
home) AND if P2Y12 is yes at any time point AND 
patient is “high risk” 
 
Where “high risk” in this case is any of the following: 
High risk nSTEMI=1 (4.32) OR Troponin elevated 
OR Grace>140 
 
UK Guidelines only: People who received 
angiography/PCI within 24hours were also eligible. 
If IV_2b/3a (3.24) = 1 No, can’t identify all 
eligibility criteria (low risk of 
bleeding and visible 
thrombus data not 
available). 
 
 
Anticoagulation All patients If unfractioned heparin (3.20) 
=1 OR if low molecular weight 
heparin (3.21) = 1 OR if 
fondaparinux (3.38) =1 
No- not well recorded in 
MINAP. 
Angiography Timing    
            Urgent Invasive  
        (<120 min) 
High risk patients defined by refractory angina, 
recurrent angina despite intense antianginal 
treatment,clinical symptoms of heart failure or shock, 
life-threating arrhythmias. 
 
If time from first medical 
contact to angiography is <120 
minutes 
No – cannot accurately 
define all “high risk” factors 
for this (i.e. refractory 
angine, recurrent angina). 
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Care Pathway Components – Detail 
Care Pathway 
Components 
Eligibility Criteria Opportunity Received Include in OMT definition 
(Yes/No)  
Shock=yes: If Systolic blood pressure>90 OR killip 
class=2, 3 or 4 
Heart Failure=yes: if heart failure (2.13)=1 
Cardiac arrest=yes if delay before treatment 
(3.10)=5 OR cardiac arrest location=2,3,4,5,6,7 or 8 
OR arrest presenting rhythm (3.15)=1,2, or 3 OR 
outcome of arrest=1,2,3,4,5 or 6. 
          Early Invasive   
         (<24 hours) 
 
 
High risk patients as defined below. 
 
If high risk nSTEMI=1 (4.32) OR Troponin elevated 
OR GRACE>140  
 
If time from first medical 
contact to angiography is <24 
hours  
No – cannot accurately 
define all “high risk” factors 
for this (i.e. dynamic ST or 
T wave changes). 
 
         Invasive   
         (<72 hours) 
[adjust as      necessary 
for different guidelines]. 
 
Patients with one or more secondary high risk 
criterion as defined below. 
 
If Diabetes (2.17)=1,2,3,4,5 OR chronic renal 
failure=1 OR creatine (2.14)>200 OR LV function 
(2.31)=3 OR history of CHD (2.32)=1 OR previous 
PCI (2.18)=1 OR previous CABG (2.19)=1 OR 
Intermediate GRACE >109 & <=140. 
If time from first medical 
contact to angiography is <72 
hours 
Yes.  
β-Blocker  
 
All patients with reduced LV function and no 
contraindications.  
 
If LV Function (2.31)=3 OR history of CHD (2.32)=1 
AND discharged on beta blocker (4.05)!=2,3,4 or 8. 
 
NOTE: For UK guidelines everyone is eligible for β-
Blockers.  
If  discharged on beta 
blocker(4.05)=1 
 
If oral beta blocker (3.43)=1 
and if discharged on beta 
blocker(4.05)=1 
Yes 
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Care Pathway Components – Detail 
Care Pathway 
Components 
Eligibility Criteria Opportunity Received Include in OMT definition 
(Yes/No)  
ACE inhibitors/ARBs 
 
All patients with reduced LV function and no 
contraindications.  
 
If LV Function (2.31)=3 OR history of CHD (2.32)=1 
AND  
if discharged on ACEi/ARB (4.06)!= 2,3,4,8. 
 
If ACEi/ARB (3.32)=1 OR if 
discharged ACEi/ARB 
(4.06)=1 
Yes 
Statin All patients unless contraindicated  
 
If statin (4.06) is yes or no (i.e. exclude 
contraindications, not applicable, unknown etc). 
If statin (4.06)=1 Yes 
Aldosterone 
antagonist/eplerenone 
Patients with depressed LV function (LVEF ≤35%) 
and either diabetes or heart failure, without 
significant renal dysfunction  and already treated 
with ACE inhibitors and β blockers 
 
 
If aldosterone (4.33)=yes. Yes 
Echocardiography  All patients unless not indicated. 
 
If stress echo!=8  
OR if echocardiography (4.11)!=8 
 
 
If stress echo=1 or 2 OR if 
echocardiography=1 OR 2. 
Yes. 
Referral for Cardiac 
Rehabilitation  
All patients eligible unless not indicated 
 
If cardiac rehabilitation (4.09)!=8  
If cardiac rehabilitation 
(4.09)=1 or 3 
Yes 
Smoking Cessation 
Advice 
All patients eligible unless not applicable 
 
If smoking cessation (5.01)!=3 
If smoking cessation (5.1)=1 
OR 2 
Yes 
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Care Pathway Components – Detail 
Care Pathway 
Components 
Eligibility Criteria Opportunity Received Include in OMT definition 
(Yes/No)  
Dietary Advice All patients eligible if applicable. 
 
If dietary advice (5.2)!=4 
If dietary advice (5.2)=1 OR 3  
 
 
Yes  
Abbreviations: CHD, coronary heart disease; PCI, percutaneous coronary intervention; OMT, optimal medical therapy, ESC; European Society Of Cardiology; MINAP, Myocardial Ischaemia National 
Audit Project, LVEF, left ventricular ejection fraction; ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers. 
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3.4.1 Quality of care definition  
The 13 guidelines indicated care interventions that were considered for the 
present study after mapping and data assessment were as follows: 
 recording of an electrocardiogram (pre-hospital and on admission 
combined) 
 prescription of aspirin acutely (pre-hospital and on admission 
prescription of aspirin) 
 P2Y12 inhibitors at discharge 
 aspirin at discharge 
 β blockers at discharge  
 ACEi or ARBs at discharge  
 a HMG CoA reductase enzyme inhibitors (statins) at discharge  
 aldosterone antagonists in patients with left ventricular systolic 
dysfunction and either diabetes or heart failure without significant 
renal dysfunction 
 echocardiogram 
 coronary angiography 
 smoking cessation advice 
 dietary advice 
 enrolment into a cardiac rehabilitation programme. 
Patients were deemed eligible for each treatment as recommended by ESC 
guidelines and patients were considered ineligible if a care intervention was 
contra-indicated, not indicated, not applicable or if the patient declined 
treatment as documented in MINAP. If a patient was hospitalised before 
treatment was introduced into the guidelines, they were also considered 
ineligible for the treatment (for example, P2Y12 inhibitors were not 
introduced to the guidelines until 2004 and aldosterone antagonists until 
2007). The considered guideline-indicated care interventions were chosen 
as they are representative of the guideline-indicated care interventions that 
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span the full NSTEMI care pathway and give an opportunity to assess the 
impact of cumulative missed opportunities for care on avoidable deaths 
after suffering an NSTEMI. In order to assess quality of care, a suitable 
aggregation method of the multiple, individual care interventions had to be 
employed to define receipt of optimal care for NSTEMI patients.  
 
Composite performance measures that are commonly used for healthcare 
performance assessment include; opportunity scoring, linear combinations 
approach, regression-based composite measures, latent trait composite 
measures, all-or-none scoring/defect-free scoring, and any-or-none scoring 
of outcome measures(93). Of these various approaches the all-or-none 
scoring/defect-free scoring, opportunity scoring, and latent trait composite 
measures were used for objective one and two of the thesis. 
 
The all-or-none scoring/defect-free scoring was chosen as it promotes a 
high standard of health care assessment, it gives greater variation in scores 
of receipt of care and is structured at patient level(94, 95). Using this 
approach, for each patient a score was calculated by dividing the total 
number of care interventions for which the patient received by the total 
number they were eligible for (opportunity scoring) and then grouping the 
patients by their score into an optimal care group (received all care 
interventions) vs. sub-optimal care group (missed one or more care 
interventions for which they were eligible)(95). This method has been 
deemed the gold standard measure of assessing quality of care for patients.  
 
However, because the all-or-none scoring/defect-free scoring is a strict 
method of defining optimal care (although it offers a gold standard 
definition), it weights less important commonly prescribed care interventions 
equally to infrequently prescribed more important care interventions and 
does not capture ‘real world’ clinical practice, an alternative method had to 
be employed as a sensitivity analysis. The latent trait composite measures 
approach: Latent Class Analysis (LCA) was conducted. LCA identifies 
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complex patterns of association among observations based on observed 
characteristics(96). This method is commonly implemented when variables 
are related due to unobserved influences. For this thesis, LCA was used to 
identify the underlying subgroups of receipt of care based on the 13 
guideline-indicated care interventions considered, with the underlying 
unobserved influence in this case being quality of receipt of care. LCA is 
used when the underlying unobserved variables are classes, categories or 
discrete(96). The method estimates the latent class prevalences (class 
probabilities) as well as the probabilities of specific response given class 
membership (conditional item probabilities)(96). The conditional item 
probabilities are specific to a given class and provide information about the 
probability that an individual in that class will endorse that item (97, 98). The 
class probabilities specify the proportion of the population that is in a 
particular class(97, 98).  
 
The advantage of using the LCA approach compared with the all-or-none 
scoring/defect-free scoring is that it allows modelling the real life scenario 
of receipt of care, which goes beyond a dichotomised composite measure 
by considering the actual combinations of care interventions which the 
patients receive and classifying them into groups which are both statistically 
valid and clinically interpretable. The demographic and socioeconomic 
factors associated with the latent classes can be determined to help 
characterise the subgroups.  The classes are latent in that the underlying 
sub-groups are not directly observed(99). Latent classes of receipt of care 
using the 13 observed guideline-indicated care interventions were derived 
using Mplus software(99, 100). 
 
In order to determine the optimal class solution that could adequately 
describe the patterns of receipt of care for the NSTEMI patients, several 
class solutions starting from two up to seven classes were explored. The 
preferred latent class solution was selected based on minimisation of the 
Bayesian Information Criteria (BIC) and Akaike’s Information Criterion (AIC) 
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(101), clinical interpretability of the emergent latent classes and the class 
solution where the log likelihood plot started to level off. The log likelihood 
plot is a plot of the log likelihood of the different class solutions models 
against the number of latent classes. The best class solution is determined 
by the point where the plot levels off.  When using AIC and BIC criteria to 
compare nested models, the  model  with minimal AIC and BIC are 
indicative of best fit. When there is a discrepancy between the AIC vs. BIC 
when determining the optimal class solution, the BIC would be considered 
as BIC has been shown to outperform AIC especially when small classes 
are present(102).  A seven class solution was considered as the maximum 
as class solutions beyond seven were not clinically interpretable. The 
entropy statistic was also calculated to evaluate classification quality of the 
optimal class solution. Entropy values range from 0 to 1 and closer to 1 
indicates a latent class solution that is more distinct(103). 
 
3.5 Statistical analysis  
Statistical analyses were performed in Stata MP64, version 14 
(StataCorp,www.stata.com). R version 3.1.2 (https://cran.r-
project.org/bin/windows/base/) was used to perform multiple imputation by 
chained equations (MICE) using the ‘mice’ package and Mplus version 7 
was used to conduct latent class analyses. All the tests were two-sided and 
P-values of <0.05 were considered statistically significant. 
 
3.5.1 Descriptive data analysis  
For each of the four objectives, four different analytical cohorts were derived 
from the MINAP database based on the exclusion criteria for the specific 
objective (§3.6.1, §3.7.1, §3.8.1, §3.9.1). Baseline characteristics for the 
analytical cohorts for the four objectives of the thesis were summarised as 
frequencies and percentages for categorical data and continuous data as 
means and standard deviations (normally distributed) or medians and 
interquartile ranges (IQR) (non-normally distributed). Unadjusted and 
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adjusted Kaplan-Meier curves were used to assess survival differences for 
objective one and four. The log rank test was used to compare survival 
differences for the unadjusted Kaplan-Meier curves for objective one.  For 
objectives three and four differences in characteristics were assessed using 
two sample t-tests and, for categorical data, the Chi-square tests, and test 
of proportions.  
 
3.5.2 Handling missing data 
Electronic health records offer a vast amount of routine data, however the 
major weakness of using these resources is missing data, which if left 
unaddressed could result in biased estimates (e.g. regression parameters), 
biased standard errors (e.g. incorrect p-values and confidence intervals) 
and inefficiency due to exclusion of observations with missing data hence 
limiting the generalisability of study findings(104). There are several 
reasons why data ends up missing which include; data never being 
collected , being lost accidentally, incorrectly recorded such that it has to be 
deleted or even wrongly deleted(104). Thus missing data have different 
mechanisms of missingness which must be taken into account when 
making inference using the data. The missing data mechanisms that are 
recognised in literature are as follows; missing completely at random 
(MCAR), missing at random (MAR), and the missing not at random 
(MNAR)(105, 106). There is no definitive way of determining which 
mechanism the missing data follows therefore the decision is centred on 
assumptions that should be reasonable and sensible given the situation. 
The missing data mechanisms mentioned are assumptions made on why 
the data is missing and they inform on the type of strategy that is utilised to 
handle the missing data. MCAR mechanism is assumed when the 
missingness of the data is not dependent on observed or unobserved 
values of the data, such that there are no systematic differences between 
the observed and missing data(105). For the MCAR mechanism the existing 
data cannot be used to predict the missing data(105). An example of when 
data can be said to be missing by the MCAR mechanism is when a 
laboratory sample is dropped accidentally(105). MAR mechanism is 
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assumed when the missingness of the data depends on observed data but 
not on the unobserved, such that the systematic differences between the 
observed and missing data can be explained by the observed data(105). 
An example of when data can be said to be missing by the MAR mechanism 
is when data on PCI for elderly comorbid AMI patients is missing. PCI data 
would be MAR conditional on the patients’ age and comorbidity profile. 
Under the MAR mechanism assumption the observed data can be used to 
predict the missing data(105). MNAR mechanism is assumed when the 
missingness of the data depends on unobserved data (non-ignorable or 
informative missingness), such that the observed data cannot explain the 
systematic differences between the missing and observed data(105).  An 
example of when data can be said to be missing by the MNAR mechanism 
is when a patient misses an appointment because they are feeling unwell 
and their illness is related to the data intended to be collected(105). As I 
mentioned before identifying the missing data mechanism is important 
when deciding the strategy to handle missing data to minimise the negative 
implications of drawing inference from incomplete datasets. Several 
methods have been used  in literature to handle missing data and these 
include listwise deletion, single imputation, single regression imputation, 
multiple imputation, maximum likelihood estimation and inverse probability 
weighting(107). Of these methods, the most commonly used in 
epidemiological research are listwise deletion, single imputation, single 
regression imputation, and multiple imputation. The techniques have been 
proven to be robust when handling ignorable missing data, i.e. data missing 
at MCAR and MAR. Details on the methods for handling missing data are 
given below: 
3.5.2.1 Listwise deletion 
The listwise deletion methods which involve excluding subjects with missing 
data (complete case analysis)  usually suffice for data that is missing under 
the MCAR mechanism(107). The methods are very simple and easy to 
implement however exclusion of subjects with missing data compromises 
precision. Complete case analysis has also been reported to suffice in 
incidences when there is minimal  missingness (~5% )(108, 109). For this 
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thesis this mechanism was not implemented as some of the variables 
considered for the various analyses had missing data >5%.   
3.5.2.2 Single imputation 
Single imputation involves filling in missing data with an alternative value 
and then analysing it as if it were the true complete data(107). Examples of 
this technique are single mean imputation and the “last observation carried 
forward”(107).  The single mean imputation approach is specifically for 
continuous data whereby the missing data is replaced with the mean. The 
“last observation carried forward” approach is most commonly used for 
imputing longitudinal data with main assumption being that after loss to 
follow-up the value that was last recorded will suffice to replace the missing 
data(107). The single imputation methods have the same advantage as the 
listwise deletion methods in that they are simple and easy to implement 
however this results in reduced standard errors as they produce data that 
is highly concentrated around the mean. Single imputation does not take 
into account uncertainty in the missing data. It only works well when there 
is minimal missing data. In this thesis single imputation was not used 
because of the limitations described in this section. 
3.5.2.3 Regression imputation 
Regression imputation involves using a regression model adjusted for 
variables that are predictive of the missing data to predict the missing 
data(107). Similar to the techniques discussed before, this technique  is 
simple and easy to implement however the method does not take it account 
the uncertainty in the missing values and usually exaggerates correlations. 
The predictor variables used in the regression model should not have 
missing data in them or else this will bias the predicted data.   
3.5.2.4 Multiple imputation  
Multiple imputation is regression imputation repeated many times to 
account for uncertainty about the missing data(110). This is achieved by 
creating several ‘complete’ datasets whereby in each dataset the missing 
values are filled in by regression imputation(110). Analysis is then 
undertaken on each of the imputed datasets and the parameter estimates 
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are pooled using Rubin’s rules(111) to get the final parameter estimate. The 
multiple imputation approach is highly applicable when data are MAR and 
the more predictive variables included in the multivariate model the more 
accurate the predictions(110).  Multiple imputation has advantages over the 
other missing data techniques in that it accounts for the uncertainty about 
the missing data by the use of multiple ‘complete’ datasets which yields 
more precise standard errors. The technique is very flexible in that it can 
handle different types of variables i.e. continuous or categorical data(110). 
Also multiple imputation is useful when there is high levels of missing data. 
An example of a multiple imputation approach is MICE.  
 
As with other sources of data arising from EHRs, MINAP also has missing 
data that needs to be addressed before making inference using it. So before 
proceeding on to analyses for each of the four objectives of the thesis 
missing data were imputed using the multiple imputation approach; MICE 
(using mice package in R software)(105, 112). The decision to use this 
approach was informed by past literature that has imputed missing data for 
MINAP(105) and from prior statistical knowledge (discussed in §3.5.2.4)   on 
the utility of the multiple imputation approach compared with other 
techniques discussed in the earlier section (§3.5.2). Also, the same default 
imputation strategy used for medical history and drug therapies by Cattle et 
al.(105) was used for medical history and drug therapies for the work of this 
thesis. The default imputation strategy involves replacing the missing data 
for the binary medical history and drug therapies variables with a “no”. As 
upon consultation with the medical and clerical staff involved in derivation 
of MINAP, Cattle et al.(105) reported that it was more likely that a condition 
or treatment would go unrecorded if the patient had no history of the 
condition or did not receive treatment. Other studies considered in the 
literature review have also implemented the default imputation strategy 
approach(71).  The imputation strategies detailing the variables that were 
imputed, the variable types, level of missing data per variable, and 
imputation method employed  for the four objectives are given in Table 3.2-
Table 3.4 below. 
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Table 3.2. Imputation Strategy for objective 1(§2.3.1) and objective 2 
(§2.3.1). 
Variable Variable 
Type 
Missing 
(%) 
Imputation method 
ECG appearances on which 
treatment was based 
Categorical 9.2 Polytomous regression 
Cardiac arrest Binary 5.9 Logistic regression 
Uncensored peak troponin 
measurement in ng/ml 
Continuous  4.9  Predictive mean 
matching 
Age Continuous 0.2 Predictive mean 
matching 
Systolic blood pressure Continuous 17.1 Predictive mean 
matching 
Heart rate Continuous 16.9 Predictive mean 
matching 
Loop diuretic used Binary  17.4 Logistic regression 
Creatinine level Continuous 42.6 Predictive mean 
matching 
Ethnicity Categorical  9.8 Polytomous regression 
Sex Binary  0.2 Logistic regression 
Index of multiple deprivation 
score 
Continuous 7.8 Predictive mean 
matching 
Latent classes Categorical  0 Predictor/ Auxiliary 
/Partially Observed 
Cumulative receipt of care Continuous 0 Predictor/ Auxiliary 
/Partially Observed 
Optimal care* Binary  0 Predictor/ Auxiliary 
/Partially Observed 
Year of admission  Continuous 0 Predictor/ Auxiliary 
/Partially Observed 
Nelson-Aalen survival estimate Continuous 0 Predictor/ Auxiliary 
/Partially Observed 
Censoring indicator Binary 0 Predictor/ Auxiliary 
/Partially Observed 
Previous myocardial infarction Binary 8.0 Predictor/ Auxiliary  and 
Default imputed 
Previous angina Binary 8.9 Predictor/ Auxiliary  and 
Default imputed 
Hypercholesterolaemia Binary 11.0 Predictor/ Auxiliary  and 
Default imputed 
Previous hypertension Binary 8.3 Predictor/ Auxiliary  and 
Default imputed 
Peripheral vascular disease Binary 11.5 Predictor/ Auxiliary  and 
Default imputed 
Cerebrovascular disease Binary 10.6 Predictor/ Auxiliary  and 
Default imputed 
Chronic obstructive pulmonary 
disease or asthma 
Binary 11.4 Predictor/ Auxiliary  and 
Default imputed 
Congestive cardiac failure Binary 10.4 Predictor/ Auxiliary  and 
Default imputed 
Previous percutaneous coronary 
intervention 
Binary 10.1 Predictor/ Auxiliary  and 
Default imputed 
Previous coronary artery bypass 
graft 
Binary 9.8 Predictor/ Auxiliary  and 
Default imputed 
Smoker (current or previous 
smoker vs. non-smoker) 
Binary 7.5 Predictor/ Auxiliary  and 
Default imputed 
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Variable Variable 
Type 
Missing 
(%) 
Imputation method 
Diabetes mellitus Binary 7.1 Predictor/ Auxiliary  and 
Default imputed 
Family history of chronic heart 
disease 
Binary 37.3 Predictor/ Auxiliary  and 
Default imputed 
Care by cardiologist Binary 39.1 Predictor/ Auxiliary  and 
Default imputed 
*Defined as receipt of all care interventions for which the patients were eligible for.   
Abbreviations: ECG, Electrocardiogram. 
 
Table 3.3. Imputation Strategy for objective 3 (§2.3.1). 
Variable Variable 
Type 
Missing 
(%) 
Imputation method 
Cardiac arrest Binary 7.9 Logistic regression 
Uncensored peak troponin 
measurement in ng/ml 
Continuous  22.0 Predictive mean 
matching 
Age Continuous 0.1 Predictive mean 
matching 
Systolic blood pressure Continuous 22.3 Predictive mean 
matching 
Heart rate Continuous 21.9 Predictive mean 
matching 
Loop diuretic used Binary  24.0 Logistic regression 
Creatinine level Continuous 45.6 Predictive mean 
matching 
Ethnicity Categorical  12.3 Polytomous regression 
Sex Binary  0.4 Logistic regression 
Index of multiple deprivation 
score 
Continuous 8.3 Predictive mean 
matching 
Year of admission  Continuous 0 Predictor/ Auxiliary 
/Partially Observed 
Nelson-Aalen survival estimate Continuous 0 Predictor/ Auxiliary 
/Partially Observed 
Censoring indicator Binary 0 Predictor/ Auxiliary 
/Partially Observed 
Hypercholesterolaemia Binary 16.5 Predictor/ Auxiliary  and 
Default imputed 
Previous hypertension Binary 13.2 Predictor/ Auxiliary  and 
Default imputed 
Previous myocardial infarction Binary 12.8 Predictor/ Auxiliary  and 
Default imputed 
Previous angina Binary 14.1 Predictor/ Auxiliary  and 
Default imputed 
Previous PCI Binary 15.0 Predictor/ Auxiliary  and 
Default imputed 
Previous CABG Binary 14.8 Predictor/ Auxiliary  and 
Default imputed 
Peripheral vascular disease Binary 16.2 Predictor/ Auxiliary  and 
Default imputed 
Cerebrovascular disease Binary 15.6 Predictor/ Auxiliary  and 
Default imputed 
Chronic obstructive pulmonary 
disease or asthma 
Binary 16.2 Predictor/ Auxiliary  and 
Default imputed 
Smoker (current or previous 
smoker vs non-smoker) 
Binary 9.7 Logistic regression 
Diabetes mellitus  Binary 11.2 Predictor/ Auxiliary  and 
Default imputed 
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Variable Variable 
Type 
Missing 
(%) 
Imputation method 
Family history of chronic heart 
disease 
Binary 36.3 Predictor/ Auxiliary  and 
Default imputed 
Care by cardiologist Binary 38.3 Predictor/ Auxiliary  and 
Default imputed 
Chronic renal failure Binary  15.5 Predictor/ Auxiliary  and 
Default imputed 
Congestive cardiac failure Binary 15.3 Predictor/ Auxiliary  and 
Default imputed 
Electrocardiogram appearance  Categorical 3.5 Polytomous regression 
Preadmission medication    
  Aspirin Categorical 0 Predictor/ Auxiliary  and 
Default imputed 
  β-blockers Categorical 33.7 Predictor/ Auxiliary  and 
Default imputed 
  Statins Categorical 31.1 Predictor/ Auxiliary  and 
Default imputed 
  ACEi or ARBs Categorical 33.8 Predictor/ Auxiliary  and 
Default imputed 
  P2Y12 inhibitors Categorical 63.2 Predictor/ Auxiliary  and 
Default imputed 
  Warfarin Categorical 23.9 Predictor/ Auxiliary  and 
Default imputed 
Discharge medication     
  Aspirin  Categorical 9.3 Polytomous regression 
  P2Y12 inhibitors  Categorical 60.4 Polytomous regression 
  ACEi/ARBs  Categorical 10.5 Polytomous regression 
  Statins  Categorical 31.1 Polytomous regression 
  β blockers  Categorical 18.2 Polytomous regression 
  Aldosterone antagonist Categorical 72.3 Polytomous regression 
Use of an invasive strategy Categorical 7.2 Polytomous regression 
Enzyme elevation  Binary 10.8 Predictor/ Auxiliary 
variable 
Admission diagnosis  Categorical 0 Predictor/ Auxiliary 
variable  
Admitting consultant  Binary 5.4 Predictor/ Auxiliary 
variable 
Serum cholesterol  Continuous 25.6 Predictor/ Auxiliary 
variable 
Coronary angiography  Categorical 12.7 Polytomous regression 
Coronary intervention Categorical 18.6 Polytomous regression 
Cardiac rehabilitation  Categorical 11.5 Polytomous regression 
Abbreviations: ECG, Electrocardiogram; CABG, coronary artery bypass graft; PCI, percutaneous coronary 
intervention; ARB, angiotensin receptor blocker; ACE, angiotensin converting enzyme. 
 
Table 3.4. Imputation Strategy for objective 4 (§2.3.1). 
Variable Variable Type Missing 
(%) 
Imputation method 
Cardiac arrest Binary 3.6 Logistic regression 
Uncensored peak troponin 
measurement in ng/ml 
Continuous  11.9  Predictive mean matching 
Age Continuous 0.07 Predictive mean matching 
Systolic blood pressure Continuous 19.5 Predictive mean matching 
Heart rate Continuous 19.6 Predictive mean matching 
Loop diuretic used Binary  17.4 Logistic regression 
Creatinine level Continuous 17.8 Predictive mean matching 
Ethnicity Categorical   Polytomous regression 
Sex Binary  0.3 Logistic regression 
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Variable Variable Type Missing 
(%) 
Imputation method 
Index of multiple 
deprivation score 
Continuous 5.8 Predictive mean matching 
Derived identification Continuous 0 Predictor/ Auxiliary 
/Partially Observed 
Arrival year Continuous 0 Predictor/ Auxiliary 
/Partially Observed 
Nelson-Aalen survival 
estimate 
Continuous 0 Predictor/ Auxiliary 
/Partially Observed 
Censoring indicator Binary 0 Predictor/ Auxiliary 
/Partially Observed 
Hypercholesterolaemia Binary 12.2 Predictor/ Auxiliary  and 
Default imputed 
Previous hypertension Binary 9.6 Predictor/ Auxiliary  and 
Default imputed 
Peripheral vascular 
disease 
Binary 12.9 Predictor/ Auxiliary  and 
Default imputed 
Cerebrovascular disease Binary 11.5 Predictor/ Auxiliary  and 
Default imputed 
Chronic obstructive 
pulmonary disease or 
asthma 
Binary 12.1 Predictor/ Auxiliary  and 
Default imputed 
Smoker (current or 
previous smoker vs. non-
smoker)  
Binary 5.9 Logistic regression 
Diabetes mellitus  Binary 4.0 Predictor/ Auxiliary  and 
Default imputed 
Family history of chronic 
heart disease 
Binary 20.1 Predictor/ Auxiliary  and 
Default imputed 
Care by cardiologist Binary 39.1 Predictor/ Auxiliary  and 
Default imputed 
Chronic renal failure Binary  11.6 Predictor/ Auxiliary  and 
Default imputed 
Electrocardiogram 
appearance  
Categorical 5.8 Polytomous regression 
Aspirin at discharge  Categorical 7.9 Polytomous regression 
P2Y12 inhibitors at 
discharge  
Categorical 34.7 Polytomous regression 
ACEi/ARBs at discharge  Categorical 9.2 Polytomous regression 
Statins at discharge  Categorical 8.2 Polytomous regression 
Coronary angiography  Categorical 6.1 Polytomous regression 
Enzyme elevation  Binary 6.0 Predictor/ Auxiliary 
variable 
Admission diagnosis  Categorical 0.02 Predictor/ Auxiliary 
variable  
Care by cardiologist  Binary 8.4 Logistic regression 
Admitting consultant  Binary 5.4 Predictor/ Auxiliary 
variable 
Discharge diagnosis  Binary 0 Predictor/ Auxiliary 
variable 
Serum cholesterol  Continuous 31.3 Predictor/ Auxiliary 
variable 
Admission method  Categorical 66.9 Predictor/ Auxiliary 
variable 
Coronary intervention Categorical 19.7 Polytomous regression 
β blockers at discharge  Binary 17.5 Logistic regression 
Cardiac rehabilitation  Categorical 9.6 Polytomous regression 
Abbreviations: ARB, angiotensin receptor blocker; ACE, angiotensin converting enzyme. 
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Prior to each imputation process a predictor matrix was constructed using 
the automated predmatrix command in R(113). The predictor matrix 
defines the variables that would be used as predictors in the imputation 
models(113). The i’th row of the matrix consist of zeros and ones, with a 
one in the j’th column indicating the j’th variable be used as a covariate 
when imputing the i’th variable(113). The variables included in the 
imputation models were confirmed to be predictive of the missingness 
which confirmed that the MAR missing mechanism assumption was 
plausible in this instance so as the application of MICE as a method to 
handle the missing data.  
 
The choice of number of imputations is usually governed by the proportion 
of missing data (114). There is inconclusive evidence in literature on the 
level of missingness in the data that is appropriate for the application of 
MICE. Some studies have suggested that if the level of missingness is 
>70% more imputations than the five imputed datasets that have been 
suggested in literature should be carried out(115). However, with the use of 
a greater number of imputed datasets, factors such as, reproducibility of the 
results and computational time to run the imputation model (especially when 
the dataset is large) have to be considered. Most of the variables 
considered to be imputed for the work of the thesis had <45% missing data 
with only two variables having >60%.   
 
Monte Carlo error estimates were used to assess the reliability and 
consistency of the imputation results. These error estimates reflect the 
variability of the imputation results which is useful for determining whether 
an adequate number of imputation datasets were used to create stable 
results(112). In this thesis Monte Carlo errors less than 10% of the 
estimated standard errors gave evidence that the imputed datasets used 
gave stable estimates of the results(107). Ten imputation datasets were 
found to suffice for the analyses after considering reliability of the findings 
as well as computational time and power required to run the imputation 
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models. The parameter estimates from the analyses were pooled using 
Rubin’s rules (111) over the imputed datasets using the mi estimate in 
Stata command. Using Rubin’s rules the pooled estimate is derived as an 
average of the estimates from each of the multiple imputations 
datasets(111). The within-imputation variance and between-imputation 
variance are estimated and the total variance associated with the pooled 
estimate is the total(111). 
 
3.6 Objective 1: Quantifying excess mortality associated 
with sub-optimal implementation of care of NSTEMI 
patients and determining predictors of sub-optimal 
care. 
This section details the analyses methods that were carried out for objective 
one of the thesis i.e. to quantify the excess mortality (avoidable deaths) 
associated with receiving sub-optimal care after suffering an NSTEMI. 
Initially the derivation of the analytical cohort (§3.6.1) will be described, 
followed by model selection (§3.6.2), model assessment (§3.6.3), and 
finally, avoidable deaths estimation (§3.6.4).  
 
3.6.1 Analytical cohort derivation   
Of the 787,202 AMI patients recorded in MINAP, 441,945 had a discharge 
diagnosis of NSTEMI. The final analytical cohort of n=389,057 was arrived 
at after excluding 31,321 (7.1%) patients because they died in hospital and 
21,567 (4.9%) patients due to missing death data Figure 3.2. Patients who 
died in hospital were excluded as it was not possible to determine their 
receipt of pharmacological therapies upon discharge from hospital. Patients 
with missing mortality data were excluded as it was difficult to ascertain their 
mortality data and a correctly imputed outcome adds nothing except Monte 
Carlo error, whereas an incorrectly imputed outcome adds more error(105). 
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As previously reported in §3.5.2  missing data were imputed using MICE in 
R software and details of the strategy are mentioned in §3.5.2. 
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Index admission of NSTEMI 
recorded in MINAP 
1st January 2003 to 30th June 2013 
N=441,945 
Patients who survived to 
discharge 
N=410,624 
Analytical Cohort 
N=389,057 
Patients who died 
in hospital 
31,321 removed 
Missing mortality 
data 
21,567 removed 
Figure 3.2 Analytical cohort derivation flowchart. STROBE diagram showing the 
derivation of the analytical cohort from the Myocardial Ischaemia National Audit 
Project (MINAP) dataset. 
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3.6.2 Model selection process for objective 1  
3.6.2.1 Survival analysis 
Time to event data analysis was conducted initially using the Cox 
Proportional Hazard (PH) model to investigate the association between 
receiving sub-optimal care (defined by all-or-none scoring/defect-free 
scoring and latent classes) and time to all-cause mortality. The advantage 
of using the Cox PH model is that it is a  semi-parametric approach, the 
distribution of the baseline hazard function does not have to be specified in 
the model and is estimated non-parametrically(116). However the Cox PH 
assumption must not be violated for inference to be accurate. The Cox PH 
model assumes that the effects of the covariates in the model are the same 
throughout the study or follow-up time(116). The proportional hazards 
assumption was assessed using the log cumulative hazard plots for each 
variable adjusted for in the model. For categorical covariates the log 
cumulative hazard plots enable a visual test of the proportional hazards 
assumption by plotting –log[-log S(t)] against time for each strata of each 
covariate(117).  
    
The PH assumption was found to be violated and the log-log plots for the 
variables for which the assumption was violated (shown by the non-parallel 
or crossing curves) are presented in Figure 3.3, Figure 3.4, and Figure 3.5. 
After the PH assumption for the Cox PH model was violated, the Cox model 
with time-dependent covariates was implemented using the tvc option in 
Stata software. However, model convergence problems were encountered 
as the survival models became more complex by the introduction of each 
time varying covariate. Since the semi-parametric model could not be used 
a parametric approach had to be implemented. Unlike semi parametric 
approaches, parametric approaches assume a distribution for the baseline 
hazard function. However assuming a distribution for the baseline hazard is 
a limitation because if there is misspecification of the baseline hazard in the 
modelling this may potentially bias the estimates. 
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Accelerated Failure Time models (AFT)(118) were employed instead. The 
AFT model was used because it has been proposed as an alternative to the 
Cox PH model in literature(118-120). The AFT model quantifies the impact 
on survival time using Time Ratios (TR), by measuring the effect of the 
exposure of interest on the mean survival time(118). The TR gives an 
intuitive summary measure of survival that is more interpretable in a clinical 
setting as it is based on survival time instead of hazard(118, 121). The TR 
is the estimated ratio of the expected survival times of two groups. A TR 
greater than one for a covariate indicates that this covariate prolongs 
expected survival time and a TR less than one indicates decreased 
expected survival time. For example, if missing one or more care 
interventions decreases survival by 70%, the estimated TR would be 0.30. 
 
Figure 3.3 Log-log plots for variables: A) optimal care, B) sex, C) smoking 
status, and D) previous myocardial infarction. 
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Figure 3.4 Log-log plots for variables: E) previous angina, F) 
hypercholesterolemia, G) hypertension, and H) prior or new diabetes. 
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Figure 3.5 Log-log plots for variables: I) peripheral vascular disease, J) 
cerebrovascular disease, K) asthma/ COPD, and L) prior or previous 
CABG. 
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MINAP data consists of patients nested within hospitals, thus to account for 
the multilevel structure of the data, the shared frailty AFT models were used.  
Failure to account for the clustering in the data will bias the statistical 
inference by underestimating the standard errors. Thus all the models 
comprised of a shared frailty term to account for the hierarchical structure 
of the data.  
 
The shared frailty AFT models were adjusted for case mix using the 
adjusted six-month mini–GRACE risk score (categorised in line with NICE 
guidelines (16) as lowest (≤70), low (71 to 87), and intermediate to high risk 
(>88))  (31), the 2010 Index of Multiple Deprivation (IMD) score (categorised 
according to the 2010 cut-offs), previous history of AMI, cerebrovascular 
disease, angina, previous CABG, diabetes, hypertension, peripheral 
vascular disease, a family history of CHD, COPD/asthma, 
hypercholesterolaemia, and previous coronary revascularisation. Details of 
the adjusted six-month mini-GRACE risk score are given in §1.5.3, in 
Chapter one. Methods commonly used for variable selection such as 
forward, backward and stepwise selection approaches were not used as 
they are data driven approaches that could result in omission of key 
variables for case mix adjustment as choice of inclusion is based on a pre-
specified significance level which does not take into account clinical expert 
opinion(116). DAGs could have been used to determine the minimal 
adjustment set of confounder variables to adjust for in multivariable 
analyses. However for this objective DAGs would have not been suitable to 
inform variable selection for the modelling as they are more suited for use 
in instances where there is one main exposure not a composite exposure 
derived from multiple indicators. The main exposure for this objective was 
a composite score of receipt of care derived from 13 variables and latent 
classes of receipt of care.  
 
Establishing  causal relationships between covariates and a composite 
exposure of treatment can be difficult as there is limited evidence for such 
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causal links in literature, unlike if one is considering causal relationships 
between covariates and individual guideline-indicated care interventions. 
The utility of DAGs in identifying confounders is reliant on prior knowledge 
and assumed causal effects(122). Deriving a DAG with limited knowledge 
on the causal mechanisms can result in inaccurate determination of minimal 
adjustment set of confounders thus introducing more bias to the parameter 
estimates of the findings. Thus, for the work for this thesis DAGs were not 
implemented. The choice of potential confounders adjusted for in the 
models that were fitted for objective one was based on clinical input from 
Professor CP Gale and past literature reviewed in Chapter two.     
 
Fifteen shared frailty AFT models were fitted, 13 models for each of the 
considered guideline-indicated care interventions to assess the impact of 
each of the care interventions on survival as well as one for the 
dichotomised receipt of optimal care (primary outcome model),  and one 
for the latent class receipt of care. All the shared frailty AFT models were 
adjusted for the case mix variables mentioned above. The separate 
individual assessment models for each care intervention were fitted to 
assess the impact of each of the care interventions on survival as using 
aggregate composite measures only suffers the weakness that it weights 
less important commonly prescribed care interventions equally to 
infrequently prescribed more important care interventions, as a result 
making it difficult for clinicians and policy makers to determine specific 
targets for quality improvements in receipt of care. Individual assessments 
of the care interventions were conducted to determine the robustness of the 
composite measure, as the measure maybe degraded if the included 
individual care interventions used to derive it have weak associations with 
the outcome of interest. 
3.6.2.2  Patient-level predictors of optimal care for NSTEMI 
To determine patient level predictors of optimal care for NSTEMI, a 
descriptive table of patient baseline characteristics by the dichotomised “all-
or-none” receipt of optimal care variable, and by the determined latent 
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classes of receipt of care was produced as an exploratory approach. Data 
exploration using descriptive statistics was followed by fitting logistic 
regression models to determine the predictors of receipt of optimal NSTEMI 
care. Logistic regression models were fit for the “all-or-none” receipt of 
optimal care binary variable and for the individual care interventions 
separately. Detail on the variables that were investigated as potential 
predictors for this objective are given in Table 3.5. The omitted variables for 
each care intervention were excluded because the variable was part of the 
eligibility criteria for the care intervention.  
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Table 3.5 Potential predictor variables for receipt of optimal care and each guideline indicated care interventions. 
 Care interventions 
 Optimal 
care 
ECG Acute 
aspirin 
ACEi/ 
ARBs 
β 
blockers 
Statins 
 
P2Y12 
inhibitors 
Aldosterone 
antagonist 
Echo Coronary 
angio 
Aspirin 
 
Smoking 
cessation 
advice 
Dietary 
advice 
Cardiac 
rehab 
Predictors               
Age ×         ×     
Sex (male vs 
female) 
              
Deprivation 
(IMD) 
              
Cardiovascular 
History 
              
Myocardial 
infarction 
              
Congestive 
cardiac   failure 
×   × ×   ×  ×     
PCI ×         ×     
CABG ×         ×     
Angina               
Cerebrovascul
ar disease 
              
Peripheral 
vascular 
disease 
              
Cardiovascular 
Risk Factors 
              
Diabetes ×       ×  ×     
Chronic renal 
failure 
×       ×  ×     
Hypercholester
olaemia 
              
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 Care interventions 
 Optimal 
care 
ECG Acute 
aspirin 
ACEi/ 
ARBs 
β 
blockers 
Statins 
 
P2Y12 
inhibitors 
Aldosterone 
antagonist 
Echo Coronary 
angio 
Aspirin 
 
Smoking 
cessation 
advice 
Dietary 
advice 
Cardiac 
rehab 
Predictors               
Hypertension               
Current/ ex-
smoker   
×           ×   
Asthma or 
COPD 
              
Family history 
of CHD            
              
Care by 
cardiologist 
              
Presenting 
Characteristics 
              
Systolic blood 
pressure (<90 
mmHg) 
×         ×     
Heart rate 
(>110 bpm) 
×         ×     
Peak troponin 
(≥ 0.06) 
×         ×     
Creatinine 
(>200 (μmol/l)) 
×       ×  ×     
Use of a loop 
diuretic 
×       ×  ×     
Cardiac arrest ×         ×     
 predictor variable included in model as potential predictor; × predictor variable not included as it is part of the eligibility criteria for the care intervention. 
Abbreviations: IMD, Index of multiple deprivation; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; coronary heart disease; COPD, chronic obstructive pulmonary 
disease; Echo, echocardiography.  
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3.6.3 Model assessment for objective 1 
3.6.3.1 Parametric survival analysis  
Parametric survival analysis assume several distributions for the baseline 
hazard function and these include the exponential, Weibull, Gompertz, log-
logistic and generalised gamma distributions(116). Preliminary models 
were fit in order to determine the distribution of the survival times that best 
fit the data. The distributions explored and combination frailty distributions 
are summarised in Table 3.6. The default gamma distribution for frailty was 
adopted as the alternative inverse Gaussian distribution option models all 
failed to converge.  
Table 3.6 Model fit diagnostics for the Shared frailty AFT models  
Model Model fit criteria 
Distribution  Frailty  BIC 
Weibull  Gamma  142263.6 
Exponential  Gamma  146808.2 
Log logistic  Gamma  141736.2 
Log normal  Gamma  141338.4 
Abbreviations: BIC, Bayesian Information Criteria. 
The selected model was selected based on the minimisation of the BIC. 
According to the BIC criterion, the log normal distribution was the 
appropriate distribution to assume as it had the minimum BIC. 
3.6.3.2 Patient-level predictors of optimal care for NSTEMI 
As previously described in §3.6.2.2, a logistic regression model was fitted 
to investigate the patient level predictors of receipt of optimal care for 
NSTEMI patients. Model fit for the logistic regression models was assessed 
using the Hosmer-Lemeshow test (123), discriminatory power (the 
sensitivity versus one minus specificity)  of the model was assessed using 
Area Under the Receiver Operator Curve (AUROC) (also known as the C 
statistic), and Pseudo R squared(124). Good models have a discriminatory 
C statistic of >0.80, Pseudo R squared (usually ranges from 0 to 1) higher 
values indicate better model fit and a non-significant Hosmer-Lemeshow P 
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value >0.05.  The Hosmer-Lemeshow test goodness of fit test, tests the null 
hypothesis that the observed probability of the event (receipt of care) and 
the expected probability of the event obtained from the model are the same, 
such that a non-significant result provides no evidence against model 
fit(123). These thresholds were used in this thesis to judge the goodness of 
fit of the logistic regression models that were used. The results are 
summarised in Table 3.7. The  discriminatory power of the fitted models 
were low, with only models for P2Y12 inhibitors prescription at discharge, 
smoking cessation advice, dietary advice, and recording of an 
electrocardiogram being having an ROC >0.80. The low pseudo-R2 values 
observed for the models strongly indicated that some important predictors 
beyond the ones evaluated were missing. However, because the covariates 
included in the models were statistically significant therefore important 
conclusions could still be drawn from them in terms of the covariates 
associated with receipt of care for NSTEMI patients.   
Table 3.7 Model fit statistics for the logistic regression models 
 Hosmer-Lemeshow 
test P value 
C-statistic Pseudo-
R2 
Predictor model for:    
Optimal care <0.001 0.77 0.190 
ECG <0.001 0.82 0.183 
Acute aspirin 0.234 0.63 0.029 
ACEi/ARBs <0.001 0.59 0.022 
β blockers <0.001 0.63 0.045 
Statins <0.001 0.66 0.050 
P2Y12 inhibitors <0.001 0.82 0.315 
Aldosterone antagonist 0.141 0.70 0.087 
Echocardiography <0.001 0.62 0.033 
Coronary angiography <0.001 0.76 0.154 
Aspirin <0.001 0.65 0.039 
Smoking cessation   advice <0.001 0.88 0.329 
Dietary advice <0.001 0.81 0.287 
Cardiac rehabilitation <0.001 0.66 0.052 
Abbreviations: ARB, angiotensin receptor blocker; ACE, angiotensin converting enzyme; ECG, 
electrocardiogram. 
 
3.6.4 Avoidable deaths estimation  
In order to calculate the avoidable deaths associated with NSTEMI patients 
not receiving optimal care (receiving all guideline-indicated care 
interventions for which they were eligible), a method developed by Ford et 
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al(125). was used as it has been used by previous studies to estimate 
avoidable deaths associated with sub-optimal care(52). The risk associated 
with receiving sub-optimal care (adjusted time ratios derived from the 
shared frailty AFT survival models, (a)), was multiplied by the total number 
of NSTEMI admissions from 2003-2013 (b). The product was then 
multiplied by the proportion at risk (c) that is the proportion of NSTEMI 
patients who had received sub-optimal care. The resultant figure was then 
multiplied by the 12-month case fatality rate (d) for the NSTEMI patients 
who had received sub-optimal care. The formula to summarise the method 
is given below: 
 𝐴𝑣𝑜𝑖𝑑𝑎𝑏𝑙𝑒 𝑑𝑒𝑎𝑡ℎ𝑠 = 𝑎 × 𝑏 × 𝑐 × 𝑑 3.1 
 
For example in chapter 4, the results show that not receiving OMT reduces 
time to death by 56% (a=0.44), 86.9% of the NSTEMI patients did not 
receive OMT (b=0.87), total number of NSTEMI admissions for the study 
duration was 389,057 (d=389,057), and the sub-optimally managed 
patients’ 12 month case fatality rate was 22.1% (c=0.22). Calculating the 
total number of avoidable/premature deaths using formula 3.1 would give: 
 ((0.44 × 0.87)) × 0.22 × 389,057 =32,765 avoidable/preventable deaths. 
The same approach was adopted for calculating potential avoidable deaths 
that were associated to being in a latent class of sub-optimal care compared 
to being in a latent class of high receipt of care, by substituting the 
appropriate time ratio into the formula.  
 
3.7 Objective 2: Assess geographic variation in receipt of 
care for NSTEMI patients and, predominantly, to 
develop an online, interactive platform. 
This section details the analyses that were carried out for objective two of 
this thesis, to investigate the geographical variation in receipt of care for 
NSTEMI patients. The analyses were conducted using the same analytical 
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cohort that was used for objective one of the thesis (§3.6.1). Objective two 
of the thesis was an extension of objective one in order to assess the 
geographic variation in receipt of care for the NSTEMI patients. The 
analytical cohort data was geocoded and linked to boundary data of the 
areas under investigation in order to allow the for the geographic variation 
assessment in receipt of NSTEMI care. The UK boundary data used were 
of the 211 Clinical Commissioning Groups (CCGs) and 12 Strategic Clinical 
Networks (SCNs).(126) These data boundaries were selected because for 
the NHS of England the CCGs working in partnership with hospitals via 
SCNs are responsible for commissioning the management of AMI.(126) 
This section of the methodology chapter will detail the geocoding 
information of the data(§3.7.1), temporal trends assessments 
methodologies used(§3.7.2), model selection process(§3.7.3) and model 
assessment for the statistical analyses(3.7.4). 
 
3.7.1 Data geocoding and quality of care  
The analytical cohort data was geocoded and linked to the April 2015 
Geographic Information System CCGs and SCNs layer data which were 
accessed from NHS England.(127) As MINAP data was anonymised, full 
patient postcodes were not available. Instead, the data were mapped by the 
aid of eastings and northings recorded in MINAP. The eastings and 
northings of the centroid of the output area of residence shared between 
one and 80 addresses are made available in MINAP data to enable 
geographic mapping(39).  Of the 389,057 NSTEMI patients, 357,228 were 
mapped successfully to boundary data. The failure to map of the other 
observations was due to missing eastings and northings information to 
geocode on. To assess the geographic variation in receipt of guideline-
indicated care interventions for NSTEMI choropleth maps were created 
using ArcGIS version 10.2.2.  
 
Two composite measure approaches were used to define quality of care for 
objective 2 of this thesis, and these are opportunity scoring and the all-or-
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none scoring/defect-free scoring (described in §3.4.1, earlier). Briefly, 
opportunity scoring composite measure was derived by dividing the total 
number of patients who received a care intervention  by CCGs and SCNs 
(numerator) by the total number of patients eligible for the care intervention 
in the CCGs and SCNs (denominator)(95). The opportunity score by CCGS 
and SCNs was derived for receipt of optimal care variable (receiving all (up 
to 13) guideline-indicated treatments for which patients were eligible) 
(derived using the all-or-none scoring/defect-free scoring)), as well as for 
each of the 13 considered guideline-indicated care interventions. To aid 
categorisation and presentation on the choropleth maps the opportunity 
scores data were divided into quintiles. Also for descriptive purposes cut-
offs that are frequently used by other studies in past literature were used to 
categorise the score ( high receipt ( >79%), intermediate (40 to ≤79%), and 
low (≤40%))(67, 128). 
 
3.7.2 Temporal changes assessments methodologies  
In order to determine whether there were any improvements in guideline 
recommended care over time, temporal trends in receipt of care were 
assessed. The Spearman’s correlation coefficient was used to assess the 
correlation of receipt of care in the earlier years (2003-2004) compared to 
the later years (2012-2013) by CCGs as the receipt of care distribution was 
skewed thus the Pearson’s correlation test could not be used as the test 
requires the data to be normally distributed. A correlation coefficient close 
to 1 indicated strong correlation.    
3.7.2.1 Web platform development  
Evaluation of receipt of care for AMI patients’ needs to be an on-going 
process to guarantee continuous assessment in AMI management. In order 
to allow for this on-going assessment a platform termed “Cardiovascular 
Landscapes: Using Data to Improve Cardiovascular Care and Outcomes” 
was created. This work was done in collaboration with the Leeds Institute 
for Data Analytics (LIDA) IT team. The platform was created to aid better 
data visualisation and aid wider dissemination of the results from the 
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assessment of geographic variation in receipt of care. The platform will be 
used by patients as well as clinicians and commissioners to allow them the 
opportunity to identify variation and take action to reduce unwarranted 
variation in AMI care within or between their localities and other areas of 
the country such that new policy initiatives can be implemented to improve 
quality of care for AMI patients. Receipt of care data of the 13 guideline-
indicated care interventions was uploaded on to the interactive web platform 
and presented on choropleth maps, heat maps over time and summary 
statistics by CCGs.  
 
Optimal care was derived based on the opportunity scoring composite 
measure that is dividing the total number of patients receiving optimal care 
(derived using the all-or-none scoring/defect-free scoring) in a CCG by the 
total number of NSTEMI patients in the CCG over a time period from 2010-
2013. The opportunity scoring approach was also used to derive receipt of 
the 13 guideline-indicated care interventions by CCGs over a time period 
from 2010-2013. Besides the care interventions more variables were added 
for presentation on the platform to give the patient profile per area and these 
included comorbidities: diabetes, COPD/asthma, chronic heart failure, 
chronic renal failure, peripheral vascular disease and hypertension. A high 
resolution investigation into Yorkshire and Humber was undertaken as was 
commissioned by NHS England. Receipt of care data was assessed for a 
period from 2003-2013, for 49,499 NSTEMI patients. For each of the care 
interventions that were assessed, a proportion was derived for receipt of 
care at CCG level. Similar to the Cardiovascular Landscapes web 
development, the 13 guideline-indicated care interventions and optimal care 
were assessed. The care interventions were described by numbers and 
percentages, means and standard deviations or medians and IQRs for 
normally and non-normally distributed continuous data, respectively. These 
data were presented in funnel plots and temporal trend line graphs. 
Choropleth maps were used to show the distribution of receipt of guideline-
indicated treatments using ArcGIS and class intervals with equal cut-offs for 
categorisation were used. In order to assess hospital performances funnel 
 - 129 -  
 
plots(129)  were employed.  The standardised receipt of care ratios (SRR) 
were derived by dividing the observed receipt of care rates by the expected 
receipt of care rates (derived from a multilevel Poisson model adjusted for 
age, sex and year of admission), The SRRs were plotted against the total 
number of patients eligible for each care intervention by Clinical 
Commissioning Groups (CCG) (volume by CCG) and superimposing  95% 
(2 standard deviation) and 99.9% (3 standard deviations) control limits 
around the overall receipt of care rates. CCGs performing well were plotted 
within and over the upper control limits with underperforming CCGs plotted 
outside and under the lower control limits. The results were summarised in 
a report titled “Acute Myocardial Infarction: A Report of Care in Yorkshire 
and Humber, 2003-2013” and the first user feedback session was held on 
the 3rd of May 2017 at the University of Leeds. Both the “Cardiovascular 
Landscapes: Using Data to Improve Cardiovascular Care and Outcomes” 
platform and Yorkshire and Humber report are still under development and 
are yet to be released for wider dissemination to the public. 
 
3.7.3 Model selection process for objective 2 
As mentioned earlier in §2.3.1, objective two of the thesis was to assess 
geographic variation in receipt of care for NSTEMI patients and determine 
whether the source of variation in receipt of guideline indicated care for 
NSTEMI patients was as a result of differing management at hospital level 
or differing planning and commissioning of health care services at CCGs or 
SCNs level. To assess the source of variation in rates of receipt of care 
Poisson regression modelling was undertaken. The outcome variable was 
(receipt of care: derived by using the opportunity scoring approach) was 
modelled as a count variable with a conditional Poisson distribution and all 
NSTEMI patients in the cohort as the exposure.  The Poisson model was 
chosen because it is used for modelling count data(130). Furthermore 
Poisson regression has several extensions that can prove useful when 
analysing count data and these include: negative binomial regression which 
can be employed for over dispersed count data, zero-inflated regression 
models which can be employed to account for excess zeros in count data, 
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and ordinary least squares (OLS) regression which can only be employed 
if the count data follow a normal distribution(130). Hierarchical modelling 
also known as multilevel modelling was taken as the data were hierarchical 
constituting patients nested within hospitals, hospitals nested within CCGs 
and CCGs nested within SCNs. Ignoring the hierarchical nature of the data 
was considered inappropriate as this may result in underestimation of 
regression coefficients standard errors thereby inflating type 1 errors. 
    
A multilevel Poisson model with fixed effects and random effects was fitted. 
The random effects partition variance into within unit and between unit 
variation hence known as variance components. The patient baseline 
characteristics described in §3.6.2.1 were adjusted for in the model. Model 
convergence issues were encountered such that the model had to be run 
using the meqrpoisson Stata command to aid model convergence. The 
Interclass Correlation Coefficient (ICC) derived from the regression 
modelling was used to quantify the proportion of variation in receipt of 
guideline indicated care interventions attributable to hospitals, CCGs and 
SCNs, respectively. The ICC is the proportion of variance that is explained 
by the grouping structure of the multilevel model and it is calculated as a 
ratio of group level error variance over the total error variance(131). The 
ICC reports the amount of variation unexplained by any predictors already 
adjusted for in the model that can be attributed to the grouping variable, as 
compared to the overall unexplained variance(131). Avoidable deaths at 
hospital level were also determined using the shared frailty AFT models. 
 
3.7.4 Model assessment for objective 2 
The goodness of fit for the Poisson model was tested using the estat gof 
command in Stata, which reports the Hosmer-Lemeshow goodness of fit 
test. The Hosmer-Lemeshow test goodness of fit test was described earlier 
on in §3.6.3.(123). The Poisson model fit the data well (P-value not 
significant). Violation of the non-over dispersion assumption of the Poisson 
model often means implementation of the negative binomial model instead. 
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In this thesis there was evidence of overdispersion hence the multilevel 
negative binomial model was fitted as a sensitivity analysis (using the 
menbreg Stata command). Due to the complex nature of the model serious 
convergence problems were encountered such the model took over three 
weeks to run without converging ultimately. Due to the convergence 
limitation of the multilevel negative binomial model, the multilevel Poisson 
model was by default used as the regression model of choice. The results 
obtained made sense clinically and the modelling approach was adopted. 
OLS regression could not be considered as the data were skewed. 
 
3.8 Objective 3: Investigating the association of clinical 
factors and therapeutic strategies with improvements 
in survival following STEMI.  
Previous studies have assessed quality of care and associated outcomes 
for STEMI patients as well as predictors of receipt of STEMI care.(61) Still 
following the quality of care and impact on mortality framework, objective 
three of the thesis focused on determining the factors (i.e. changes in 
patient demographics, comorbidities, pharmacological and reperfusion 
treatments) associated with the temporal improvements in  six months and 
one year mortality that have been observed over the last decade (between 
2004 and 2013) for STEMI patients. This section details the analyses that 
were carried out for this objective. Initially the analytical cohort derivation 
will be described (§3.8.1), followed by the model selection process (§3.8.2) 
and model assessment detail (§3.8.3).  
 
3.8.1 Analytical cohort derivation  
The analytical cohort for the objective 3 of the thesis was derived from 
272,263 STEMI admissions recorded in MINAP from January 2004-June 
2013. For patients with multiple admissions the index event was considered 
in order to reduce potential bias from previous treatment. The derivation of 
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the analytical cohort to get to n=232,353 is shown in Figure 3.6. The 
reasons why patients with missing mortality data and those who had died 
in hospital were excluded for this thesis were mentioned earlier in §3.6.1. 
Missing data were imputed using MICE in R software and details of the 
imputation strategy are mentioned in §3.5.2. 
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Index admission of STEMI 
recorded in MINAP 
1st January 2003 to 30th June 2013 
N=272,263 
Patients who survived to 
discharge 
N=248,759 
Analytical Cohort 
N=232,353 
Patients who died in 
hospital 
23,504 removed 
Missing mortality 
data 
16,406 removed 
Figure 3.6 Analytical cohort derivation flowchart. STROBE diagram showing 
the derivation of the analytical cohort from the Myocardial Ischaemia 
National Audit Project (MINAP) dataset. 
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3.8.2 Model selection process for objective 3 
3.8.2.1 Flexible parametric survival models 
To investigate the association of clinical factors and therapeutic strategies 
with improvements in survival following STEMI, Royston-Parmar flexible 
parametric survival models (132) were adopted for the survival analysis. 
These models fall under the parametric time to event modelling approach 
but instead of assuming the baseline hazard function follows a pre-defined 
distribution, flexible parametric models model the shape of the baseline 
hazard using restricted splines(132). This allows for flexibility in the shape 
but restricts the function to be linear on the ends were the data is 
sparse(132). The conventional survival modelling approach Cox PH 
modelling was not employed due to the violation of the proportional hazards 
assumption. The primary outcome of interest was one year survival and the 
exposure of interest was year of admission to hospital.  
 
The covariates that were included in the survival models comprised: patient 
demographics (age, sex, deprivation (2010 IMD score), cardiovascular risk 
factors (diabetes, hypercholesterolaemia, hypertension, smoking status, 
COPD, family history of coronary heart disease, chronic renal failure, 
chronic cardiac failure), cardiovascular history (cerebrovascular disease, 
peripheral vascular disease, previous angina, previous AMI, previous PCI, 
previous CABG), hospital discharge medications (statins, aspirin, P2Y12 
inhibitors,  ACEi)/ARBs), year of admission to hospital, reperfusion 
(dichotomised to received PPCI or not) and cardiac rehabilitation. The 
discharge medication variables had to be included in the models as binary 
(receipt: yes/no), as including them as three level categorical variables 
(receipt: yes/no/contraindicated) was biasing the analysis in such a way that 
change in contraindication over time as well as prescription of the drugs 
was being captured. As a result masking the change in the prescription of 
the secondary drugs over time, of which this was one of the exposures of 
interest.  
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Twenty iterations of the survival models were run, the first model was a 
univariable unadjusted model including year of admission only (to 
determine the overall temporal trend by year), then a series of models (nine) 
including the following categories of variables individually (as well as year 
of admission) : reperfusion, comorbidities and risk factors, cardiac 
rehabilitation, aspirin at discharge, statin at discharge, P2Y12 inhibitors at 
discharge, ACEi/ARBs at discharge, β-blockers at discharge and all the 
hospital discharge drugs (together rather than individually). Change in 
temporal trend by year was noted after addition of these categories of 
variables. To these nine models age, sex and IMD scores (demographics) 
were added and change in temporal trend was also noted after addition of 
these three variables. The final model then included all the considered 
variables. This pattern of adding variables to the model was followed in 
order to map out how the category of variables being added to the model 
affected temporal changes in one year survival. The flexible parametric 
models were fitted using the stpm2 command for each imputation, and 
model estimates combined using Rubin’s rules via the mi estimate 
command. The analysis was repeated but focusing on the secondary 
outcome, six month survival.  
3.8.2.2 Mediation analysis  
As a sensitivity analysis, mediation analysis was carried out to investigate 
the causal mechanisms by examining the role of the potential mediators 
(determined through flexible parametric modelling) thought to lie on the 
causal pathway between year of admission of the STEMI patients and 
survival (one year (primary outcome) and six months mortality).  A 
mediating variable is a variable that appears on the causal pathway of an 
exposure outcome relationship (post-treatment variable that occurs before 
the outcome happens(133)) for example the variable M shown in Figure 3.7 
is a mediator as it lies on the causal pathway between exposure T and 
outcome Y(134). Mediation analysis falls under the Structural Equation 
Modelling (SEM) framework and the illustration of mediation analysis given 
in this section follow that as in Linden et al.(134).  
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Figure 3.7 The conceptual mediation model with a single mediator. 
where T: is treatment assignment. 
   M: is the mediating variable  
   Y: is the outcome  
    a,b,c’: represent the SEM coefficients.  
 
The mediating variable (M) explains the relationship between the 
dependent (T) and the independent variable (Y) . However it’s not always 
the case that the mediator explains 100% of the relationship as there maybe 
other unmeasured mediators, such that the total treatment effects are the 
sum of both the direct (c) and indirect effects (a+b). The direct and indirect 
effects are quantified as illustrated by the equations below: 
    
 Y𝑖 = 𝛼1 + 𝑐T𝑖 + 𝛽1X𝑖 + 𝜀𝑖 3.2 
 
 M𝑖 = 𝛼2 + 𝑎T𝑖 + 𝛽2X𝑖 + 𝜀𝑖 3.3 
 
 Y𝑖 = 𝛼3 + 𝑏M𝑖 + 𝑐
′𝑇𝑖 + 𝛽3X𝑖 + 𝜀𝑖 3.4 
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Equation 3.2 represents the outcome model estimating the average total 
effects of the intervention by regressing Y (outcome variable) on T 
(treatment variable) adjusted for X (pre-treatment covariates)(134). 
Equation 3.3 represents the a pathway in Figure 3.7 in which M (mediating 
variable) is regressed on T (treatment variable) and X (pre-treatment 
covariates)(134). All the equations were adopted from Linden et al.(134) 
Equation 3.4 represents both the b and c’ pathways shown in Figure 3.7 
which regress Y (outcome variable) on T (treatment variable), M (mediating 
variable) and X (pre-treatment covariates).  
After modelling as shown in the equations, the mediated effects can be 
estimated using the “product of coefficients” approach or “difference in 
coefficients” approach. The “product of coefficients” approach uses the 
product of a and b paths to quantify the indirect effects (mediated effects) 
and the “difference in coefficients” subtracts the direct effects c’ from the 
total effects c(135, 136). The total effect can also be quantified by adding 
the indirect and direct effects (c=ab+c’).The advantage of using mediation 
analysis is that it not only gives point estimates of the mediation, but also 
the extent to which a variable mediates a relationship(134). The mediated 
effects are derived as a ratio of the indirect to the total direct effect and 
quantified as a percentage(134). The estimation described so far is for a 
single mediator model and in the event of multiple mediators, each mediator 
is regressed individually on the treatment (including pre-intervention 
characteristics) and then the outcome model regresses the outcome (Y) on 
all the mediators as well as on T and X(134).  
 
The SEM approach described above utilizes the ordinary least squares 
regression with the assumption that the mediator and outcome variables 
are continuous, however for the thesis the outcome and potential mediators 
were binary hence an approach that is suitable for binary outcomes and 
mediators was needed. For the purpose of this thesis the mediation analysis 
was carried out using the R package; mediation(137). This R mediation 
package accommodates a larger class of statistical models but still based 
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on model-based causal mediation analysis under the assumption of 
sequential ignorability similar to the SEM approach(137). This is achieved 
through the mediate function(137). The mediation analysis was 
undertaken following a two-step approach represented by equations 3.2 
and 3.3. A logistic regression model for the mediating models (equation 3.3) 
was fitted, as the potential mediators were binary. For the outcome models 
(equation 3.2), a Poisson regression modelling framework with log survival 
time as the offset was used. The Poisson modelling approach was 
undertaken as to the best of my knowledge there were no software 
packages available to fit flexible parametric survival models for mediation 
analysis).  
 
The potential pre-treatment covariates that were used for the analyses 
include; age, IMD score, sex, previous history of AMI, angina, previous 
CABG, diabetes, hypertension, peripheral vascular disease, a family history 
of coronary heart disease, COPD/asthma, hypercholesterolaemia, and 
previous coronary revascularisation, chronic renal failure, elevated 
cholesterol, current or ex-smoker status, and cardiac rehabilitation. In 
addition to these covariates in the outcome model the discharge 
medications (aspirin, β blockers, ACEi/ARBs and statins) not determined as 
potential mediators.  
 
The analyses were undertaken for the primary outcome one year mortality 
and secondary outcome six month mortality. Average Direct Effects (ADE) 
(represented by c’ in Figure 3.7) and Average Causal Mediation Effects 
(ACME) (represented by paths a and b) were derived to quantify the 
percentage mediated by the potential mediator. The ACME and ADE are 
estimated under the potential outcomes framework whereby the impact of 
the mediator on the outcome is quantified comparing impact on outcomes 
if everyone in the population received treatment/mediating variable vs. if no 
one in the population received treatment/mediating variable(133). The 
potential outcomes come into play in the sense that not everyone has an 
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observed outcome if shifted to the different treatment groups other than 
their observed treatment group, thus the employment of counterfactual 
outcomes (potential outcomes)(133). Causal inference can only be 
concluded if the sequential ignorability assumption is not violated(134). The 
mediation analysis was only conducted on the complete STEMI cases only 
(n=82,637). 
 
3.8.3 Model assessment for objective 3 
The flexible parametric modelling used in this thesis employs cubic 
splines(132) to estimate the baseline hazard function. Cubic splines are 
defined as piecewise cubic polynomials with a separate cubic polynomial fit 
in a predefined number of intervals and the splits points for the intervals are 
known as knots(132). The cubic polynomial function being defined as 
shown in equation 3.5 below: 
 
 𝑦 = 𝛽0 + 𝛽1𝑥 + 𝛽2𝑥
2 + 𝛽3𝑥
3 3.5 
 
The number of knots to be used is usually defined by the user thus optimal 
scale and complexity of the splines had to be estimated. The degrees of 
freedom of the spline part of the model were selected based on the 
minimisation of the AIC and BIC. These parameters were also used to 
select the scale part (the distribution of the baseline function) of the model. 
Scales that were considered included; normal, theta, odds and hazard 
scale. The degrees of freedom ranged from one to seven. Default knot 
positions corresponding to the best model according to the AIC and BIC 
were used.  
 
In order to infer causal inference the mediation analysis main assumption 
is the sequential ignorability assumption. The sequential ignorability 
assumption assumes that the mediator is effectively randomly assigned 
given baseline covariates and the randomised treatment(134). There is no 
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formal test for this assumption however there is a sensitivity analysis for 
possible existence of unobserved covariates using the medsens function in 
R. However the sensitivity analysis could not be carried out for the 
mediation analysis carried out for this thesis work as it has only been 
developed so far to fit linear structural equation models framework(137).   
 
3.9 Objective 4: Determining the efficacy of β-blockers 
during and after AMI in patients without heart failure or 
LVSD.  
This section details the analyses that were carried out in order to determine 
the effectiveness of β-blockers in reducing mortality for AMI patients without 
heart failure or left ventricular systolic dysfunction (LVSD). Initially the 
analytical cohort derivation (§3.9.1) will be described, followed model 
selection (§3.9.2), and model assessment (§3.9.3) detail.  
 
3.9.1 Analytical cohort derivation  
The analytical cohort for this objective of the thesis was derived from 
531,282 AMI admissions from MINAP. This cohort was derived from 
admissions recorded in MINAP from 2007-2013. This time period was 
considered as it is the era all major cardio-protective medications and care 
interventions were recommended in the guidelines and MINAP had minimal 
missing data. For patients with multiple admissions the index event was 
considered in order to reduce potential bias from previous treatment. The 
derivation of the analytical cohort to get to n=179,810 is shown in Figure 
3.8. 
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Figure 3.8 Analytical cohort derivation flowchart. STROBE diagram 
showing the derivation of the analytical cohort from the Myocardial 
Ischaemia National Audit Project (MINAP) dataset. 
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Patients with missing mortality data were excluded as it was difficult to 
ascertain their mortality data and a correctly imputed outcome adds nothing 
except Monte Carlo error, whereas an incorrectly imputed outcome adds 
more error(105). Those who had died in hospital were excluded also as it 
was difficult to ascertain their receipt of guideline-indicated care 
interventions. In order to minimise potential bias from prior β-blockers use, 
patients who had a prior use were excluded as well those with a previous 
history of AMI, angina and those who had received previous PCI and CABG. 
AMI patients eligible for the study were those without heart failure or LVSD, 
so patients with a history of heart failure and use of a loop diuretic were 
excluded.    
 
Heart failure was defined as a previous history of heart failure as recorded 
in MINAP and also those used a loop diuretic (on admission and during 
admission) and/or left ventricular ejection fraction(LVEF) <30% as recorded 
in MINAP.  The choice to use a cut off <30% LVEF than the <40% frequently 
used in literature was made due to data recording restrictions in MINAP. 
LVEF is recorded in MINAP as a categorical variable defined as ‘good’ for 
an LVEF ≥ 50%, ‘moderate’ for an LVEF 30-49% and ‘poor’ for an LVEF 
<30%. So it was difficult to assess LVEF at different cut-offs other than the 
ones given in MINAP. Ultimately, for the analysis for this objective LVEF 
<30% category was used to define heart failure. Although a cut off of <40% 
due to data restrictions could not be used, a sensitivity analysis using both 
the moderate (30-49%) and poor (<30%) LVEF categories to define heart 
failure was also performed. Missing data were imputed using mice in R and 
details of the strategy used are mentioned in §3.5.2. β blockers receipt was 
assessed as receipt of β blockers on hospital discharge unless 
contraindicated.  
 
3.9.2 Model selection process for objective 4 
Due to the causal inference nature of objective 4 of the thesis, the methods 
that account for treatment selection bias in observational studies had to be 
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considered. Literature has suggested propensity scoring and instrumental 
variable analysis as the best methods to employ for treatment effects 
studies(138, 139). Propensity scoring and instrumental variable analysis (as 
a sensitivity analysis) were adopted over the multivariable model risk 
adjustment (the conventional modelling approach) for the thesis. 
 
Propensity scoring (with the propensity score been defined as the 
probability of receiving treatment conditioning on observed baseline patient 
characteristics (139)) only removes overt bias conditional on observed 
covariates, however because the propensity score model can be adjusted 
for as many observed patient characteristics as available if a large 
comprehensive dataset is used (in this instance MINAP registry)  bias may 
be removed adequately. The score from propensity scoring is used to 
create comparable treatment groups in terms of baseline covariates by 
either matching, stratification, inverse probability of treatment weighting on 
the propensity score or covariate adjustment using the propensity 
score(139). For the thesis weighting using the inverse of probability of 
treatment was used. This is because inverse probability weighting is the 
most robust way of balancing covariates without losing patient information 
as matching and stratification involve excluding patients that fail to match 
on the propensity score, thereby potentially losing important information as 
well as reducing study power.  The primary outcome for this objective of the 
thesis was one year all-cause mortality. Secondary outcomes included six 
months and 30 day mortality. Due to the survival nature of the study, a 
survival model had to be employed and this case a survival model under 
propensity scoring modelling.  The survival-time inverse-probability 
weighting propensity score analysis was adopted for propensity scoring 
survival modelling. This method was adopted as it incorporates propensity 
scoring for survival data for causal inference. The method works by 
estimating the treatment effects as Average Treatment Effects (ATE) and 
Average Treatment Effect on the Treated (ATET) through two models: 1) 
the treatment assignment model which estimates the propensity for 
treatment assignment and 2) the survival model which is the outcome model 
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were the treatment effects estimated(140, 141). The ATE coefficients 
derived are the absolute difference in survival times when all patients 
receive treatment compared to when all the patients do not receive 
treatment. The ATET is then the absolute difference in survival time only for 
those who were treated compared to when they did not receive treatment. 
The ATE and ATET are derived as follows:  
Each patient, the treatment effect is a difference of two potential outcomes 
which can be denoted by the equation below: 
 𝑌𝑖 (1) − 𝑌𝑖 (0) 3.6 
 
Where 𝑌𝑖 (0) : outcome (survival time) when the patient does not receive 
treatment. 
            𝑌𝑖 (1): outcome (survival time) when the patient receives treatment.  
The ATE is the average of moving the entire population from treated to 
untreated as shown by the equation below: 
 𝐸 [𝑌𝑖 (1) − 𝑌𝑖 (0)] 3.7 
 
 The ATET is then the average treatment on the treated patients only, i.e. 
the conditional expectation as shown below: 
 𝐸 [𝑌𝑖 (1) − 𝑌𝑖 (0)| 𝑍 = 1] 3.8 
 
where 𝑍 = 1 : is for the treated patients only(142). 
The treatment assignment model (propensity scoring model) is used to 
derive inverse-probability weights that are used to weight the data before 
the survival model is fitted in order to balance the systematic differences 
between the treatment and control observations so that the treatment 
effects can only be attributed to the treatment administered.  
For this thesis a non-parsimonious multivariable logistic regression model 
was adopted as the treatment assignment model and a Weibull model for 
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the survival model. The treatment assignment model was adjusted for 24 
variables: patient demographics (sex, deprivation (index of multiple 
deprivation score), year of admission to hospital), cardiovascular risk 
factors (diabetes, hypercholesterolaemia, hypertension, smoking status, 
COPD, family history of coronary heart disease), cardiovascular history 
(cerebrovascular disease, peripheral vascular disease), hospital discharge 
medications (statins, aspirin, P2Y12 inhibitors, ACEi/ARBs), adjusted mini-
GRACE risk score variables (age, cardiac arrest, elevated enzyme, systolic 
blood pressure and heart rate at hospitalisation and creatinine) and care by 
cardiologist. The treatment assignment model should be adjusted for as 
many pre-treatment covariates (that can potentially predict treatment 
assignment) as possible in order to ensure the propensity scores derived 
can be adequately used to even out the systematic differences between the 
treated vs. the non-treated, such that the treatment effects observed can be 
accurately attributed to the care intervention under investigation(138). The 
24 variables adjusted for in the model were the pre-treatment variables 
available in the data source (MINAP) used for the analysis. Choice of 
variables to add to the treatment assignment model was also guided by 
literature and clinical input from Professor CP Gale.  
 
Using the inverse probability weights derived from the treatment 
assignment model to balance the covariate distribution between the treated 
vs. the non-treated, the survival model was fitted also adjusted for the earlier 
mentioned covariates as well as cardiac rehabilitation. This further 
adjustment of the covariates was done to reduce residual confounding in 
the survival model and cardiac rehabilitation was only included in the 
survival model as it was a post treatment variable and could therefore not 
predict treatment assignment. Adjusted Kaplan-Meier curves to assess 
survival differences between patients who received β blockers and those 
who did not were derived using the survci command. The models were 
adjusted for the propensity scores derived from the non-parsimonious 
multivariable logistic regression model, i.e. the treatment assignment 
model.  
 - 146 -  
 
 
As mentioned earlier in this section, propensity scoring adjusts for 
measured confounding adequately especially in the incidence of use of 
large comprehensive datasets. However, because unmeasured 
confounding is also a major problem when analysing observational data 
instrumental variable analysis had to be employed as a sensitivity analysis. 
The method allows for the determination of treatments effects that are 
similar to those obtained from randomised clinical trials by the use of an 
instrumental variable that behaves like a natural randomisation of patients 
to “treatment groups” that differ in their likelihood of receiving care(138). 
The instrumental variable acts as an unconfounded proxy of treatment and 
allows for comparison of groups of patients that differ in their likelihood of 
receiving treatment instead of comparing the actual treatment groups(143). 
This allows for the estimation of causal effects after accounting for 
measured and unmeasured confounding(143). However, for the analysis to 
be robust the instrument should be a strong predictor of treatment and 
should not be associated with the outcome of interest(138). 
 
In literature several examples of instrumental variables have been 
employed which include: physician prescribing preferences, differential 
distances, density of cardiologists, distance to healthcare facilities, personal 
beliefs, calendar time, exogenous shocks (sudden shift in patient or 
physician behaviour) and state laws/policies(143, 144). Physician 
Prescribing Preferences (PPP) has been found to be a good instrument in 
clinical epidemiology for investigating drug effectiveness when using 
instrumental variable analysis(143). So for the current thesis PPP was 
chosen as the instrumental variable. However, because in MINAP there is 
not actual data capture of PPP a proxy was derived using hospital 
prescribing rates of guideline-indicated hospital discharge medications 
(aspirin, P2Y12 inhibitors, β blockers, statins and ACEi/ARBs). 
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To the best of my knowledge, at the time of analysis there were no 
packages that allowed survival analysis for instrumental variables. Most 
studies have adopted a logistic regression approach, however this has 
potential for survivorship bias as it does not consider follow-up time. In order 
to avoid this survivorship bias a Poisson regression modelling approach 
with an offset of the log of survival time was used for the thesis as has been 
adopted in other studies(145). To further mitigate potential bias from 
residual confounding the 24 case mix variables were also adjusted for in 
the Poisson model.  
 
For both the instrumental variable analysis and survival-time inverse-
probability weighting propensity score analysis, the analyses were 
conducted by overall AMI cohort and stratified by AMI phenotype (STEMI 
and NSTEMI) for three survival time points (one month, six months and one 
year). 
 
3.9.3 Model assessment for objective 4 
Propensity score modelling is based on strongly ignorable treatment 
assignment assumption(146). The assumption consists of two components, 
which are: 
 treatment assignment is independent of the outcomes, conditional 
on observed covariates(141, 146) 
 probability of treatment assignment is bounded away from 0 and 1, 
“the overlap assumption” (implying that for propensity score to 
assume confoundedness, the estimated propensity scores for all 
patients should be greater than zero and less than one)(146).  
To assess the first assumption, balance in covariate distributions between 
the treated (those that received β blockers at hospital discharge) and control 
(those that did not receive) patients was assessed using standardised 
differences and variance ratios (a perfectly balanced covariate had a 
standardised difference of zero and variance ratio of one). A comparison 
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was done between the raw data versus the weighted data (weights derived 
from the treatment assignment model). Using standardised differences and 
variance ratios as mode of assessment is an exploratory diagnostic 
approach, a formal over-identification test was also used to test for 
covariate balance(140). If the treatment assignment model is well specified 
the weights derived from the model will balance the covariates. Balance 
checks were only performed for the main effects. The over-identification test 
further assessed whether the main effects as well as the interactions terms 
were balanced. Violation of the overlap assumption was assessed using 
overlap plots and summarising the estimated probabilities of treatment 
assignment. A method to determine the cut-offs of how farther away from 0 
and 1 the propensity scores of the patients have to be avoid the violation of 
the overlap assumption has been proposed by Crump et al. (2009)(147). 
They derived that limited overlap could be achieved by discarding patients 
that had a propensity scores outside the range: [𝛼, 1 − 𝛼](146). 
 
Based on this line of thought Crump et al.(147) managed to suggest a rule 
of thumb for trimming, which is to discard all observations with an estimated 
propensity score outside the range 0.1-0.9(146). For this thesis, the rule of 
thumb proposed by Crumb et al.(147) was used for trimming the analytical 
cohort. The models were fitted using trimmed data according to the Crumb 
et al.(147) rule of thumb, i.e. after excluding all patients that had their 
propensity scores outside the range 0.1-0.9. A sensitivity analysis to check 
the robustness of the balanced analysis was done were the models were 
fitted including all the patient despite their propensity scores. For the AMI 
and NSTEMI groups, aspirin and ACEi/ARBs at hospital discharge were 
found to be poorly balanced, thus interaction terms of these variables with 
all of the other 24 model variables were added to the treatment assignment 
model to improve balance.  Predictive ability of the treatment assignment 
model was assessed using the area under the receiver operator 
characteristic (AUROC) curve. The tebalance post estimation diagnostics 
commands in Stata software were used and the assessments were done 
across each of the ten imputed datasets separately as methods to pool the 
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diagnostics estimates have not been defined, only those for pooling the 
estimates for the treatment effects had been established.   
   
For the instrumental variable analysis, the validity of the instrument was 
assessed by checking that the instrument was a strong predictor of 
prescription of β blockers at discharge using a multilevel logistic regression 
model to predict prescription of β blockers as a function of hospital 
prescription rates. To investigate if the instrumental variable was not 
associated with the outcome of interest, mortality was regressed on the 
instrumental variable after adjusting for β blockers use and other patient 
characteristics. Also independence of the instrumental variable on other 
patient characteristics was assessed by comparing patient characteristics 
across quintiles of the instrument.     
 
3.9.4 Chapter conclusion  
This chapter described the methods that were used in this thesis for the four 
objectives of the thesis.  The chapter also provides a critique of analytical 
methods that were used in previous studies and justification of the methods 
that were used. The methodology that was used in this current thesis was 
supported by literature and the utility of the methods has been 
demonstrated in previous studies. The next chapters (4 to 7) present the 
results of each of the four specific objectives of the thesis. 
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Chapter 4 : Results 
Excess mortality and guideline-indicated care following non 
ST-elevation myocardial infarction 
The following publications have arisen from the analysis and results in this 
chapter: 
1. Dondo TB, Hall M, Timmis A, Gilthorpe M, Alabas O, Batin P, 
Deanfield J, Hemingway H, Gale CP. (2016). Excess mortality and 
guideline-indicated care following non ST-elevation myocardial 
infarction. Eur Heart J Acute Cardiovasc Care.  
2. Dondo TB, Hall M, Timmis A, Gilthorpe M, Alabas O, Batin P, 
Deanfield J, Hemingway H, Gale CP. (2015) Guideline 
recommended care and excess mortality for NSTEMI: A national 
cohort study. Eur Heart J (Vol. 36, pp. 174-174). Conference 
abstract (Presented as a moderated poster at the European Society 
Congress 2015, London). 
4.1 Introduction  
This chapter presents the results for objective one of the thesis:  quantifying 
the excess mortality associated with sub-optimal implementation of care for 
NSTEMI patients. Initially, general descriptive statistics are presented in the 
following categories: 
 Study population (§4.2.1) 
 Guideline indicated interventions (§4.2.2) 
 Patterns of care (§4.2.3). 
This will be followed by the results sections on the predictors of receipt of 
NSTEMI care (§4.3.1), the association between receipt of care and long-
term survival (§4.4), and finally estimation of potentially avoidable deaths 
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associated with sub-optimal care for NSTEMI patients (§4.4.1.1). The final 
section will be a summary of the key findings (§4.5) as well as a chapter 
conclusion §4.6. A detailed description of the methods employed for the 
analyses is given in Chapter 3, §3.6.     
 
4.2 Descriptive statistics 
4.2.1 Study population  
The total number of NSTEMI patients used as the analytical cohort for thesis 
objective one was n=389,057. Details on the analytical cohort derivation are 
given in Chapter 3, §3.6.1. The mean age for the NSTEMI patients in the 
analytical cohort was 70.9 years (SD 13.3) and 63.1% (n=244,837) were 
male (Table 4.1). A third of the patients (31.5%, n=122,566) had previous 
angina, a quarter (24.9%, n=97,002) had previous AMI, with well over half 
of them (71.8%, n=279,178) being current or ex-smokers. Almost half 
(48.5%, n=188,503) of the NSTEMI patients were hypertensive, 20.9% 
(n=81,469) were diabetic and 14.6% (n=56,708) had COPD or asthma. 
According to the mini-GRACE risk score, 79.8% (n=146,456) patients were 
at intermediate or high risk. In terms of electrocardiographic changes 56.8% 
(n=200,905) of the patients had ST-segment deviation and 15.7% 
(n=55,498) had no acute changes. Over 90% (n=327,625) of the analytical 
cohort were white. Patient’s ethnic group is recorded in MINAP as perceived 
by the patient. The classification criteria used for recording the ethnicity data 
is consistent with the NHS classification criteria and is listed below: 
1. White – Includes British, Irish, any other White background 
2. Black – Incudes Caribbean, African, Black British, any other Black 
background  
3. Asian – Includes Indian, Pakistani, Bangladeshi, Asian British, any 
other Asian background  
4. Mixed – Includes White and Black Caribbean, White and Black 
African, White and Asian, any other mixed background.  
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5. Not stated – Where the patient cannot or does not wish to state 
his/her ethic background   
6. Other – Includes Chinese, any other ethnic group  
7. Unknown  
Table 4.1 Baseline demographic and clinical characteristics of the 2003-
2013 NSTEMI cohort. 
Characteristics 
N=389,057 
Cases Missing  
 
Age, years* 70.9 (13.3) 638 (0.2) 
Male  244,837 (63.1) 832 (0.2) 
Deprivation (IMD score, (categorised according to the 2010 cut-offs)) 
   Least deprived (1)(<8.49) 61,697 (17.2) 
30,417 (7.8) 
   2 (8.49 to <13.79) 70,526 (19.7) 
   3 (13.79 to <21.35) 75,459 (21.0) 
   4 (21.35 to 34.17) 72,539 (20.2) 
   Most deprived (5) (≥34.17) 78,419 (21.8) 
Year of admission    
   2003-2005 102,207 (26.3) 
0 
   2006-2008 102,324 (26.3) 
   2009-2011    127,877 (32.9) 
   2012-2013 56,649 (14.6) 
Ethnicity 
   White  327,625 (93.3) 
37,922 (9.8) 
   Black  2,560 (0.7) 
   Asian  15,422 (4.4) 
   Mixed  424 (0.1) 
   Other  5,104 (1.5) 
Cardiovascular history                                                                             
  Myocardial infarction 97,002 (24.9) 0¥ 
  Congestive cardiac failure 24,529 (6.3) 0¥ 
  PCI 32,663 (8.4) 0¥ 
  CABG 27,637 (7.1) 0¥ 
  Angina 122,566 (31.5) 0¥ 
  Cerebrovascular disease 34,146 (8.9) 0¥ 
  Peripheral vascular disease 18,324 (4.7) 0¥ 
Cardiovascular risk factors 
  Diabetes 81,469 (20.9) 0¥ 
  Chronic renal failure 21,938 (5.6) 0¥ 
  Hypercholesterolaemia  121,243 (31.2) 0¥ 
  Hypertension 188,503 (48.5) 0¥ 
  Smoker ever / current                                                                                                                                                                       279,178 (71.8) 0¥ 
  Asthma or COPD 56,708 (14.6) 0¥ 
  Family history of CHD            77,288 (19.9) 0¥ 
Presenting characteristics 
  Systolic blood pressure, mmHg*   142.5 (28.4) 66,688 (17.1) 
  Systolic blood pressure, <90 mmHg 6,483 (2.0) 66,688 (17.1) 
  Heart rate* 80 (67-95) 65,863 (16.9) 
  Heart rate >110 bpm 177,810 (55.0) 65,863 (16.9) 
  Creatinine* 92 (76-114) 165,622 (42.6) 
  Creatinine >200 (μmol/l) 9,546 (4.3) 165,622 (42.6) 
  Peak troponin§* 1.2 (0.3-8.2) 19,114 (4.9) 
  Peak troponin ≥ 0.06§ 350,368 (94.7) 19,114 (4.9) 
Cardiac arrest  6,740 (1.8) 22,901 (5.9) 
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Characteristics 
N=389,057 
Cases Missing  
 
Electrocardiographic characteristics 
  No acute changes 55,498 (15.7) 
35,699 (9.2) 
  ST-segment elevation  15,962 (4.5) 
  Left bundle branch block 23,066 (6.5) 
  ST segment depression 92,227 (26.1) 
  T wave changes only 92,716 (26.2) 
  Other acute abnormality 73,889 (20.9) 
Use of a loop diuretic  97,972 (30.5) 67,556 (17.4) 
Grace risk score classification 
  Lowest (≤70) 16,657 (9.1) 
205.461 (52.8)   Low (71-87)   20,483 (11.2) 
  Intermediate to high (>88)  146,456 (79.8) 
*All are numbers (%), unless normally distributed continuous data (mean (SD)), or non-normally distributed 
continuous data (median (IQR)).  
Abbreviations. IMD, Index of multiple deprivation; CABG, coronary artery bypass graft; CHD, coronary heart 
disease; COPD, chronic obstructive pulmonary disease; PCI, percutaneous coronary intervention; SD, standard 
deviation; IQR, interquartile range; ¥ missing data default imputed to “No”, § peak troponin values truncated at 
50. 
 
4.2.2 Guideline-indicated care interventions  
A small proportion of the patients received optimal care (13.2%, n=51,176), 
with the most frequently missed care interventions being dietary advice 
(68.1%, n=254,869), smoking cessation advice (87.9%, n=245,357), 
echocardiography (49.7%, n=193,483), P2Y12 inhibitors at discharge from 
hospital (n=192,906, 66.3%), coronary angiography (43.4%, n=161,853) 
and in-hospital aspirin (45.0%, n=106,407) (Table 4.2). Pre-hospital care 
interventions which were assessed but not included in the derivation of the 
OMT score included pre-hospital electrocardiogram (96.2%, n=115,702) 
and pre-hospital aspirin (55.0%, n=49,682). Increases in receipt of the ESC 
guideline-indicated care interventions from 2003-2013 were noted (Figure 
4.1), with exceptions for pre-hospital aspirin and pre-hospital 
electrocardiogram where decreases over time were observed. Figure 4.1 
also shows over the years, the time the care interventions were already 
recommended by the guidelines shown by a tick and when they were not 
yet recommended shown by an x. Most of the care interventions were 
already recommended in the ESC guidelines during the time of the study 
except for P2Y12 inhibitors which came in 2004 and in-hospital aldosterone 
antagonists in 2007. 
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Table 4.2 Eligibility and receipt of guideline-indicated care for NSTEMI 
between 2003 and 2013. 
Treatment Patients receiving 
treatment 
n (%) 
Patients eligible 
 
 
Pre-hospital  electrocardiogram  115,702 (96.2) 120,270 
Pre-hospital aspirin  49,682 (55.0) 90,304 
Electrocardiogram 364,760 (93.8) 389,057 
Acute aspirin  230,822 (88.7) 260,384 
In-hospital aspirin 130,185 (55.0) 236,592 
Echocardiography 195,537 (50.3) 389,020 
Coronary angiography 211,267 (56.6) 373,120 
Coronary angiography in high risk patients  29,274 (53.9) 54,325 
Aspirin at discharge 301,639 (88.5) 340,982 
P2Y12 inhibitors at discharge 126,995 (39.7) 319,901 
ACE inhibition or ARB 91,159 (67.5) 135,131 
β Blockers at discharge  90,185 (74.5) 121,094 
Statin at discharge 297,045 (85.4) 347,701 
In-hospital aldosterone antagonists  144 (24.3) 592 
Dietary advice  119,321 (31.9) 374,190 
Smoking cessation advice  33,821 (12.1) 279,178 
Cardiac rehabilitation  279,027 (76.0) 366,938 
Care by cardiologist 220,208 (56.6) 389,057 
Optimal care  51,176 (13.2) 389,057 
Abbreviations: ARB, angiotensin receptor blocker; ACE, angiotensin converting enzyme. 
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Figure 4.1 Temporal trends of guideline-indicated interventions by year of publication in ESC guidelines. 
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4.2.3 Patterns of care 
Considering the latent trait composite measure approach derived using 
latent class analysis, the three class solution was selected as the optimal 
class solution to define receipt of care for NSTEMI patients (Table 
4.3,Figure 4.2). The methods used to derive this three class solution have 
already been described in Chapter 3 (§3.4.1). Statistical model fit improved 
with increasing class sizes beyond the three class solution. However, the 
change in log likelihood and difference in BIC, and increase in entropy 
became minimal beyond the class three solution. The conditional 
probabilities of receipt of care for the class solutions are provided in Table 
4.4-Table 4.8. The higher class solutions did not offer improved separation 
between the classes beyond the separation shown in the three class 
solution, for example for the four class solution (Table 4.5), class 2, 3 and 
class 4 probabilities of receipt of care were similar to those observed for 
class 2, 1 and 3 of the three class solution, respectively. However, the fourth 
class defined was difficult to characterise as it was quite similar to the class 
3 of the three class solution but with a lower receipt of statin and aspirin at 
discharge, but higher receipt of diet advice and coronary angiography. The 
three class solution was deemed the best class solution to model the real 
life scenario of management of care of NSTEMI patients for this thesis. 
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Table 4.3 Model fit statistics for class solutions  
 Latent classes 
 1 2 3 4 5 6 7 
    No of free parameters  25 51 77 103 129 155 181 
    Log likelihood  -
3532640.519 
-
3054522.657 
-
2937808.427 
-
2851964.135 
-
2773145.008 
-2740668.520 -
2713668.637 
    Bayesian information 
criteria 
7065602.826 6109701.760 5876607.957 5705254.032 5547950.438 5483332.121 5429667.012 
    Lo-Mendell-Rubin LRT (P)  953386.889 
(0.0000) 
232733.027 
(0.0000) 
171177.086 
(0.0000) 
157168.614 
(0.0000) 
64751.750 
(0.0000) 
53838.890 
(0.6908) 
    Entropy  0.928 0.946 0.952 0.958 0.960 0.938 
    AIC 7065331.039 6109147.315 5875770.853 5704134.269 5546548.017 5481647.041 5427699.273 
    SSABIC 7065523.375 6109539.680 5876363.247 5704926.693 5547540.469 5482839.523 5429091.785 
    Best H0 replicated Yes Yes Yes Yes Yes Yes Yes 
    Difference in BIC  955901.066 233093.803 171353.925 157303.594 64618.317 53665.109 
Abbreviations: AIC, Akaike information criterion; BIC, Bayesian information criterion; SSABIC, Sample size adjusted BIC. 
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Figure 4.2 Plot of the log likelihood for the different classes. 
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Table 4.4 Latent class structure identifying three classes of received care 
patterns for patients with NSTEMI showing the probability of receipt 
per care opportunity within each class. 
 Latent Class Structure (probabilities) 
Care Opportunity Class1 
High receipt of 
care 
Class 2 
Intermediate 
receipt of care 
Class 3 
Low receipt of 
care 
Electrocardiogram 0.99 0.85 0.97 
Acute aspirin 0.65 0.55 0.58 
ACE inhibitor or ARB 0.01 0.67 0.01 
β blockers 0.04 0.61 0.03 
Statin at discharge 0.78 0.77 0.73 
P2Y12 inhibitors 0.72 0.004 0.18 
Aldosterone 
antagonist 
0.001 0.000 0.000 
Echocardiography 0.60 0.43 0.46 
Cardiac rehabilitation 0.80 0.69 0.65 
Smoking cessation 
advice 
0.22 0.000 0.004 
Dietary advice 0.78 0.000 0.01 
Coronary 
angiography 
0.69 0.38 0.54 
Aspirin at discharge 0.78 0.80 0.74 
Abbreviations. ARB, angiotensin receptor blocker; ACE, angiotensin converting enzyme. 
 
Table 4.5 Latent class structure identifying four classes of received care 
patterns for patients with NSTEMI showing the probability of receipt 
per care opportunity within each class.  
 Latent class structure 
Care opportunity Class 1 Class 2 Class 3 Class 4 
Electrocardiogram 0.99 0.85 0.99 0.97 
Acute aspirin 0.63 0.54 0.65 0.58 
ACE inhibition or ARB 0.001 0.67 0.01 0.01 
β Blocker    0.005 0.61 0.05 0.03 
Statin at discharge 0.07 0.77 0.95 0.80 
P2Y12 inhibitors 0.012 0.004 0.88 0.19 
Aldosterone antagonist  0.000 0.000 0.001 0.000 
Echocardiography / Stress 
echocardiography 
0.48 0.43 0.62 0.46 
Cardiac rehabilitation 0.69 0.68 0.81 0.65 
Smoking cessation advice 0.17 0.000 0.22 0.002 
Diet advice 0.56 0.000 0.79 0.01 
Coronary angiography 0.75 0.38 0.67 0.53 
Aspirin at discharge  0.04 0.80 0.96 0.80 
Abbreviations. ARB, angiotensin receptor blocker; ACE, angiotensin converting enzyme. 
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Table 4.6 Latent class structure identifying five classes of received care 
patterns for patients with NSTEMI showing the probability of receipt 
per care opportunity within each class. 
 Latent class structure 
Care opportunity Class 1 Class 2 Class 3 Class 4 Class 5 
Electrocardiogram 0.995 0.90 0.99 0.97 0.85 
Acute aspirin 0.63 0.54 0.65 0.58 0.55 
ACE inhibition or ARB 0.000 0.06 0.01 0.01 0.77 
β Blocker    0.007 0.01 0.05 0.03 0.71 
Statin at discharge 0.09 0.01 0.94 0.85 0.90 
P2Y12 inhibitors 0.012 0.01 0.88 0.19 0.01 
Aldosterone antagonist  0.000 0.000 0.001 0.000 0.00 
Echocardiography / Stress 
echocardiography 
0.49 0.33 0.62 0.48 0.45 
Cardiac rehabilitation 0.69 0.52 0.81 0.68 0.72 
Smoking cessation advice 0.18 0.03 0.22 0.001 0.00 
Diet advice 0.62 0.11 0.79 0.004 0.00 
Coronary angiography 0.75 0.59 0.67 0.53 0.35 
Aspirin at discharge  0.04 0.05 0.96 0.85 0.92 
Abbreviations. ARB, angiotensin receptor blocker; ACE, angiotensin converting enzyme. 
 
Table 4.7 Latent class structure identifying six classes of received care 
patterns for patients with NSTEMI showing the probability of receipt per care 
opportunity within each class. 
 Latent class structure 
Care opportunity Class 1 Class 2 Class 3 Class 
4 
Class 5 Class 6 
Electrocardiogram 0.97 0.99 0.995 0.96 0.85 0.85 
Acute aspirin 0.58 0.65 0.63 0.58 0.55 0.49 
ACE inhibition or 
ARB 
0.01 0.01 0.00 0.002 0.77 0.12 
β Blocker    0.03 0.05 0.01 0.01 0.72 0.02 
Statin at discharge 0.85 0.95 0.09 0.07 0.90 0.03 
P2Y12 inhibitors 0.19 0.88 0.01 0.05 0.01 0.00 
Aldosterone 
antagonist  
0.00 0.001 0.00 0.00 0.00 0.00 
Echocardiography / 
Stress 
echocardiography 
0.48 0.62 0.49 0.36 0.45 0.31 
Cardiac 
rehabilitation 
0.68 0.81 0.69 0.56 0.72 0.49 
Smoking cessation 
advice 
0.001 0.22 0.18 0.08 0.00 0.00 
Diet advice 0.003 0.79 0.62 0.26 0.00 0.00 
Coronary 
angiography 
0.53 0.67 0.75 0.63 0.35 0.52 
Aspirin at discharge  0.85 0.96 0.04 0.07 0.92 0.10 
Abbreviations. ARB, angiotensin receptor blocker; ACE, angiotensin converting enzyme. 
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Table 4.8 Latent class structure identifying seven classes of received care 
patterns for patients with NSTEMI showing the probability of receipt per care 
opportunity within each class. 
 Latent class structure 
Care opportunity Class 
1 
Class 
2 
Class 
3 
Class 
4 
Class 
5 
Class 
6 
Class 
7 
Electrocardiogram 0.995 0.97 0.993 0.994 0.85 0.96 0.85 
Acute aspirin 0.64 0.59 0.68 0.52 0.55 0.59 0.49 
ACE inhibition or 
ARB 
0.00 0.01 0.01 0.003 0.77 0.002 0.12 
β Blocker    0.001 0.03 0.04 0.08 0.72 0.003 0.02 
Statin at discharge 0.05 0.85 0.97 0.82 0.90 0.05 0.03 
P2Y12 inhibitors 0.002 0.18 0.91 0.70 0.01 0.04 0.00 
Aldosterone 
antagonist  
0.00 0.00 0.001 0.00 0.00 0.00 0.00 
Echocardiography 
/ Stress 
echocardiography 
0.50 0.48 0.66 0.45 0.45 0.36 0.31 
Cardiac 
rehabilitation 
0.73 0.70 0.94 0.26 0.72 0.58 0.49 
Smoking cessation 
advice 
0.20 0.002 0.26 0.06 0.00 0.08 0.00 
Diet advice 0.64 0.003 0.91 0.29 0.00 0.27 0.00 
Coronary 
angiography 
0.82 0.55 0.77 0.26 0.35 0.66 0.52 
Aspirin at 
discharge  
0.01 0.85 0.97 0.85 0.92 0.03 0.10 
Abbreviations. ARB, angiotensin receptor blocker; ACE, angiotensin converting enzyme. 
 
The three classes derived were labelled as follows: class 1 “high”, class 2 
“intermediate” and class 3 “low” receipt of care according to the conditional 
item probabilities of receipt of each of the 13 ESC recommended care 
interventions considered for the thesis work, to aid with understanding and 
interpretation. Class 1 was labelled as “high” because of the observed high 
conditional item probabilities for receipt of care for most of the care 
interventions (use of an electrocardiogram (0.99), acute aspirin (0.65), 
statin at hospital discharge (0.78), P2Y12 inhibitors at hospital discharge 
(0.72), echocardiography (0.60), cardiac rehabilitation (0.80), dietary advice 
(0.78), coronary angiography (0.69) and aspirin at hospital discharge (0.78). 
The conditional item probabilities were highest in the high receipt class 
compared to the other 2 classes. The low conditional item probabilities of 
receipt of ACEi/ARBs and β-blockers observed in the class labelled as high 
receipt of care class were because this group of patients consisted mainly 
of patients who were not eligible to receive the care interventions (see Table 
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B 1-Table B 26, Appendix B). ACEi/ARBs and β-blockers are indicated for 
patients who have an ejection fraction ≤ 35% (21), this shows that the 
patients in the high receipt group were the healthier patients of the NSTEMI 
patients considered for the study. Use of an electrocardiogram, aspirin at 
discharge and statins at discharge were high in all three classes (>0.70), 
thus these interventions were not distinguishing factors from the other latent 
classes. Patients in the intermediate class had a low probability of 
echocardiography and coronary angiography (0.43 and 0.38, respectively) 
and very low (<0.01) probabilities of receiving P2Y12 inhibitors, aldosterone 
antagonist, smoking cessation advice, and dietary advice. Patients in the 
low class had, in addition to the care probabilities of those in the 
intermediate class, very low probabilities of receiving ACEi/ARBs and β-
blockers (0.01 and 0.03, respectively). The findings are summarised in 
Table 4.4.  
 
4.3 Predictors of receipt of care  
Overall, there were minor differences in baseline patient characteristics of 
the patients in the different latent classes. Marked class differences were 
only observed in: period of hospitalisation, 99.5% of those in the high receipt 
of care class were hospitalised between 2009 and 2013 compared with 
0.5% being hospitalised between 2003 and 2008 (Table 4.9).  
 
However comparing the patients stratified according to the all or none 
approach (comparing patients who received optimal care with those who 
did not), the sub-optimal care receivers had a higher proportion of advanced 
age (>85 years) patients (15.3 vs. 6.7%), previous angina (40.0 vs. 28.3%), 
congestive cardiac failure (6.6. vs. 4.1%), cerebrovascular disease (8.9 vs. 
7.8%) and use of a loop diuretic (30.9 vs. 23.7%) (Table 4.9). The optimal 
care receivers had a higher proportion of males (68.3 vs 62.3%), a higher 
proportion of patients with hypercholesterolaemia (38.9 vs. 30.0%), 
diabetes (22.6 vs. 20.7%), hypertension (53.5 vs. 47.7%), family history of 
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CHD (30.5 vs. 18.3%) and were current or ex-smokers (63.5 vs. 54.6%) 
(Table 4.9). Similar to what was observed for the latent classes, a marked 
difference between those who received optimal care and those who did not 
was most apparent by period of hospitalisation: 99.8% of those in the 
optimal care group were hospitalised between 2009 and 2013 compared 
with 0.2% being hospitalised between 2003 and 2008 (Table 4.9). Beyond 
the descriptive statistics, further analyses were conducted to determine the 
predictors of receipt of care using logistic regression analysis. 
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Table 4.9 Patient characteristics by receipt of care for NSTEMI patients between 2003 and 2013.  
 Receipt of care groups Latent classes 
Characteristics  
N=389,057 
Optimal care 
n=51,176 
(13.2%) 
Sub-optimal 
care 
n=337,881 
(86.9%) 
P value High receipt 
n= 151,010 
(38.8%) 
Intermediate 
receipt 
n=133,546 
(34.3%) 
Low receipt 
n=104,501 
(26.9%) 
P value 
Age        
Below 55 9,916.6 (19.4) 45,059.1 (13.3) <0.001 23,467.2 
(15.5) 
17,416.2 (13.0) 14,092.3 
(13.5) 
<0.001 
Between 55-65 11,493 (22.5) 58,879.6 (17.4) <0.001 28,394.4 
(18.8) 
23,810 (17.8) 18,168.2 
(17.4) 
<0.001 
Between 66-75 13,839 (27.0) 82,390.2 (24.4) <0.001 36,767.7 
(24.4) 
34,570.2 (25.9) 24,891.3 
(23.8) 
<0.001 
Between 76-85 12,484 (24.4) 99,762.2 (29.5) <0.001 41,289.1 
(27.3) 
40,504.7 (30.3) 30,452.4 
(29.1) 
<0.001 
Above 85 3,443.4 (6.7) 51,789.9 (15.3) <0.001 21,091.6 
(14.0) 
17,2449 (12.9) 16,896.8 
(16.2) 
<0.001 
Male  34,925.1 (68.3) 210,426.5 (62.3) <0.001 96,481.1 
(63.9) 
83,470.5 (62.5) 65,400 (62.6) <0.001 
Deprivation (IMD)        
Least deprived (1) 8,922.8 (17.4) 58,054.3 (17.2) 0.128 26,177.3 
(17.3) 
22,198.4 (16.6) 18,601.4 
(17.8) 
<0.001 
2 9,640.8 (18.8) 66,910.7 (19.8) <0.001 29,360.2 
(19.4) 
26,054.4 (19.5) 21,136.9 
(20.2) 
<0.001 
3 10,407.6 (20.3) 71,599.7 (21.2) <0.001 31,478.3 
(20.9) 
28,173.3 (21.1) 22,355.7 
(21.4) 
<0.001 
4 10,327.7 (20.2) 68,383.3 (20.2) 0.695 30,408 (20.1) 27,170.6 (20.4) 21,132.4 
(20.2) 
<0.001 
Most deprived (5) 11,877.1 (23.2) 72,933 (21.6) <0.001 33,586.2 
(22.2) 
29,949.3 (22.4) 21,274.6 
(20.4) 
<0.001 
Year of Admission        
2003-2005  *(<0.1) 102,205 (30.3) <0.001 12 (0.01) 100,986 (75.6) 1,209 (1.2) <0.001 
 - 165 -  
 
 Receipt of care groups Latent classes 
Characteristics  
N=389,057 
Optimal care 
n=51,176 
(13.2%) 
Sub-optimal 
care 
n=337,881 
(86.9%) 
P value High receipt 
n= 151,010 
(38.8%) 
Intermediate 
receipt 
n=133,546 
(34.3%) 
Low receipt 
n=104,501 
(26.9%) 
P value 
2006-2008 115 (0.2) 102,209 (30.3) <0.001 671 (0.4) 32,429 (24.3) 69,224 (66.2) <0.001 
2009-2011    31,152 (60.9) 96,725 (28.6) <0.001 100,127 (66.3) 111 (0.1) 27,639 (26.5) <0.001 
2012-2013 19,907 (38.9) 36,742 (10.9) <0.001 50,200 (33.2) 20 (0.01) 6,429 (6.2) <0.001 
Ethnicity        
White  47,277.4 (92.4) 315,784.7 (93.5) <0.001 140,581.1 
(93.1) 
124,633.5 (93.3) 97,847.5 
(93.6) 
<0.001 
Black  451.1 (0.9) 2,357.2 (0.7) <0.001 1,209.4 (0.8) 853.6 (0.6) 745.3 (0.7) <0.001 
Asian  2,892.6 (5.7) 14,058.6 (4.2) <0.001 7,712.9 (5.1) 4,654.2 (3.5) 4,584.1 (4.4) <0.001 
Mixed  101.8 (0.2) 352.1 (0.1) <0.001 238.2 (0.2) 13.6 (0.01) 202.1 (0.2) <0.001 
Other  453.1 (0.9) 5,328.4 (1.6) <0.001 1,268.4 (0.80) 3,391.1 (2.5) 1,122 (1.1) <0.001 
Cardiovascular History        
Myocardial infarction  11,771 (23.0) 85,231 (25.2) <0.001 39,423 (26.1) 31,535 (23.6) 26,044 (24.9) <0.001 
Congestive cardiac failure 2,089 (4.1) 22,440 (6.6) <0.001 9,492 (6.3) 7,326 (5.5) 7,711 (7.4) <0.001 
PCI 5,364 (10.5) 27,299 (8.1) <0.001 16,601 (11.0) 7,000 (5.2) 9,062 (8.7) <0.001 
CABG 3,847 (7.5) 23,790 (7.0) <0.001 12,768 (8.5) 7,204 (5.4) 7,665 (7.3) <0.001 
Angina 14,498 (28.3) 108,068 (40.0) <0.001 46,872 (31.0) 42,255 (31.6) 33,439 (32.0) <0.001 
Cerebrovascular disease 3,988 (7.8) 30,158 (8.9) <0.001 14,496 (9.6) 10,180 (7.6) 9,470 (9.1) <0.001 
Peripheral vascular disease 2,393 (4.7) 15,931 (4.7) 0.698 7,254 (4.8) 6,124 (4.6) 4,946 (4.7) 0.022 
Cardiovascular Risk Factors        
Diabetes 11,555 (22.6) 69,914 (20.7) <0.001 35,614 (23.6) 22,914 (17.2) 22,941 (22.0) <0.001 
Chronic renal failure 2,773 (5.4) 19,165 (5.7) 0.020 10,767 (7.1) 4,463 (3.3) 6,708 (6.4) <0.001 
Hypercholesterolaemia  19,896 (38.9) 101,347 (30.0) <0.001 52,935 (35.1) 33,972 (25.4) 34,336 (32.9) <0.001 
Hypertension 27,355 (53.5) 161,148 (47.7) <0.001 79,539 (52.7) 55,931 (41.9) 53,033 (50.8) <0.001 
Current/ ex-smoker                                                                                                                                                                    32,483 (63.5) 184,633 (54.6) <0.001 89,221 (59.1) 70,613 (52.9) 57,282 (54.8) <0.001 
Asthma or COPD 7,603 (14.9) 49,105 (14.5) 0.053 23,844 (15.8) 17,108 (12.8) 15,756 (15.1) <0.001 
Family history of CHD            15,584 (30.5) 61,704(18.3) <0.001 38,015 (25.2) 14,659 (11.0) 24,614 (23.6) <0.001 
Presenting Characteristics        
Systolic blood pressure,  
(Mean (SD)) 
143.1 (27.1) 142.3 (28.7) <0.001 142.2 (27.6) 142.8 (29.4) 142.0 (28.5)   
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 Receipt of care groups Latent classes 
Characteristics  
N=389,057 
Optimal care 
n=51,176 
(13.2%) 
Sub-optimal 
care 
n=337,881 
(86.9%) 
P value High receipt 
n= 151,010 
(38.8%) 
Intermediate 
receipt 
n=133,546 
(34.3%) 
Low receipt 
n=104,501 
(26.9%) 
P value 
<90 mmHg 843.2 (1.7) 8,928.1 (2.6) <0.001 3,007.8 (2.0) 3,835.6 (2.9) 2,927.9 (2.8) <0.001 
Heart rate (Median (IQR)) 78 (66-91)  80 (67-95)  <0.001 78 (66-92)  80 (68-96) 80 (68-95)  
>110 bpm 4,388.1 (8.6) 38,834 (11.5) <0.001 14,009.6 (9.3) 16,932 (12.7) 12,280.5 
(11.8) 
<0.001 
Cardiac arrest  1,029.6 (2.0) 6,207.6 (1.8) 0.011 2,427.8 (1.6) 3,071.8 (2.3) 1,737.6 (1.7) <0.001 
Peak troponin (Median 
(IQR)) 
3.3 (0.4-50) 1.1 (0.2-6.5) <0.001 2.3 (0.3-44) 1 (0.3-4.3) 0.8 (0.2-4.3)  
≥ 0.06 48,753 (95.3) 319,716.7 (94.6) <0.001 142,886.6 
(94.6) 
128,090 (95.9) 97,493.1 
(93.3) 
<0.001 
Creatinine (Median (IQR)) 88 (74-106) 96 (79-120) <0.001 90 (74-112) 99 (82-125) 96 (80-119)  
>200 (μmol/l)  1,340 (2.7) 8,206 (4.7) <0.001 5,779 (4.1) 127 (4.6) 3,640 (4.5) <0.001 
Use of a loop diuretic 12,141.8 (23.7) 104,404.4 (30.9) <0.001 41,649.9 
(27.6) 
43,657.3 (32.7) 31,239 (29.9) <0.001 
Electrocardiographic characteristics       
No acute changes 10,274.7 (20.1) 49,764.6 (14.7) <0.001 29,564.8 
(19.6) 
15,150.3 (11.3) 15,324.2 
(14.7) 
<0.001 
ST-segment elevation  1,359.1 (2.7) 16,824.1 (5.0) <0.001 3,894.9 (2.6) 11,489.5 (8.6) 2,798.8 (2.7) <0.001 
Left bundle branch block 2,599.4 (5.1) 23,020.2 (6.8) <0.001 9,119.6 (6.0) 9,340.5 (7.0) 7,159.5 (6.9) <0.001 
ST segment depression 12,707.9 (24.8) 89,212.9 (26.4) <0.001 36,637.3 
(24.3) 
37,212.4 (27.9) 28,071.1 
(26.9) 
<0.001 
T wave changes only 15,083.9 (29.5) 86,323.1 (25.6) <0.001 41,854.6 
(27.7) 
32,200.8 (24.1) 27,351.6 
(26.2) 
<0.001 
Other acute abnormality 9,151 (17.9) 72,736.1 (21.5) <0.001 29,938.8 
(19.8) 
28,152.5 (21.1) 23,795.8 
(22.8) 
<0.001 
Grace risk score 
classification 
       
Lowest (≤70)  1,174.3 (2.3) 5,157.5 (1.5) <0.001 2,698 (1.8) 1,886.1 (1.4) 1,747.7 (1.7) <0.001 
Low (71-87)   3,817.4 (7.5) 17,166.5 (5.1) <0.001 9,040.9 (6.0) 6,297.5 (4.7) 5,645.5 (5.4) <0.001 
 - 167 -  
 
 Receipt of care groups Latent classes 
Characteristics  
N=389,057 
Optimal care 
n=51,176 
(13.2%) 
Sub-optimal 
care 
n=337,881 
(86.9%) 
P value High receipt 
n= 151,010 
(38.8%) 
Intermediate 
receipt 
n=133,546 
(34.3%) 
Low receipt 
n=104,501 
(26.9%) 
P value 
Intermediate to high (>88)   46,184.3 (90.3) 315,557 (93.4) <0.001 139,271.1 
(92.2) 
125,362.4 (93.9) 97,107.8 
(92.9) 
<0.001 
*All are numbers (%), unless normally distributed continuous data (mean (SD)), or non-normally distributed continuous data (median (IQR)).  
Abbreviations. IMD, Index of multiple deprivation; CABG, coronary artery bypass graft; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; PCI, percutaneous coronary 
intervention; SD, standard deviation; IQR, interquartile range. 
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4.3.1 Predictors of receipt of care 
The results from the logistic regression analysis to investigate the predictors 
of receipt of care are summarised in Table 4.10. Being cared for by a 
cardiologist was a  positive predictor for receipt of optimal care (OR: 55.04, 
95% CI: 51.41-58.91),recording of an electrocardiogram (OR: 4.35, 95% CI: 
4.04-4.69), prescription at discharge of ACEi/ARBs (OR: 1.48, 95% CI: 
1.32-1.67), β blockers (OR: 2.94, 95% CI: 2.65-3.26), statins (OR: 2.63, 
95% CI: 2.55-2.72), P2Y12  inhibitors (OR: 8.50, 95% CI: 8.25-8.77), 
aldosterone antagonists (OR: 4.80, 95% CI: 1.43-16.12), aspirin (OR: 2.70, 
95% CI: 2.60-2.81), getting an echocardiogram (OR: 1.97, 95% CI: 1.92-
2.01), coronary angiography (OR: 4.01, 95% CI: 3.95-4.07), receipt of 
dietary advice (OR: 12.28, 95% CI: 11.85-12.72) and smoking cessation 
advice (OR: 16.61, 95% CI: 15.43-17.88). Being a current or ex-smoker was 
a positive  predictor for receipt of acute aspirin (OR: 1.37, 95% CI: 1.32-
1.42) and having a peak troponin ≥0.06 a positive predictor (OR: 2.26, 95% 
CI: 2.18-2.34) for enrolment into cardiac rehabilitation. Having a creatinine 
concentration >200 μmol/l was a negative predictor for recording of an 
electrocardiogram (OR: 0.16, 95% CI: 0.15-0.18), receipt of acute aspirin 
(OR: 0.60, 95% CI: 0.56-0.64), prescription of P2Y12 inhibitors (OR: 0.22, 
95% CI: 0.21-0.23) and receipt of dietary advice (OR: 0.30, 95% CI: 0.29-
0.31). Having previous angina was found to be a negative predictor of 
receipt of optimal care (OR: 0.84, 95% CI: 0.82-0.86), for prescription of β 
blockers having COPD/asthma (OR: 0.38, 95% CI: 0.37-0.40), ACEi/ARBs 
having chronic renal failure (OR: 0.46, 95% CI: 0.43-0.49), and for statins 
and aspirin prescription, having a cardiac arrest (OR: 0.57, 95% CI: 0.53-
0.61, OR: 0.53, 95% CI: 0.49-0.57, respectively) and for getting an 
angiogram having cerebrovascular disease (OR: 0.48, 95% CI: 0.46-0.49). 
Advanced age was found to be a negative predictor of enrolment into 
cardiac rehabilitation (OR: 0.55, 95% CI: 0.53-0.57) and receiving smoking 
cessation advice (OR: 0.11, 95% CI: 0.10-0.12).   
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Table 4.10. Predictors of receipt of optimal care and individual guideline 
indicated care interventions, according to multivariable multilevel logistic 
regression analyses. 
Care intervention Positive predictors Negative predictor 
Optimal care  Care by cardiologist (OR: 55.04, 
95% CI: 51.41-58.91) 
Family history of CHD (OR: 
1.32, 95% CI: 1.29-1.34) 
Hypercholesterolaemia (OR: 
1.24, 95% CI: 1.21-1.27) 
Sex (OR: 1.23, 95% CI: 1.20-
1.25) 
Previous angina (OR: 0.84, 
95% CI: 0.82-0.86) 
Previous MI (OR: 0.85, 95% 
CI: 0.83-0.87) 
Cerebrovascular disease 
(OR: 0.86, 95% CI: 0.83-
0.89) 
Electrocardiogram  Care by cardiologist (OR: 4.35, 
95% CI: 4.04-4.69) 
Family history of CHD (OR: 
1.89, 95% CI: 1.78-2.02) 
Creatinine (>200 (μmol/l)) 
(OR: 0.16, 95% CI: 0.15-
0.18) 
Acute aspirin  Current or ex-smoker (OR: 1.37, 
95% CI: 1.32-1.42) 
Creatinine (>200 (μmol/l)) 
(OR: 0.60, 95% CI: 0.56-
0.64) 
ACEi/ARBs Care by cardiologist (OR: 1.48, 
95% CI: 1.32-1.67) 
Hypertension (OR: 1.38, 95% 
CI: 1.34-1.43) 
Diabetes (OR: 1.26, 95% CI: 
1.21-1.31) 
Use of a loop diuretic (OR: 1.26, 
95% CI: 1.22-1.31) 
Previous MI (OR: 1.28, 95% CI: 
1.24-1.33) 
Chronic renal failure (OR: 
0.46, 95% CI: 0.43-0.49) 
Creatinine (>200 (μmol/l)) 
(OR: 0.58, 95% CI: 0.50-
0.68) 
Systolic blood pressure (<90 
mmHg) (OR: 0.72, 95% CI: 
0.66-0.79) 
Advanced age (>85) (OR: 
0.75, 95% CI: 0.71-0.80) 
Cardiac arrest (OR: 0.78, 
95% CI: 0.71-0.86) 
β blockers Care by cardiologist (OR: 2.94, 
95% CI: 2.65-3.26) 
Asthma or COPD (OR: 0.38, 
95% CI: 0.37-0.40) 
Creatinine (>200 (μmol/l)) 
(OR: 0.48, 95% CI: 0.42-
0.54) 
Cardiac arrest (OR: 0.60, 
95% CI: 0.54-0.66) 
Systolic blood pressure (<90 
mmHg) (OR: 0.71, 95% CI: 
0.64-0.79) 
Advanced age (OR: 0.74, 
95% CI: 0.69-0.79) 
Statins Care by cardiologist (OR: 2.63, 
95% CI: 2.55-2.72) 
Hypercholesterolaemia (OR: 
1.47, 95% CI: 1.43-1.51) 
Cardiac arrest (OR: 0.57, 
95% CI: 0.53-0.61) 
Systolic blood pressure (<90 
mmHg) (OR: 0.73, 95% CI: 
0.68-0.79) 
Advanced age (OR: 0.80, 
95% CI: 0.76-0.83) 
P2Y12  inhibitors  Care by cardiologist (OR: 8.50, 
95% CI: 8.25-8.77) 
Chronic renal failure (OR: 2.32, 
95% CI: 2.23-2.42) 
Advanced age (OR: 1.30, 95% 
CI: 1.25-1.36) 
 
Creatinine (>200 (μmol/l)) 
(OR: 0.22, 95% CI: 0.21-
0.23) 
Cardiac arrest (OR: 0.69, 
95% CI: 0.64-0.74) 
Heart rate (>110 bpm) (OR: 
0.69, 95% CI: 0.67-0.70) 
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Care intervention Positive predictors Negative predictor 
 Systolic blood pressure (<90 
mmHg) (OR: 0.73, 95% CI: 
0.68-0.79) 
 
Aldosterone 
antagonists  
Care by cardiologist (OR: 4.80, 
95% CI: 1.43-16.12) 
Peripheral vascular disease 
(OR: 2.80, 95% CI: 1.54-5.08) 
 
Echocardiogram  Care by cardiologist (OR: 1.97, 
95% CI: 1.92-2.01) 
Cardiac arrest (OR: 1.86, 95% 
CI: 1.75-1.97) 
Use of a loop diuretic (OR: 1.72, 
95% CI: 1.69-1.75) 
Previous PCI (OR: 0.77, 
95% CI: 0.75-0.80) 
Advanced age (OR: 0.81, 
95% CI: 0.78-0.83) 
 
Cardiac 
rehabilitation  
Peak troponin (≥ 0.06) (OR: 
2.26, 95% CI: 2.18-2.34) 
Care by cardiologist (OR: 2.17, 
95% CI: 2.11-2.23) 
Current or ex-smoker (OR: 1.24, 
95% CI: 1.21-1.26) 
Family history of CHD (OR: 
1.22, 95% CI: 1.19-1.26) 
Advanced age (OR: 0.55, 
95% CI: 0.53-0.57) 
Most deprived (OR: 0.72, 
95% CI: 0.70-0.74) 
Systolic blood pressure (<90 
mmHg) (OR: 0.72, 95% CI: 
0.68-0.76) 
 
Smoking cessation 
advice  
Care by cardiologist (OR: 16.61, 
95% CI: 15.43-17.88) 
Most deprived (OR: 1.95, 95% 
CI: 1.86-2.04) 
Asthma or COPD (OR: 1.45, 
95% CI: 1.39-1.51) 
Peripheral vascular disease 
(OR: 1.40, 95% CI: 1.31-1.50) 
Chronic renal failure (OR: 1.39, 
95% CI: 1.29-1.50) 
Advanced age (OR: 0.11, 
95% CI: 0.10-0.12) 
Creatinine (>200 (μmol/l)) 
(OR: 0.38, 95% CI: 0.36-
0.41) 
Heart rate (>110 bpm) (OR: 
0.64, 95% CI: 0.61-0.66) 
 
Dietary advice  Care by cardiologist (OR: 12.28, 
95% CI: 11.85-12.72) 
Chronic renal failure (OR: 1.81, 
95% CI: 1.74-1.88) 
Peak troponin (≥ 0.06) (OR: 
1.34, 95% CI: 1.29-1.39) 
Creatinine (>200 (μmol/l)) 
(OR: 0.30, 95% CI: 0.29-
0.31) 
Heart rate (>110 bpm) (OR: 
0.73, 95% CI: 0.71-0.75) 
Systolic blood pressure (<90 
mmHg) (OR: 0.76, 95% CI: 
0.71-0.82) 
 
Coronary 
angiography  
Care by cardiologist (OR: 4.01, 
95% CI: 3.95-4.07) 
Family history of CHD (OR: 
2.41, 95% CI: 2.37-2.46) 
Sex (OR: 1.82, 95% CI: 1.80-
1.85) 
Hypercholesterolaemia (OR: 
1.62, 95% CI: 1.60-1.65) 
Current or ex-smoker (OR: 1.44, 
95% CI: 1.42-1.46) 
 
Cerebrovascular disease 
(OR: 0.48, 95% CI: 0.46-
0.49) 
 Previous MI (OR: 0.68, 95% 
CI: 0.67-0.69) 
Asthma or COPD (OR: 0.75, 
95% CI: 0.73-0.76) 
 
Aspirin at discharge   Care by cardiologist (OR: 2.70, 
95% CI: 2.60-2.81) 
Advanced age (OR: 1.64, 95% 
CI: 1.55-1.73) 
 
Cardiac arrest (OR: 0.53, 
95% CI: 0.49-0.57) 
Systolic blood pressure (<90 
mmHg) (OR: 0.70, 95% CI: 
0.65-0.76) 
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Abbreviations: ARB, angiotensin receptor blocker; ACE, angiotensin converting enzyme; MI, myocardial 
infarction; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; PCI, percutaneous 
coronary intervention; OR, odds ratio. 
 
4.4 Impact of quality of care on survival for patients with 
NSTEMI 
4.4.1 Survival  
The median time to death for the analytical cohort was 1.1 (IQR 0.3 to 2.4) 
years, with 29.2% (113,586) deaths, corresponding to 10.5 deaths per 100 
person years (1,079,044 person years). The crude mortality rates were 
lower for the optimally cared for patients ((10.4% (5,342) vs. 32.0% 
(108,244), P<0.001)) and there was a significant difference in unadjusted 
survival rates between those who received optimal care compared with 
those who did not (Figure 4.3). Similarly, there were significant differences 
in unadjusted survival rates for the latent classes between the high receipt 
class compared with the intermediate and low receipt classes, with the 
poorest survival being observed in the low receipt class (Figure 4.3). 
However, overlapping confidence intervals were observed in later follow-up 
times due to the low numbers at risk in the high receipt class at the time 
point (Figure 4.3).   
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Figure 4.3. Unadjusted Kaplan-Meier curves for time to death by receipt of guideline-indicated care for NSTEMI patients. 
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After adjustment, patients who received sub optimal care’s survival time 
was reduced by 56% (Time ratio (TR) 0.44, 95% CI 0.41–0.45) compared 
with those who received all the guideline indicated care interventions for 
which they were eligible (Figure 4.4). For the latent classes, patients in the 
intermediate receipt of care class’s survival was shortened by 16% (TR 
0.84, 95% CI 0.79–0.88) and those in the low receipt of care class by 23% 
(TR 0.77, 95% CI 0.74–0.80), compared with the patients in the high receipt 
of care class (Figure 4.4). Individual assessments of the impact of missing 
each of the 13 care interventions considered were done and not getting a 
coronary angiogram was found to have the biggest impact on survival i.e. 
survival time was shortened by 82% (TR 0.18, 95% CI 0.17–0.18) when 
NSTEMI patients missed this care intervention. Other care interventions 
that were found to have a strong impact on survival included cardiac 
rehabilitation (TR 0.49, 95% CI 0.48–0.50), smoking cessation advice (TR 
0.53, 95% CI 0.51–0.57), and statins (TR 0.56, 95% CI 0.55–0.58), with the 
ones with the lowest impact being recording of an Electrocardiogram (TR 
0.92, 95% CI 0.89-0.96) and echocardiography (TR 0.94, 95% CI 0.92-0.96) 
(Figure 4.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 - 174 -  
 
 
 
 
Figure 4.4 Impact of missing specific guideline-indicated interventions, sub-
optimal care, and intermediate and low receipt of care on survival. 
 
4.4.1.1 Avoidable deaths 
If all the NSTEMI patients in the analytical cohort had received all the 
guideline recommended care for which they were eligible, 32,765 (28.9%) 
(95% CI 30,531-33,509) deaths could have been potentially avoided or 
postponed (Table 4.11). By latent classes, 17,778 (15.7%) (95% CI 16,720–
18,625) deaths could have been potentially prevented or postponed if 
patients in the intermediate class of receipt of care had been treated 
equivalent to those in the high receipt of care class and  16,177 (14.3%) 
(95% CI 15,547–16,807) deaths could have been prevented or postponed 
in the low receipt class if the patients had been treated similar to those in 
the high receipt class (Table 4.11). For the individual assessments of the 
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13 guideline indicated care interventions, avoidable deaths ranged from 
123-40,228 (median 7,104, IQR 4,653-23,383) deaths (Table 4.11).    
Table 4.11 Estimated number of preventable deaths and median survival 
times by quality of care and by care interventions.  
Treatment Preventable deaths (based on 
imputed data estimates) 
 
Median (IQR) 
survival time 
(years) 
Sub-optimal care 32,765 (30,531 - 33,509) 2.5 (1.2 – 4.4) 
Intermediate receipt class* 17,778 (16,720 - 18,625 )  5.0 (2.3 -6.5) 
Low receipt class* 16,177 (15,547 – 16,807) 2.5 (1.4 – 3.3) 
Electrocardiogram 3,866 (3,740 – 4,034) 4.5 (1.7 – 6.7) 
Acute aspirin 4,653 (4,438 – 4,796) 2.6 (1.2 – 5.1) 
ACE inhibition or ARBs 5,991 (5,820 – 6,163) 4.9 (1.6 – 6.4) 
β blockers    4,118 (3,987 – 4,249) 4.7 (1.5 -6.2) 
Statin at discharge 7,081 (6,954 – 7,334) 2.6 (1.0 – 4.9) 
 P2Y12 inhibitors at discharge 25,133 (24,141 – 26,125) 3.2 (1.7 – 5.07) 
Aldosterone antagonist  123 (71 – 211) 1.7 (0.8 - 2.5) 
Echocardiography  40,228 (39,373 – 41,084) 2.5 (1.2 – 4.4) 
Cardiac rehabilitation 11,400 (11,167 – 11,633) 2.4 (1.0 – 4.4) 
Smoking cessation advice 23,383 (22,501 – 25,148) 3.2 (1.6 – 5.3) 
Dietary advice 31,712 (30,736 – 33,176) 3.1 (1.5 – 5.2) 
Coronary angiography 8,236 (7,778 – 8,236) 2.4 (0.8 – 4.6) 
Aspirin at discharge  7,104 (6,847 – 7,275) 3.0 (1.3 – 5.1) 
*compared to the high receipt class. 
Abbreviations: ARB, angiotensin receptor blocker; ACE, angiotensin converting enzyme. 
4.4.1.1.1 Monte Carlo Errors (MCE) 
A sensitivity analysis was conducted by making comparisons of the results 
from univariable unadjusted analysis, complete case analysis and imputed 
data analysis and a difference was noted (see Appendix C) in the estimates 
thus warranting the imputed data analysis to be carried out. After 
assessment of the MCEs, they were found to be sufficiently less than 10% 
of the estimated standard errors (Table 4.12), which gave evidence that the 
results from the 10 imputed datasets used were stable estimates of the 
results. 
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Table 4.12 Multivariable hierarchical accelerated failure time survival model 
for the effect of latent classes of receipt of care on survival. 
Variable Coefficient Coefficient 
± MCE 
P-
value 
P-value 
± MCE 
Latent class     
  High receipt  1 - - - 
  Intermediate receipt  -0.18  -0.1802, -
0.1798 
<0.001 <0.001,  
<0.001 
  Low receipt   -0.26 -0.2602, -
0.2598 
<0.001 <0.001,  
<0.001 
Receipt of care group     
  Optimal care 1 - - - 
  Sub-optimal care  -0.84 -0.8401, -
0.8399 
<0.001 <0.001,  
<0.001 
Care intervention       
Electrocardiogram  -0.08 -0.0805, -
0.0795 
<0.001 <0.001,  
<0.001 
Acute aspirin -0.44 -0.4405, -
0.4395 
<0.001 <0.001,  
<0.001 
Echocardiography -0.06 -0.0602, -
0.0598 
<0.001 <0.001,  
<0.001 
Coronary  angiography -1.73 -1.7301, -
1.7299 
<0.001 <0.001,  
<0.001 
Aspirin at discharge -0.19 -0.1903, -
0.1897 
<0.001 <0.001,  
<0.001 
P2Y12 inhibitors at 
discharge 
-0.28 -0.2802, -
0.2798 
<0.001 <0.001,  
<0.001 
ACE inhibition or ARBs -0.35 -0.3504, -
0.3496 
<0.001 <0.001,  
<0.001 
β blockers    -0.46 -0.4602, -
0.4596 
<0.001 <0.001,  
<0.001 
Statin at discharge 
-0.57 -0.5702, -
0.5698 
<0.001 <0.001,  
<0.001 
Aldosterone antagonist 
-0.13 -0.1324, -
0.1276  
0.639 0.633, 0.645 
Dietary advice 
-0.43 -0.4298, -
0.4302 
<0.001 <0.001,  
<0.001 
Smoking cessation advice -0.63 -0.6296, -
0.6304 
<0.001 <0.001,  
<0.001 
Cardiac rehabilitation -0.71 -0.7103, -
0.7097 
<0.001 <0.001,  
<0.001 
Abbreviations: MCE, Monte Carlo errors. 
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4.5 Summary of key findings  
 Over half of the NSTEMI patients in the analytical cohort were either 
previous or current smokers, a third had previous angina, a quarter 
had previous AMI, a fifth were diabetic and over half were 
hypertensive. 
  A large proportion (86.8%) of the NSTEMI patients in the analytical 
cohort received sub-optimal care ( missed one or more guideline 
indicated care interventions), with most frequently missed care 
interventions being dietary advice, smoking cessation advice, 
echocardiography, P2Y12 prescription at discharge, prescription of 
in-hospital aspirin and coronary angiography.  
 A three class solution was found optimal in defining ‘real life’ clinical 
practice patterns of receipt of care for NSTEMI patients recorded in 
the nationwide registry MINAP and the classes were nominally 
labelled ‘high’, ‘intermediate’, and ‘low’ depending on the conditional 
item probabilities of receipt of each of the 13 guideline indicated care 
interventions in each class. Use of an electrocardiogram, aspirin at 
discharge and statins at discharge were high in all three classes with 
receipt of P2Y12 inhibitors at discharge, echocardiography, cardiac 
rehabilitation, dietary advice, coronary angiography and acute 
aspirin being highest in the high receipt class. Patients in the high 
receipt class had low conditional item probabilities for ACEi/ARBs 
and β blockers, however the intermediate receipt class had highest 
conditional item probabilities of receipt for ACEi/ARBs and β blockers 
compared to the two other classes.  
 Of the potential predictors of receipt of care (optimal or individual 
care interventions) care by cardiologist was a positive predictor of 
receipt of guideline indicated care, with the exception for acute 
aspirin and cardiac rehabilitation were being a current or ex-smoker 
and peak troponin ≥0.06 were positive predictors, respectively.       
 Not receiving all the guideline recommended care interventions for 
NSTEMI patients resulted to a shortened survival time by over 50% 
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compared to the NSTEMI patients who received optimal medical 
care.  
 Individual assessments of the 13 considered care interventions 
showed that coronary angiography, cardiac rehabilitation, smoking 
cessation advice and statins had the strongest impact on reduced 
survival, with coronary angiography having the strongest impact of 
all the care interventions. 
 Receipt of sub-optimal NSTEMI care was found to be associated with 
32,765 avoidable/preventable deaths.   
4.6 Conclusion  
The results presented in this chapter focused on the potentially avoidable 
harm associated with sub-optimal care management of NSTEMI patients 
across a single national health care system. The findings show that if all the 
patients during the study period (2003-2013) had received all the guideline 
indicated care interventions for which they were eligible for then 
approximately 33,000 deaths may have been prevented. This equates to 
about one avoidable death per month per hospital over the last decade in 
the National Health Service.  
 
This present chapter has given evidence of excess mortality associated with 
sub-optimal NSTEMI care, highlighted the care interventions that are being 
frequently missed, and also identified the most important predictor of receipt 
of guideline indicated care. The next chapter (Chapter 5) presents results 
on how NSTEMI care varied between hospitals, Strategic Clinical Networks 
and Clinical Commissioning Group. 
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Chapter 5 : Results 
Geographic variation in the treatment of non ST-segment 
myocardial infarction in the English National Health Service: 
a cohort study. 
The following publications have arisen from the analysis and results in this 
chapter: 
1. Dondo, TB, Hall, M, Timmis, AD, Yan, AT, Batin, PD, Oliver, G, 
Alabas, OA, Norman, PD, Deanfield, JE, Bloor, K, Hemingway, H, 
Gale, CP. (2016). Geographic variation in the treatment of non ST-
segment myocardial infarction in the English National Health 
Service: a cohort study. BMJ Open. doi: 10.1136/bmjopen-2016-
011600. 
2. Dondo, TB, Hall, M, Timmis, AD, Yan, AT, Batin, PD, Oliver, G, 
Alabas, OA, Norman, PD, Deanfield, JE, Bloor, K, Hemingway, H, 
Gale, CP. (2016). Geographic variation in the treatment of non ST-
segment elevation myocardial infarction: a national cohort study. Eur 
Heart J (Vol. 37, No. S1, pp. 1177-1178). Oxford University Press. 
(Presented as a poster at the European Society Congress 2016, 
London). 
5.1 Introduction  
Following on from quantifying avoidable deaths associated with sub-optimal 
care of NSTEMI patients and highlighting the care interventions that were 
mostly missed in Chapter 4, geographic variation in receipt of the guideline 
indicated care was assessed. This chapter summarises the analyses’ 
results of objective two of the thesis that aimed to study the geographic 
variation in receipt of care for NSTEMI patients. The chapter includes five 
sections of results as listed below: 
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 Descriptive statistics: Study population and guideline indicated care 
interventions (§5.2) 
 Geographic variation in receipt of care for NSTEMI patients (§5.3)   
 Variance components from multi-level models (§5.4) 
 Temporal changes in receipt of care for NSTEMI patients  (§5.5)  
 Avoidable deaths associated with sub-optimal care for NSTEMI 
patients (§5.6)    
 Summary of key findings (§5.7) 
 Conclusion (§5.8).  
A detailed description of the methods employed for the analyses has 
already been given in Chapter 3, §3.7.     
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5.2 Descriptive statistics 
5.2.1 Study population and guideline indicated care 
interventions  
Of the 389,057 NSTEMI patients used as the analytical cohort, 357,228 
patients were geocoded to boundary data and the remaining 31,829 (8.2%) 
cases excluded from analyses in this chapter due to missing location data. 
The distribution of the patient characteristics for the geocoded patients was 
similar to the full analytical cohort, i.e. mean age 70.9 (SD 13.3) years, 
63.1% (n=225,009) male, majority white (93.1%, n=301,312), a third with 
previous history of angina (31.7% (n=113,059)), a quarter with previous 
myocardial infarction (21.5% (n=89,571)), over half previous or current 
smokers (71.2% (n=254,215)), almost half hypertensive (48.9% 
(n=174,596)), a fifth diabetic (21.1% (n=75,433)), 14.6% (n=52,030) having 
asthma or COPD and over half of the patients were not treated by a 
cardiologist (n=207,355, 58.1%)  (Table 5.1). With similar distributions being 
noted for the rest of the characteristics summarised in Table 5.1, these 
results showed that exclusion of the non-geocoded patients (8.1%) did not 
affect the generalisability of the geocoded patients to the full cohort. Receipt 
of guideline-indicated care ranged from 12.5% to 94.1% (median 67.9%, 
IQR 41.0% to 86.2%) (Table 5.2). According to the cut-offs ≤40%, >40% to 
≤79% and >79% (commonly used in past studies(67, 128)), 11.8% 
(n=42,229) patients received ≤40% of the guideline indicated care 
interventions for which they were eligible, 58.5% (n=208,930) received 
>40% to ≤79% and 29.7% (n=106,069) received >79%.  
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Table 5.1 Baseline characteristics of geo coded patients, NSTEMI, 2003-
2013. 
Characteristics 
 
Cases 
n=357,228 
Missing 
Age, years; mean (sd) 70.9 (13.3) 504 (0.1) 
Male  225,009 (63.1) 593 (0.2) 
Deprivation according to IMD score 
   1 (least deprived) 
 
61,235 (17.2) 
419 (0.1) 
   2 70,084  (19.6) 
   3 74,842  (21.0) 
   4 72,121  (20.2) 
   5(most deprived) 78,527  (22.0) 
Past medical history 
  Myocardial infarction 
 
89,571 (25.1) 
 
0¥ 
  Heart failure 22,581 (6.3) 0¥ 
  PCI 30,835 (8.6) 0¥ 
  CABG 26,021 (7.3) 0¥ 
  Angina 113,059 (31.7) 0¥ 
  Cerebrovascular disease 31,366 (8.8) 0¥ 
  Peripheral vascular disease 16,868 (4.7) 0¥ 
  Diabetes 75,433 (21.1) 0¥ 
  Chronic renal failure 20,349 (5.7) 0¥ 
  Hypercholesterolaemia  112,713 (31.5) 0¥ 
  Hypertension 174,596 (48.9) 0¥ 
  Previous or current smoker                                                                                                                                                                       254,215 (71.2) 0¥ 
  Asthma or COPD 52,030 (14.6) 0¥ 
  Family history of CHD 72,444 (20.3) 0¥ 
Presenting characteristics          
  Systolic blood pressure, mmHg, mean (sd)   142.5 (28.4) 59,962 (16.8) 
  Systolic blood pressure, <90 mmHg 7,280 (2.5) 59,962 (16.8) 
  Heart rate, bpm, mean (sd) 80 (67-95) 59,177 (16.6) 
  Heart rate >110 bpm 32,964 (11.1) 59,177 (16.9) 
  Creatinine; mean (sd) 92 (76-114) 147,959 (41.4) 
  Troponin elevation 321,212 (94.6) 17,559 (4.9) 
Cardiac arrest  6,178 (1.8) 21,038 (5.9) 
Electrocardiogram changes    
  No acute changes 51,214 (15.7) 
31,825 (8.9) 
  ST-segment elevation  14,336 (4.4) 
  Left bundle branch block 21,149 (6.5) 
  ST-segment depression 84,821 (26.1) 
  T wave changes only 85,474 (26.3) 
  Other acute abnormality 68,409  (21.0) 
Use of a loop diuretic  89,438 (30.2) 61,294 (17.1) 
GRACE risk score category   
  Low (≤88) 25,787 (18.2) 
215,599 (60.4)   Intermediate (88-110)   38,897 (27.5) 
  High (>110)  76,945 (54.3) 
Abbreviations: NSTEMI, non-ST-segment elevation myocardial infarction; sd, standard deviation; IMD, Index of 
multiple deprivation; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; COPD, 
chronic obstructive pulmonary disease; CHD, coronary heart disease; bpm, beats per minute; GRACE risk score 
category as defined by NICE. ¥ missing data default imputed to “No”.  
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Table 5.2. Eligibility and receipt of guideline-indicated interventions in geo 
coded patients, NSTEMI, 2003-2013. 
Guideline-indicated intervention Number (%) of 
NSTEMI who 
received a 
guideline-indicated 
intervention 
Number of NSTEMI 
eligible for a 
guideline-
indicated 
intervention 
Electrocardiogram 336,094 (94.1) 357,228 
Acute aspirin  212,837 (88.7) 239,876 
Echocardiography 178,851 (50.1) 357,195 
Coronary angiography 196,781 (57.4) 342,856 
Aspirin at discharge 279,584 (89.1) 313,901 
P2Y12 inhibitors 121,427 (41.0) 296,450 
ACEis/ARBs 81,176 (67.9) 119,625 
β Blockers 80,600 (74.8) 107,698 
Statins at discharge 275,626 (86.2) 319,747 
Aldosterone antagonists  134 (23.7) 566 
Dietary advice  111,759 (32.6) 342,960 
Smoking cessation advice  31,683 (12.5) 254,215 
Cardiac rehabilitation  257,875 (76.7) 336,146 
Abbreviations: ACEis, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers. 
 
5.3 Geographic variation in receipt of care for NSTEMI 
patients  
5.3.1 Variation by Clinical Commissioning Groups (CCGs) 
At CCG level a low proportion of patients received optimal care (median 
12.8%, interquartile range (IQR) 0.7 to 18.1%) (Figure 5.1). High 
prescription rates of aspirin acutely (median 92.8%, interquartile range 88.6 
to 97.1%), aspirin at discharge from hospital (90.1%, 85.1 to 93.3%) and 
statins (86.4%, 82.3 to 91.2%) were noted consistently across the CCGs 
(Figure 5.1). The greatest variation was noted for in hospital aldosterone 
antagonists (median 16.7%, IQR 0.0 to 40.0%) and least for use of an 
electrocardiogram (96.7%, 92.5 to 98.7%) (Figure 5.1). The provision of 
echocardiography (50.3%, 38.3 to 61.9%), cardiac rehabilitation (79.7%, 
68.2 to 87.1%), coronary angiography (57.4%, 48.8 to 66.7%), the 
prescription of ACEi/ARBs (69.0%, 63.6 to 74.0%) and β blockers (76.3%, 
70.4 to 82.0%) was intermediate and varied, whilst the provision of smoking 
cessation advice (11.6%, 8.7 to 16.6%), dietary advice (32.4%, 23.9 to 
41.7%)  and P2Y12 inhibitors (39.7%, 32.4 to 46.9%) was poor (Figure 5.1). 
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Figure 5.1 Geographic variation proportions of eligible patients who 
received guideline-indicated interventions, for each intervention and 
for optimal care, by CCG. 
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5.3.2 Variation by Strategic Clinical Networks (SCNs) 
Similar to the CCGs, proportion of patients who received optimal care was 
low across the SCNs (median 12.2%, IQR 11.5 to 15.9%) (Table 5.3). North 
East and North Cumbria, and East Midlands had the highest proportion of 
patients receiving optimal care (20.0% (n=7,045) and 10.3% (n=3,409), 
respectively) (Table 5.3). Low receipt rates were noted consistently for 
P2Y12 inhibitors (median 40.0%, IQR 39.0 to 42.0%), aldosterone 
antagonists (27.0%, 20.0 to 28.0%), smoking cessation advice (13.0%, 12.0 
to 17.0%) and dietary advice (32.0%, 28.0 to 37.0%) across the SCNs 
(Table 5.3). Intermediate to high receipt rates with minimal variation were 
noted for electrocardiogram (median 95.0%, IQR 92.0 to 96.0%), acute 
aspirin (91.0%, 88.0 to 92.0%), statins (86.0%, 84.0 to 87.0%), aspirin on 
discharge (89.0%, 87.0 to 90.0%), cardiac rehabilitation (79.0, 72.0 to 
82.0%), β blockers (76.0%, 73.0 to 76.0%), the prescription of ACEi/ARBs 
(68.0%, 67.0 to 70.0%) across the SCNs, with echocardiography and 
coronary angiography being received at an intermediate rate (median 
50.0%, IQR 45.0 to 55.0% and 58.0%, 52.0 to 61.0%, respectively) (Table 
5.3).  
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Table 5.3. Proportions of patients (of the eligible) receiving each care intervention by SCNs. 
 GEOGRAPHIC REGION (SCNs) 
 
Treatments 
n (%) 
Cheshire 
and 
Merseyside 
 
East  
Midlands 
 
East of  
England 
 
G Manchester 
Lancashire 
and S 
Cumbria 
 
London 
 
North East 
and N 
Cumbria 
 
South 
East 
coast 
 
South 
West 
 
Thames 
Valley 
 
Wessex 
 
West 
Midlands 
 
Yorkshire 
and 
Northern 
 
ECG 
 
18,412 
(94.3) 
32,080 
(96.7) 
45,553 
(95.9) 
26,346 
(88.8) 
32,524 
(94.6) 
34.149 
(96.9) 
24,522 
(95.8) 
27,612 
(94.6) 
9,236 
(94.9) 
14,903 
(93.1) 
28,563 
(90.7) 
42,194 
(92.3) 
Acute 
aspirin 
11,921 
(91.6) 
18,412 
(92.3) 
30,302 
(91.5) 
19,993 
(90.5) 
20,143 
(90.3) 
18,733 
(88.4) 
16,291 
(92.6) 
17,045 
(90.0) 
6,034 
(94.2) 
10,385 
(95.1) 
20,103 
(85.3) 
23,475 
(76.3) 
ACEi/ARB 3,577 
(64.5) 
7,522 
(68.1) 
10,670 
(66.8) 
6,746 
(70.6) 
7,654 
(70.1) 
8,440 
(64.4) 
5,667 
(67.3) 
6,824 
(66.3) 
2,402 
(72.3) 
4,333 
(73.7) 
6,892 
(70.0) 
10,449 
(67.7) 
β blockers 3,252 
(68.9) 
7,849 
(74.7) 
10,046 
(72.7) 
6,834 
(76.2) 
7,543 
(75.5) 
8,720 
(73.1) 
5,798 
(75.9) 
6,612 
(71.5) 
2,367 
(76.3) 
4,089 
(78.9) 
7,032 
(76.4) 
10,458 
(78.3) 
Statins 13,292 
(84.9) 
 
25,153 
(84.9) 
35,808 
(84.4) 
24,896 
(90.6) 
27,022 
(86.7) 
25,154 
(84.4) 
20,574 
(86.2) 
22,005 
(83.2) 
8,060 
(88.5) 
12,260 
(88.1) 
24,513 
(87.4) 
36,889 
(87.4) 
P2Y12 
inhibitors 
5,564 
(39.3) 
11,180 
(39.9) 
15,646 
(39.1) 
11,836 
(42.3) 
12,388 
(42.3) 
11,570  
(43.2) 
9,388 
(41.5) 
9,863 
(41.4) 
3,944 
(46.7) 
4,599 
(40.0) 
10,468 
(40.4) 
14,981 
(38.4) 
Aldosterone 
antagonists 
8  
(33.3) 
9 
(18.4) 
15 
(27.3) 
10 
(33.3) 
20 
(27.4) 
19 
(18.1) 
12 
(28.6) 
7 
(20.0) 
5 
(31.3) 
6 
(14.6) 
12 
(21.1) 
11 
(28.2) 
Echocardio
graphy 
11,918 
(61.0) 
 
17,252 
(52.0) 
21,268 
(44.8) 
15,938 
(53.7) 
19,453 
(56.6) 
20,788 
(59.0) 
10,666 
(41.7) 
14,001 
(50.0) 
4,524 
(46.5) 
8,850 
(55.3) 
14,570 
(46.3) 
19,623 
(42.9) 
Cardiac 
rehabilitatio
n 
14,120 
(74.2) 
22,050 
(71.8) 
35,708 
(81.4) 
21,464 
(77.7) 
21,295 
(65.1) 
26,916 
(78.8) 
17,418 
(71.8) 
17,147 
(64.9) 
7,029 
(79.1) 
13,443 
(87.0) 
24,180 
(81.9) 
37,105 
(85.4) 
Smoking 
cessation 
advice 
2,215 
(17.0) 
2,888 
(11.8) 
3,310 
(9.3) 
3,396 
(17.2) 
2,983 
(11.5) 
3,709 
(14.6) 
2,052  
(11.7) 
2,033 
(9.9) 
848 
(13.1) 
1,227 
(10.5) 
2,515 
(11.5) 
4,507 
(14.1) 
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 GEOGRAPHIC REGION (SCNs) 
 
Treatments 
n (%) 
Cheshire 
and 
Merseyside 
 
East  
Midlands 
 
East of  
England 
 
G Manchester 
Lancashire 
and S 
Cumbria 
 
London 
 
North East 
and N 
Cumbria 
 
South 
East 
coast 
 
South 
West 
 
Thames 
Valley 
 
Wessex 
 
West 
Midlands 
 
Yorkshire 
and 
Northern 
 
Dietary 
advice 
7,488 
(39.6) 
8,214 
(26.3) 
16,187 
(34.9) 
10,946 
(38.7) 
8,592 
(26.1) 
12,627  
(36.9) 
7,632 
(31.3) 
7,721 
(27.9) 
3,510 
(38.7) 
4,980 
(31.8) 
9,712 
(33.0) 
14,150 
(31.6) 
Coronary 
angiography 
8,569 
(47.6) 
15,379 
(47.8) 
26,371 
(57.7) 
14,618 
(51.3) 
23,269 
(69.6) 
17,773 
(52.6) 
14,718 
(59.6) 
16,869 
(61.3) 
5,741 
(59.9) 
10,493 
(66.1) 
20,370 
(67.0) 
22,611 
(52.3) 
Aspirin on 
discharge 
12,887 
(86.9) 
25,395 
(87.3) 
36,255 
(87.4) 
24,797 
(93.2) 
27,371 
(88.8) 
26,056 
(88.0) 
21,060 
(90.1) 
23,441 
(89.8) 
8,179 
(89.9) 
12,940 
(91.5) 
24,450 
(88.6) 
36,753  
(89.3) 
Optimal 
care  
3,099 (15.9) 3,409 
(10.3) 
5,498 
(11.6) 
5,128 (17.3) 4,194 
(12.2) 
7,045 
(20.0) 
3,133 
(12.2) 
3,342 
(11.5) 
1,757 
(18.0) 
2,386 
(14.9) 
4,356 
(13.8) 
4,910 
(10.7) 
Abbreviations: ARB, angiotensin receptor blocker; ACE, angiotensin converting enzyme.
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5.4 Variance components from multi-level models 
As described in the methodology section in Chapter 3 (§3.7), multilevel models 
were fitted to quantify the proportion of variance in receipt of optimal care for 
NSTEMI patients that is explained by the clustering structure (patients nested 
within hospitals, nested within CCGs, nested within SCNs) of the hierarchical 
model. After adjustment for case mix (fixed effects), the between unit variance 
was low for SCNs (0.004, 95% CI 0.0004 to 0.03), for CCGs (0.004, 0.001 to 
0.03) and higher for hospitals (1.92, 95% CI 1.51 to 2.44) (Table 5.4). The 
findings showed that 99.6% of the remaining variability in provision of optimal 
guideline indicated care after case mix adjustment was between hospitals (ICC 
0.996, 95% CI 0.976 to 0.999) with 0.2% between SCNs (ICC 0.002, 95% CI 
0.0002 to 0.01) and 0.2% between CCGs (ICC 0.002, 95% CI 0.0007 to 0.01).    
Table 5.4. Results from the multi-level Poisson model fitted to investigate 
variation in optimal receipt of care (Parameter estimates, p-values, standard 
errors and 95% CIs). 
Fixed Effects Incidence ratios P-value 95% CI 
Sex (male vs. female) 1.12 >0.001 1.11, 1.15 
Deprivation according to IMD score    
   1 (least deprived) 1 - 1 
   2 0.98 0.34 0.95, 1.02 
   3 0.99 0.41 0.95, 1.02 
   4 0.97 0.06 0.93, 1.00 
   5 (most deprived) 0.96 0.02 0.92, 0.99 
Ethnicity    
   White 1 - 1 
   Black 0.99 0.78 0.90, 1.08 
   Asian 1.02 0.32 0.98, 1.07 
   Mixed 1.21 0.07 0.98, 1.48 
  Other 0.92 0.10 0.84, 1.02 
GRACE risk score category     
   Low (≤88) 1 - 1 
   Intermediate (88-110)   0.97 0.16 0.94, 1.01 
   High (>110) 0.78 >0.001 0.76, 0.81 
Current or ex-smokers (Yes vs. No) 1.16 >0.001 1.14, 1.19 
Prior diabetes (Yes vs. No) 0.99 0.88 0.98, 1.02 
Prior MI (Yes vs. No) 0.90 >0.001 0.88, 0.92 
Prior angina (Yes vs. No) 0.91 >0.001 0.89, 0.93 
rior PCI (Yes vs. No) 0.98 0.33 0.95, 1.02 
Prior CABG (Yes vs. No) 0.95 0.01 0.92, 0.99 
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Prior peripheral vascular disease (Yes 
vs. No) 
0.95 0.03 0.91, 0.99 
Hypercholesterolemia 1.11 >0.001 1.08, 1.13 
Prior hypertension (Yes vs. No) 1.02 0.08 1.00, 1.04 
Prior cerebrovascular disease (Yes vs. 
No) 
0.88 >0.001 0.84, 0.90 
Prior chronic obstructive pulmonary 
disease/asthma (Yes vs. No) 
0.94 >0.001 0.92, 0.97 
Family history of CHD (Yes vs. No) 1.15 >0.001 1.13, 1.17 
Year  1.60 >0.001 1.60, 1.62 
Random Effects Variance  Standard 
error 
95% CI 
Hospital    
  variance  1.92 0.24 1.51, 2.44 
CCG    
  variance  0.004 0.004 0.001, 
0.03 
SCN    
  variance  0.004 0.004 0.0004, 
0.03 
Abbreviations: IMD, Index of multiple deprivation; CABG, coronary artery bypass graft; CHD, coronary heart disease; 
COPD, chronic obstructive pulmonary disease; PCI, percutaneous coronary intervention; Clinical Commissioning 
Groups (CCGs); Strategic Clinical Networks (SCNs). 
5.5 Temporal changes in receipt of care for NSTEMI patients  
An improvement in the provision of care for NSTEMI patients was observed 
after comparing rates of receipt of care for the years 2003/04 with 2012/13 
across CCGs (Table 5.5). Improvement in provision of care was most 
pronounced for smoking cessation advice (median CCG rates: 0.00 vs. 69%), 
dietary advice (0.00 vs.84%), coronary angiography (33 vs. 83%), ACEis/ARBs 
(71 vs. 100%) and β blockers (77 vs. 100%). An improvement was also 
observed for receipt of optimal care (0.00 vs. 43%) and although the correlation 
between care in CCGs over the study period was significant, it was weak (rho 
= 0.36, P<0.001).  
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Table 5.5. Temporal changes in the proportion of NSTEMI receiving guideline-
indicated treatments, 2003/04 vs. 2012/13 in CCGs. 
Guideline-indicated  intervention Biennial year 
2003/04 
Median (IQR) 
 2012/13 
Median (IQR) 
Optimal care 0.00  0.34 (0.23-0.46) 
Electrocardiogram  0.86 (0.69-0.96)  1.00 (0.99-1.00) 
Acute aspirin 0.88 (0.81-0.94)  0.97 (0.93-0.99) 
ACEis/ARBs 0.71 (0.65-0.76)  1.00 (1.00-1.00) 
β blockers 0.77 (0.71-0.83)  1.00 (0.93-1.00) 
Statins 0.83 (0.77-0.88)  0.95 (0.91-0.98) 
P2Y12 inhibitors 0.00  0.94 (0.88-0.98) 
Aldosterone antagonist -  0.00 (0.00-1.00) 
Echocardiography 0.41 (0.27-0.57)  0.63 (0.51-0.76) 
Cardiac rehabilitation 0.73 (0.60-0.83)  0.87 (0.74-0.94) 
Smoking cessation advice 0.00  0.69 (0.47-0.87) 
Dietary advice 0.00  0.84 (0.62-0.93) 
Coronary angiography 0.33 (0.21-0.47)  0.83 (0.75-0.89) 
Aspirin on discharge 0.89 (0.83-0.93)  0.97 (0.94-0.99) 
Median represents the median of the proportion of eligible NSTEMI who received the.  
Abbreviations. IQR, interquartile range; ACEis, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor 
blockers. 
5.6 Avoidable deaths associated with sub-optimal care for 
NSTEMI patients 
In order to determine the potentially preventable deaths associated with sub-
optimal treatment for hospitals, the adjusted mortality risk (Table 5.6) obtained 
from the multilevel accelerated failure time modelling were multiplied by the 
corresponding mortality rates and proportions of patients in the sub-optimal 
treatment groups per hospital. The product was then multiplied by the total 
number of NSTEMI between 2003 and 2013 for each hospital. The quantified 
avoidable deaths associated with sub-optimal care at hospital level over the 
study period (2003-2013) varied between hospitals (median number of deaths 
39, interquartile range 15 to 62).   
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Table 5.6. Impact of receiving sub-optimal care on NSTEMI patients’ survival  
Treatment  Complete case analysis 
Adjusted TRs (95% CI) 
Multiple imputation analyses 
Adjusted TRs (95% CI)  
P-value  
Optimal care  1 1 - 
Sub-optimal care 0.40 (0.38, 0.43) 0.44 (0.41, 0.45) < 0.001 
 
5.7 Summary of key findings  
 Over a 10 year study period, evidence for wide spread sub-optimal use 
of guideline indicated care for the management of NSTEMI was found. 
 The greatest variation in provision of care across CCGs was for 
aldosterone antagonists and least for use of an electrocardiogram, with 
high prescription rates and minimal variation for prescription of aspirin 
acutely, aspirin at discharge from hospital and statins. Intermediate 
provision rates and wide variation across CCGs were observed for 
provision of echocardiography, cardiac rehabilitation, coronary 
angiography, prescription of ACEi/ARBs and β blockers, with low 
provision rates for and little variation across CCGs for provision of 
smoking cessation advice, dietary advice and P2Y12 inhibitors. 
 Across SCNs the areas that had the highest proportion of patients 
receiving optimal care were North East and North Cumbria, and East 
Midlands. 
 Similar to the CCGs, low provision of care rates with minimal variation 
between SCNs were noted for provision of smoking cessation advice, 
dietary advice, aldosterone antagonists and P2Y12 inhibitors, and high 
provision rates with minimal variation were noted for use of an 
electrocardiogram, acute aspirin, statins, aspirin on discharge, cardiac 
rehabilitation, β blockers and prescription of ACEi/ARBs, with an 
intermediate provision of coronary angiography and echocardiography.  
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 The between unit variance, standardised for case mix, was low for SCNs 
and CCGs but much higher for hospitals.  
 Improvements in provision of guideline indicated care for NSTEMI 
management were observed over the 10 year study period (2003-2013), 
with notable improvements being noted for smoking cessation advice, 
dietary advice, coronary angiography, ACEi/ARBs and β blockers. 
However a modest improvement in receipt of optimal care was found. 
 Geographical variation in receipt of optimal care was identified and was 
found to be associated with geographical variation in excess deaths. 
 
5.8 Conclusion  
The findings presented in this chapter provide evidence that there is variation 
in provision of care for NSTEMI patients in the UK, and that most of the 
variation was explained by differences in the provision of care by hospitals. 
The next chapter presents results for objective three of this thesis.
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Chapter 6 : Results 
Association of clinical factors and therapeutic strategies with 
improvements in survival following STEMI. 
6.1 Introduction  
Quality of care and associated outcomes for NSTEMI patients have been 
assessed and the results presented in chapters four and five. These aspects 
for the STEMI phenotype have been undertaken in previous literature.(61) 
Over the years marked improvements in outcomes for STEMI patients have 
been noted, for example the MINAP 2014 report reported unadjusted 30-day 
mortality rates for STEMI patients had fallen by a third over the last 10 years, 
equating to an estimated 110 fewer deaths each month. Similarly, reductions 
in length of stay in hospital for STEMI patients have been reported. For STEMI 
patients the most obvious care intervention that has been reported to drive this 
improvement is the change to PPCI. However, there is a paucity of 
contemporary studies of sufficient duration and representation from a 
population perspective that enable a detailed evaluation of the association of 
baseline risk and guideline-indicated therapies with temporal trends in mortality 
among patients with STEMI. 
 
This chapter comprises of sections presenting results for objective three of the 
thesis which aimed to investigate using MINAP data whether temporal 
improvements in one year mortality between 2004 and 2013 were associated 
with changes in patients’ baseline clinical risk or use of guideline-indicated 
treatments for management of STEMI and estimate the relative contribution of 
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the determined factors going beyond the estimation of simple point association 
effects. The chapter sections are outlined as listed below: 
 Study population descriptive statistics (§6.2) 
 Temporal trends in clinical characteristics (§6.3) 
 Temporal trends in guideline-indicated treatments (§6.4) 
 Temporal trends in mortality (§6.5) 
 Association between changing risk profile and improved outcomes 
(§6.6) 
 Mediation analysis (§6.6.2) 
 Summary of key findings (§6.7) 
 Conclusion (§6.8). 
A detailed description of the methods employed for the analyses has already 
been given in Chapter 3, §3.8.     
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6.2 Study population descriptive statistics 
Of the total analytical cohort (N= 232,353), 72.0% (n=166,690) were male and 
had a median age of 64.6 (IQR 55.0 to 75.0). Their median survival time was 
2.5 years (IQR 1.4 to 4.1 years) (maximum, 7.5 years; 666,576.4 person 
years). A high proportion of the STEMI patients were hypertensive (37.9 % 
(n=87,990)), had a family history of coronary heart disease (25.7% (n=59,709)) 
and were current or ex-smokers (68.1% (n=143,508) (Table 6.1). There were 
33,311 (14.3%) deaths during the full follow up time and at one year after 
hospital discharge 16,239 (7.0%) deaths (5,517 (2.4%) and 12,143 (5.2%) at 
30 day and six months after hospital discharge, respectively).  
 
6.3 Temporal trends in clinical characteristics   
Over the study period, the proportion of the STEMI patients who had previous 
AMI (12.9 vs. 10.8%) and previous angina (16.5 vs. 10.9%), and were current 
or ex-smokers (69.9 vs. 66.0%) decreased (all P<0.001 for trend) whilst the 
proportion of patients who had diabetes (12.3 vs. 13.9%), chronic renal failure 
(1.4 vs. 2.1%) and previous PCI (3.5 vs. 6.3%) increased (all P<0.001 for 
trend). The temporal trends in the baseline characteristics are shown in Table 
6.1 and Figure 6.1. A reduced ejection fraction (EF<50%) was present in 53.2% 
in 2004-05 and decreased to 49.5% in 2012-13 (Table 6.1). 
 
6.4 Temporal trends in guideline-indicated treatments  
Overall of the eligible STEMI patients the use of the secondary prevention 
drugs was high (<90% for all five drugs) and temporal improvements in the 
prescription of the drugs were noted over the study period (Figure 6.2) i.e. 
prescription of aspirin (98.1 vs. 99.2%, difference, 1.1%, 95% CI 1.0-1.3), β-
blockers (94.1 vs. 97.5%, difference, 3.4%, 95% CI 3.1-3.7), statins (97.3 vs. 
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98.8%, difference, 1.5%, 95% CI 1.3-1.7) and ACEi/ARBs (93.1 vs. 97.3%, 
difference, 4.2%, 95% CI 3.8-4.5) (Table 6.1). Overall reperfusion rates, 39.6% 
(n=83,627) of the STEMI patients received PPCI and 39.6% (n=83,800) 
received thrombolysis. Of those admitted in the years 2004/05 81.1% 
(n=30,220) received thrombolysis and of those admitted in the years 2012/13 
80.2% (n=26,799) received PPCI. 
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Table 6.1 Patients’ characteristics according to date of hospitalisation. 
Variable  2004-2013 
N=232,353 
(Total cohort) 
2004-2005 
N=42,799 
(18.4% of the 
cohort) 
2012-2013 
N=37,081 
(16.0% of 
cohort) 
Difference 
between 2004-
2005 and 2012-
2013 (95% CI) 
P-value 
for 
linear 
trend, 
2004-
2013a 
Missing (%) 
Age (years) Median 
(IQR) 
64.6 (55.0-
75.0) 
65.3 (55.8-
74.9) 
64.0 (54.5-
74.9) 
1.30 (1.04-1.56) <0.001 118 (0.1) 
Sex (male) N (%) 166,690 (72.0) 30,332 (71.2) 26,590 (72.2) 0.93 (0.30-1.56) 0.004 796 (0.3) 
Deprivation (IMD Score) Median 
(IQR) 
18.4 (10.5-
32.2) 
18.7 (10.6-
32.6) 
18.4 (10.5-
32.1) 
0.37 (0.08-0.66) 0.012 17,613 (7.6) 
Systolic blood pressure (mm 
Hg) 
Mean (sd) 136.5 (28.2) 139.9 (29.2) 132.8 (26.9) -7.18 (-7.61 to -
6.74) 
<0.001 42,949 (18.5) 
Heart rate (beat per min) Mean (sd) 77.9 (20.8) 77.1 (21.4) 77.9 (19.4) 0.83 (0.51-1.14) <0.001 41,967 (18.1) 
Total cholesterol (mg/dL) Median 
(IQR) 
5.1 (4.2-6.0) 5.4 (4.5-6.3) 4.9 (4.0-5.8) 0.50 (0.47-0.53) <0.001 60,629 (26.1) 
Creatinine (mg/dL) Median 
(IQR) 
87.0 (74.0-
104.0) 
101.0 (90.0-
116.0) 
82.0 (70.0-
99.0) 
19.0 (17.3-20.7) <0.001 95,721(41.2) 
Ejection fraction < 50% N (%) 38,634 (49.3) 1,753 (53.2) 9,598 (49.5) -3.72 (-5.56 to -
1.88) 
<0.001 153,942 
(66.3) 
Medical history        
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Variable  2004-2013 
N=232,353 
(Total cohort) 
2004-2005 
N=42,799 
(18.4% of the 
cohort) 
2012-2013 
N=37,081 
(16.0% of 
cohort) 
Difference 
between 2004-
2005 and 2012-
2013 (95% CI) 
P-value 
for 
linear 
trend, 
2004-
2013a 
Missing (%) 
  Previous diabetes N (%) 29,083 (12.5) 5,265 (12.3) 5,158 (13.9)  1.61 (1.14-2.08) <0.001 0d 
  Current or ex-smoker N (%) 143,508 (68.1) 27,098 (69.9) 22,338 (66.0) 3.93 (-4.61 to 
3.25) 
<0.001 21,662 (9.3) 
  Family history of  CHD N (%) 59,709 (25.7) 4,633 (10.8) 10,249 (27.6) 16.8 1 (16.27-
17.34) 
<0.001 0d 
  Hypertension N (%) 87,990 (37.9) 15,938 (37.2) 13,960 (37.7) 0.41 (-0.26 to 
1.08) 
0.235 0d 
  Previous myocardial 
infarction 
N (%) 26,892 (11.6)   5,525 (12.9) 4,012 (10.8) -2.09 (-2.54 to -
1.64) 
<0.001 0d 
  Previous angina N (%) 31,060 (13.4) 7,050 (16.5) 4,036 (10.9) -5.59 (-6.06 to -
5.11) 
<0.001 0d 
  Peripheral vascular disease N (%) 5,868 (2.5) 1,168 (2.7) 950 (2.7) -0.17 (-0.39 to 
0.06) 
0.143 0d 
  Cerebrovascular disease N (%) 10,415 (4.5)   1,896 (4.4) 1,612 (4.4) -0.08 (-0.37 to 
0.20) 
0.569 0d 
  COPD or asthma N (%) 23,404 (10.1) 4,444 (10.4) 3,745 (10.1) -0.28 (-0.71 to 
0.14) 
0.187 0d 
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Variable  2004-2013 
N=232,353 
(Total cohort) 
2004-2005 
N=42,799 
(18.4% of the 
cohort) 
2012-2013 
N=37,081 
(16.0% of 
cohort) 
Difference 
between 2004-
2005 and 2012-
2013 (95% CI) 
P-value 
for 
linear 
trend, 
2004-
2013a 
Missing (%) 
  Chronic renal failure N (%) 4,410 (1.9) 576 (1.4) 793 (2.1)   0.79 (0.61-0.98) <0.001 0d 
  Congestive cardiac failure N (%) 3,593 (1.6) 762 (1.8) 529 (1.4) -0.35 (-0.53 to -
0.18) 
<0.001 0d 
  Previous PCI N (%) 12,006 (5.2)  1,488 (3.5) 2,318 (6.3) 2.77 (2.47-3.08) <0.001 0d 
  Previous CABG N (%) 5,217 (2.3) 921 (2.2) 840 (2.3) 0.11 (-0.09 to 
0.32) 
0.276 0d 
Admission diagnosis        
  ACS or probable myocardial 
infarction 
N (%) 217,563 (93.6) 40,231 (94.0) 35,270 (95.1) 1.12 (0.80-1.43) <0.001 4 (<0.1) 
  Chest pain unknown cause N (%) 6,810 (2.9) 1,313 (3.1) 797 (2.2) -0.92 (-1.14 to 
0.70) 
<0.001  
  Other N (%) 7,976 (3.4) 1,255 (2.9) 1,014 (2.7) -0.20 (-0.43 to 
0.03) 
0.093  
Preadmission medicationb        
  Aspirin N (%) 146,742 (64.4) 26,121 ( 62.9)   25,229 (68.8) 5.88 (5.22-6.55) <0.001 0 
  β-blocker N (%) 37,199 (22.3) 4,294 (32.2)   6,097 (20.3) -11.94 (-12.85 to -
11.0) 
<0.001 65,383 (28.1) 
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Variable  2004-2013 
N=232,353 
(Total cohort) 
2004-2005 
N=42,799 
(18.4% of the 
cohort) 
2012-2013 
N=37,081 
(16.0% of 
cohort) 
Difference 
between 2004-
2005 and 2012-
2013 (95% CI) 
P-value 
for 
linear 
trend, 
2004-
2013a 
Missing (%) 
  Statin N (%) 54,151 (31.2) 5,008 (37.7) 9,654 (30.2) -7.47 (-8.44 to -
6.50) 
<0.001 58,835 (25.3) 
  ACEi or ARBs N (%) 45,897 (27.5) 4,264 (32.2) 8,424 (28.0) -4.20 (-5.14 to -
3.25) 
<0.001 65,633 (28.3) 
  P2Y12 inhibitor N (%) 13,136 (14.2) - 4,566 (14.8) -  139,488 
(60.03)   
  Warfarin N (%) 6,891 (3.7) 1,558 (4.6) 1,060 (3.6) -1.00 (-1.31 to -
0.69) 
<0.001 46,897 (20.2) 
Discharge medicationb        
  Aspirin N (%) 186,098 (98.8)   35,753 (98.1) 30,197 (99.2) 1.13 (0.96-1.30) <0.001 19,497 (8.4)   
  β-blocker N (%) 165,472 (95.7) 30,375 (94.1) 28,207 (97.5) 3.40 (3.09-3.72) <0.001 37,691 (16.2) 
  Statin N (%) 185,710 (98.1) 35,708 (97.3) 30,029 (98.8) 1.46 (1.26-1.67) <0.001 20,063 (8.6) 
  ACEi or ARB N (%) 173,303 (95.3) 32,616 (93.1) 28,567 (97.3) 4.16 (3.83-4.48) <0.001 21,322 (9.2)   
  P2Y12 inhibitor N (%) 89,676 (96.7) 190 (94.5) 28,694 (97.6) 3.05 (-0.10 to 
6.20) 
0.005 121,483 
(52.3) 
  Aldosterone antagonist N (%) 7,296 (12.6)   0(0) 3,031 (15.8) - - 131,778 
(56.7) 
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Variable  2004-2013 
N=232,353 
(Total cohort) 
2004-2005 
N=42,799 
(18.4% of the 
cohort) 
2012-2013 
N=37,081 
(16.0% of 
cohort) 
Difference 
between 2004-
2005 and 2012-
2013 (95% CI) 
P-value 
for 
linear 
trend, 
2004-
2013a 
Missing (%) 
Reperfusion strategy        
  PPCI N (%) 83,627 (39.6) 148 (2.1) 26,799 (80.2) 78.15 (77.61-
78.69) 
<0.001  
  Thrombolysis N (%) 83,800 (39.6) 30,220 (81.1) 1,218 (15.6) -65.54 (-66.44 to -
64.65) 
<0.001 20,934 (9.0) 
  None N (%) 43,992 (20.8) 7,045 (18.8) 6,613 (19.1) 0.30 (-0.27 to 
0.87) 
0.307  
Cardiac rehabilitation N (%) 182,575 (92.4) 33,933 (89.8) 30,387 (94.3) 4.44 (4.05-4.84) <0.001 26,591 (11.4) 
GRACE risk score category        
  Lowest (<70) N (%) 5,034 (5.0) 30 (5.6) 1,099 (4.7) -0.84 (-2.79 to 
1.11) 
0.362  
  Low (70-87) N (%) 11,541 (11.4) 61 (11.3)   2,654 (11.4) 0.08 (-2.61 to 
2.78) 
0.952 131,188 
(56.5) 
  Intermediate to high (≥88) N (%) 84,509 (83.6) 450 (83.2) 19,612 (83.9) 0.76 (-2.43 to 
3.95) 
0.635  
Crude mortality         
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Variable  2004-2013 
N=232,353 
(Total cohort) 
2004-2005 
N=42,799 
(18.4% of the 
cohort) 
2012-2013 
N=37,081 
(16.0% of 
cohort) 
Difference 
between 2004-
2005 and 2012-
2013 (95% CI) 
P-value 
for 
linear 
trend, 
2004-
2013a 
Missing (%) 
  30 day N (%) 5,517 (2.4) 1,046 (2.4) 836 (2.3) -0.18 (-0.40 to 
0.02) 
0.078  
  Six months  N (%) 12,143 (5.2) 2,347 (5.5) 1,703 (4.6) -0.89 (-1.19 to -
0.59) 
<0.001 0 
  One year N (%) 16,239 (7.0) 3,221 (7.5) 2,090 (5.6) -1.89 (-2.23 to -
1.55) 
<0.001  
aP-value for linear trend across all study years (2004 to 2013) derived using linear regression for continuous variables and the non-parametric test for trend across ordered groups for 
categorical variables. bOnly patients eligible to receive treatments were included in the denominator. cPPCI or thrombolysis. dMissing data default imputed to “No”. 
Abbreviations: ACS – Acute coronary syndrome; ARB – Angiotensin receptor blocker; ACEi – angiotensin-converting enzyme inhibitor; CABG – coronary artery bypass grafting; COPD 
– chronic obstructive pulmonary disease; CHD- coronary heart disease; GRACE – Global Registry of Acute Coronary Events; IMD – index of multiple deprivation;   PCI – percutaneous 
coronary intervention; SBP – systolic blood pressure.
 - 203 -  
 
6.5 Temporal trends in mortality  
From 2004 to 2013, a temporal decline in mortality was observed for six 
months and one year mortality, with no pronounced decline being observed 
for 30 days mortality (Figure 6.3). Comparing 2004-2005 vs. 2012-2013, 
unadjusted crude mortality rates at six months following hospital discharge 
decreased from 5.5% (95% CI, 5.5%-5.6%) to 4.6% (95% CI, 4.5%-4.6%), 
at one year from 7.5% (95% CI, 7.4%-7.6%) to 5.6% (95% CI, 5.5%-5.7%) 
and no statistical significant differences were noted for 30 days mortality. 
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Figure 6.1. Local polynomial smoothed curves showing temporal trends in comorbidities and risk factors per month, 2004-2013. 
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Figure 6.2. Local polynomial smoothed curves showing temporal trends in use of care interventions for the management of STEMI  
per month, 2004-2013. 
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Figure 6.3. Local polynomial smoothed curves showing monthly crude all-cause mortality at 30 days, six months and one year, 2004-
2013.  
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6.6 Association between changing risk profile and 
improved outcomes 
6.6.1 Flexible parametric modelling results  
6.6.1.1 Six months survival  
The results are summarised in Table 6.2. Unadjusted all-cause six months 
survival improved by 0.9% per year on average over the study period 
(hazard ratio [HR] 0.991, 95% CI 0.988-0.994). This temporal improvement 
remained after adjusting for age, sex and deprivation (HR 0.991 [95% CI, 
0.988-0.994]), cardiac rehabilitation (HR 0.990 [95% CI, 0.987-0.993]) and 
Comorbidities and risk factors (HR 0.994 [95% CI, 0.991-0.997]). However, 
the direction of association was reversed after adjustment for PPCI (HR 
1.025 [95% CI, 1.021-1.029]) and there was no temporal trend after 
adjusting for pharmacotherapies (HR 0.998 [95% CI, 0.993-1.002]). 
Individual assessments of the pharmacotherapy drugs showed that the 
temporal improvement remained after adjusting for aspirin (HR, 0.988 [95% 
CI, 0.985-0.992]), statins (HR, 0.987 [95% CI, 0.984-0.990]), β blockers 
(HR, 0.994 [95% CI, 0.991-0.998]), ACEi/ARBs (HR, 0.991 [95% CI, 0.987-
0.993]) and only after adjustment of P2Y12 inhibitors (HR 1.055 [95% CI, 
1.050-1.060]) was the direction of association reversed. In the fully adjusted 
model including all the variables under investigation the direction of 
association was reversed (HR, 1.006 [95% CI, 0.1.001-1.011]).  
6.6.1.2 One year survival  
The results are summarised in Table 6.2. Unadjusted all-cause one year 
survival improved by 1.0% per year on average over the study period 
(hazard ratio [HR] 0.990, 95% CI 0.987-0.993). This temporal improvement 
remained after adjusting for age, sex and deprivation (HR 0.990 [95% CI, 
0.987-0.993]), cardiac rehabilitation (HR 0.989 [95% CI, 0.986-0.992]) and 
Comorbidities and risk factors (HR 0.993 [95% CI, 0.990-0.996]). However, 
the direction of association was reversed after adjustment for PPCI (HR 
1.025 [95% CI, 1.021-1.028]) and there was no temporal trend after 
adjusting for pharmacotherapies (HR 0.998 [95% CI, 0.994-1.002]). 
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Individual assessments of the pharmacotherapy drugs showed that the 
temporal improvement remained after adjusting for aspirin (HR, 0.988 [95% 
CI, 0.985-0.991]), statins (HR, 0.987 [95% CI, 0.984-0.989]), β blockers 
(HR, 0.993 [95% CI, 0.990-0.996]), ACEi/ARBs (HR, 0.989 [95% CI, 0.986-
0.992]) and only after adjustment of P2Y12 inhibitors (HR 1.035 [95% CI, 
1.031-1.039]) was the direction of association reversed. In the fully adjusted 
model including all the variables under investigation the direction of 
association was reversed (HR, 1.006 [95% CI, 0.1.001-1.011]).  
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Table 6.2 Temporal Trends by Year in Overall Survival between 2003 and 2013 for Unadjusted and Adjusted Flexible Parametric 
Survival Models. 
  Six months  One year  
Model 
number 
Variables included Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value 
Model 1 Year 0.991 (0.988-0.994) <0.001 0.990 (0.987-0.993) <0.001 
 Year +     
Model 2 Age, sex, IMD 0.991 (0.988-0.994) <0.001 0.990 (0.987-0.993) <0.001 
Model 3 PPCI 1.025 (1.021-1.029) <0.001 1.025 (1.021-1.028) <0.001 
Model 4 Comorbidities and risk factors 0.994 (0.991-0.997) <0.001 0.993 (0.990-0.996) <0.001 
Model 5 Five discharge drugs  0.998 (0.993-1.002) 0.404 0.998 (0.994-1.002) 0.379 
Model 6 Aspirin 0.988 (0.985-0.992) <0.001 0.988 (0.985-0.991) <0.001 
Model 7 Statins 0.987 (0.984-0.990) <0.001 0.987 (0.984-0.989) <0.001 
Model 8 P2Y12 inhibitors 1.040 (1.037-1.045) <0.001 1.035 (1.031-1.039) <0.001 
Model 9 ACEi/ARBs 0.991 (0.987-0.993) <0.001 0.989 (0.986-0.992) <0.001 
Model 10 β-blockers 0.994 (0.991-0.998) <0.001 0.993 (0.990-0.996) <0.001 
Model 11 Cardiac rehabilitation     0.990 (0.987-0.993) <0.001 0.989 (0.986-0.992) <0.001 
 Year + age + sex + IMD +     
Model 12 PPCI 1.014 (1.010-1.018) <0.001 1.013 (1.009-1.016) <0.001 
Model 13 Comorbidities and risk factors 0.992 (0.989-0.996) <0.001 0.991 (0.988-0.994) <0.001 
Model 14 Five discharge drugs 0.993 (0.988-0.988) 0.003 0.993 (0.989-0.997) 0.001 
Model 15 Aspirin 0.987 (0.984-0.991) <0.001 0.987 (0.984-0.990) <0.001 
Model 16 Statins 0.968 (0.983-0.990) <0.001 0.986 (0.982-0.989) <0.001 
Model 17 P2Y12 inhibitors 1.040 (1.035-1.044) <0.001 1.034 (1.030-1.038) <0.001 
Model 18 ACEi/ARBs 0.990 (0.986-0.993) <0.001 0.988 (0.985-0.992) <0.001 
Model 19 β-blockers 0.994 (0.991-0.998) 0.001 0.993 (0.990-0.996) <0.001 
Model 20 Cardiac rehabilitation 0.991 (0.987-0.994) <0.001 0.989 (0.986-0.992) <0.001 
Model 21 Year + age + sex + IMD + PPCI + Comorbidities and risk 
factors + Aspirin + Statins + P2Y12 inhibitors + ACEi/ARBs 
+   β-blockers + Cardiac rehabilitation 
1.006 (1.001-1.011) 0.014 1.006 (1.001-1.011) 0.013   
Abbreviations: IMD – index of multiple deprivation; PPCI – primary percutaneous coronary intervention; ARB – Angiotensin receptor blocker and ACEi – angiotensin-converting enzyme inhibitor.
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6.6.2 Mediation analysis results  
A mediation analysis was conducted to determine the proportion of 
temporal improvements in survival that were mediated by use of PPCI and 
prescription of P2Y12 inhibitors (Figure 6.4). The mediation analysis was 
carried out as a sensitivity analysis and was undertaken on complete cases 
(n=82,637).  
 
 
Figure 6.4. A path diagram indicating PPCI and P2Y12 inhibitors as potential 
mediators for the temporal trend in survival. 
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6.6.2.1 One year survival  
The results are reported following a four step procedure to represent the 
mediation analysis technique(148). 
 Step 1-Show that the causal variable is associated with the outcome. 
The main analysis (Table 6.2) showed that there was a temporal trend in 
survival at one year (HR=0.990, 95% CI 0.987-0.993). Therefore, there was 
potential for this effect to be mediated. 
Step 2-Show that the causal variable is associated with the mediator (s) 
In order to test this assumption, an adjusted model with each mediator (PPCI 
or P2Y12 inhibitors) treated as the outcome variable consecutively was fitted to 
determine whether there was an effect for paths a1 and a2 (Figure 6.4). The 
paths were tested using logistic regression with binary outcome for the 
mediators with year as the exposure variable and all other variables as 
confounders. All the paths were non-zero (standardised coefficients -0.16, 95% 
CI -0.19 to -0.14 (a1 path) and 0.33, 95% CI 0.32 to 0.34 (a2 path), therefore 
meeting the requirements for the mediation analysis.  
Step 3 – Show that the mediator variable(s) are associated with the 
outcome.   
In order to test this assumption, an adjusted Poisson regression model with 
one year mortality as the outcome and log survival time as the offset was fitted 
adjusting for each mediator consecutively to test the significance of paths b1 
and b2. All paths were non-zero (standardised coefficients -0.08, 95% CI -0.19 
to 0.03 (path b1) and -0.37, 95% CI -0.43 to -0.31 (path b2). Path b1 was found 
not statistically significant thereby violating the mediator outcome association 
assumption for P2Y12 inhibitors. The assumption was not violated for PPCI. 
Step 4 – To establish the degree of mediation. 
The degree of mediation was established by estimating the direct (path c) and 
indirect effects (a2 multiplied by path b2) as well as the proportion of the effects 
that were mediated by the potential mediator. Indirect effects and 95% 
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confidence intervals were calculated using bootstrap methods over 1000 
simulations. Degree of mediation was only undertaken for PPCI as the P2Y12 
inhibitors were found not to be associated with the outcome in step 3 thus no 
mediation analysis could be undertaken.  
Proportion mediated by PPCI. 
The introduction of PPCI explained 27.9% (95% CI, 15.5-83.8%) of the 
observed temporal improvements in one year survival for the STEMI patients.  
6.6.2.2 Six months survival  
The results  are reported following a four step procedure to represent the 
mediation analysis technique(148). 
Step 1-Show that the causal variable is associated with the outcome. 
The main analysis (Table 6.2) showed that there was a temporal trend in 
survival at six months (HR=0.991, 95% CI 0.988-0.994). Therefore, there was 
potential for this effect to be mediated. 
Step 2-Show that the causal variable is associated with the mediator (s) 
In order to test this assumption, an adjusted model with each mediator (PPCI 
or P2Y12 inhibitors) treated as the outcome variable consecutively was fitted to 
determine whether there was an effect for paths a1 and a2 (Figure 6.4). The 
paths were tested using logistic regression with binary outcome for the 
mediators with year as the exposure variable and all other variables as 
confounders. All the paths were non-zero (standardised coefficients -0.16, 95% 
CI -0.19 to -0.14 (a1 path) and 0.33, 95% CI 0.32 to 0.34 (a2 path), therefore 
meeting the requirements for the mediation analysis.  
Step 3 – Show that the mediator variable(s) are associated with the 
outcome.   
In order to test this assumption, an adjusted Poisson regression model with 
one year mortality as the outcome and log survival time as the offset was fitted 
adjusting for each mediator consecutively to test the significance of paths b1 
and b2. All paths were non-zero (standardised coefficients -0.02, 95% CI -0.15 
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to 0.13 (path b1) and -0.40, 95% CI -0.47 to -0.32 (path b2). Path b1 was found 
not statistically significant thereby violating the mediator outcome association 
assumption for P2Y12 inhibitors. The assumption was not violated for PPCI. 
Step 4 – To establish the degree of mediation. 
The degree of mediation was established by estimating the direct (path c) and 
indirect effects (a2 multiplied by path b2) as well as the proportion of the effects 
that were mediated by the potential mediator. Indirect effects and 95% 
confidence intervals were calculated using bootstrap methods over 1000 
simulations. Degree of mediation was only undertaken for PPCI as the P2Y12 
inhibitors were found not to be associated with the outcome in step 3 thus no 
mediation analysis could be undertaken.  
Proportion mediated by PPCI. 
The proportion mediated by the introduction of PPCI for six months survival 
was not statistically significant. 
 
6.7 Summary of key findings  
 Overall, a high proportion of the STEMI patients were hypertensive,  had 
a family history of coronary heart disease, and were current or ex-
smokers.  
 Over the study period the proportion of STEMI patients who had 
previous AMI, previous angina and were current or ex-smokers 
decreased whilst the proportion of patients who had diabetes, 
hypertension, chronic renal failure and received previous PCI increased.  
 Overall of the eligible STEMI patients the use of the secondary 
prevention drugs was high and temporal improvements in the 
prescription of the drugs were noted over the study period. 
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 The determined mediators for the temporal improvements in one year 
survival noted for patients hospitalized with STEMI between 2004 and 
2013 were reperfusion (PPCI) and P2Y12 inhibitors. 
 
6.8 Conclusion  
Among patients hospitalized with STEMI in England and Wales, improvements 
in all-cause mortality were observed between 2004 and 2013. This was 
significantly associated with the introduction of PPCI and P2Y12 inhibitors. The 
next chapter presents results of  objective 4 of this thesis.
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Chapter 7 : Results 
Role of β-blockers during and after AMI in patients without 
heart failure or LVSD. 
The following publications have arisen from the analysis and results in this 
chapter: 
1. Dondo, TB, Hall, M, West, RM, Jernberg, T, Lindahl, B, Bueno, H, 
Danchin, N, Deanfield, JE, Hemingway, H, Fox, KAA, Timmis, AD, Gale, 
CP. (2017).  β-Blockers and Mortality After Acute Myocardial Infarction 
in Patients Without Heart Failure or Ventricular 
Dysfunction. JACC, 69(22), 2710-2720. 
2. Dondo, TB, Hall, M, West, R, Jernberg, T, Lindahl, B, Bueno, H, 
Danchin, N, Deanfield, JE, Hemingway, H, Fox, KAA, Timmis, AD, Gale, 
CP. (2016, August). Beta blocker use and mortality in hospital survivors 
of acute myocardial infarction without heart failure. Congress of the 
European-Society-of-Cardiology (ESC). 
 
7.1 Introduction 
Assessment of quality of care for AMI patients also involves assessments of 
efficacy of individual care interventions on the AMI care pathway. This chapter 
presents results on the investigation of efficacy of β blockers as there has been 
uncertainty on their effectiveness in reducing mortality among AMI patients 
who do not have heart failure or LVSD, especially in the reperfusion era.(4) 
There are no contemporary randomised data for survivors of AMI without heart 
failure or LVSD in relation to the use of β blockers, as such international 
guidelines differ in their recommendation about the use of β blockers in this 
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group of patients.(4, 22-24) The results presented in this chapter to date,  are 
the first (to the best of my knowledge) large scale dataset analyses results after 
investigating the impact of β blockers on survival after AMI among patients 
without heart failure or LVSD in the reperfusion era. 
The chapter will be outlined as shown below: 
 Study population descriptive statistics (§7.2) 
 Impact of β blockers use on survival: Propensity score analyses  
(§7.3) 
 Impact of β blockers use on survival: Instrumental variable analyses 
(§7.4) 
 Summary of key findings (§7.5) 
 Conclusion (§7.6). 
A detailed description of the methods employed for the analyses has already 
been given in Chapter 3, §3.9.      
 
7.2 Study population descriptive statistics 
Details on the analytical cohort derivation are given in Chapter 3, §3.9. Over 
half of the analytical cohort (N=179,810) were STEMI patients (51.1% 
(n=91,895)) with 48.9 % (n=87,915) being NSTEMI patients.  Significant 
differences in baseline characteristics were found between the patients who 
received β blockers vs. those who did not receive β blockers at discharge 
(Table 7.1). Comparing the β blockers receivers to the non-receivers, those 
who received were younger (mean 63.3 (SD 13.4)) years vs. mean 68.6 (SD 
15.1) years), male (71.1 vs. 61.7%) and less co-morbid (diabetes-11.6 
vs.15.4%, chronic renal failure-1.6 vs. 3.2%, cerebrovascular disease-3.8 vs. 
7.0%, peripheral vascular disease-1.9 vs. 3.3%, hypertension-36.4 vs. 42.0% 
and asthma or COPD-7.8 vs. 20.6%. Higher rates of receipt of secondary 
prevention drugs were observed for the β blocker receipt patients compared to 
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the non-receipt patients (aspirin-99.4 vs. 84.3%, P2Y12 inhibitors-97.3 vs. 
72.9%, ACEi/ARBs-95.6 vs. 60.2% and statins-98.9 vs. 76.8%) (Table 7.1). 
Enrolment into cardiac rehabilitation was higher for patients in the receipt of β 
blockers group compared to the non-receipt patients (94.7 vs. 76.9%) (Table 
7.1). The patients who did not receive β blockers were also of higher ischaemic 
risk (intermediate or high GRACE risk score (76.5 vs. 69.8%)) upon admission 
with AMI.  
Table 7.1 Baseline characteristics of hospital survivors of AMI without heart 
failure or LVSD according to prescription of β blockers at hospital 
discharge 
 β blockers at time of discharge from hospital 
 
Variable  Yes 
(n=141,097) 
No 
(n=7,217) 
P-value Missing 
n (%) 
Age, mean (SD), years 63.3 (13.4) 68.6 (15.1) <0.001 130 (0.07) 
Male 100,774 (71.6) 4,441 (61.7) <0.001 537 (0.3) 
Deprivation (IMD)     
  Least deprived (1) 24,615 (18.3) 1,379 (20.1) <0.001  
  2 26,677 (19.9) 1,381 (20.1) 0.639  
  3 27,604 (20.6) 1,408 (20.5) 0.894 10,429 (5.8) 
  4 26,616 (19.8) 1,392 (20.3) 0.376  
  Most deprived (5) 28,818 (21.5) 1,314 (19.2) <0.001  
Year of admission    
  2007 17,709 (12.6) 1,298 (18.0) <0.001  
  2008 19,369 (13.7) 1,230 (17.0) <0.001  
  2009 21,899 (15.5) 1,255 (17.4) <0.001  
  2010 23,720 (16.8) 1,107 (15.3) 0.001  
  2011 24,925 (17.7) 1,115 (15.5) <0.001  
  2012    25,387 (18.0) 930 (12.9) <0.001 0 
  2013 8,088 (5.8) 282 (3.9) <0.001  
Cardiovascular history                                                                             
Cerebrovascular disease 4,835 (3.8) 457 (7.0) <0.001 20,754 (11.5) 
Peripheral vascular 
disease 
2,365 (1.9) 210 (3.3) <0.001 23,107 (12.9) 
Cardiovascular risk factors 
Diabetes 15,785 (11.6) 1,076 (15.4) <0.001 7,195 (4.0) 
Chronic renal failure 1,953 (1.6) 208 (3.2) <0.001 20,924 (11.6) 
Hypercholesterolaemia 33,788 (26.9) 1,710 (26.3) 0.305 21,838 (12.2) 
Hypertension 47,040 (36.4) 2,814 (42.0) <0.001 17,306 (9.6) 
Current or ex-smoker                                                                                                                                                                       88,468 (65.7) 3,898 (58.5) <0.001 10,654 (5.9) 
Asthma or COPD 9,813 (7.8) 1,348 (20.6) <0.001 21,752 (12.1) 
Family history of CHD            44,056 (38.2) 1,699 (30.1) <0.001 36,139 (20.1) 
Presenting characteristics 
Systolic blood pressure, 
mmHg , mean (SD) 
140.4 (27.1) 138.7 (27.8) <0.001 35,001 (19.5) 
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 β blockers at time of discharge from hospital 
 
Variable  Yes 
(n=141,097) 
No 
(n=7,217) 
P-value Missing 
n (%) 
Systolic blood pressure, 
<90 mmHg 
2,824 (2.5) 200 (3.3) <0.001  
Heart rate, median (IQR) 76.0 (66.0 to 
89.0) 
77.0 (64.0 to 
90.0) 
0.134 35,176 (19.6) 
Heart rate >110 bpm 6,070 (5.3) 416 (7.0) 0.196  
Creatinine, median (IQR) 85.0 (72.0 to 
99.0) 
87.0 (74.0 to 
106.0) 
<0.001 32,003 (17.8) 
Creatinine >200 (μmol/l) 1,159 (1.0) 166 (2.8) <0.001  
Peak troponin§, median 
(IQR)  
4.8 (0.7 to 50.0) 1.7 (0.2 to 
19.0) 
<0.001 21,359 (11.9) 
Peak troponin ≥ 0.06§ 119,302 (95.5) 6,146 (93.0) <0.001  
Cardiac arrest 5,449 (4.0) 178 (2.5) <0.001 6,428 (3.6) 
Electrocardiographic characteristics 
No acute changes 13,816 (10.4) 942 (14.5) <0.001  
ST-segment elevation 69,888 (52.3) 2,364 (36.3) <0.001  
Left bundle branch block 2,523 (1.9) 219 (3.4) <0.001 10,360 (5.8) 
ST segment depression 15,063 (11.3) 867 (13.3) <0.001  
T wave changes only 20,150 (15.1) 1,171 (18.0) <0.001  
Other acute abnormality 12,094 (9.1) 954 (14.7) <0.001  
Grace risk score 
Lowest (≤70) 11,358 (12.7) 496 (11.4) 0.011  
Low (71-87)   15,709 (17.5) 531 (12.2) <0.001 68,471 (38.1) 
Intermediate to high 
(>88) 
62,676 (69.8) 3,342 (76.5) <0.001  
Index event     
STEMI 75,697 (53.7) 2,539 (35.2) <0.001 0 
NSTEMI 65,400 (46.4) 4,678 (64.8) <0.001 0 
Medication at dischargea  Missingb  
n (%) 
Aspirin  (n=176,040c) 137,509 (99.4) 5,929 (84.3) <0.001 13,942 (7.9) 
P2Y12 inhibitors 
(n=173,967c) 
95,292 (97.3) 3,313 (72.9) <0.001 60,385 (34.7) 
ACEi/ARBs (n=165,575c) 126,812 (95.6) 4,222 (60.2) <0.001 15,584 (9.2) 
Statin (n=176,979c) 137,402 (98.9) 5,479 (76.8) <0.001 14,483 (8.2) 
In-hospital proceduresa  
Coronary angiography 
(n=173,473c) 
91,738 (71.3) 4,024 (61.3) <0.001 10,543 (6.1) 
Coronary intervention 
(PCI/CABG) 
(n=171,906c) 
65,937 (58.7) 2,158 (41.9) <0.001 33,905 (19.7) 
Rehabilitationa  
 Enrolment into cardiac 
rehabilitation 
(n=173,473c) 
120,371 (94.7) 4,544 (76.9) <0.001 16,505 (9.6) 
All values are expressed as numbers (%) unless otherwise indicated. 
Abbreviations: ACE, angiotensin converting enzyme inhibitor;  ARB, angiotensin receptor blocker; CABG, coronary 
artery bypass graft; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; IMD, Index of 
multiple deprivation; IQR, interquartile range; M, missing; N, number; NSTEMI, non ST-segment elevation myocardial 
infarction; a Of the eligible patients for the care intervention; PCI, percutaneous coronary intervention; , b Proportion 
missing of the eligible patients for the care intervention; SD, standard deviation; c Total eligible for care intervention; § 
peak troponin was truncated at 50. Patients with missing information for β blocker use at hospital discharge totalled 
31,496. 
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7.3 Impact of β blocker use on survival: Propensity score 
analysis  
There were 5.2% (n=9,373) deaths and 163,772 person years of 
observation (follow-up capped to one year) for the total analytical cohort. 
Unadjusted one year mortality was significantly lower for patients who 
received β blockers compared with those who did not (4.9 vs. 11.2%, 
P<0.001). 
 
7.3.1 Propensity score analysis approach results  
7.3.1.1 Treatment Assignment model  
Observations with estimated propensity scores outside the pre-specified 
range 0.1 to 0.9 were discarded to avoid violation of the overlap assumption 
(see Methods §7.3). After trimming the analytical cohort at the tails of the 
estimated propensity score distribution, 16,683 patients (29.6% (n=4,932) 
STEMI and 70.4% (n=11,751) NSTEMI) were left for inclusion in further 
analysis. The results of the assessment of the overlap assumption are 
shown in Figure 7.1-Figure 7.5; the minimum propensity score for each 
treatment level was sufficiently greater than zero and the maximum 
propensity score for each treatment level sufficiently less than 1 thus 
providing evidence that the assumption was not violated. Balance checks 
comparing the standardised differences and variance ratios between the 
raw and the weighted data were performed for the main effects and most of 
the standardised differences and variance ratios for variables in the 
weighted data were close to zero and one, respectively (Table 7.2-Table 
7.11). The over-identification which tested whether the main effects as well 
as the interactions terms were balanced, showed that there was no 
evidence against the null hypothesis that the covariates were balanced thus 
the treatment assignment models were well specified (Table 7.12). 
Assessment was done across each of the ten imputed datasets individually 
as methods to pool the balance checks results, to the best of my knowledge 
have not been defined, however the treatment effects were estimated 
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based on pooled estimates from the imputed data. The diagnostic 
assessments suggested that weighting by the inverse probability of 
treatment created a sample in which the prevalence of baseline 
characteristics were similar between the treated and control subjects. The 
area under the curve for the propensity score model was 0.80 (Figure 7.6), 
which indicated a good discrimination for the model.    
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Figure 7.1. Overlap assumption assessment plots showing the estimated densities of probability of getting each treatment level for 
the patients in the analytical cohort for imputation 1 and 2 (treated vs non-treated). 
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Figure 7.2. Overlap assumption assessment plots showing the estimated densities of probability of getting each treatment level for 
the patients in the analytical cohort for imputation 3 and 4. 
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Figure 7.3. Overlap assumption assessment plots showing the estimated densities of probability of getting each treatment level for 
the patients in the analytical cohort for imputation 5 and 6. 
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Figure 7.4. Overlap assumption assessment plots showing the estimated densities of probability of getting each treatment level for 
the patients in the analytical cohort for imputation 7 and 8. 
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Figure 7.5. Overlap assumption assessment plots showing the estimated densities of probability of getting each treatment level for 
the patients in the analytical cohort for imputation 9 and 10. 
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Table 7.2. Balance check parameters using standardized differences and 
variance ratios (imputation dataset 1). 
 Standardized 
differences 
Variance ratios 
Data Raw Weighted Raw Weighted 
Age     
  Below 55 ref ref ref ref 
  55-65 0.03 0.02 1.05 1.04 
  66-75 0.06 0.01 1.08 1.01 
  76-85 0.03 -0.02 1.04 0.98 
  Above 85 -0.08 -0.01 0.87 0.99 
Male 0.02 0.001 0.99 1.00 
Deprivation (IMD)     
  Least deprived (1) re ref re ref 
  2 0.02 0.02 1.03 1.03 
  3 0.03 -0.002 1.05 1.00 
  4 -0.02 -0.01 0.97 0.99 
  Most deprived (5) -0.003 -0.00001 0.99 1.00 
Year of admission        
  2007 ref ref ref ref 
  2008 0.05 0.01 1.08 1.01 
  2009    -0.02 0.02 0.96 1.03 
  2010 -0.02 0.01 0.96 1.02 
  2011 -0.04 -0.02 0.90 0.95 
  2012 -0.05 -0.001 0.87 1.00 
  2013 -0.06 -0.01 0.71 0.93 
Cardiovascular 
history                                                                             
    
Cerebrovascular 
disease 
0.003 0.003 1.01 1.01 
Peripheral vascular 
disease 
0.05 0.01 1.31 1.05 
Cardiovascular risk 
factors 
    
Diabetes 0.05 0.02 1.10 1.03 
Hypercholesterolaemia 0.05 -0.01 1.07 0.99 
Hypertension 0.07 0.003 1.03 1.00 
Current or ex-smoker                                                                                                                                                                       0.07 1.56x10-6 0.98 1.00
Asthma or COPD 0.07 0.002 1.05 1.00 
Family history of CHD            0.05 -0.002 1.08 1.00 
Presenting 
characteristics 
    
Heart rate >110 bpm -0.03 -0.03 0.90 0.93 
Creatinine >200 (μmol/l) -0.03 -0.02 0.86 0.91 
Peak troponin  0.02 0.01 0.94 0.98 
Cardiac arrest 0.01 -0.02 1.11 0.86 
Electrocardiographic 
characteristics 
    
  ST-segment deviation 0.03 -0.01 1.01 1.00 
Care by cardiologist  -0.01 -0.01 1.00 1.00 
Medication at 
discharge  
    
Aspirin       
  Received  0.46 0.03 0.44 0.94 
  Contraindicated/ not 
applicable 
0.01 0.01 1.07 1.07 
P2Y12 inhibitors     
  Received 0.58 0.02 0.63 0.98 
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 Standardized 
differences 
Variance ratios 
Data Raw Weighted Raw Weighted 
  Contraindicated/ not 
applicable 
0.05 0.02 1.28 1.09 
ACEi/ARBs      
  Received 0.45 0.01 1.25 1.00 
  Contraindicated/ not 
applicable 
0.12 0.01 2.27 1.05 
Statins      
  Received 0.61 0.03 0.50 0.96 
  Contraindicated/ not 
applicable 
0.04 -0.001 1.43 0.99 
In-hospital procedures      
Coronary angiography      
  Received 0.13 -0.001 0.97 1.00 
  Contraindicated/ not 
applicable 
-0.03 0.003 0.88 1.01 
Coronary intervention 
(PCI/CABG)  
    
  Received 0.06 0.002 1.03 1.00 
  Contraindicated/ not 
applicable 
0.0002 0.01 1.00 1.02 
Abbreviations. ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery 
bypass graft; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; IMD, Index of multiple 
deprivation; PCI, percutaneous coronary intervention; ref, reference category. 
 
Table 7.3. Balance check parameters using standardized differences and 
variance ratios (imputation dataset 2). 
 Standardized differences Variance ratios 
Data Raw Weighted Raw Weighted 
Age     
  Below 55 ref ref ref ref 
  55-65 0.02 0.01 1.04 1.02 
  66-75 0.07 0.003 1.10 1.00 
  76-85 0.03 -0.004 1.03 1.00 
  Above 85 -0.08 -0.02 0.87 0.97 
Male 0.02 -0.01 0.99 1.00 
Deprivation (IMD)     
  Least deprived (1) ref ref ref ref 
  2 0.02 0.01 1.02 1.01 
  3 0.04 -0.004 1.06 1.00 
  4 0.004 -0.003 1.01 1.00 
  Most deprived (5) -0.02 0.01 0.98 1.01 
Year of admission        
  2007 ref ref ref ref 
  2008 0.05 0.004 1.07 1.01 
  2009    -0.02 0.0003 0.97 1.00 
  2010 -0.03 0.0001 0.93 1.00 
  2011 -0.05 -0.01 0.89 0.97 
  2012 -0.06 -0.01 0.85 0.98 
  2013 -0.05 -0.03 0.74 0.83 
Cardiovascular history                                                                              
Cerebrovascular disease 0.01 -0.003 1.03 0.99 
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 Standardized differences Variance ratios 
Data Raw Weighted Raw Weighted 
Peripheral vascular 
disease 
0.04 0.01 1.21 1.05 
Cardiovascular risk 
factors 
    
Diabetes 0.03 0.02 1.05 1.03 
Hypercholesterolaemia 0.06 -0.002 1.08 1.00 
Hypertension 0.07 0.001 1.03 1.00 
Current or ex-smoker                                                                                                                                                                       0.09 0.02 0.97 0.99
Asthma or COPD 0.06 -0.002 1.04 1.00 
Family history of CHD            0.06 -0.002 1.09 1.00 
Presenting 
characteristics 
    
Heart rate >110 bpm -0.06 -0.003 0.84 0.99 
Creatinine >200 (μmol/l) -0.04 -0.002 0.77 0.99 
Peak troponin  0.02 0.02 0.94 0.94 
Cardiac arrest 0.03 -0.01 1.19 0.95 
Electrocardiographic 
characteristics 
    
  ST-segment deviation 0.03 -0.006 1.01 1.00 
Care by cardiologist  -0.02 -0.04 1.01 1.02 
Medication at discharge      
Aspirin       
  Received  0.46 0.03 0.43 0.94 
  Contraindicated/ not 
applicable 
0.01 -0.01 1.09 0.97 
P2Y12 inhibitors     
  Received 0.56 0.02 0.63 0.98 
  Contraindicated/ not 
applicable 
0.04 0.004 1.24 1.02 
ACEi/ARBs  0.11 -0.02 1.11 0.98 
  Received 0.44 -0.01 1.24 1.00 
  Contraindicated/ not 
applicable 
0.10 0.03 1.99 1.20 
Statins      
  Received 0.61 0.02 0.50 0.97 
  Contraindicated/ not 
applicable 
0.03 0.004 1.26 1.03 
In-hospital procedures      
Coronary angiography      
  Received 0.16 -0.01 0.96 1.00 
  Contraindicated/ not 
applicable 
-0.04 0.002 0.84 1.01 
Coronary intervention 
(PCI/CABG)  
    
  Received 0.09 -0.01 1.06 1.00 
  Contraindicated/ not 
applicable 
0.003 0.002 1.01 1.01 
  Contraindicated/ not 
applicable 
0.003 0.002 1.01 1.01 
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery 
bypass graft; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; IMD, Index of multiple 
deprivation; PCI, percutaneous coronary intervention; ref, reference category 
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Table 7.4. Balance check parameters using standardized differences and 
variance ratios (imputation dataset 3). 
 Standardized 
differences 
Variance ratios 
Data Raw Weighted Raw Weighted 
Age     
  Below 55 ref ref ref ref 
  55-65 0.03 0.01 1.05 1.02 
  66-75 0.06 0.002 1.09 1.00 
  76-85 0.03 -0.01 1.03 0.99 
  Above 85 -0.08 -0.02 0.88 0.96 
Male 0.02 0.004 0.99 1.00 
Deprivation (IMD)     
  Least deprived (1) ref ref ref ref 
  2 -0.01 0.01 0.99 1.01 
  3 0.05 0.002 1.07 1.00 
  4 -0.01 -0.01 0.98 0.99 
  Most deprived (5) -0.01 0.01 0.98 1.01 
Year of admission        
  2007 ref ref ref ref 
  2008 0.05 0.001 1.08 1.00 
  2009    -0.02 0.01 0.97 1.01 
  2010 -0.01 -0.02 0.97 0.95 
  2011 -0.05 -0.01 0.89 0.98 
  2012 -0.07 0.001 0.83 1.00 
  2013 -0.05 -0.01 0.75 0.93 
Cardiovascular 
history                                                                             
    
Cerebrovascular 
disease 
-0.0001 -0.003 0.99 0.99 
Peripheral vascular 
disease 
0.05 0.01 1.27 1.06 
Cardiovascular 
risk factors 
    
Diabetes 0.04 0.02 1.07 1.04 
Hypercholesterolae
mia 
0.06 -0.01 1.08 0.98 
Hypertension 0.06 -0.01 1.03 0.99 
Current or ex-
smoker                                                                                                                                                                       
0.09 0.01 0.97 1.00 
Asthma or COPD 0.08 0.002 1.06 1.00 
Family history of 
CHD            
0.06 0.001 1.09 1.00 
Presenting 
characteristics 
    
Heart rate >110 
bpm 
-0.05 -0.01 0.88 0.97 
Creatinine >200 
(μmol/l) 
-0.04 -0.01 0.80 0.94 
Peak troponin  -0.003 -0.001 1.01 1.00 
Cardiac arrest 0.03 0.02 1.23 1.14 
Electrocardiograp
hic characteristics 
    
  ST-segment 
deviation 
0.03 -0.003 1.01 1.00 
Care by cardiologist  -0.01 -0.02 1.01 1.02 
Medication at 
discharge  
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 Standardized 
differences 
Variance ratios 
Data Raw Weighted Raw Weighted 
Aspirin       
  Received  0.45 0.03 0.45 0.95 
  Contraindicated/ 
not applicable 
0.03 0.003 1.17 1.01 
P2Y12 inhibitors     
  Received 0.56 0.02 0.64 0.98 
  Contraindicated/ 
not applicable 
0.06 0.001 1.37 1.01 
ACEi/ARBs      
  Received 0.44 0.01 1.25 1.00 
  Contraindicated/ 
not applicable 
0.12 0.01 2.31 1.04 
Statins      
  Received 0.62 0.03 0.50 0.96 
  Contraindicated/ 
not applicable 
0.05 0.002 1.63 1.02 
In-hospital 
procedures  
    
Coronary 
angiography  
    
  Received 0.13 0.003 0.97 1.00 
  Contraindicated/ 
not applicable 
-0.04 -0.003 0.85 0.99 
Coronary 
intervention 
(PCI/CABG)  
    
  Received 0.06 -0.003 1.04 1.00 
  Contraindicated/ 
not applicable 
-0.01 0.01 0.96 1.02 
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery 
bypass graft; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; IMD, Index of multiple 
deprivation; PCI, percutaneous coronary intervention; ref, reference category. 
 
 
Table 7.5. Balance check parameters using standardized differences and 
variance ratios (imputation dataset 4). 
 Standardized 
differences 
Variance ratios 
Data Raw Weighted Raw Weighted 
Age     
  Below 55 ref ref ref ref 
  55-65 0.01 0.02 1.02 1.04 
  66-75 0.06 -0.02 1.09 0.97 
  76-85 0.03 -0.01 1.03 0.99 
  Above 85 -0.08 -0.01 0.87 0.99 
Male 0.01 -0.01 1.00 1.00 
Deprivation (IMD)     
  Least deprived (1) ref ref ref ref 
  2 0.02 -0.01 1.03 0.99 
  3 0.03 0.02 1.04 1.03 
  4 -0.01 0.004 0.99 1.01 
  Most deprived (5) -0.01 0.01 0.98 1.02 
Year of admission        
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 Standardized 
differences 
Variance ratios 
Data Raw Weighted Raw Weighted 
  2007 ref ref ref ref 
  2008 0.05 0.01 1.08 1.01 
  2009    -0.01 -0.02 0.98 0.97 
  2010 -0.02 0.01 0.95 1.02 
  2011 -0.07 0.01 0.86 1.01 
  2012 -0.06 -0.01 0.84 0.99 
  2013 -0.06 -0.01 0.72 0.95 
Cardiovascular 
history                                                                             
    
Cerebrovascular 
disease 
-0.003 -0.002 0.99 0.99 
Peripheral vascular 
disease 
0.05 0.003 1.28 1.02 
Cardiovascular 
risk factors 
    
Diabetes 0.03 0.01 1.06 1.01 
Hypercholesterolae
mia 
0.06 -0.01 1.08 0.98 
Hypertension 0.06 0.004 1.03 1.00 
Current or ex-
smoker                                                                                                                                                                       
0.09 0.01 0.97 1.00 
Asthma or COPD 0.06 0.01 1.04 1.00 
Family history of 
CHD            
0.07 0.01 1.11 1.02 
Presenting 
characteristics 
    
Heart rate >110 
bpm 
-0.07 -0.01 1.01 1.00 
Creatinine >200 
(μmol/l) 
-0.05 0.004 0.94 1.02 
Peak troponin  0.02 -0.02 0.94 1.04 
Cardiac arrest 0.02 -0.02 1.16 0.87 
Electrocardiograp
hic 
characteristics 
    
  ST-segment 
deviation 
0.02 -0.003 1.01 1.00 
Care by 
cardiologist  
-0.01 -0.01 1.00 1.01 
Medication at 
discharge  
    
Aspirin       
  Received  0.47 0.03 0.43 0.94 
  Contraindicated/ 
not applicable 
0.01 -0.004 1.04 0.98 
P2Y12 inhibitors     
  Received 0.54 0.03 0.64 0.96 
  Contraindicated/ 
not applicable 
0.07 -0.02 1.42 0.98 
ACEi/ARBs      
  Received 0.45 0.02 1.27 1.01 
  Contraindicated/ 
not applicable 
0.12 -0.02 2.24 0.88 
Statins      
  Received 0.63 0.04 0.50 0.95 
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 Standardized 
differences 
Variance ratios 
Data Raw Weighted Raw Weighted 
  Contraindicated/ 
not applicable 
0.03 -0.03 1.42 0.77 
In-hospital 
procedures  
    
Coronary 
angiography  
    
  Received 0.14 -0.002 0.97 1.00 
  Contraindicated/ 
not applicable 
-0.04 -0.001 0.86 1.00 
Coronary 
intervention 
(PCI/CABG)  
    
  Received 0.07 0.002 1.04 1.00 
  Contraindicated/ 
not applicable 
-0.01 0.01 0.97 1.03 
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery 
bypass graft; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; IMD, Index of multiple 
deprivation; PCI, percutaneous coronary intervention; ref, reference category. 
 
Table 7.6. Balance check parameters using standardized differences and 
variance ratios (imputation dataset 5). 
 Standardized 
differences 
Variance ratios 
Data Raw Weighted Raw Weighted 
Age     
  Below 55 ref ref ref ref 
  55-65 0.03 0.01 1.05 1.02 
  66-75 0.07 -0.001 1.10 1.00 
  76-85 0.02 -0.02 1.02 0.98 
  Above 85 -0.09 0.001 0.87 1.00 
Male 0.01 0.0001 1.00 1.00 
Deprivation (IMD)     
  Least deprived (1) ref ref ref ref 
  2 0.03 -0.002 1.04 1.00 
  3 0.04 -0.01 1.05 1.00 
  4 -0.03 0.01 0.96 1.01 
  Most deprived (5) -0.01 0.01 0.98 1.01 
Year of admission        
  2007 ref ref ref ref 
  2008 0.06 0.004 1.09 1.01 
  2009    -0.02 0.01 0.97 1.01 
  2010 -0.04 0.004 0.92 1.01 
  2011 -0.05 -0.01 0.89 0.97 
  2012 -0.06 -0.01 0.83 0.96 
  2013 -0.05 -0.02 0.77 0.91 
Cardiovascular 
history                                                                             
    
Cerebrovascular 
disease 
0.01 -0.02 1.01 0.95 
Peripheral vascular 
disease 
0.05 0.01 1.28 1.06 
Cardiovascular risk 
factors 
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 Standardized 
differences 
Variance ratios 
Data Raw Weighted Raw Weighted 
Diabetes 0.03 0.03 1.06 1.05 
Hypercholesterolaemia 0.05 -0.01 1.06 0.99 
Hypertension 0.05 0.002 1.02 1.00 
Current or ex-smoker                                                                                                                                                                       0.08 0.0002 0.98 1.00 
Asthma or COPD 0.08 0.0003 1.06 1.00 
Family history of CHD            0.05 0.002 1.07 1.00 
Presenting 
characteristics 
    
Heart rate >110 bpm -0.05 -0.01 0.88 0.98 
Creatinine >200 
(μmol/l) 
-0.04 -0.003 0.79 0.99 
Peak troponin  0.01 -0.002 0.97 1.00 
Cardiac arrest 0.03 -0.03 1.23 0.84 
Electrocardiographic 
characteristics 
    
  ST-segment deviation 0.04 -0.001 1.01 1.00 
Care by cardiologist  -0.01 -0.03 1.00 1.02 
Medication at 
discharge  
    
Aspirin       
  Received  0.46 0.02 0.44 0.97 
  Contraindicated/ not 
applicable 
0.02 0.01 1.13 1.06 
P2Y12 inhibitors     
  Received 0.58 0.02 0.63 0.98 
  Contraindicated/ not 
applicable 
0.07 0.01 1.41 1.04 
ACEi/ARBs      
  Received 0.44 0.01 1.26 1.00 
  Contraindicated/ not 
applicable 
0.10 0.01 2.03 1.09 
Statins      
  Received 0.63 0.02 0.50 0.97 
  Contraindicated/ not 
applicable 
0.02 -0.01 1.20 0.95 
In-hospital 
procedures  
    
Coronary angiography      
  Received 0.16 -0.01 0.96 1.00 
  Contraindicated/ not 
applicable 
-0.04 -0.01 0.83 0.98 
Coronary intervention 
(PCI/CABG)  
    
  Received 0.07 0.01 1.04 1.00 
  Contraindicated/ not 
applicable 
-0.01 -0.01 0.97 0.98 
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery 
bypass graft; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; IMD, Index of multiple 
deprivation; PCI, percutaneous coronary intervention; ref, reference category. 
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Table 7.7. Balance check parameters using standardized differences and 
variance ratios (imputation dataset 6). 
 Standardized 
differences 
Variance ratios 
Data Raw Weighted Raw Weighted 
Age     
  Below 55 ref ref ref ref 
  55-65 0.04 0.02 1.08 1.04 
  66-75 0.06 -0.01 1.08 0.99 
  76-85 0.03 -0.02 1.03 0.98 
  Above 85 -0.09 0.001 0.86 1.00 
Male 0.05 -0.01 0.99 1.00 
Deprivation (IMD)     
  Least deprived (1) ref ref ref ref 
  2 0.03 -0.001 1.04 1.00 
  3 0.04 0.01 1.06 1.01 
  4 -0.03 0.01 0.95 1.01 
  Most deprived (5) -0.01 -0.02 0.98 0.97 
Year of admission        
  2007 ref ref ref ref 
  2008 0.06 0.004 1.10 1.01 
  2009    -0.02 0.02 0.97 1.04 
  2010 -0.03 -0.03 0.94 0.94 
  2011 -0.05 -0.01 0.88 0.98 
  2012 -0.06 -0.002 0.84 0.99 
  2013 -0.06 -0.01 0.69 0.92 
Cardiovascular 
history                                                                             
    
Cerebrovascular 
disease 
-0.01 -0.01 0.98 0.97 
Peripheral vascular 
disease 
0.05 0.002 1.33 1.01 
Cardiovascular 
risk factors 
    
Diabetes 0.03 0.02 1.06 1.03 
Hypercholesterolae
mia 
0.05 -0.01 1.07 0.99 
Hypertension 0.07 0.01 1.03 1.00 
Current or ex-
smoker                                                                                                                                                                       
0.08 0.01 0.97 1.00 
Asthma or COPD 0.06 -0.004 1.04 1.00 
Family history of 
CHD            
0.06 0.01 1.09 1.01 
Presenting 
characteristics 
    
Heart rate >110 
bpm 
-0.05 -0.04 0.85 0.88 
Creatinine >200 
(μmol/l) 
-0.05 -0.001 0.75 0.99 
Peak troponin  0.01 0.003 0.97 0.99 
Cardiac arrest 0.02 -0.02 1.19 0.89 
Electrocardiograp
hic characteristics 
    
  ST-segment 
deviation 
0.05 -0.01 1.02 1.00 
Care by 
cardiologist  
-0.02 -0.01 1.02 1.01 
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 Standardized 
differences 
Variance ratios 
Data Raw Weighted Raw Weighted 
Medication at 
discharge  
    
Aspirin       
  Received  0.46 0.04 0.44 0.93 
  Contraindicated/ 
not applicable 
0.03 0.001 1.17 1.00 
P2Y12 inhibitors     
  Received 0.53 0.03 0.66 0.97 
  Contraindicated/ 
not applicable 
0.08 0.01 1.52 1.05 
ACEi/ARBs      
  Received 0.43 0.02 1.24 1.01 
  Contraindicated/ 
not applicable 
0.10 -0.03 1.98 0.85 
Statins      
  Received 0.61 0.05 0.51 0.94 
  Contraindicated/ 
not applicable 
0.06 -0.06 1.62 0.65 
In-hospital 
procedures  
    
Coronary 
angiography  
    
  Received 0.15 -0.01 0.96 1.00 
  Contraindicated/ 
not applicable 
-0.03 -0.004 0.88 0.98 
Coronary 
intervention 
(PCI/CABG)  
    
  Received 0.09 -0.01 1.06 0.99 
  Contraindicated/ 
not applicable 
-0.02 0.0003 0.94 1.00 
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery 
bypass graft; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; IMD, Index of multiple 
deprivation; PCI, percutaneous coronary intervention; ref, reference category. 
 
Table 7.8. Balance check parameters using standardized differences and 
variance ratios (imputation dataset 7). 
 Standardized 
differences 
Variance ratios 
Data Raw Weighted Raw Weighted 
Age     
  Below 55 ref ref ref ref 
  55-65 0.02 0.02 1.04 1.03 
  66-75 0.06 0.02 1.09 1.03 
  76-85 0.02 -0.03 1.03 0.97 
  Above 85 -0.08 0.01 0.88 1.01 
Male 0.03 -0.001 0.99 1.00 
Deprivation (IMD)     
  Least deprived (1) ref ref ref ref 
  2 0.01 0.01 1.02 1.02 
  3 0.03 -0.002 1.04 1.00 
  4 -0.01 0.01 0.99 1.02 
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 Standardized 
differences 
Variance ratios 
Data Raw Weighted Raw Weighted 
  Most deprived (5) -0.01 0.003 0.99 1.00 
Year of admission        
  2007 ref ref ref ref 
  2008 0.04 0.02 1.06 1.03 
  2009    -0.02 0.02 0.97 1.03 
  2010 -0.01 -0.03 0.98 0.93 
  2011 -0.05 -0.01 0.89 0.98 
  2012 -0.05 -0.01 0.86 0.98 
  2013 -0.04 -0.02 0.77 0.89 
Cardiovascular 
history                                                                             
    
Cerebrovascular 
disease 
-0.004 -0.02 0.99 0.95 
Peripheral vascular 
disease 
0.06 0.01 1.34 1.06 
Cardiovascular risk 
factors 
    
Diabetes 0.04 0.02 1.08 1.03 
Hypercholesterolaemia 0.06 0.004 1.08 1.01 
Hypertension 0.06 0.001 1.03 1.00 
Current or ex-smoker                                                                                                                                                                       0.07 0.02 0.97 0.99
Asthma or COPD 0.07 -0.01 1.05 1.00 
Family history of CHD            0.05 -0.02 1.08 0.97 
Presenting 
characteristics 
    
Heart rate >110 bpm -0.05 -0.02 0.88 0.96 
Creatinine >200 
(μmol/l) 
-0.04 0.002 0.82 1.01 
Peak troponin  -0.01 -0.01 1.01 1.04 
Cardiac arrest 0.03 -0.01 1.20 0.91 
Electrocardiographic 
characteristics 
    
  ST-segment 
deviation 
0.04 -0.003 1.01 1.00 
Care by cardiologist  0.01 -0.02 1.00 1.01 
Medication at 
discharge  
    
Aspirin       
  Received  0.47 0.02 0.43 0.96 
  Contraindicated/ not 
applicable 
0.004 0.01 1.02 1.06 
P2Y12 inhibitors     
  Received 0.55 0.02 0.65 0.98 
  Contraindicated/ not 
applicable 
0.07 -0.001 1.43 1.00 
ACEi/ARBs      
  Received 0.45 0.01 1.27 1.00 
  Contraindicated/ not 
applicable 
0.12 -0.03 2.31 0.85 
Statins      
  Received 0.61 0.03 0.51 0.96 
  Contraindicated/ not 
applicable 
0.06 -0.04 1.71 0.72 
In-hospital 
procedures  
    
Coronary angiography      
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 Standardized 
differences 
Variance ratios 
Data Raw Weighted Raw Weighted 
  Received 0.13 -0.01 0.97 1.00 
  Contraindicated/ not 
applicable 
-0.03 -0.01 0.86 0.98 
Coronary intervention 
(PCI/CABG)  
    
  Received 0.07 -0.003 1.04 1.00 
  Contraindicated/ not 
applicable 
0.01 0.0002 1.02 1.00 
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery 
bypass graft; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; IMD, Index of multiple 
deprivation; PCI, percutaneous coronary intervention; ref, reference category. 
 
Table 7.9. Balance check parameters using standardized differences and 
variance ratios (imputation dataset 8). 
 Standardized 
differences 
Variance ratios 
Data Raw Weighted Raw Weighted 
Age     
  Below 55 ref ref ref ref 
  55-65 0.02 0.02 1.04 1.03 
  66-75 0.06 -0.01 1.08 0.99 
  76-85 0.02 -0.01 1.03 0.99 
  Above 85 -0.07 -0.01 0.89 0.98 
Male 0.03 0.01 0.99 1.00 
Deprivation (IMD)     
  Least deprived (1) ref ref ref ref 
  2 0.01 0.004 1.02 1.01 
  3 0.04 -0.01 1.06 0.99 
  4 -0.002 0.01 1.00 1.02 
  Most deprived (5) -0.02 0.001 0.97 1.00 
Year of admission        
  2007 ref ref ref ref 
  2008 0.05 0.01 1.08 1.02 
  2009    -0.02 0.01 0.97 1.02 
  2010 -0.03 -0.003 0.94 0.99 
  2011 -0.04 -0.02 0.91 0.95 
  2012 -0.06 -0.008 0.84 0.98 
  2013 -0.06 -0.02 0.73 0.89 
Cardiovascular 
history                                                                             
    
Cerebrovascular 
disease 
0.01 0.001 1.04 1.00 
Peripheral vascular 
disease 
0.05 0.003 1.27 1.02 
Cardiovascular risk 
factors 
    
Diabetes 0.03 0.01 1.05 1.03 
Hypercholesterolaemia 0.04 -0.003 1.06 1.00 
Hypertension 0.07 0.004 1.03 1.00 
Current or ex-smoker                                                                                                                                                                       0.06 0.01 0.98 0.99 
Asthma or COPD 0.07 0.01 1.05 1.00 
Family history of CHD            0.05 -0.02 1.08 0.97 
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 Standardized 
differences 
Variance ratios 
Data Raw Weighted Raw Weighted 
Presenting 
characteristics 
    
Heart rate >110 bpm -0.06 -0.01 0.83 0.97 
Creatinine >200 
(μmol/l) 
-0.04 -0.0003 0.80 1.00 
Peak troponin  0.0001 -0.01 1.00 1.01 
Cardiac arrest 0.02 -0.01 1.17 0.90 
Electrocardiographic 
characteristics 
    
  ST-segment 
deviation 
0.03 0.01 1.01 1.00 
Care by cardiologist  -0.003 -0.02 1.00 1.01 
Medication at 
discharge  
    
Aspirin       
  Received  0.45 0.03 0.44 0.94 
  Contraindicated/ not 
applicable 
0.03 0.01 1.17 1.06 
P2Y12 inhibitors     
  Received 0.56 0.02 0.65 0.98 
  Contraindicated/ not 
applicable 
0.07 0.01 1.37 1.06 
ACEi/ARBs      
  Received 045 0.01 1.26 1.00 
  Contraindicated/ not 
applicable 
0.12 -0.01 2.30 0.95 
Statins      
  Received 0.62 0.03 0.50 0.96 
  Contraindicated/ not 
applicable 
0.04 -0.01 1.39 0.95 
In-hospital 
procedures  
    
Coronary angiography      
  Received 0.14 -0.01 0.97 1.00 
  Contraindicated/ not 
applicable 
-0.03 -0.01 0.88 0.97 
Coronary intervention 
(PCI/CABG)  
    
  Received 0.06 -0.01 1.03 0.99 
  Contraindicated/ not 
applicable 
-
0.0003 
0.0003 1.00 1.00 
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery 
bypass graft; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; IMD, Index of multiple 
deprivation; PCI, percutaneous coronary intervention; ref, reference category. 
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Table 7.10. Balance check parameters using standardized differences and 
variance ratios (imputation dataset 9). 
 Standardized 
differences 
Variance ratios 
Data Raw Weighted Raw Weighted 
Age     
  Below 55 ref ref ref ref 
  55-65 0.028 0.026 1.05 1.05 
  66-75 0.08 0.01 1.11 1.01 
  76-85 0.02 -0.02 1.02 0.98 
  Above 85 -0.09 -0.02 0.86 0.97 
Male 0.02 0.001 0.99 1.00 
Deprivation (IMD)     
  Least deprived (1) ref ref ref ref 
  2 0.01 0.004 1.01 1.01 
  3 0.04 -0.02 1.06 0.97 
  4 -0.02 0.01 0.97 1.01 
  Most deprived (5) -0.02 -0.001 0.96 1.00 
Year of admission        
  2007 ref ref ref ref 
  2008 0.07 -0.01 1.12 0.99 
  2009    -0.02 0.01 0.97 1.01 
  2010 -0.02 0.001 0.95 1.00 
  2011 -0.05 -0.01 0.89 0.97 
  2012 -0.06 -0.01 0.84 0.97 
  2013 -0.06 -0.02 0.72 0.92 
Cardiovascular 
history                                                                             
    
Cerebrovascular 
disease 
0.01 -0.003 1.02 0.99 
Peripheral vascular 
disease 
0.04 0.004 1.22 1.02 
Cardiovascular risk 
factors 
    
Diabetes 0.02 0.02 1.05 1.03 
Hypercholesterolaemi
a 
0.05 -0.002 1.06 1.00 
Hypertension 0.05 0.001 1.02 1.00 
Current or ex-smoker                                                                                                                                                                       0.09 0.02 0.97 0.99 
Asthma or COPD 0.06 -0.01 1.04 0.99 
Family history of CHD            0.06 0.001 1.09 1.00 
Presenting 
characteristics 
    
Heart rate >110 bpm -0.07 -0.02 0.82 0.95 
Creatinine >200 
(μmol/l) 
-0.05 -0.01 0.76 0.94 
Peak troponin  0.01 0.01 0.97 0.98 
Cardiac arrest 0.03 -0.03 1.21 0.81 
Electrocardiographi
c characteristics 
    
  ST-segment 
deviation 
0.03 0.001 1.01 1.00 
Care by cardiologist  -0.02 -0.02 1.02 1.01 
Medication at 
discharge  
    
Aspirin       
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 Standardized 
differences 
Variance ratios 
Data Raw Weighted Raw Weighted 
  Received  0.45 0.03 0.44 0.93 
  Contraindicated/ not 
applicable 
0.03 -0.001 1.18 0.99 
P2Y12 inhibitors     
  Received 0.55 0.03 0.65 0.97 
  Contraindicated/ not 
applicable 
0.08 0.01 1.47 1.04 
ACEi/ARBs      
  Received 0.43 0.02 1.25 1.01 
  Contraindicated/ not 
applicable 
0.11 -0.03 2.15 0.86 
Statins      
  Received 0.60 0.03 0.51 0.96 
  Contraindicated/ not 
applicable 
0.04 -0.01 1.37 0.94 
In-hospital 
procedures  
    
Coronary 
angiography  
    
  Received 0.14 0.002 0.97 1.00 
  Contraindicated/ not 
applicable 
-0.04 -0.01 0.84 0.98 
Coronary intervention 
(PCI/CABG)  
    
  Received 0.07 -0.01 1.04 0.99 
  Contraindicated/ not 
applicable 
-0.02 -0.001 0.93 1.00 
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery 
bypass graft; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; IMD, Index of multiple 
deprivation; PCI, percutaneous coronary intervention; ref, reference category. 
 
Table 7.11. Balance check parameters using standardized differences and 
variance ratios (imputation dataset 10). 
 Standardized 
differences 
Variance ratios 
Data Raw Weighted Raw Weighted 
Age     
  Below 55 ref ref ref ref 
  55-65 0.03 0.02 1.06 1.04 
  66-75 0.07 -0.01 1.09 0.99 
  76-85 0.02 -0.01 1.02 0.99 
  Above 85 -0.09 -0.01 0.86 0.99 
Male 0.02 0.02 1.00 1.00 
Deprivation (IMD)     
  Least deprived (1) ref ref ref ref 
  2 0.01 -0.003 1.02 1.00 
  3 0.03 -0.01 1.04 0.98 
  4 -0.02 -0.01 0.97 0.99 
  Most deprived (5) 0.004 0.01 1.01 1.02 
Year of admission        
  2007 ref ref ref ref 
  2008 0.07 0.02 1.11 1.02 
  2009    -0.01 0.01 0.98 1.01 
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 Standardized 
differences 
Variance ratios 
Data Raw Weighted Raw Weighted 
  2010 -0.03 -0.01 0.94 0.99 
  2011 -0.05 -0.01 0.90 0.97 
  2012 -0.06 -0.01 0.83 0.97 
  2013 -0.06 -0.01 0.72 0.92 
Cardiovascular 
history                                                                             
    
Cerebrovascular 
disease 
-0.003 -0.01 0.99 0.96 
Peripheral vascular 
disease 
0.06 0.01 1.37 1.07 
Cardiovascular risk 
factors 
    
Diabetes 0.03 0.02 1.07 1.04 
Hypercholesterolaemi
a 
0.05 -0.01 1.07 0.99 
Hypertension 0.05 -0.01 1.02 1.00 
Current or ex-smoker                                                                                                                                                                       0.10 0.01 0.97 1.00 
Asthma or COPD 0.08 -0.002 1.06 1.00 
Family history of CHD            0.08 -0.02 1.12 0.98 
Presenting 
characteristics 
    
Heart rate >110 bpm -0.06 -0.02 0.85 0.95 
Creatinine >200 
(μmol/l) 
-0.05 -0.01 0.76 0.95 
Peak troponin  0.02 0.02 0.94 0.95 
Cardiac arrest 0.03 -0.01 1.27 0.93 
Electrocardiographi
c characteristics 
    
  ST-segment 
deviation 
0.04 -0.01 1.01 1.00 
Care by cardiologist  0.004 -0.02 1.00 1.01 
Medication at 
discharge  
    
Aspirin       
  Received  0.46 0.03 0.44 0.93 
  Contraindicated/ not 
applicable 
0.02 0.003 1.10 1.01 
P2Y12 inhibitors     
  Received 0.55 0.03 0.64 0.97 
  Contraindicated/ not 
applicable 
0.06 -0.01 1.37 0.95 
ACEi/ARBs      
  Received 0.44 0.01 1.25 1.00 
  Contraindicated/ not 
applicable 
0.12 0.02 2.34 1.13 
Statins      
  Received 0.63 0.03 0.50 0.96 
  Contraindicated/ not 
applicable 
0.04 0.01 1.38 1.10 
In-hospital 
procedures  
    
Coronary angiography      
  Received 0.15 -0.001 0.96 1.00 
  Contraindicated/ not 
applicable 
-0.03 -0.01 0.89 0.95 
Coronary intervention 
(PCI/CABG)  
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 Standardized 
differences 
Variance ratios 
Data Raw Weighted Raw Weighted 
  Received 0.07 -0.01 1.04 1.00 
  Contraindicated/ not 
applicable 
-0.002 0.01 0.99 1.02 
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery 
bypass graft; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; IMD, Index of multiple 
deprivation; PCI, percutaneous coronary intervention; ref, reference category. 
 
Table 7.12. Over-identification test results for each of the imputed datasets 
used for the analysis. 
Imputation P-value for AMI 
analysis 
P-value for STEMI 
analysis 
P-value for 
NSTEMI analysis 
1 0.20 0.27 0.47 
2 0.07 0.87 0.10 
3 0.89 0.48 0.35 
4 0.39 0.87 0.17 
5 0.55 0.36 0.70 
6 0.07 0.64 0.10 
7 0.25 0.87 0.05 
8 0.29 0.89 0.60 
9 0.36 0.88 0.22 
10 0.28 0.53 0.71 
Abbreviations: AMI, acute myocardial infarction; NSTEMI, non ST-segment elevation myocardial infarction; 
STEMI, ST-segment elevation myocardial infarction. 
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Figure 7.6. Area under ROC curve for the propensity scoring model. 
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7.3.2 Outcome model  
After weighting and adjustment, there were no survival differences between 
AMI patients without heart failure or LVSD who received β blockers and 
those who did not at any time point to one year (Figure 7.7 and Figure 7.8). 
No significant treatment effects were found if all patients in the analytical 
cohort had received β blockers compared with if no patients in the analytical 
cohort had not received β blockers for the three survival times investigated 
(ATE coefficient 0.47, 95% CI -2.99 to 3.94, P=0.785; 0.06, -0.35 to 0.46, 
P=0.768; 0.07, -0.60-0.75, P=0.827, respectively) (Table 7.13). The 
stratified analysis by AMI phenotype (STEMI and NSTEMI) found no 
significant treatment effects for the use of β blockers at 1 month, 6 months 
and 1 year for both phenotypes (Table 7.13). Sensitivity analysis results of 
the untrimmed analytical cohort (n=179,810), after weighting and 
adjustment showed consistent results with the balanced analysis (trimmed 
analytical cohort analysis, n=16,683). There was no significant association 
of β blockers use with survival at 1 month, 6 months and 1 year, for AMI 
analysis combined as well as separately for STEMI and NSTEMI (Table 
7.13). A complete case analysis was carried out too and consistent results 
with the imputed data were found (see Appendix D), however with 
convergence problems for some of the models due to the small sample 
sizes in the groups thus the imputation employed was warranted. 
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Figure 7.7. Adjusted survival (Kaplan-Meier estimates) among patients prescribed β blockers at discharge and those not prescribed 
(For trimmed analytical cohort (n=16,683)). 
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Figure 7.8. Adjusted survival (Kaplan-Meier estimates) among patients prescribed β blockers at discharge and those not prescribed 
(For full analytical cohort (N= 179,810)). 
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Table 7.13. Effect of β blockers at time of discharge from hospital on all-cause mortality for hospital survivors of AMI without heart 
failure or LVSD estimated using survival-time inverse-probability weighting propensity score analysis. 
Trimmed cohort analysis Full analytical cohort analysis 
 Average treatment effects Average treatment effects 
on the treated only 
 Average treatment effects Average treatment effects 
on the treated only 
Follow-up Coefficients¥ 
(95%CI) 
P-
value 
Coefficients¥ 
(95%CI) 
P-value Follow-up Coefficients¥ 
(95%CI) 
P-
value 
Coefficients¥ 
(95%CI) 
P-
value 
AMI (N=16,683)     AMI 
(N=179,810) 
    
  One month 0.47 (-2.99-3.94) 0.785 0.08 (-4.13-4.29) 0.971   One month 0.04 (-1.54-1.61) 0.964 -0.11 (-1.78-1.56) 0.897 
  Six months 0.06 (-0.35-0.46) 0.768 -0.05 (-0.52-0.43) 0.849   Six months 0.0001 (-0.29-0.29) 0.999 -0.04 (-0.35-0.28) 0.820 
  One year 0.07 (-0.60-0.75) 0.827 0.02 (-0.80-0.85) 0.954   One year 0.47 (-0.13-1.08) 0.121 0.47 (-0.19-1.12) 0.159 
STEMI 
(n=4,932) 
    STEMI 
(n=91,895) 
    
  One month -0.14 (-5.89-5.61) 0.960 -0.50 (-7.06-6.06) 0.879   One month 0.57 (-2.31-3.45) 0.693 0.54 (-2.20-3.28) 0.697 
  Six months -0.15 (-0.97-0.67) 0.712 -0.28 (-1.27-0.72) 0.575   Six months -0.33 (-0.87-0.20) 0.223 -0.40 (-0.95-0.15) 0.158 
  One year 0.30 (-0.98-1.58) 0.637 0.26 (-1.37-1.88) 0.748   One year 0.49 (-0.34-1.32) 0.246 0.49 (-0.36-1.36) 0.260 
NSTEMI 
(n=11,751) 
    NSTEMI 
(n=87,915) 
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Trimmed cohort analysis Full analytical cohort analysis 
 Average treatment effects Average treatment effects 
on the treated only 
 Average treatment effects Average treatment effects 
on the treated only 
Follow-up Coefficients¥ 
(95%CI) 
P-
value 
Coefficients¥ 
(95%CI) 
P-value Follow-up Coefficients¥ 
(95%CI) 
P-
value 
Coefficients¥ 
(95%CI) 
P-
value 
  One month 0.12 (-3.34-3.58) 0.947 -0.72 (-4.95-3.52) 0.735   One month -0.16 (-3.62-3.31) 0.926 -0.45 (-4.22-3.33) 0.812 
  Six months 0.10 (-0.26-0.46) 0.565  0.02 (-0.38-0.42) 0.932   Six months 0.19 (-0.16-0.55) 0.286 0.18 (-0.20-0.56) 0.357 
  One year -0.07 (-0.68-0.54) 0.819 -0.11 (-0.84-0.64) 0.777   One year 0.40 (-0.39-1.18) 0.314 0.39 (-0.48-1.26) 0.368 
Abbreviations. AMI, Acute myocardial infarction; ¥ The average treatment effects (ATE) represents the absolute difference in survival time (months, respective to the follow-up time category) between 
β blocker treatment vs. no treatment across the whole cohort (comparing survival times in a scenario in which all patients were treated with survival times in a scenario in which no patients were 
treated). The average treatment effects on the treated (ATET) represents the absolute difference in survival time between β blocker treatment vs. no β blocker treatment estimated only amongst those 
who were treated (comparing survival times for all β blocker patients with the potential survival time in the scenario that the treated patients did not receive β blockers). The ATE and ATET are 
presented as coefficients with 95% confidence interval for the respective follow-up time categories. ; NSTEMI, non ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction. 
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7.4 Instrumental variable analysis  
The instrumental variable used for the analysis was “hospital rates of 
prescription of guideline-indicated treatments (aspirin, P2Y12 inhibitors, β 
blockers, statins and ACEi/ARB))”. Detail on the choice of the instrumental 
variable is given in Chapter 3, §3.9.2. The instrumental variable was found to 
be valid i.e. the instrument was a good predictor of use of β blockers, was well 
balanced across patient characteristics (Table 7.14) and was independent of 
patient outcomes (OR for 30 day mortality 1.11, 95% CI 0.38 to 3.23, P=0.847, 
6 months mortality; 1.45, 0.68 to 3.07, P=0.337 and 1 year mortality; 1.25, 
0.63 to 2.46, P=0.522).  
Table 7.14. Patient characteristics and mortality according to quintiles of 
hospital prescribing rates of five drugs at discharge*. 
 Quintile of hospital prescribing rates of five drugs at 
discharge 
Variablea 1 
N=28,870 
2 
N=35,981 
3 
N=33,775 
4 
N=39,021 
5 
N=42,163 
Age, mean (SD), years 65.0 
(13.7) 
64.4 
(13.7) 
64.0 
(13.8) 
64.1 
(13.5) 
63.7 
(13.6) 
Male 19,767 
(68.5) 
25,166 
(69.9) 
23,258 
(68.9) 
27,641 
(70.8) 
30,029 
(71.2) 
Deprivation (IMD score), 
median (IQR) 
17.7 (10.6 
-30.1) 
16.5 (9.5-
28.4) 
20.1 
(11.6-
35.1) 
17.0 (9.9-
30.2) 
17.5 (9.7-
32.4) 
Year of admission         
2007 5,090 
(17.6) 
5,398 
(15.0) 
4,607 
(13.6) 
5,228 
(13.4) 
4,703 
(11.2) 
2008 4,905 
(17.0) 
5,026 
(14.0)   
4,675 
(13.8) 
5,956 
(15.3) 
5,556 
(13.2) 
2009 5,195 
(18.0) 
5,242 
(14.6) 
5,086 
(15.1) 
6,264 
(16.1) 
6,911 
(16.4) 
2010 4,522 
(15.7) 
6,148 
(17.1)  
5,534 
(16.4) 
6,277 
(16.1)   
7,425 
(17.6) 
2011 4,166 
(14.4) 
6,064 
(16.9)  
5,935 
(17.6) 
6,551 
(16.8) 
7,487 
(17.8) 
2012 3,973 
(13.8) 
6,114 
(17.0) 
5,970 
(17.7) 
6,577 
(16.9) 
7,609 
(18.1) 
2013 1,019 
(3.5) 
1,989 
(5.5) 
1,968 
(5.8) 
2,168 
(5.6) 
2,472 
(5.9) 
Cardiovascular history                                                                               
Cerebrovascular 
disease 
1,272 
(4.4) 
1,271 
(3.5)  
1,542 
(4.6)  
1,374 
(3.5) 
1,456 
(3.5) 
Peripheral vascular 
disease 
476 (1.7) 644 (1.8)    818 (2.4) 668 (1.7) 805 (1.9) 
Cardiovascular risk 
factors 
     
Diabetes 3,266 
(11.3) 
4,253 
(11.8) 
3,985 
(11.8)  
4,614 
(11.8) 
4,637 
(11.0) 
Chronic renal failure 505 (1.8)  537 (1.5) 631 (1.9) 578 (1.5) 652 (1.6) 
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 Quintile of hospital prescribing rates of five drugs at 
discharge 
Variablea 1 
N=28,870 
2 
N=35,981 
3 
N=33,775 
4 
N=39,021 
5 
N=42,163 
Hypercholesterolaemia 6,371 
(22.1) 
7,955 
(22.1) 
8,122 
(24.1) 
8,577 
(22.0) 
10,925 
(25.9) 
Hypertension 10,012 
(34.7) 
11,955 
(33.2) 
11,754 
(34.8) 
12,392 
(31.8) 
14,231 
(33.8) 
Current or Ex-smoker                                                                                                                                                                       18,555
(64.3) 
23,175
(64.4) 
22,306 
(66.0) 
25,401
(65.1) 
27,899
(66.2) 
Asthma or COPD 3,348 
(11.6) 
3,698 
(10.3) 
3,922 
(11.6)   
3,930 
(10.1) 
4,442 
(10.5) 
Family history of CHD            9,052 
(31.4) 
9,850 
(27.4) 
10,211 
(30.2) 
10,946 
(28.1) 
13,140 
(31.2) 
Presenting 
characteristics 
     
Systolic blood pressure, 
mmHg , mean (SD) 
141.3 
(27.2) 
140.4 
(27.5) 
140.6 
(27.7) 
139.1 
(27.4) 
138.1 
(27.0) 
Heart rate, (beat/min), 
median (IQR) 
77.0 
(66.0-
90.0) 
78.0 
(67.0-
90.0) 
77.0 
(66.0-
90.0) 
76.0 
(66.0-
89.0) 
76.0 
(65.0-
89.0) 
Creatinine, (mg/dL), 
median (IQR) 
86.0 
(73.0-
101.0) 
86.0 
(73.0-
101.0) 
84.0 
(71.0-
99.0) 
85.0 
(72.0-
99.0) 
85.0 
(73.0-
100.0) 
Peak troponin§, median 
(IQR) 
3.3 (0.4-
45.3) 
3.6 (0.4-
50.0) 
4.3 (0.5-
44.7) 
5.8 (0.7-
50.0) 
3.7 (0.5-
45.7) 
Cardiac arrest 860 (3.0) 1,222 
(3.4) 
1,106 
(3.3) 
1,535 
(3.9) 
1,900 
(4.5) 
Electrocardiographic 
characteristics 
     
No acute changes 3,862 
(13.4) 
3,981 
(11.1) 
4,177 
(12.4) 
3,807 
(9.8) 
3,401 
(8.1) 
ST-segment elevation 11,879 
(41.2)  
17,137 
(47.6) 
16,105 
(47.7) 
20,617 
(52.8)   
23,281 
(55.2) 
Left bundle branch block 612 (2.1) 860 (2.4) 704 (2.1) 852 (2.2) 828 (2.0)  
ST segment depression 4,185 
(14.5) 
4,429 
(12.3)   
3,797 
(11.2) 
4,373 
(11.2) 
4,534 
(10.8) 
T wave changes only 5,146 
(17.8) 
5,761 
(16.0)  
4,951 
(14.7) 
6,105 
(15.7) 
6,516 
(15.5) 
Other acute abnormality 3,186 
(11.0) 
3,813 
(10.6) 
4,041 
(12.0)     
3,267 
(8.4) 
3,603 
(8.6) 
Grace risk score      
Lowest (≤70) 3,195 
(11.1) 
3,749 
(10.4)  
3,402 
(10.1) 
3,321 
(8.5)  
3,659 
(8.7) 
Low (71-87)   4,235 
(14.7) 
5,207 
(14.5)   
4,693 
(13.9) 
5,040 
(12.9) 
5,684 
(13.5) 
Intermediate to high 
(>88) 
21,440 
(74.3)  
27,025 
(75.1) 
25,680 
(76.0) 
30,660 
(78.6) 
32,820 
(77.8) 
Index event      
NSTEMI 16,435 
(56.9) 
18,285 
(50.8) 
17,038 
(50.5) 
17,661 
(45.3)    
18,496 
(43.9) 
Medication at 
dischargeb 
     
Aspirin  27,309 
(97.0) 
34,402 
(98.0) 
32,715 
(99.1) 
37,869 
(99.2) 
40,965 
(99.4) 
P2Y12 inhibitors 25,535 
(91.7) 
32,368 
(94.1) 
30,911 
(96.5)   
36,063 
(96.8)   
39,094 
(97.3)   
ACEi/ARBs 23,618 
(86.2)  
31,322 
(92.3) 
30,035 
(94.7) 
34,463 
(95.5)   
38,255 
(97.4) 
Statin 27,060 
(94.9) 
34,206 
(96.7) 
32,634 
(98.1)  
37,704 
(98.6)   
40,807 
(99.0)   
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 Quintile of hospital prescribing rates of five drugs at 
discharge 
Variablea 1 
N=28,870 
2 
N=35,981 
3 
N=33,775 
4 
N=39,021 
5 
N=42,163 
β blockers 25,835 
(89.5) 
33,650 
(93.5) 
32,262 
(95.5)   
37,680 
(96.6) 
41,063 
(97.4) 
In-hospital 
proceduresb 
     
Coronary angiography 19,751 
(71.1) 
24,455 
(69.8) 
24,055 
(74.3)   
23,628 
(63.3)   
28,978 
(71.6) 
Coronary intervention 14,846 
(54.6) 
18,610 
(54.3)   
18,895 
(59.3) 
18,071 
(49.9)    
23,606 
(59.7) 
Rehabilitationb      
Enrolment into cardiac 
rehabilitation 
24,665 
(89.2)  
32,398 
(94.1) 
29,885 
(92.7)   
34,571 
(92.2) 
38,444 
(96.3) 
Abbreviations: ACE, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary 
artery bypass graft; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; PCI, percutaneous 
coronary intervention; IMD, Index of multiple deprivation; IQR, interquartile range; SD, standard deviation; § peak 
troponin was truncated at 50; *Five discharge drugs (aspirin, P2Y12 inhibitors, β blockers, statins and angiotensin 
converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB)). 
 
7.4.1 Treatments effects  
Similar to the propensity score analysis results, the instrumental variable 
analysis found no significant difference in mortality at 1 month, 6 months and 
1 year for patients who did not receive β blockers (coefficient -0.003, 95% CI 
-1.56 to 1.55, P=0.997; 0.18, -0.76 to 1.12, P=0.712; 0.02, -0.64 to 0.68, 
P=0.953, respectively), a result which was consistent across cases of STEMI 
and NSTEMI (Table 7.15). 
Table 7.15. Effect of β blockers at time of discharge from hospital on all-cause 
mortality for hospital survivors of AMI without heart failure or LVSD estimated 
using instrumental variable analysis. 
 Treatment effects 
Follow-up Coefficient¥  (95% CI) P-value 
AMI (n=179,810)   
One month -0.003 (-1.56-1.55) 0.997 
Six months 0.18 (-0.76-1.12) 0.712 
One year 0.02 (-0.64-0.68) 0.953 
STEMI (n=91,895)   
One month -0.42 (-2.81-1.96) 0.725 
Six months 0.32 (-2.54-3.18) 0.826 
One year 0.03 (-1.82-1.87) 0.976 
NSTEMI (n=87,915)   
One month -0.57 (-1.64-0.49) 0.291 
Six months -0.34 (-0.91-0.22) 0.235 
One year -0.50 (-1.57-0.58) 0.365 
Abbreviations: AMI, acute myocardial infarction; ¥Estimate represents the effect of β blockers on survival for the 
respective follow-up time categories; NSTEMI, non ST- elevation myocardial infarction; STEMI, ST- elevation 
myocardial infarction. 
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7.5 Summary of key findings  
 β blocker users tended to be younger, male, less co morbid and lower 
risk compared with the non β blocker users. 
 After propensity weighting and confounder adjustment, if all the 
patients in the population had received β blockers, there was no 
significant difference in the average time to death compared with if no 
patients had received β blockers.  
 
7.6 Conclusion  
In this nationwide observational study of survivors of hospitalisation with AMI 
without heart failure or LVSD, the use of β blockers was not associated with a 
lower risk of death at up to year. The next Chapter is the discussion of the 
findings of this thesis. 
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Chapter 8 : Discussion 
8.1 Introduction  
Cardiovascular disease is the main cause of death in Europe, with CHD being 
the most common cause of premature death in the UK(1, 14). Despite 
substantial improvements in its treatment, the global burden persists and a 
large proportion of patients fail to receive appropriate care. This thesis set out 
to evaluate quality of care and associated outcomes for the most common 
manifestation of CHD, ACS using readily available electronic health records 
and applying advanced statistical techniques.   
 
The study makes a contribution to knowledge by being the first ever study to 
provide a comprehensive assessment of receipt of optimal care (considering 
care interventions beyond the five main cardio-protective drugs on the AMI 
care pathway) for the more vulnerable of the two AMI phenotypes, NSTEMI 
as well as quantify the associated harm of missing care interventions. The 
study also sought out to determine whether temporal changes in STEMI 
treatments or patient characteristics were associated with improvements in 
survival, and finally determine the efficacy of β blockers for AMI patients 
without heart failure or LVSD since there is no contemporary randomised data 
for survivors of AMI without heart failure or LVSD in relation to the use of β 
blockers. As such, international guidelines differ in their recommendation on 
the use of β blockers following AMI. 
The findings from the four objectives of the thesis were presented in the earlier 
chapters:  
 Chapter 4 reports findings for objective one of the thesis whereby 
avoidable deaths associated with sub-optimal care for NSTEMI 
patients were quantified and predictors of receipt of NSTEMI care 
determined. 
 Chapter 5 reports findings for objective two of the thesis whereby within 
country variation in receipt of care for NSTEMI patients was evaluated.  
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 Chapter 6 reports findings for objective three of the thesis whereby 
factors (temporal changes in treatments or patient baseline 
characteristics) attributed to the temporal improvements in six months 
and one year survival for STEMI patients were determined.  
 Chapter 7 reports findings for objective four of the thesis whereby the 
efficacy of β blockers use at hospital discharge was determined for AMI 
patients without heart failure or LVSD. 
Summary of key findings of the objectives of the thesis are given in §8.2 as 
well as detailed discussion and synthesis of the results in §8.3. This will be 
followed by a detailed discussion of strengths and limitations of the thesis in 
§8.4, implications of the study in §8.5, recommendations for future research 
in §8.6, and future publications in §8.7. Finally an overall conclusion is given 
in §8.8.  
 
8.2 Summary of key findings from thesis  
Excess mortality (avoidable deaths) and guideline-indicated care 
following non ST-elevation myocardial infarction. (Objective one) 
The study quantified the excess mortality associated with poor receipt of 
international guideline indicated care for patients hospitalised with NSTEMI 
across a single healthcare system (the National Health Service of England 
and Wales). Only 13.2% of the NSTEMI patients received all the care 
interventions they were eligible for (optimal care). In total approximately 
33,000 deaths were estimated to have been potentially avoidable if all patients 
during the study period had received the investigations and treatments for 
which they were eligible. The care interventions that were frequently missed 
included: dietary and smoking cessation advice, echocardiography to 
evaluative left ventricular systolic function, coronary angiography, the 
prescription of P2Y12 inhibitors at hospital discharge, and pre-hospital aspirin. 
All of the 13 care interventions if missed, except aldosterone antagonists, had 
significant and strong associations with reduced survival, in particular 
coronary angiography, cardiac rehabilitation, smoking cessation advice and 
the use of statins. This current study found that the care intervention that had 
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the strongest impact on survival if missed was coronary angiography. Care by 
a cardiologist was found to be a positive predictor of receipt of optimal care.   
Geographic variation in the treatment of non ST-segment myocardial 
infarction in the English National Health Service: a cohort study. 
(Objective two) 
Receipt of optimal care varied geographically, however wider variations were 
observed when individual assessments of the care interventions were 
undertaken. The greatest variation in provision of care across CCGs was for 
aldosterone antagonists and least for use of electrocardiogram, with high 
prescription rates and minimal variation for prescription of aspirin acutely, 
aspirin at discharge from hospital and statins. Intermediate provision rates and 
wide variation across CCGs were observed for provision of echocardiography, 
cardiac rehabilitation, coronary angiography, prescription of ACEi/ARBs and 
β blockers, with low provision rates for and little variation across CCGs for 
provision of smoking cessation advice, dietary advice and P2Y12 inhibitors. 
Similar findings were noted for SCNs, with high receipt of optimal care being 
observed in North East and North Cumbria, and East Midlands. Most of the 
variation (after accounting for differences in patients) was explained by 
differences in the provision of care by hospitals. 
Association of clinical factors and therapeutic strategies with 
improvements in survival following STEMI. (Objective three) 
Among patients hospitalized with STEMI in England and Wales, 
improvements in all cause six months, and one year mortality were observed 
between 2004 and 2013. This was significantly associated with the 
introduction of PPCI and P2Y12 inhibitors use at hospital discharge, with 
introduction of PPCI having the greatest impact on one year mortality. 
Role of β-blockers during and after AMI in patients without heart failure 
or LVSD. (Objective four) 
In the first large cohort study to investigate the impact of β blockers on survival 
following AMI among patients without heart failure or LVSD, the use of β 
blockers at hospital discharge among nearly 17,000 (propensity score 
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balanced) and 180,000 (instrumental variable analysis) patients between 
2007 and 2013 was not associated with a lower risk of death at up to one year. 
 
8.3 Findings in the context of literature  
8.3.1 Excess mortality (avoidable deaths) and guideline-indicated 
care following non ST-elevation myocardial infarction. 
Prevalence of patients who received optimal care 
The ESC and the ACC/AHA have defined care for NSTEMI patients, with the 
recommendations from the guidelines being supported by evidence from 
clinical trials and observational data(4, 21, 23). Several cohort studies have 
reported the survival benefits from adherence to these evidence based 
interventions after suffering an AMI(67, 149, 150). Even so, a large proportion 
of patients fail to get optimal care. This current study of 389,057 NSTEMI 
patients found that 86.8% of the patients received sub-optimal care. 
Comparing these findings to past literature, similar findings were observed. 
Prevalence of sub optimal care has been reported to be high for AMI patients 
(median 53.8%, IQR 50.6-70.9%)(51-61). For example a study by Bramlage 
et al.(51) of 5,353 AMI patients found that optimal care was provided to just 
about half of the patients, with optimal care being defined as prescription of 
the five main pharmacotherapy at hospital discharge (aspirin, ACEi/ARBs, β-
blockers, statin and clopidogrel) unless contraindicated. Similarly to the 
Bramlage et al.(51) study,  the majority of past studies that have assessed 
receipt of optimal care for AMI patients have focused mainly on prescription 
of the five main cardio-protective drugs (of the entire AMI care pathway), with 
the exception of one study by Longenecker et al.(59) that also considered 
reperfusion in their definition. The major concern with defining optimal care 
defined restricted to prescription of the five cardio-protective drugs is that it 
restricts the analyses to focus  more on patients who are managed the 
conservative approach of care and   it biases  the survival benefits inherent if 
the AMI patients receive all care interventions for which they were eligible 
across the entire guideline indicated AMI care pathway. It should be expected 
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that greater survival benefits would be observed when a patient receives all 
the guideline-indicated care interventions for which they are eligible including 
the cardio-protective drugs. 
 
Only one study by Simms et al.(61) assessed receipt of optimal care including 
care interventions beyond receipt of the five cardio-protective drugs. However 
the work was only restricted to STEMI patients, as a result the work for this 
thesis focused mainly on NSTEMI patients as no comprehensive analysis 
equivalent to the work carried out by Simms et al.(61) has been undertaken 
for NSTEMI patients. For STEMI patients, Simms et al.(61) found of the nine 
STEMI care interventions (i.e. pre-hospital ECG, acute use of aspirin, timely 
reperfusion, five pharmacotherapies and referral for cardiac rehabilitation) 
they considered only half (50.6%) of the STEMI patients (N=112,286) received 
optimal care.  
 
Unlike other previous studies, this current study assessed optimal care 
focusing on care interventions that span the entire NSTEMI care pathway (13 
guideline-indicated care interventions). Focusing on receipt of 13 care 
interventions makes this study’s findings more novel and comprehensive 
compared to other studies found in literature that carried out similar research 
work. The definition of optimal care based on the 13 care interventions used 
in this current study may potentially explain the higher proportion of receipt of 
sub-optimal NSTEMI care observed for this current work compared to the 
other studies as it considered more care interventions on the NSTEMI 
pathway i.e. beyond the five drugs prescription at hospital discharge. 
Assessing quality of care focusing on the five cardio-protective drugs only can 
also be miss-leading (potentially over estimates receipt of optimal care) as 
prescription rates of the drugs at discharge has been reported in literature to 
be high compared to the other care interventions(51, 52, 54, 59, 62). The care 
interventions that were found to be frequently missed in the this current study 
included: dietary and smoking cessation advice, echocardiography to 
evaluative left ventricular systolic function, the prescription of P2Y12 inhibitors, 
coronary angiography and the acute prescription of aspirin (pre-hospital). 
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Comparing these findings to other studies in literature (just restricted to the 
five cardio-protective drugs to aid comparability), prescription of P2Y12 
inhibitors (i.e. termed clopidogrel in some of the other studies) was found to 
be consistently frequently missed compared to the other cardio-protective 
drugs(51-53).  
  
Impact of individual care interventions on survival 
In addition to assessing prevalence of optimal care amongst NSTEMI patients, 
the impact of the individual care interventions on survival were undertaken. 
Non-adherence to the frequently missed care interventions that were identified 
in this study was associated with reduced survival. Coronary angiography had 
the greatest impact on survival i.e. not getting an angiogram was associated 
with  a reduction in time to death  by  82%, cardiac rehabilitation  51%, 
smoking cessation advice  47%, dietary advice  35%,  and P2Y12 inhibitors  
24%. Of the studies considered in the literature review only Bramlage et 
al.(51), Danchin et al.(58) and Hamood et al.(60) assessed the relative 
importance of individual components of their composite definitions of receipt 
of optimal care. Bramlage et al.(51) assessed the impact of withdrawing each 
of the cardio-protective drugs from their receipt of all five drugs scores. The 
optimal care survival benefits observed in the study by Bramlage et al.(51) 
disappeared after withdrawal of β blockers and antiplatelet therapy 
(aspirin/clopidogrel) from the composite score definition of optimal care used 
for the study. Hamood et al.(60) found that individual pharmacotherapy non-
adherence was associated with increased risk of all-cause mortality, aspirin 
non-adherence by 28%, statins by 36%, ACEi/ARBs by 57% with no survival 
benefits being observed for β blockers non-adherence. However it is quite 
difficult to compare their findings to the work of the thesis due their restricted 
definition of optimal care and select cohorts used for their studies. 
 
However, consistently with the findings of this study a study by Hall et al.(145) 
investigating the association of changes in NSTEMI patients’ characteristics 
or treatment with temporal improvements in survival noted between 2003 to 
2013 found that the temporal survival improvements noted in the study were 
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significantly associated with the temporal increase of receipt of an angiogram. 
The mediation analysis carried by this study found 88.3% of the temporal 
change in survival was explained by the increased use of angiography(145).  
 
Reasons for not receiving optimal care and predictors of receiving 
optimal care 
Reasons behind the noted care deficits for NSTEMI patients have been 
attributed to constraints around the availability of specialists and associated 
equipment. Also the management of NSTEMI patients is heterogeneous and 
the decision to prescribe evidence based medications or to proceed to 
coronary angiography is determined by the treating physician. NSTEMI care 
is heavily influenced by treating physician preferences. STEMI management 
is not as heterogeneous as the NSTEMI, in the UK it is institutionally 
operationalised through a national primary PCI programme(151, 152). Other 
studies in literature have attributed the physician treating preferences to be 
the major contribution to AMI patients not receiving appropriate care(68, 153-
155). It has been reported that physicians are more likely to treat lower risk 
patients more aggressively compared to high risk patients, a recognised 
practice in literature termed the “treatment paradox”.  
 
Care by cardiologist was determined as the most important positive predictor 
of receipt of optimal care in this study. This has been attributed to the fact that 
cardiologists are continuously exposed to clinical trials findings, 
local/international conferences such as the annual ESC congress and 
recommendations by international guidelines compared with other health 
experts such that they are highly knowledgeable on the management of AMI 
patients and are always updated on the developments in AMI care(68). Only 
56.6% of the NSTEMI patients in the study received care from a cardiologist 
which can potentially explain the care deficits observed. NSTEMI patients are 
rarely treated by cardiologists as there is a perception that NSTEMI patients 
are at lower risk of mortality compared with the other AMI phenotype 
STEMI(156).  
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Most of the patients who received optimal care in the study were found to be 
hospitalised between 2009-13. This potentially is a reflection of utility of the 
guidelines. In the earlier years treatment was mainly informed by consensus 
documents, with more specific (for each phenotype) detailed guidelines to 
inform NSTEMI treatment being developed in the recent years. Also marked 
improvements in NSTEMI care have been noted over the years(145).   
  
Optimal care definition  
In Chapter 4, LCA was used to define receipt of care for NSTEMI patients 
based on 13 guide-indicated care interventions. This study is the first to define 
receipt of care using the LCA approach which is very useful when trying to 
define receipt of care using multiple indicators mimicking ‘real world clinical 
practice’. Compared to the other approaches that have been used in past 
literature such as the dose response technique or all or none approach, LCA 
captures ‘real world clinical practice’ by identifying unmeasured class 
membership (latent prescribing patterns) among subjects based on observed 
variables of the subjects.  A three class solution was determined optimal and 
labelled high, intermediate, and low receipt of care classes to aid 
interpretation. However, the classes were representative of more complex 
patient patterns of care rather than all patients receiving either high, 
intermediate or low levels of care.  Patients in the high class had low 
probabilities for receipt of ACEis/ARBs and β blockers. The reason for low 
receipt of ACEi/ARBs and β blockers within this class is because most of the 
patients in this class were not eligible for these two care interventions (see 
Table B 1-Table B 4 in Appendix B). ACEi/ARBs and β blockers are indicated 
for patients with left ventricular dysfunction, and, therefore, form a distinct 
group of patients. In effect, the high latent class patients were healthier and 
more likely to receive evidence-based care and confirm findings from others 
who have shown that the patients who are most likely to receive guideline-
indicated treatments tend to be the lower risk patients(157-159). These 
findings implicate treatment of NSTEMI patients in that it confirms that patients 
who are multi-morbid have a lower chance of receiving optimal care.  
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As a sensitivity analysis a cross tabulation of the rest of the care interventions 
with the latent class sub-groups was undertaken and confirmed that the low 
probability of use captured in the intermediate and low receipt classes was 
indeed because of poor receipt and not contraindication (as noted for 
ACEi/ARBs and β blockers in the high receipt class) (see Table B 1-Table B 
26 in Appendix B) as a lot of the eligible patients were not receiving treatment. 
 
Analytical cohort size  
Compared to the other studies in past literature that have evaluated 
adherence to guideline-indicated care interventions and associated outcomes 
for AMI patients the current study is the largest to date with an analytical cohort 
of 389,057 NSTEMI patients from a comprehensive registry of ACS (MINAP) 
across a single health system (the National Health Service, England and 
Wales). The other studies used select cohorts (median sample size 6,080, 
IQR 3,180-11,671) that may not be representative of the general population 
and thus compromise generalisability. Data are lacking on assessment of 
receipt of optimal care and associated outcomes for the larger populations of 
AMI patients mirroring “real-life clinical practice”(77) and the current work fills 
this gap in knowledge. The use of national registries such as MINAP allows 
higher resolution investigation of sequential care deficits significantly 
associated with premature cardiovascular death. Addressing these care 
deficits has potential to save lives.  
 
However, although there has been much enthusiasm for the use of ‘big data’ 
from EHRs for health research, basing on the assumption that large sample 
sizes yield less biased findings than small sample sizes. There can be 
systematic biases in the sample of people in the EHR system or biases in the 
way information is captured or recorded, such that even with a large sample 
size the analytical cohort of a study may not be representative of the 
population to which the results will be generalised. Caution has to be taken 
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when drawing inference from data from EHRs (even with large sample sizes) 
and necessary steps have to be taken to reduce the potential inherent bias.      
 
Impact of not receiving optimal care  
This thesis found that 32,765 deaths could have been postponed if all the 
NSTEMI patients received optimal care. Chew et al.(52) using an analytical  
cohort of n=1,630 investigated the impact of combined use AMI care and 
reported that if all the AMI patients in their analytical cohort had received 
optimal care (defined as prescription of four or more pharmacotherapies) 104 
lives could have been saved and 191 recurrent events prevented per 10,000 
presentations. Our findings are similar to Chew et al.(52) in that both studies 
showed that negative impact of sub-optimal care on survival and both studies 
quantified the burden (preventable deaths) associated with sub-optimal care. 
However, unlike the Chew et al.(52) study that quantified preventable 
recurrent ischaemic events, the current work was restricted to only focusing 
on mortality as MINAP does not record non-fatal outcomes. An ideal approach 
would have been to focus on both fatal and non-fatal outcomes as receipt of 
optimal guideline-indicated care should result to better outcomes besides 
reduced mortality only. 
The current work found that patients who received sub-optimal care had a 
56% shortened mean time to death compared with patients who received 
optimal care. Besides the current study and the study by Chew et al.(52) that 
quantified the preventable deaths associated with sub-optimal AMI care, a 
vast amount of literature have quantified the impact on survival using risk 
ratios such as hazard of dying or odds of dying without estimating avoidable 
deaths(51-53, 55, 58, 59, 64, 78). Bramlage et al.(51) found that total mortality 
was reduced by 74%, Yan et al.(55) by 42%, Danchin et al.(58) by 48%, 
Hamood et al.(60) and Bauer et al.(53) found that those who received sub-
optimal care had an increased risk of death by 38% and 60%, respectively 
compared with those who received optimal care. The differing percentages on 
impact on survival noted for the studies compared with the current study can 
be attributed to the heterogeneity in definitions of optimal care definitions 
across the studies thus differing impact on survival. 
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The research work conducted in this current thesis on quantifying the excess 
mortality due to non-adherence to guideline recommended care following 
NSTEMI might yield important actionable insights to guide healthcare policy 
and clinical practice to improve the quality of health systems and prevent 
avoidable deaths from acute myocardial infarction.  
 
8.3.2 Geographic variation in the treatment of non ST-segment 
myocardial infarction in the English National Health Service: 
a cohort study. 
The body of evidence prior to this thesis has focused mainly on between 
country evaluation of variations in receipt of care for ACS patients (48, 59, 63, 
66, 68, 73, 160, 161), including international comparisons by Awad et al.(64) 
and Karrowni et al.(65).  The current study is the first to assess within country 
geographic variation in receipt of NSTEMI care (the most common and 
vulnerable type of AMI) in the UK using a nationwide clinical registry designed 
specifically to evaluate quality of NSTEMI care.  
 
For the NHS of England it is the responsibility of the 211 CCGs who work in 
partnership with hospitals, via SCNs to commission NSTEMI care(126). Over 
the 10 year evaluation receipt of optimal care for the NSTEMI patients varied 
between CCGs, with wider variations being observed for the individual care 
interventions. The greatest variation in provision of care across CCGs was for 
aldosterone antagonists and least for use of an electrocardiogram, with high 
prescription rates and minimal variation for prescription of aspirin acutely, 
aspirin and statins at discharge from hospital. Intermediate provision rates and 
wide variation across CCGs were observed for provision of echocardiography, 
cardiac rehabilitation, coronary angiography, prescription of ACEi/ARBs and 
β blockers, with low provision rates for and little variation across CCGs for 
provision of smoking cessation advice, dietary advice and P2Y12 inhibitors. 
Similar findings were noted for SCNs, with high receipt of optimal care being 
observed in North East and North Cumbria, and East Midlands. One can only 
 - 264 -  
 
speculate that since Northern England and East Midlands compared to other 
SCNs in England have a greater proportion of high volume hospitals (hospitals 
that perform <400 PCIs per annum)(162), AMI patients treated in these high 
volume hospitals are more likely to receive optimal care. It has been reported 
in past literature that higher volume hospitals have better care pathways 
because they follow more structured protocols and practice more evidence 
based treatment (163-165). 
 
After adjusting for case mix, most of the remaining variation (99.6%) was 
explained by differences in provision of care by hospitals and to a much lesser 
extent by CCGs or SCNs. This finding is consistent with evidence from 
previous studies that also found that type and size of hospital influenced 
receipt of AMI care(55, 56, 160, 166, 167). For example, Mehta et al.(166) 
reported that hospitals that had both low adherence to guideline-indicated 
care  and low safety metrics for dosage were the smaller non-teaching 
hospitals which were less likely to have percutaneous or surgical coronary 
revascularisation. Fox et al.(160) also found that PPCI was mostly carried out 
in university or university affiliated hospitals than community hospitals. 
Similarly, Tuppin et al.(56) reported that high rates of statins, ACEi/ARBs, β 
blockers, antiplatelet agents and optimal care were observed in patients 
treated in university hospitals or high volume centres.  
The causes of the healthcare variations observed are complex and have been 
attributed to differences in patient characteristics, clinicians’ behaviour or the 
effects of incentives in the financing of healthcare(168, 169). The work of this 
thesis found that variation in the provision of NSTEMI treatment remained 
after adjusting for patient sociodemographic and clinical characteristics, 
suggesting that modifiable factors such as procurement, infrastructure, 
availability of specialist services and physician treating preferences/education 
are critical(168). Treating physicians have been reported to select lower risk 
and less comorbid patients for more aggressive treatment under the 
perception that the risk that may be associated with aggressive treatment for 
higher risk, multimorbid and elderly patients may outweigh the benefits from 
treatment(156). 
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The research work conducted in this thesis on variation in NSTEMI care was 
conducted to specifically target evaluation of variation at CCG level to allow 
commissioners to identify where and what service may require closer 
attention. The findings from this study suggested variation in care was mostly 
attributed to providers (hospitals). Initiatives such as the introduction of a 
performance-based tariff for NSTEMI (or an additional best practice 
payment(170)) may reduce hospital variation and potentially improve patient 
outcomes. An example were performance-based commissioning has been 
applied and found to be associated with favourable outcomes is the 
introduction of the Advancing Quality Program (171) across all NHS hospitals 
in the north-west of England. The program was found to be associated with a 
significant reduction in combined short-term mortality for pneumonia, heart 
failure and acute myocardial infarction(171).  
 
8.3.3 Association of clinical factors and therapeutic strategies 
with improvements in survival following STEMI. 
The work for objective three of the thesis was conducted in the framework of 
assessing quality of care and associated outcomes for AMI patients focusing 
on the STEMI phenotype, i.e. to determine whether temporal changes in 
STEMI treatments and patient characteristics were associated with 
improvements in survival. The study found that among patients hospitalized 
with STEMI in England and Wales, temporal improvements in all cause six 
months,  and one year mortality  were observed between 2004 and 2013. This 
was significantly associated with PPCI and P2Y12 inhibitors use at hospital 
discharge, with introduction of PPCI having the greatest impact on one year 
mortality. Other studies in literature that have carried out similar work have 
found consistent findings as this thesis. Puymirat et al.(172) and Szummer et 
al.(173) found that greater use of reperfusion therapy and recommended 
medications amongst STEMI patients was associated with improved temporal 
survival improvements. 
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International studies have reported a decline in mortality following AMI(174-
178). Comprehensive work has previously been undertaken quantifying the 
avoidable harm associated with sub-optimal care for STEMI patients(61) and 
also determining the factors associated with temporal improvements in 
survival for NSTEMI patients(145). However there is a paucity of 
contemporary studies of sufficient duration and representation from a 
population perspective that enable a detailed evaluation of the association of 
baseline risk and guideline-indicated therapies with mortality among patients 
with STEMI(145, 172, 173, 179-181), with only two studies in past literature 
focusing mainly on STEMI patients(172, 173).   
 
The most recent study by Szummer et al.(173) evaluating the association of 
baseline risk factors, guideline-indicated therapies and fatal or non-fatal 
outcomes among patients with STEMI found that increased use of new and 
established evidence-based treatments during the 20 years follow-up was 
associated with prolonged survival and lower risk of ischaemic events. 
Changes in treatment and outcomes were most distinct between 1994 and 
2008. Reperfusion increased from 66 to 94% (PPCI) between 1995/96 and 
2013/14 over the 20 years, similarly for medical treatments: aspirin  increased  
from 82-94%, dual antiplatelet therapy 0-90%, β blockers 78-91%, ACEi/ARBs 
41-85% and statins 14-94%. Of all the factors considered, change in 
reperfusion and PPCI were found to be associated with improved in-hospital 
outcomes and change in discharge medications as well as change in 
reperfusion and PPCI were found to be associated with improved within one 
year outcomes. It is not surprising that the discharge medications had no 
impact on in-hospital outcomes as the patients would have not received the 
care interventions as they died in hospital before hospital discharge 
prescription. The modelling approach undertaken by Szummer et al.(173)  of 
including all the cardio-protective drugs into the mediation model is concerning 
as it makes it difficult to identify which of the drugs has the greatest impact on 
survival. It may also give a misleading impression that all the drugs are 
associated with improved temporal improvements in survival yet it might be a 
specific drug. For example as observed in the current study’s findings when 
the five drugs were adjusted for in the mediation model the temporal trend 
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became  non-significant which implied that the increased prescription of all 
cardio-protective drugs explained temporal improvements in survival. 
However, it was upon further investigation by adjusting for each drug 
individually that it was revealed that it was the increased prescription of P2Y12 
inhibitors at hospital discharge that actually explained the temporal survival 
improvements.  
 
Marked changes in the prescription of the cardio-protective drugs were 
observed in the Swedish study, yet for the current UK study prescription of the 
drugs the entire study (although improved) was very high (>90%) with the 
introduction of PPCI in 2007 onwards which came with a P2Y12 inhibitors 
indication (Class I, Level A) for all STEMI patients before or at latest at time 
of PPCI.(182) Which explains the finding that the introduction of PPCI and 
P2Y12 inhibitors were found to be associated with improved survival in the 
current work.  
 
The care intervention for which the improvements in survival for STEMI 
patients have been mostly attributed is PPCI (172), and past literature has 
reported that for STEMI patients the introduction of PPCI has been reported 
to be associated with a decline in mortality (151, 183-185), as has the use of 
antithrombotic therapies and secondary prevention medications(172, 173, 
186, 187). Consistently with the findings of the current study, PPCI and P2Y12 
inhibitors at hospital discharge were associated with six month and one year 
temporal survival improvements. No pronounced decline was observed for 30 
day mortality for the STEMI patients recorded in MINAP between 2004-2013 
used as the analytical cohort for objective three of the thesis. No association 
was found between introduction of PPCI and improved 30 day mortality, this 
could be attributed to lack of statistical power to draw inference on the impact 
of introduction of PPCI on 30 day mortality.  
 
However upon conducting the mediation analysis improvements in one year 
survival between 2004 and 2013 were significantly explained by the uptake of 
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PPCI for in-hospital survivors of STEMI. Short term survival (six months), the 
mediated effects by PPCI were not significant. However the mediated effects 
identified for P2Y12 inhibitors were found to be non-significant in the mediation 
analysis. Potentially this could be explained by a potential moderation 
relationship between PPCI and P2Y12 inhibitors. Individually the care 
interventions confer survival benefits, however when used in combination they 
have a greater impact.   
 
Compared with past literature, the current study is the first study to date to 
quantify temporal trends survival improvements for STEMI patients using 
mediation analysis to explore various causal pathways, going beyond the 
estimation of simple treatment effects. The mediated effects by PPCI for six 
months survival were not significant; this finding is consistent with what past 
literature has found i.e. survival benefits of an invasive strategy were most 
pronounced long term after suffering an ACS(188).  
 
The mediation analysis showed that the determined mediators did not account 
for all the one year survival improvements for STEMI patients observed (only 
accounted for 27%). This shows that there are other unmeasured factors 
beyond those measured in MINAP that have also accounted for the survival 
improvements observed for the STEMI patients in the considered analytical 
cohort. Other studies in literature have suggested that factors beyond change 
in treatment effects and patients baseline characteristics  are also important 
in explaining MI mortality trends, for example changes in health seeking 
behaviours when confronted with symptoms of MI have significant 
associations with temporal improvements in survival trends(172). Further 
work considering variables that measure such aspects needs to be 
undertaken and unfortunately for this thesis MINAP did not have such 
information.  
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8.3.4 Role of β-blockers during and after AMI in patients without 
heart failure or LVSD. 
Beta blockers have been a cornerstone in the treatment of patients with AMI. 
However, uncertainty exists on their efficacy among AMI patients without heart 
failure or LVSD in contemporary practice. The 2015 ESC NSTEMI guidelines 
highlighted that there is a gap in knowledge on the efficacy of β blockers for 
patients with normal or mildly depressed LV function(4). Many of the RCT data 
to support β blockers use in AMI in this sub group of patients predate 
contemporary medical therapy and the available recent studies findings to 
date are conflicting such that international guidelines differ in their 
recommendation on the use of β blockers in this group of patients(4, 22-24). 
There is sufficient evidence to support the efficacy of β blockers use in patients 
with AMI and heart failure(189-193). The current study is the first large scale 
population based analysis investigating the impact of β blockers on survival 
after AMI among patients without heart failure or LVSD in the reperfusion era.  
 
This current  study found that  among survivors of hospitalisation with AMI 
(hospitalised between 2007 and 2013) who did not have heart failure or LVSD 
as recorded in hospital, the use of β blockers was not associated with a lower 
risk of death at one month, six months and at one year. The results remained 
consistent when the analyses were carried out stratified by AMI phenotype i.e. 
NSTEMI and STEMI. The findings from this study are similar with findings from 
other studies in literature which have focused on similar work(194-197). An 
individual patient data meta-analysis of 11 trials by Cleland et al.(194) found 
that β blockers reduced all cause and cardiovascular mortality compared to 
the placebo, an effect that was consistent across the considered LVEF strata 
except in those in the sub-group with LVEF≥ 50% were no survival benefits in 
use of β blockers were observed.  
 
A study by  Puymirat et al.(195) conducted using the nationwide French 
registry; FAST-MI found that early use of β blockers (within 48 hours of 
admission) was associated with a substantial decrease in 30 day mortality 
(56% reduction), however no significant survival effects were observed for one 
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year and five year survival(195). In contrast to the results of no beneficial effect 
of β blockers, other studies have reported survival benefits(198). Misumida et 
al.(198) found that for STEMI patients who received PPCI survival benefits 
were observed for patients with oral β blockers compared with those without. 
Conflicting evidence in literature as such warrants the need for a clinical trial 
testing the efficacy of β blockers among patients with AMI who do not have 
heart failure or LVSD which will lead to a better understanding on the impact 
of β blockers on fatal and non-fatal outcomes in this sub group of AMI patients.  
 
The lack in survival benefits observed for β blocker use in the reperfusion era 
has been attributed to both reperfusion and aggressive contemporary medical 
therapy (i.e. increased use of ACEI/ARBs, dual antiplatelet therapy and 
statins)(197). The pre-invention of reperfusion and lack of aggressive 
contemporary medical therapy in the pre-reperfusion era meant that after 
suffering an AMI the patients were most likely to get extensive myocardial 
scarring. This would result to the AMI patients suffering fatal ventricular 
arrhythmias. Use of β blockers for such patients was found to prevent the 
sudden death, hence the observed efficacy of β blockers in the pre-
reperfusion era(197). Prompt reperfusion which is readily available in the 
contemporary era means reduced scarring for AMI patients thus reduced risk 
of arrhythmic deaths, thereby further reducing the impact of β blockers(197). 
Use of reperfusion therapy, aspirin and statins reduces infarct size(197). 
Bangalore et al.(197), reported that the use of β blockers in the contemporary 
era had no mortality benefit; however use reduced recurrent myocardial 
infarction and angina at the expense of increased risk of heart failure, 
cardiogenic shock and drug discontinuation. The current study’s findings were 
limited to an all-cause mortality outcome since MINAP only records all-cause 
mortality data (through linkage to ONS data) and no other forms of non-fatal 
outcomes. Further work needs to be undertaken using advanced 
methodologies and comprehensive datasets (similar to the current study) 
exploring non-fatal outcomes, for example heart failure, cardiogenic shock, 
angina and recurrent MI. 
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Based on findings from this study and complimentary findings from other 
studies that have been identified, secondary prevention medications at 
discharge from hospital for AMI patients without heart failure or LVSD may not 
need to include β blockers in the contemporary era. Continued use might put 
the patients at increased risk of developing heart failure or cardiogenic shock 
as highlighted by the Bangalore et al.(197) study and poor adherence to other 
cardio-protective drugs that actually confer survival benefits after use(199).  
 
The findings from this study add to the increasing body of evidence that the 
routine prescription of β blockers may not be indicated in patients with a 
normal ejection fraction or without heart failure post AMI patients. However, 
because the current study was only limited to all-cause mortality further work 
is required focusing on non-fatal outcomes. A randomised controlled trial is a 
necessary next step for the contemporary evaluation of β blockers in AMI 
without heart failure or LVSD. 
 
8.4 Strengths and Limitations of the Study  
The major strength of the work in this thesis is that it is based on a detailed 
population-based national clinical registry designed specifically to evaluate 
quality of heart attack care, MINAP and is mandated by the department of 
health in England and Wales(39). A detailed evaluation of MINAP is given in 
Chapter one, §1.6.4.  Besides the Swedish Web-System for Enhancement 
and Development of Evidence-Based Care in Heart Disease Evaluated 
According to Recommended Therapies (SWEDEHEART) registry(200), there 
are no other databases of comparable size, coverage and quality which 
include all hospitals within a country across a single national health care 
system. In this big data era and increased use of electronic health records, 
MINAP offered data on a 10 year evaluation of quality of care and outcomes 
(over one million person years of follow-up) for AMI patients. The findings from 
this study provided comprehensive and original findings on the care deficits 
and associated avoidable harm for NSTEMI patients (the most vulnerable of 
the AMI phenotypes) in an otherwise modern and efficient national health care 
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system. NSTEMI patients have been under represented in research, yet they 
are highest risk of death and have the most heterogeneous pathways of care.  
 
Other strengths of the thesis work include use of advanced statistical 
techniques such as latent class analysis to capture real life clinical practice in 
management of NSTEMI patients. Latent class analysis has not been used to 
define quality of care before for NSTEMI patients or even for ACS patients in 
past literature. The technique allowed for high resolution analysis of 
combinations of pathways of care according to their eligibility and receipt. The 
work also employed advanced statistical time to event modelling techniques, 
which include; shared frailty accelerated failure time models, flexible 
parametric models and survival-time inverse-probability weighting propensity 
score analysis for objectives one, three and four of the thesis. The literature 
review revealed that most studies use simple traditional approaches like 
logistic regression. Traditional regression methods are not suited to 
accommodate both the event and time aspect nature of time to event data in 
the modelling. This aspect challenges the utility of logistic regression models 
when analysing survival data. Ignoring the time-dependent information in the 
data may bias the analysis i.e. parameter estimates maybe overestimated 
especially in scenarios with high event rates which maybe misleading to 
clinicians when quantifying treatment effects of medications(82).     Also unlike 
survival analysis techniques, traditional methods like logistic regression do not 
cater for a special type of missing data inherent when using time to event data 
which is called censoring. Censoring occurs when subjects do not experience 
the event under investigation during the follow-up time. Other advanced 
statistical techniques that are outside the time to event techniques framework 
used in the thesis include mediation analysis. The technique was undertaken 
to quantify the impact of the determined mediators on the STEMI six months 
and one year survival temporal improvements noted. The mediation analysis 
was carried out to substantiate the flexible parametric modelling findings of 
association going beyond simple point estimates by exploring various causal 
pathways as well as the extent (percentage) to which the mediating variable 
explained the exposure outcome relationship. This makes the findings more 
useful and interpretable clinically. Mediation analysis has rarely been used in 
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past literature in AMI research and the thesis is one of the few studies to 
demonstrate its utility in this field. 
  
Most of the studies that assessed variation in receipt of NSTEMI care 
considered in the literature review used simple descriptive statistics (i.e. 
frequencies, percentages, means and medians) and univariate statistics such 
as Chi-square test for comparing categorical variables and t-test for 
comparing continuous variables. This thesis employed a four level hierarchical 
Poisson model which allowed for a robust extensive evaluation of the source 
of variation in receipt of care for NSTEMI patients in the English NHS. The 
multilevel Poison model accounted for the clustering in the data. Analysing the 
data, ignoring the clustering in the data creates bias by underestimating the 
standard errors of regression coefficients hence inflating type I errors in 
hypothesis testing. Furthermore the hierarchical modelling provides estimates 
of ICC statistics that are relevant for providing information on the proportion 
of variance in the outcome explained by the grouping variables in the 
hierarchical structure. The multilevel structure comprised of patients nested 
within hospitals, hospitals nested within CCGs and CCGs nested within SCNs. 
This allowed for the identification of the source, i.e. is the variation due to poor 
commissioning thus at CCGs and SCNs level or due to differences in 
treatment by providers thus at hospital level or due to differences in patients 
characteristics thus at patient level. Tackling inequalities in care at the level of 
the healthcare professional, services provider and commissioner will allow 
identification of where and what service require close attention. Which will lead 
to improved receipt of guideline-indicated care for NSTEMI patients and result 
to a reduction in avoidable deaths.  
 
The efficacy of β blocker use after suffering an AMI for patients without heart 
failure or LVSD work carried out in this thesis is to date the largest analysis 
focusing on this work (comprising of 179,810 cases). The analytical cohort 
was derived from a population-based national clinical registry, MINAP. Novel 
advanced causal inference methods that have been recommended in 
literature when using observational data to quantify treatment effects, 
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including instrumental variable analysis and propensity scoring (survival-time 
inverse-probability weighting propensity score analysis) were used. Both 
methods minimise measured and unmeasured bias due to systematic 
differences between patients when using observational data from electronic 
health records such as MINAP. The utility of the techniques is in that 
employing them allows for quantification of marginal treatment effects that are 
similar to those that would have been obtained had a clinical trial been carried 
out instead. However the strength offered by using these techniques beyond 
the use of clinical trials is that treatment effects are estimated using ‘real world 
clinical population’ whilst trials tend to focus on very select non-complex 
patient groups that rarely represent the general population. Inference from 
such studies is very useful for informing policy making.  
 
The thesis work, however, has limitations. All the work that was undertaken is 
reliant upon the accurate recording of data in MINAP. One of the major 
weaknesses of using electronic health records is missing data, and MINAP is 
no exception. Missing data could have potentially biased the results of the 
work, as missing data can result to exclusion of observations. Excluding 
observations from the analytical cohorts reduces the power and precision of 
the study as well as compromise generalisability of the study findings. 
However robust missing data approaches that have been used in past 
literature for MINAP data were employed i.e. MICE and default imputation 
strategies. Recording bias could have been inherent for receipt of smoking 
cessation and dietary advice as a sudden upstroke was noted for these care 
interventions around 2008. Imputation strategies informed by past literature 
that have used MINAP data were implemented to account for the missing data 
for the care interventions(105). This would have potentially minimised the 
impact of the missing data. Also the poor receipt of smoking cessation and 
dietary advice observed for objective one of the thesis may be inflated 
because advice about smoking and diet are embedded in cardiac 
rehabilitation programmes and there may have been preferencing by coders 
towards recording cardiac rehabilitation rather than counselling. However the 
occurrence of this should be minimal as high rates of smoking cessation and 
dietary advice as well as cardiac rehabilitation were noted in later years if 
 - 275 -  
 
preferred recording of cardiac rehabilitation instead of the advice was 
consistent then the poor recording of smoking cessation and dietary advice 
should have been consistent throughout the study follow-up time. 
 
Data on prescription of anticoagulants was not well recorded in MINAP such 
that investigation of ESC guideline-indicated care for NSTEMI was not able to 
be extended to all Class 1 Level A recommendations for the management of 
NSTEMI. It is therefore possible that the deficits and their consequences are 
greater than reported. The eligibility criteria used for in-hospital aldosterone 
as defined by the ESC guidelines reduced the sample size of the patients 
eligible for this care intervention such that the resultant estimates could be 
imprecise. For example the lack of association with improved survival noted 
in the results for objective one of the thesis.  
 
Poor case ascertainment for NSTEMI patients in   MINAP could have 
potentially biased the findings of the thesis . The Myocardial Ischaemia 
National Audit Project has almost half a million NSTEMI admissions recorded, 
however it is estimated that MINAP captures less than half of all NSTEMI 
patients in England and Wales which can compromise generalisability of the 
study’s findings. Such that although MINAP offers a large NSTEMI analytical 
cohort compared to other data sources, the NSTEMI data recorded in MINAP 
may not be representative of the population to which the results will be 
generalised. The avoidable deaths quantified and underuse of care 
interventions for NSTEMI patients determined in this thesis could also be 
underestimated. However for the STEMI patients’ generalisability of the 
study’s findings is not compromised as MINAP captures the great majority of 
patients suffering a STEMI in England and Wales.       
 
MINAP only records in-hospital management of AMI patients and patient 
baseline characteristics so there was no information beyond hospital stay 
such as long term drug adherence and primary care visits to account for in the 
various analyses carried out. Objective one of the thesis focused on assessing 
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the impact of receipt of optimal care for NSTEMI patients on long term survival, 
in-hospital management information would only suffice if impact on short term 
survival (i.e. 30 days) was under investigation. Considering that usually 
patients are discharged from hospital with a month’s supply of 
pharmacotherapies. Assessment of the quality of care and associated 
outcomes long term could have been more precise if follow-up information on 
number of cardiac rehabilitation sessions attended as well as adherence of 
pharmacotherapies was taken into account. However, past literature has 
highlighted that usually care interventions not initiated in-hospital are less 
likely to be picked up after discharge thus in-hospital management of the 
NSTEMI patients can to a certain extent capture use of care interventions by 
NSTEMI patients with less information on discontinuation rates of the initiated 
care interventions. This limitation also applies for work for objectives three and 
four. Information on long term adherence of β blocker could have made the 
findings on efficacy of β blocker use for AMI patents without heart failure or 
LVSD more precise. However the causal inference technique used to estimate 
the treatment effects, instrumental variable analysis removed measured and 
unmeasured confounding meaning the hidden confounding from the 
unrecorded long term adherence rates of β blockers was removed thus 
reducing the bias from not accounting for this information in the modelling. 
The mediation analysis conducted for objective three of the thesis showed that 
introduction PPCI accounted for 27% of temporal improvements in one year 
survival meaning more information beyond that recorded in MINAP could have 
influenced survival for example outpatient care of the STEMI patients.  
 
Survival was evaluated using all-cause mortality, however this may bias the 
results as non-cardiovascular deaths may not be attributable to underuse of 
AMI guideline-indicated care. CCGs were used to evaluate variation in receipt 
of NSTEMI care, however they were created in 2012 and replaced Primary 
Care Trusts April 2013 which is toward the end of the study. However, since 
the CCGs are in charge of commissioning of care it would be useful to identify 
care deficits at CCGs so that going forward they can address them. Also 
another limitation of using CCGs to assess variation in receipt of NSTEMI care 
is that it is always not clear if the patients living in a CCG were treated in the 
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same CCG as the northings and eastings supplied in MINAP used to merge 
the data to CCG boundary data were based on the patients’ postcode not 
hospital postcode. However, the bias inherent with this approach implemented 
for objective two of the thesis was minimised by the use of the multilevel 
approach were by treating hospital was included into the hierarchical structure 
thus taking into account the treating hospital into the evaluation of variation of 
receipt of care. Hospital level evaluation could not be done directly as hospital 
identification is not permitted or given in MINAP data made available for 
research.  
 
Of the methodologies used the predictors of receipt of NSTEMI care models’ 
predictive power was very low, as noted by the observed low pseudo-R2 and 
AUROC estimates for all the 13 care interventions considered as well for 
optimal care. This was a strong indication that some important predictors 
beyond the ones available in MINAP were missing. These important predictors 
could include information on treating physicians prescribing/treatment 
preferences for different risk profiles patients or treating physicians’ education 
and awareness on management of AMI patients as well as provider level 
characteristics such as hospital facilities, size and type. However the 
predictors determined in this thesis were statistically significant in the 
prediction of receipt of care models thereby showing that they had predictive 
power for receipt or non-receipt of care interventions for AMI patients. The 
findings are still insightful.  
 
For objective one of the thesis, of the 13 care interventions considered, receipt 
of an angiogram was found to be associated with the greatest impact on 
survival for NSTEMI patients (associated with an 82% reduction in survival 
time if missed). However, this finding could be potentially confounded by the 
fact that angiograms could have been performed in the healthier NSTEMI 
patients, for example elderly multi-morbid NSTEMI patients are less likely to 
receive an angiogram (201). Such that the improved outcomes associated 
with angiography may not relate to the effects of angiography but, to the 
underlying condition of the patients(21). However, for the purpose of the work 
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of this thesis, patients were classified as ineligible if treatment was: contra-
indicated, not indicated, not applicable or patient declined treatment as 
recorded in MINAP. Thus, the bias inherent due to the ‘healthy adherer effect’ 
could have been minimised.           
 
8.5  Implications of the study  
The findings from this study have shown that NSTEMI patients, despite being 
the more vulnerable of the AMI phenotypes did not receive optimal care. The 
study showed that the preventable deaths associated with this receipt of sub 
optimal care were approximately 33,000 deaths. Care deficits across the 
NSTEMI guideline-indicated care pathway identified included; dietary and 
smoking cessation advice, echocardiography to evaluate left ventricular 
systolic function, the prescription of P2Y12 inhibitors and coronary 
angiography. The evaluation of geographic variation in receipt of care for 
NSTEMI patients showed that most of the variation was as a result of differing 
treatment approaches by care providers (hospitals). The study clearly shows 
that, across a modern healthcare system such as in the UK, there are 
substantial opportunities to improve receipt of guideline-indicated care for 
NSTEMI patients thereby resulting to improved outcomes. Primary PCI and 
P2Y12 inhibitors were identified as mediators for the long term temporal 
survival improvements noted for STEMI patients.  
 
The findings from this thesis yield important actionable insights to guide policy 
and clinical practice to improve the quality health systems and prevent 
avoidable harm from AMI which is line with the World Health Organisation 
Global Action Plan for non-communicable disease to protect people from 
premature deaths from heart and lung diseases, cancers and diabetes(202). 
Also these findings can also be inferred to other developed and developing 
countries which lag behind Northern Europe and North America in their 
provision of care and where greater gains in healthcare maybe realised. Work 
from objective one and two of the thesis was foundation to the development 
of a web platform “Cardiovascular Landscapes: Using Data to Improve 
 - 279 -  
 
Cardiovascular Care and Outcomes”. The work is being undertaken in 
collaboration with LIDA and once completed will aid better data visualisation 
and wider dissemination of the results from the assessment of geographic 
variation in receipt of AMI care as well as on-going assessment of variation in 
receipt of AMI care by employing new downloads of receipt of care data going 
forward. The development of CV landscapes will provide a platform for 
engaging clinicians, commissioners or providers and patients.  
 
The study findings of lack of association of β blockers and one, six and twelve 
months survival adds to the increasing body of evidence that the routine 
prescription of β blockers may not be indicated in patients with a normal 
ejection fraction or without heart failure post AMI patients and could be useful 
in informing policy on β blockers use in this subgroup of patients. 
 
The advanced statistical techniques employed in this thesis have implications 
for future research in cardiovascular epidemiology. Utility of causal inference 
techniques such as instrumental variable, survival-time inverse-probability 
weighting propensity score and mediation analysis was demonstrated as they 
are rarely used when quantifying treatment effects in cardiovascular research 
in the absence of clinical trial evidence using observational data for research. 
Also utility of using latent class analysis to capture real life clinical practice 
receipt of NSTEMI care was demonstrated in this thesis. Future 
cardiovascular epidemiologists can employ the technique in their research as 
LCA is also rarely used in this field. The utility of using electronic health 
records was also demonstrated in this thesis. The MINAP registry allowed for 
the completion of the four research strands of the thesis at a population level, 
nationwide. The absence of clinical trial evidence should not be limiting to 
health research, in this big data era observational data can suffice if 
appropriate methods to draw inference are applied. This supports NHS 
Digital’s ambition for a paperless NHS capturing routinely collected data and 
create EHR that will provide a repository for data for  audit and research(203). 
The USA is focusing on the same initiative through the ‘EHR Meaningful Use  
Programme’(204, 205). 
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This work can also be translational to other areas of cardiovascular 
epidemiology were electronic health records are available for use for research 
for example heart failure (using the National Heart Failure National Audit 
(NHFA)) or stroke (using the Sentinel Stroke National Audit Programme 
(SSNAP). 
 
8.6 Future Research Recommendations  
Whilst significant findings of the thesis can contribute to improving quality of 
care for AMI patients, further research needs to be undertaken. The work 
carried out for objective four of the thesis evaluating the impact of β blockers 
use at hospital discharge on survival for AMI patients without heart failure or 
LVSD adds to the increasing body of evidence that the routine prescription of 
β blockers may not be indicated in patients with a normal ejection fraction or 
without heart failure post AMI patients as it the largest study to focus on this 
work to date. However, a randomised controlled trial is a necessary next step 
for the contemporary evaluation of β blockers. Evidence is strongly needed to 
decide on a potentially unnecessary over-utilization of β blockers that could 
potentially translate to AMI patients developing heart failure and cardiogenic 
shock(197). 
 
All-cause mortality was considered as the main outcome for the thesis, 
however as mentioned in the strengths and limitations section non-
cardiovascular deaths may not be attributable to underuse of AMI guideline-
indicated care. Further work is required focusing not only on specifically 
cardiovascular deaths but also on non-fatal outcomes for example major 
cardiovascular and cerebrovascular events. Potentially this can be made 
possible by linking MINAP to other National Institute for Cardiovascular 
Outcomes Research (NICOR) cardiovascular registries as well as HES data 
to get the non-fatal outcomes data. 
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More insight is required on physician’s treating preferences for the different 
risk profiles of AMI patients as well as their awareness of the ever evolving 
AMI guidelines. Most of the readily available data sources do not capture such 
information. A mixed methods approach could be employed which involves 
the use of qualitative methods as well as quantitative methods. The qualitative 
methods will aid in capturing the treatment/prescribing preferences of the 
treating physicians. This data can also be linked to cardiac EHRs such as 
MINAP to aid a comprehensive evaluation of quality of care and associated 
outcomes for AMI patients.    
 
Most of the work that has assessed quality of care and outcomes for NSTEMI 
(or even AMI) patients in past literature as well as the current study has 
focused entirely on measurement of receipt of guideline-indicated care 
interventions without taking into considering safety metrics of receipt of care 
i.e. appropriate dosing of the medication(166). Further work should be 
undertaken assessing quality of care including receipt of appropriate dosage 
as well as long term adherence beyond hospital discharge. The feasibility of 
an EHR for routinely collected cardiac outpatient  data for the NHS has been 
demonstrated by Bodagh et al.(206), linkage of MINAP to such kinds of 
datasets could allow for future evaluation of quality of care and associated 
outcomes without the restriction of focusing on in-hospital treatment only.   
 
Most of the variation in receipt of care shown in this study was found to be at 
the provider level. However this study was limited in determining the hospital 
level factors that were associated with this variation as MINAP does record 
hospital level data. MINAP needs to be linked to hospital level data and further 
work needs to be done to investigate the hospital level predictors of this 
variation in receipt of NSTEMI care. Also temporal changes in geographical 
variation in receipt of NSTEMI care need to be assessed for future work as 
this would identify if an improvement has occurred in management of AMI over 
time. If not, highlight the guideline recommended care interventions that are 
persistently being missed.   
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8.7 Future planned publications  
In addition to the already published papers arising from this thesis (207-209), 
the results from chapter 6 will be submitted for a publication to the Journal of 
the American Medical Association.  
 
8.8 Conclusion   
In this first study of the pathway of care for NSTEMI patients in England and 
Wales, the optimal use of guideline-indicated treatments was low. The thesis 
identified substantial gaps in the provision of guideline-indicated interventions 
as recommended by the ESC. The deficits in receipt care identified were found 
to be associated with avoidable deaths. Most of the variation in receipt of 
NSTEMI care was explained by hospital differences in provision of care. Six 
month and one year temporal survival improvements that have been noted for 
STEMI patients over the last decade were found to be partly attributed to 
prescription of P2Y12 inhibitors at hospital discharge and introduction of PPCI. 
For AMI patients without heart failure or LVSD, prescription of β blockers at 
hospital discharge was not associated with lower all-cause mortality at any 
time point up to one year. Whilst cardiovascular care has substantially 
improved in modern healthcare systems with the resultant reductions in 
mortality, only through higher resolution investigations using whole healthcare 
system clinical registries can modifiable deficits of care be identified and, 
therefore, addressed.
 - 283 -  
 
Appendices 
Appendix A     
 
 
 
 
 - 284 -  
 
 
Figure A 1 HRA-decision tool output for sites in England. 
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Figure A 2 HRA-decision tool output for sites in Wales. 
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Appendix B  
Table B 1 Patients eligible to receive β blockers by latent class. 
 β blockers eligible 
 Yes No 
Latent class    
High receipt  6,081 112,595 
Intermediate  111,314 22,232 
Low  3,699 78,858 
 
Table B 2 Receipt of β blockers by latent class. 
 β blockers 
 Received  Did not receive  Contraindicated/not applicable 
Latent class     
High receipt  5,830 251 144,929 
Intermediate  81,076 30,238 22,232 
Low  3,279 420 100,802 
 
Table B 3 Patients eligible ACEi/ARBs by latent class. 
 ACEi/ARBs eligible 
 Yes  No 
Latent class    
High receipt  967 150,043 
Intermediate  133,436 110 
Low  728 103,773 
 
Table B 4 Receipt of ACEi/ARBs by latent class. 
 ACEi/ARBs 
 Received  Did not receive  Contraindicated/not applicable 
Latent class     
High receipt  933 34 150,043 
Intermediate  89,957 47,479 110 
Low  269 459 103,773 
 
Table B 5 Patients eligible to receive Electrocardiogram by latent class. 
 
 
 
 Electrocardiogram 
 Yes  No 
Latent class    
High receipt  151,010 0 
Intermediate  133,546 0 
Low  104,501 0 
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Table B 6 Receipt of Electrocardiogram by latent class. 
 Electrocardiogram 
 Received  Did not receive  Contraindicated / not applicable 
Latent class     
High receipt  150,023 987 0 
Intermediate  113,290 20,256 0 
Low  101,447  3,054 0 
 
Table B 7 Patients eligible to receive acute aspirin by latent class. 
  Acute aspirin eligible 
 Yes  No 
Latent class    
High receipt  103,168 47,842 
Intermediate  87,953 45,593 
Low  69,263 35,238 
 
Table B 8 Receipt of acute aspirin by latent class. 
 Acute aspirin 
 Received  Did not receive  Contraindicated / not applicable 
Latent class     
High receipt  97,358 5,810 47,842 
Intermediate  72,843 15,110   45,593 
Low  60,621 8,642 35,238 
 
Table B 9 Patients eligible to receive statins by latent class. 
 Statins eligible 
 Yes  No 
Latent class    
High receipt  125,336 25,674 
Intermediate  130,218 3,328 
Low  92,147 12,354 
 
Table B 10 Receipt of statins by latent class. 
 Statin  
 Received  Did not receive  Contraindicated / not 
applicable 
Latent class     
High receipt  117,639 7,697 25,674 
Intermediate  102,912   27,306 3,328 
Low  76,494 15,653 12,354 
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Table B 11 Patients eligible to receive P2Y12 inhibitor/ticagrelor by latent 
class. 
  P2Y12 inhibitor/ticagrelor eligible 
 Yes  No 
Latent class    
High receipt  117,187 33,823 
Intermediate  103,358 73 
Low  99,356 5,007 
 
Table B 12 Receipt of P2Y12 inhibitor/ ticagrelor by latent class. 
 P2Y12 inhibitor/ticagrelor 
 Received  Did not receive  Contraindicated / not 
applicable 
Latent class     
High receipt  108,150    9,037 33,823 
Intermediate  548 102,810 30,188 
Low  18,297   81,059 5,145 
 
Table B 13 Patients eligible to receive aldosterone antagonists by latent 
class. 
 Aldosterone antagonists eligible 
 Yes  No 
Latent class    
High receipt  397 2,027 
Intermediate  195 133,029   
Low  0 3,125 
 
Table B 14 Receipt of aldosterone antagonists by latent class. 
 Aldosterone antagonists 
 Received  Did not receive  Contraindicated / not applicable 
Latent class     
High receipt  129 268   150,613 
Intermediate  15   180 133,351 
Low  0 0 104,501 
 
Table B 15 Patients eligible to receive echocardiography by latent class. 
  Echocardiography eligible 
 Yes  No 
Latent class    
High receipt  150,973 37 
Intermediate  133,546 0 
Low  104,501 0 
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Table B 16 Receipt of echocardiography by latent class. 
 Echocardiography 
 Received  Did not receive  Contraindicated / not applicable 
Latent class     
High receipt  90,296   60,677 37 
Intermediate  57,483 76,063   0 
Low  47,758 56,743 0 
 
Table B 17 Patients eligible to receive cardiac rehabilitation by latent class. 
  Cardiac rehabilitation eligible 
 Yes  No 
Latent class    
High receipt  138,941 12,069 
Intermediate  130,713 2,833 
Low  97,284 7,217 
 
Table B 18 Receipt of cardiac rehabilitation by latent class. 
 Cardiac rehabilitation 
 Received  Did not receive  Contraindicated / not 
applicable 
Latent class     
High receipt  119,457 19,484 12,069 
Intermediate  91,589 39,124 2,833 
Low  67,981 29,303   7,217 
 
Table B 19 Patients eligible to receive smoking cessation advice by latent 
class. 
 Smoking cessation advice eligible 
 Yes  No 
Latent class    
High receipt  43,654 107,356 
Intermediate  133,538 8 
Low  101,986 2,515 
 
Table B 20 Receipt of smoking cessation advice by latent class. 
 Smoking cessation advice 
 Received  Did not receive  Contraindicated/not 
applicable 
Latent class     
High receipt  33,545    10,109 107,356 
Intermediate  0 133,538 8 
Low  276   101,710   2,515 
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Table B 21 Patients eligible to receive dietary advice by latent class. 
 Dietary advice eligible 
 Yes  No 
Latent class    
High receipt  136,275 14,735 
Intermediate  133,546 0 
Low  104,369 132 
 
Table B 22 Receipt of dietary advice by latent class. 
 Dietary advice 
 Received  Did not receive  Contraindicated/not 
applicable 
Latent class     
High receipt  118,411 17,864 14,735 
Intermediate  7 133,539 0 
Low  903 103,466 132 
 
Table B 23 Patients eligible to receive coronary angiography by latent class. 
 Coronary angiography eligible 
 Yes  No 
Latent class    
High receipt  136,835 14,175 
Intermediate  133,544 2 
Low  102,741 1,760 
 
Table B 24 Receipt of coronary angiography by latent class. 
 Coronary angiography 
 Received  Did not receive  Contraindicated / not 
applicable 
Latent class     
High receipt  103,400 33,435 14,175 
Intermediate  50,366 83,178 2 
Low  57,501 45,240 1,760 
 
Table B 25 Patients eligible to receive aspirin at discharge by latent class. 
 Aspirin at discharge eligible 
 Yes  No 
Latent class    
High receipt  123,294 27,716 
Intermediate  127,569 5,977 
Low  90,119 14,382 
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Table B 26 Receipt of coronary angiography by latent class. 
 Aspirin at discharge 
 Received  Did not receive  Contraindicated / not 
applicable 
Latent class     
High receipt  117,988   5,306    27,716 
Intermediate  106,661 20,908 5,977 
Low  76,990 13,129 14,382 
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Appendix C  
Table C 1 Modelling results (univariate unadjusted vs complete case vs imputed) by care interventions. 
Treatment Unadjusted TRs (95% CI) Complete case analysis 
Adjusted TRs (95% CI) 
Multiple imputation analyses 
Adjusted TRs (95% CI) 
P-value 
Sub-optimal care¥ 0.34 (0.32, 0.35) 0.40 (0.38, 0.43) 0.44 (0.41, 0.45) < 0.001 
Intermediate receipt class 0.73 (0.72, 0.75) 0.59 (0.47, 0.72) 0.84 (0.79, 0.88) < 0.001 
Low receipt class 0.77 (0.75, 0.79) 0.79 (0.74, 0.83) 0.77 (0.74, 0.80) < 0.001 
Electrocardiogram 0.76 (0.73, 0.79) 0.84 (0.72 ,0.98) 0.92 (0.89, 0.96) < 0.001 
Acute aspirin 0.54 (0.52, 0.56) 0.66 (0.58, 0.74) 0.65 (0.62, 0.67) < 0.001 
ACE inhibition or ARBs 0.70 (0.68, 0.72) 0.65 (0.47, 0.90) 0.70 (0.68, 0.72) < 0.001 
Beta Blockers    0.55 (0.53, 0.57) 0.82 (0.65, 1.04) 0.63 (0.61, 0.65) < 0.001 
Statin at discharge 0.50 (0.49, 0.52) 0.53 (0.50, 0.57) 0.56 (0.55, 0.58) < 0.001 
 P2Y12 inhibitors at discharge 0.69 (0.67, 0.71) 0.72 (0.68, 0.77) 0.76 (0.73, 0.79) < 0.001 
Aldosterone antagonist  1.11 (0.63, 1.98) 0.91 (0.45, 1.83) 0.88 (0.51, 1.51) 0.639 
Echocardiography  0.91 (0.89, 0.92) 0.74 (0.71, 0.76) 0.94 (0.92, 0.96) < 0.001 
Cardiac rehabilitation 0.38 (0.38, 0.39) 0.39 (0.37, 0.41) 0.49 (0.48, 0.50) < 0.001 
Smoking cessation advice 0.31 (0.30, 0.33) 0.57 (0.53, 0.62) 0.53 (0.51, 0.57) < 0.001 
Dietary advice 0.58 (0.57, 0.60) 0.63 (0.60, 0.67) 0.65 (0.63, 0.68) < 0.001 
Coronary angiography 0.12 (0.11, 0.12) 0.16 (0.15, 0.17) 0.18 (0.17, 0.18) < 0.001 
Aspirin at discharge  0.80 (0.78, 0.83) 0.79 (0.73, 0.85) 0.83 (0.80, 0.85) < 0.001 
¥Patients who missed ≥1 care interventions for which they were eligible to receive. 
Abbreviations: ARB, angiotensin receptor blocker; ACE, angiotensin converting enzyme. 
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Appendix D  
Table D 1 Effect of β blockers at discharge on all-cause mortality following AMI (survival-time inverse-probability weighting propensity 
score analysis) (trimmed analysis) 
Average treatment effects Average treatment effects on the treated only 
Follow-up Coefficient¥  (95% CI) P-value Follow-up Coefficient¥  (95% CI) P-value 
AMI   AMI   
One month - - One month - - 
Six months -0.15 (-0.63 to 0.34) 0.554 Six months -0.23 (-0.76 to 0.29) 0.386 
One year -0.32 (-1.23 to 0.60) 0.495 One year -0.35 (-1.35 to 0.64) 0.488 
STEMI   STEMI   
One month - - One month - - 
Six months 0.32 (-0.64 to 1.29) 0.511 Six months 0.02 (-1.04 to 1.08) 0.972 
One year 0.15 (-1.96 to 2.26) 0.887 One year -0.52 (-2.81 to 1.77) 0.656 
NSTEMI   NSTEMI   
One month - - One month - - 
Six months -0.19 (-0.71 to 0.32) 0.460 Six months -0.19 (-0.73 to 0.35) 0.494 
One year -0.53 (-1.58 to 0.53) 0.327 One year -0.50 (-1.64 to 0.64) 0.389 
Abbreviations: AMI, acute myocardial infarction; ¥Estimate represents the effect of β blockers on survival for the respective follow-up time categories; NSTEMI, non ST-segment elevation myocardial 
infarction; STEMI, ST-segment elevation myocardial infarction,- model converge problems. 
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Table D 2 Effect of β blockers at discharge on all-cause mortality following AMI (survival-time inverse-probability weighting propensity 
score analysis) 
Average treatment effects Average treatment effects on the treated only 
Follow-up Coefficient¥  (95% CI) P-value Follow-up Coefficient¥  (95% CI) P-value 
AMI   AMI   
One month 0.48 (-2.82 to 3.79) 0.776 One month 0.24 (-3.26 to 3.73) 0.895 
Six months -0.08 (-0.63 to 0.47) 0.782 Six months -0.13 (-0.71 to 0.45) 0.666 
One year 0.64 (-0.26 to 1.56) 0.164 One year 0.70 (-0.27 to 1.66) 0.156 
STEMI   STEMI   
One month -0.002 (-1.99 to 1.98) 0.999 One month -0.10 (-2.13 to 1.93) 0.924 
Six months -0.68 (-1.67 to 0.29) 0.168 Six months -0.73 (-1.74 to 0.28) 0.155 
One year 0.69 (-0.89 to 2.27) 0.393 One year 0.68 (-0.94 to 2.31) 0.411 
NSTEMI   NSTEMI   
One month - - One month - - 
Six months 0.42 (-0.17 to 1.01) 0.166 Six months 0.44 (-0.19 to 1.08) 0.169 
One year 0.74 (-0.24 to 1.71) 0.138 One year 0.86 (-0.18 to 1.90) 0.104 
Abbreviations: AMI, acute myocardial infarction; ¥Estimate represents the effect of β blockers on survival for the respective follow-up time categories; NSTEMI, non ST-segment elevation myocardial 
infarction; STEMI, ST-segment elevation myocardial infarction,- model converge problems. 
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